{
 "cells": [
  {
   "cell_type": "markdown",
   "id": "bb86a40c-00bd-4dfa-bd28-67dce3e720b1",
   "metadata": {},
   "source": [
    "This Jupyter Notebook serves as a proof of concept of a multi-agent solution for MedTech regulations. The intent of the system is to provide clear answers to questions on WHO and FDA documentations on medical devices, using a 3-to-4 agents system composed like this:\n",
    "\n",
    "- an LLM orchestrator that receives the question and coordinates agents\n",
    "- a RAG agent capable of retrieving documents related to the question\n",
    "- an LLM response agent to put together the answer based on the documents retrieved and the question\n",
    "- a possible fourth agent to be decided (summary agent, source-verifier, compare agent, prompt agent to improve prompts, etc.)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "id": "0ae99977-325e-4a78-b556-a63ccb3dca43",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'\\n\\npseudo code for multi agent system\\n\\nclass agent\\n\\ninstantiate orchestrator and other agents\\n\\ndefine orchestrator prompt and response false\\n\\ntake input\\n\\nwhile not response:\\n\\n    orchestrator call\\n\\n    designed agent call\\n\\nreturn response\\n\\n'"
      ]
     },
     "execution_count": 1,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "\"\"\"\n",
    "\n",
    "pseudo code for multi agent system\n",
    "\n",
    "class agent\n",
    "\n",
    "instantiate orchestrator and other agents\n",
    "\n",
    "define orchestrator prompt and response false\n",
    "\n",
    "take input\n",
    "\n",
    "while not response:\n",
    "\n",
    "    orchestrator call\n",
    "\n",
    "    designed agent call\n",
    "\n",
    "return response\n",
    "\n",
    "\"\"\""
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "id": "40713cc2-97db-4577-a884-fd2fb1f081c7",
   "metadata": {},
   "outputs": [],
   "source": [
    "# Import libraries\n",
    "\n",
    "import gradio as gr\n",
    "import chromadb\n",
    "import uuid\n",
    "import google.generativeai as genai\n",
    "import os\n",
    "from dotenv import load_dotenv\n",
    "import pymupdf4llm\n",
    "import json\n",
    "from chromadb.utils import embedding_functions"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "id": "30825fc5-b1f5-43de-a6e7-c9f0ce7f3a96",
   "metadata": {},
   "outputs": [],
   "source": [
    "# Load environmental variables and AI models\n",
    "\n",
    "load_dotenv() #loads the API key put in a .env file\n",
    "try:\n",
    "    genai.configure(api_key=os.environ['GOOGLE_API_KEY'])\n",
    "except Exception as e:\n",
    "    print(f\"Error configuring Google AI. Please ensure your API key is correct. Error: {e}\")\n",
    "\n",
    "# Configure paths to data\n",
    "current_dir = os.getcwd() \n",
    "FILE_PATH_FDA_DESIGN = os.path.join(current_dir, '..', 'documents', 'FDA_Design_Control_Guidance.pdf')\n",
    "FILE_PATH_WHO = os.path.join(current_dir, '..', 'documents', 'WHO_Medical_Device_Regulations.pdf')\n",
    "FILE_PATH_FDA_POLICY = os.path.join(current_dir, '..', 'documents', 'FDA_Policy_Device_Software_Functions.pdf')\n",
    "COLLECTION_NAME = \"multi_agent_rag\""
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "id": "1d6997c9-03e2-4a41-8f6a-327a00857e83",
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "ename": "KeyboardInterrupt",
     "evalue": "",
     "output_type": "error",
     "traceback": [
      "\u001b[1;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[1;31mKeyboardInterrupt\u001b[0m                         Traceback (most recent call last)",
      "\u001b[1;32m~\\AppData\\Local\\Temp\\ipykernel_16188\\704379584.py\u001b[0m in \u001b[0;36m?\u001b[1;34m()\u001b[0m\n\u001b[1;32m---> 23\u001b[1;33m \u001b[1;31m# Split logic (very simple, splitting paragraphs)\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0m\u001b[0;32m     24\u001b[0m \u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m     25\u001b[0m \u001b[1;32mdef\u001b[0m \u001b[0msplit_into_chunks\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0mdict_list\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m:\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m     26\u001b[0m     \u001b[0mtext_chunks\u001b[0m \u001b[1;33m=\u001b[0m \u001b[1;33m[\u001b[0m\u001b[1;33m]\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n",
      "\u001b[1;32m~\\anaconda3\\envs\\mdrag\\lib\\site-packages\\pymupdf4llm\\helpers\\pymupdf_rag.py\u001b[0m in \u001b[0;36m?\u001b[1;34m(doc, pages, hdr_info, write_images, embed_images, ignore_images, ignore_graphics, detect_bg_color, image_path, image_format, image_size_limit, filename, force_text, page_chunks, page_separators, margins, dpi, page_width, page_height, table_strategy, graphics_limit, fontsize_limit, ignore_code, extract_words, show_progress, use_glyphs, ignore_alpha)\u001b[0m\n\u001b[0;32m   1198\u001b[0m     \u001b[1;32mif\u001b[0m \u001b[0mshow_progress\u001b[0m\u001b[1;33m:\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m   1199\u001b[0m         \u001b[0mprint\u001b[0m\u001b[1;33m(\u001b[0m\u001b[1;34mf\"Processing {FILENAME}...\"\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m   1200\u001b[0m         \u001b[0mpages\u001b[0m \u001b[1;33m=\u001b[0m \u001b[0mProgressBar\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0mpages\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m   1201\u001b[0m     \u001b[1;32mfor\u001b[0m \u001b[0mpno\u001b[0m \u001b[1;32min\u001b[0m \u001b[0mpages\u001b[0m\u001b[1;33m:\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[1;32m-> 1202\u001b[1;33m         parms = get_page_output(\n\u001b[0m\u001b[0;32m   1203\u001b[0m             \u001b[0mdoc\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0mpno\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0mmargins\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0mtextflags\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0mFILENAME\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0mIGNORE_IMAGES\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0mIGNORE_GRAPHICS\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m   1204\u001b[0m         )\n\u001b[0;32m   1205\u001b[0m         \u001b[1;32mif\u001b[0m \u001b[0mpage_chunks\u001b[0m \u001b[1;32mis\u001b[0m \u001b[1;32mFalse\u001b[0m\u001b[1;33m:\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n",
      "\u001b[1;32m~\\anaconda3\\envs\\mdrag\\lib\\site-packages\\pymupdf4llm\\helpers\\pymupdf_rag.py\u001b[0m in \u001b[0;36m?\u001b[1;34m(doc, pno, margins, textflags, FILENAME, IGNORE_IMAGES, IGNORE_GRAPHICS)\u001b[0m\n\u001b[0;32m   1032\u001b[0m         \u001b[1;32mif\u001b[0m \u001b[0mIGNORE_GRAPHICS\u001b[0m \u001b[1;32mor\u001b[0m \u001b[1;32mnot\u001b[0m \u001b[0mtable_strategy\u001b[0m\u001b[1;33m:\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m   1033\u001b[0m             \u001b[1;31m# do not try to extract tables\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m   1034\u001b[0m             \u001b[1;32mpass\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m   1035\u001b[0m         \u001b[1;32melse\u001b[0m\u001b[1;33m:\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[1;32m-> 1036\u001b[1;33m             \u001b[0mtabs\u001b[0m \u001b[1;33m=\u001b[0m \u001b[0mpage\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0mfind_tables\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0mclip\u001b[0m\u001b[1;33m=\u001b[0m\u001b[0mparms\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0mclip\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0mstrategy\u001b[0m\u001b[1;33m=\u001b[0m\u001b[0mtable_strategy\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0m\u001b[0;32m   1037\u001b[0m             \u001b[1;32mfor\u001b[0m \u001b[0mt\u001b[0m \u001b[1;32min\u001b[0m \u001b[0mtabs\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0mtables\u001b[0m\u001b[1;33m:\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m   1038\u001b[0m                 \u001b[1;31m# remove tables with too few rows or columns\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m   1039\u001b[0m                 \u001b[1;32mif\u001b[0m \u001b[0mt\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0mrow_count\u001b[0m \u001b[1;33m<\u001b[0m \u001b[1;36m2\u001b[0m \u001b[1;32mor\u001b[0m \u001b[0mt\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0mcol_count\u001b[0m \u001b[1;33m<\u001b[0m \u001b[1;36m2\u001b[0m\u001b[1;33m:\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n",
      "\u001b[1;32m~\\anaconda3\\envs\\mdrag\\lib\\site-packages\\pymupdf\\table.py\u001b[0m in \u001b[0;36m?\u001b[1;34m(page, clip, vertical_strategy, horizontal_strategy, vertical_lines, horizontal_lines, snap_tolerance, snap_x_tolerance, snap_y_tolerance, join_tolerance, join_x_tolerance, join_y_tolerance, edge_min_length, min_words_vertical, min_words_horizontal, intersection_tolerance, intersection_x_tolerance, intersection_y_tolerance, text_tolerance, text_x_tolerance, text_y_tolerance, strategy, add_lines, add_boxes, paths)\u001b[0m\n\u001b[0;32m   2546\u001b[0m     \u001b[0mtset\u001b[0m \u001b[1;33m=\u001b[0m \u001b[0mTableSettings\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0mresolve\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0msettings\u001b[0m\u001b[1;33m=\u001b[0m\u001b[0msettings\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m   2547\u001b[0m     \u001b[0mpage\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0mtable_settings\u001b[0m \u001b[1;33m=\u001b[0m \u001b[0mtset\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m   2548\u001b[0m \u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m   2549\u001b[0m     \u001b[0mmake_chars\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0mpage\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0mclip\u001b[0m\u001b[1;33m=\u001b[0m\u001b[0mclip\u001b[0m\u001b[1;33m)\u001b[0m  \u001b[1;31m# create character list of page\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[1;32m-> 2550\u001b[1;33m     make_edges(\n\u001b[0m\u001b[0;32m   2551\u001b[0m         \u001b[0mpage\u001b[0m\u001b[1;33m,\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m   2552\u001b[0m         \u001b[0mclip\u001b[0m\u001b[1;33m=\u001b[0m\u001b[0mclip\u001b[0m\u001b[1;33m,\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m   2553\u001b[0m         \u001b[0mtset\u001b[0m\u001b[1;33m=\u001b[0m\u001b[0mtset\u001b[0m\u001b[1;33m,\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n",
      "\u001b[1;32m~\\anaconda3\\envs\\mdrag\\lib\\site-packages\\pymupdf\\table.py\u001b[0m in \u001b[0;36m?\u001b[1;34m(page, clip, tset, paths, add_lines, add_boxes)\u001b[0m\n\u001b[0;32m   2220\u001b[0m             \u001b[1;32mdel\u001b[0m \u001b[0mprects\u001b[0m\u001b[1;33m[\u001b[0m\u001b[1;36m0\u001b[0m\u001b[1;33m]\u001b[0m  \u001b[1;31m# remove from rect list\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m   2221\u001b[0m \u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m   2222\u001b[0m         \u001b[1;32mreturn\u001b[0m \u001b[0mnew_rects\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0mpaths\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m   2223\u001b[0m \u001b[1;33m\u001b[0m\u001b[0m\n\u001b[1;32m-> 2224\u001b[1;33m     \u001b[0mbboxes\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0mpaths\u001b[0m \u001b[1;33m=\u001b[0m \u001b[0mclean_graphics\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0mnpaths\u001b[0m\u001b[1;33m=\u001b[0m\u001b[0mpaths\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0m\u001b[0;32m   2225\u001b[0m \u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m   2226\u001b[0m     \u001b[1;32mdef\u001b[0m \u001b[0mis_parallel\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0mp1\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0mp2\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m:\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m   2227\u001b[0m         \u001b[1;34m\"\"\"Check if line is roughly axis-parallel.\"\"\"\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n",
      "\u001b[1;32m~\\anaconda3\\envs\\mdrag\\lib\\site-packages\\pymupdf\\table.py\u001b[0m in \u001b[0;36m?\u001b[1;34m(npaths)\u001b[0m\n\u001b[0;32m   2213\u001b[0m                         \u001b[1;32mdel\u001b[0m \u001b[0mprects\u001b[0m\u001b[1;33m[\u001b[0m\u001b[0mi\u001b[0m\u001b[1;33m]\u001b[0m  \u001b[1;31m# delete this rect\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m   2214\u001b[0m                         \u001b[0mrepeat\u001b[0m \u001b[1;33m=\u001b[0m \u001b[1;32mTrue\u001b[0m  \u001b[1;31m# keep checking the rest\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m   2215\u001b[0m \u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m   2216\u001b[0m             \u001b[1;31m# move rect 0 over to result list if there is some text in it\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[1;32m-> 2217\u001b[1;33m             \u001b[1;32mif\u001b[0m \u001b[1;32mnot\u001b[0m \u001b[0mwhite_spaces\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0missuperset\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0mpage\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0mget_textbox\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0mprect0\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0mtextpage\u001b[0m\u001b[1;33m=\u001b[0m\u001b[0mTEXTPAGE\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m:\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0m\u001b[0;32m   2218\u001b[0m                 \u001b[1;31m# contains text, so accept it as a table bbox candidate\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m   2219\u001b[0m                 \u001b[0mnew_rects\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0mappend\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0mprect0\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m   2220\u001b[0m             \u001b[1;32mdel\u001b[0m \u001b[0mprects\u001b[0m\u001b[1;33m[\u001b[0m\u001b[1;36m0\u001b[0m\u001b[1;33m]\u001b[0m  \u001b[1;31m# remove from rect list\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n",
      "\u001b[1;32m~\\anaconda3\\envs\\mdrag\\lib\\site-packages\\pymupdf\\utils.py\u001b[0m in \u001b[0;36m?\u001b[1;34m(page, rect, textpage)\u001b[0m\n\u001b[0;32m    712\u001b[0m     \u001b[1;32mif\u001b[0m \u001b[0mtp\u001b[0m \u001b[1;32mis\u001b[0m \u001b[1;32mNone\u001b[0m\u001b[1;33m:\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m    713\u001b[0m         \u001b[0mtp\u001b[0m \u001b[1;33m=\u001b[0m \u001b[0mpage\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0mget_textpage\u001b[0m\u001b[1;33m(\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m    714\u001b[0m     \u001b[1;32melif\u001b[0m \u001b[0mgetattr\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0mtp\u001b[0m\u001b[1;33m,\u001b[0m \u001b[1;34m\"parent\"\u001b[0m\u001b[1;33m)\u001b[0m \u001b[1;33m!=\u001b[0m \u001b[0mpage\u001b[0m\u001b[1;33m:\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m    715\u001b[0m         \u001b[1;32mraise\u001b[0m \u001b[0mValueError\u001b[0m\u001b[1;33m(\u001b[0m\u001b[1;34m\"not a textpage of this page\"\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[1;32m--> 716\u001b[1;33m     \u001b[0mrc\u001b[0m \u001b[1;33m=\u001b[0m \u001b[0mtp\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0mextractTextbox\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0mrect\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0m\u001b[0;32m    717\u001b[0m     \u001b[1;32mif\u001b[0m \u001b[0mtextpage\u001b[0m \u001b[1;32mis\u001b[0m \u001b[1;32mNone\u001b[0m\u001b[1;33m:\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m    718\u001b[0m         \u001b[1;32mdel\u001b[0m \u001b[0mtp\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m    719\u001b[0m     \u001b[1;32mreturn\u001b[0m \u001b[0mrc\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n",
      "\u001b[1;32m~\\anaconda3\\envs\\mdrag\\lib\\site-packages\\pymupdf\\__init__.py\u001b[0m in \u001b[0;36m?\u001b[1;34m(self, rect)\u001b[0m\n\u001b[0;32m  12277\u001b[0m     \u001b[1;32mdef\u001b[0m \u001b[0mextractTextbox\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0mself\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0mrect\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m:\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m  12278\u001b[0m         \u001b[0mthis_tpage\u001b[0m \u001b[1;33m=\u001b[0m \u001b[0mself\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0mthis\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m  12279\u001b[0m         \u001b[1;32massert\u001b[0m \u001b[0misinstance\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0mthis_tpage\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0mmupdf\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0mFzStextPage\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m  12280\u001b[0m         \u001b[0marea\u001b[0m \u001b[1;33m=\u001b[0m \u001b[0mJM_rect_from_py\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0mrect\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[1;32m> 12281\u001b[1;33m         \u001b[0mfound\u001b[0m \u001b[1;33m=\u001b[0m \u001b[0mJM_copy_rectangle\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0mthis_tpage\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0marea\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0m\u001b[0;32m  12282\u001b[0m         \u001b[0mrc\u001b[0m \u001b[1;33m=\u001b[0m \u001b[0mPyUnicode_DecodeRawUnicodeEscape\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0mfound\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m  12283\u001b[0m         \u001b[1;32mreturn\u001b[0m \u001b[0mrc\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n",
      "\u001b[1;32m~\\anaconda3\\envs\\mdrag\\lib\\site-packages\\pymupdf\\__init__.py\u001b[0m in \u001b[0;36m?\u001b[1;34m(page, area)\u001b[0m\n\u001b[0;32m  14488\u001b[0m             \u001b[1;32mcontinue\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m  14489\u001b[0m         \u001b[1;32mfor\u001b[0m \u001b[0mline\u001b[0m \u001b[1;32min\u001b[0m \u001b[0mblock\u001b[0m\u001b[1;33m:\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m  14490\u001b[0m             \u001b[0mline_had_text\u001b[0m \u001b[1;33m=\u001b[0m \u001b[1;36m0\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m  14491\u001b[0m             \u001b[1;32mfor\u001b[0m \u001b[0mch\u001b[0m \u001b[1;32min\u001b[0m \u001b[0mline\u001b[0m\u001b[1;33m:\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[1;32m> 14492\u001b[1;33m                 \u001b[0mr\u001b[0m \u001b[1;33m=\u001b[0m \u001b[0mJM_char_bbox\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0mline\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0mch\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0m\u001b[0;32m  14493\u001b[0m                 \u001b[1;32mif\u001b[0m \u001b[0mJM_rects_overlap\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0marea\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0mr\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m:\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m  14494\u001b[0m                     \u001b[0mline_had_text\u001b[0m \u001b[1;33m=\u001b[0m \u001b[1;36m1\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m  14495\u001b[0m                     \u001b[1;32mif\u001b[0m \u001b[0mneed_new_line\u001b[0m\u001b[1;33m:\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n",
      "\u001b[1;32m~\\anaconda3\\envs\\mdrag\\lib\\site-packages\\pymupdf\\__init__.py\u001b[0m in \u001b[0;36m?\u001b[1;34m(line, ch)\u001b[0m\n\u001b[0;32m  14213\u001b[0m \u001b[1;32mdef\u001b[0m \u001b[0mJM_char_bbox\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0mline\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0mch\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m:\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m  14214\u001b[0m     '''\n\u001b[0;32m  14215\u001b[0m     \u001b[1;32mreturn\u001b[0m \u001b[0mrect\u001b[0m \u001b[0mof\u001b[0m \u001b[0mchar\u001b[0m \u001b[0mquad\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m  14216\u001b[0m     '''\n\u001b[1;32m> 14217\u001b[1;33m     \u001b[0mq\u001b[0m \u001b[1;33m=\u001b[0m \u001b[0mJM_char_quad\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0mline\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0mch\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0m\u001b[0;32m  14218\u001b[0m     \u001b[0mr\u001b[0m \u001b[1;33m=\u001b[0m \u001b[0mmupdf\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0mfz_rect_from_quad\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0mq\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m  14219\u001b[0m     \u001b[1;32mif\u001b[0m \u001b[1;32mnot\u001b[0m \u001b[0mline\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0mm_internal\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0mwmode\u001b[0m\u001b[1;33m:\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m  14220\u001b[0m         \u001b[1;32mreturn\u001b[0m \u001b[0mr\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n",
      "\u001b[1;32m~\\anaconda3\\envs\\mdrag\\lib\\site-packages\\pymupdf\\__init__.py\u001b[0m in \u001b[0;36m?\u001b[1;34m(line, ch)\u001b[0m\n\u001b[0;32m  14240\u001b[0m     '''\n\u001b[0;32m  14241\u001b[0m     \u001b[1;32mif\u001b[0m \u001b[1;36m1\u001b[0m \u001b[1;32mand\u001b[0m \u001b[0mg_use_extra\u001b[0m\u001b[1;33m:\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m  14242\u001b[0m         \u001b[1;31m# This reduces time taken to extract text from PyMuPDF.pdf from 20s to\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m  14243\u001b[0m         \u001b[1;31m# 15s.\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[1;32m> 14244\u001b[1;33m         \u001b[1;32mreturn\u001b[0m \u001b[0mmupdf\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0mFzQuad\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0mextra\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0mJM_char_quad\u001b[0m\u001b[1;33m(\u001b[0m \u001b[0mline\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0mm_internal\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0mch\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0mm_internal\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0m\u001b[0;32m  14245\u001b[0m \u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m  14246\u001b[0m     \u001b[1;32massert\u001b[0m \u001b[0misinstance\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0mline\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0mmupdf\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0mFzStextLine\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m  14247\u001b[0m     \u001b[1;32massert\u001b[0m \u001b[0misinstance\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0mch\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0mmupdf\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0mFzStextChar\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n",
      "\u001b[1;32m~\\anaconda3\\envs\\mdrag\\lib\\site-packages\\pymupdf\\mupdf.py\u001b[0m in \u001b[0;36m?\u001b[1;34m(self, *args)\u001b[0m\n\u001b[0;32m  32082\u001b[0m \u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m  32083\u001b[0m         \u001b[1;33m*\u001b[0m\u001b[0mOverload\u001b[0m \u001b[1;36m5\u001b[0m\u001b[1;33m:\u001b[0m\u001b[1;33m*\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m  32084\u001b[0m          \u001b[0mConstructor\u001b[0m \u001b[0musing\u001b[0m \u001b[0mraw\u001b[0m \u001b[0mcopy\u001b[0m \u001b[0mof\u001b[0m \u001b[0mpre\u001b[0m\u001b[1;33m-\u001b[0m\u001b[0mexisting\u001b[0m\u001b[0;31m \u001b[0m\u001b[0;31m`\u001b[0m\u001b[1;33m:\u001b[0m\u001b[1;33m:\u001b[0m\u001b[0mfz_quad\u001b[0m\u001b[0;31m`\u001b[0m\u001b[1;33m.\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m  32085\u001b[0m         \"\"\"\n\u001b[1;32m> 32086\u001b[1;33m         \u001b[0m_mupdf\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0mFzQuad_swiginit\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0mself\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0m_mupdf\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0mnew_FzQuad\u001b[0m\u001b[1;33m(\u001b[0m\u001b[1;33m*\u001b[0m\u001b[0margs\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0m",
      "\u001b[1;31mKeyboardInterrupt\u001b[0m: "
     ]
    }
   ],
   "source": [
    "# Split logic (very simple, splitting paragraphs)\n",
    "\n",
    "def split_into_chunks(dict_list):\n",
    "    text_chunks = []\n",
    "    metadatas = []\n",
    "    \n",
    "    for document in dict_list:\n",
    "        try:\n",
    "            paragraphs = list(document.values())[0].split(\"\\n\\n\")\n",
    "    \n",
    "            for paragraph in paragraphs: # Delete short paragraphs\n",
    "                if len(paragraph) > 10:\n",
    "                    text_chunks.append(paragraph)\n",
    "                    metadatas.append({\"source\": list(document.keys())[0]})\n",
    "        except Exception as e:\n",
    "            print(f\"An error occurred while processing {list(document.keys())[0]}: {e}\")\n",
    "            \n",
    "    return text_chunks, metadatas\n",
    "\n",
    "# Use pymupdf4llm to convert pdf into text, adequately formatted. Using dicts to keep track of sources and add them to metadata while chunking\n",
    "fda_design_dict = {'FDA_Design_Control_Guidance.pdf': pymupdf4llm.to_markdown(FILE_PATH_FDA_DESIGN)}\n",
    "who_dict = {'WHO_Medical_Device_Regulations.pdf': pymupdf4llm.to_markdown(FILE_PATH_WHO)}\n",
    "fda_policy_dict = {'FDA_Policy_Device_Software_Functions.pdf': pymupdf4llm.to_markdown(FILE_PATH_FDA_POLICY)}\n",
    "\n",
    "text_chunks, metadatas = split_into_chunks([fda_design_dict, who_dict, fda_policy_dict])\n",
    "print(len(text_chunks), len(metadatas))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "e7e25a2f-373c-4d86-917d-19c23ee619f7",
   "metadata": {},
   "outputs": [],
   "source": [
    "# Second chunking logic: texting up the documents. I'll convert the pdf in txt and see if the RAG handles them better.\n",
    "\n",
    "# Configure paths to data\n",
    "current_dir = os.getcwd() \n",
    "FILE_PATH_FDA_DESIGN = os.path.join(current_dir, '..', 'documents', 'FDA_Design_Control_Guidance.txt')\n",
    "FILE_PATH_WHO = os.path.join(current_dir, '..', 'documents', 'WHO_Medical_Device_Regulations.txt')\n",
    "FILE_PATH_FDA_POLICY = os.path.join(current_dir, '..', 'documents', 'FDA_Policy_Device_Software_Functions.txt')\n",
    "COLLECTION_NAME = \"multi_agent_rag\"\n",
    "\n",
    "def process_txt_file(file_path, source_name):\n",
    "    \"\"\"\n",
    "    Reads a .txt file and splits it into chunks based on paragraphs\n",
    "    (separated by double newlines).\n",
    "\n",
    "    Args:\n",
    "        file_path (str): The path to the .txt file.\n",
    "        source_name (str): The name of the source document for metadata.\n",
    "\n",
    "    Returns:\n",
    "        tuple: A tuple containing two lists: (text_chunks, metadatas).\n",
    "    \"\"\"\n",
    "    all_text_chunks = []\n",
    "    all_metadatas = []\n",
    "    try:\n",
    "        with open(file_path, 'r', encoding='utf-8') as f:\n",
    "            full_text = f.read()\n",
    "\n",
    "        # Chunking strategy: split by double newline (a common paragraph separator)\n",
    "        paragraphs = full_text.split('\\n\\n')\n",
    "\n",
    "        for para in paragraphs:\n",
    "            stripped_para = para.strip()\n",
    "            if len(stripped_para) > 25:  # Filter out very short or empty lines\n",
    "                all_text_chunks.append(stripped_para)\n",
    "                # Metadata is simpler for a txt file, just the source\n",
    "                all_metadatas.append({'source': source_name})\n",
    "\n",
    "    except FileNotFoundError:\n",
    "        print(f\"Error: File not found at {file_path}\")\n",
    "    except Exception as e:\n",
    "        print(f\"An error occurred while processing {file_path}: {e}\")\n",
    "\n",
    "    return all_text_chunks, all_metadatas\n",
    "\n",
    "chunks_fdad, metas_fdad = process_txt_file(FILE_PATH_FDA_DESIGN, 'FDA_Design_Control_Guidance')\n",
    "print(f\"Processed FDA_Design: {len(chunks_fdad)} chunks.\")\n",
    "\n",
    "chunks_who, metas_who = process_txt_file(FILE_PATH_WHO, 'WHO_Medical_Device_Regulations')\n",
    "print(f\"Processed WHO: {len(chunks_who)} chunks.\")\n",
    "\n",
    "chunks_fdap, metas_fdap = process_txt_file(FILE_PATH_FDA_POLICY, 'FDA_Policy_Device_Software_Functions')\n",
    "print(f\"Processed FDA Policy: {len(chunks_fdap)} chunks.\")\n",
    "\n",
    "text_chunks = chunks_fdad + chunks_who + chunks_fdapS\n",
    "metadatas = metas_fdad + metas_who + metas_fdap"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "ed028aee-0d9f-4fce-8908-9151bc8a89b5",
   "metadata": {},
   "outputs": [],
   "source": [
    "# Using Langchain recursive tex splitter NEED TO ADD METADATAS THOUGH\n",
    "\n",
    "from langchain_text_splitters import RecursiveCharacterTextSplitter\n",
    "file_paths = [FILE_PATH_FDA_DESIGN, FILE_PATH_WHO, FILE_PATH_FDA_POLICY]\n",
    "\n",
    "all_text = \"\"\n",
    "for file_path in file_paths:\n",
    "    with open(file_path, \"r\", encoding=\"utf-8\") as f:\n",
    "        all_text += f.read() + \"\\n\\n\"\n",
    "\n",
    "text_splitter = RecursiveCharacterTextSplitter(\n",
    "    # Set a really small chunk size, just to show.\n",
    "    chunk_size=200,\n",
    "    chunk_overlap=20,\n",
    "    length_function=len,\n",
    "    is_separator_regex=False,\n",
    ")\n",
    "\n",
    "text_chunks = text_splitter.create_documents([all_text])\n",
    "print(texts[0])\n",
    "print(texts[1])\n",
    "len(texts)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "494f1732-06ae-4dca-8b80-138559008a96",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "id": "455b173f-006d-4f4a-8de5-e754aef4524b",
   "metadata": {},
   "outputs": [],
   "source": [
    "# Define agent classes\n",
    "\n",
    "class OrchestratorAgent:\n",
    "\n",
    "    def __init__(self, agents):\n",
    "        self.agents = agents\n",
    "        self.memory = []\n",
    "        self.memory_limit = 15\n",
    "\n",
    "        self.model = genai.GenerativeModel('gemini-1.5-flash')\n",
    "\n",
    "    def run(self):\n",
    "        print(\"Hi! I am your MedTech regulatory companion. How can I help you?\")\n",
    "        user_input = input(\"You: \")\n",
    "\n",
    "        while True:\n",
    "            self.memory = self.memory[-self.memory_limit:]\n",
    "            if user_input.lower() in [\"exit\", \"bye\", \"close\"]:\n",
    "                print(\"I hope I could be of use to you, have a great day!\")\n",
    "                break\n",
    "                \n",
    "            orch_response = self.orchestrate(user_input)\n",
    "            print(f\"Orch response is {orch_response}\")\n",
    "            if orch_response[\"agent_to_call\"] == \"No action needed\":\n",
    "                print(\"Is there anything else I can help you with?\")\n",
    "                user_input = input(\"You: \")\n",
    "            for agent in self.agents:\n",
    "                if agent.name == orch_response[\"agent_to_call\"]:\n",
    "                    print(f\"Found agent I was looking for: {agent.name}\\n\")\n",
    "                    response = agent.act(orch_response[\"output\"], orch_response[\"relevant_info\"], self.memory)\n",
    "                    self.memory.append(f\"Agent {agent.name} responded {response}\")\n",
    "                    #controllo da togliere\n",
    "                    if agent.name == \"response_agent\":\n",
    "                        return\n",
    "        \n",
    "        return response\n",
    "\n",
    "    def orchestrate(self, user_input):\n",
    "        self.memory.append(f\"User: {user_input}\")\n",
    "        self.memory = self.memory[-self.memory_limit:]\n",
    "        context = \"\\n\".join(self.memory)\n",
    "\n",
    "        response_format = {\"agent_to_call\":\"\", \"output\": \"\", \"relevant_info\":\"\"}\n",
    "        response = self.model.generate_content(self.get_prompt(context, response_format))\n",
    "        self.memory.append(f\"Orchestrator: {response.text}\")\n",
    "        response_cleaned = clean_response(response)\n",
    "        #print(f\"The next agent to call is {response_cleaned['agent_to_call']}\")\n",
    "        return response_cleaned\n",
    "\n",
    "    def get_prompt(self, context, response_format):\n",
    "        prompt = f\"\"\"\n",
    "        Act as an orchestrator agent for an intelligent RAG system for MedTech companies. Your task is to coordinate agents in order to extract relevant documents from a RAG system and package a coherent and precise answer to the query received.\n",
    "        The task is to first call the chunking agent, retrieve the chunks and pass them to the ragagent, and then use the ragagent documents to call the response_agent on them and craft a response. Make sure to call the response_agent if the history contains a previous call to the ragagent.\n",
    "        Your AI agents and their descriptions are {\", \".join([f\"- {agent.name}: {agent.description}\" for agent in self.agents])}\n",
    "\n",
    "        Use the context, which includes the current user input and the memory of previous inputs and outputs, to plan next steps.\n",
    "        Context : {context}\n",
    "\n",
    "        Guidelines:\n",
    "        At every step, you need to choose only one of the agents and provide instruction to only that agent. If the request needs multiple agent to be solved, do that in a loop.\n",
    "        Read the context, take your time to understand the task, and check if you have executed it correctly.\n",
    "        If there are no actions needed, default the \"agent_to_call\" parameter to \"No action needed\" in the response.\n",
    "        Return only the agent name in the \"agent_to_call\" parameter.\n",
    "        You must return instructions in a valid JSON in the form of {response_format}. The \"output\" item is for the query and the \"relevant_info\" is to attach documents from the RAG for the response agent.\n",
    "        If the RAG is not initialized, you should always call the chunking agent first.\n",
    "        \"\"\"\n",
    "        return prompt\n",
    "        \n",
    "    def call_agent(self, history, information):\n",
    "        prompt = self.prompt + \"\\n\\n\" + \" \".join(json.dumps(history)) + \"\\n\\n\" + information\n",
    "        response = self.model.generate_content(prompt)\n",
    "        return response\n",
    "\n",
    "class RAGAgent:\n",
    "\n",
    "    def __init__(self):\n",
    "        self.name = \"ragagent\"\n",
    "        self.description = \"\"\"I am a RAG agent that can search for relevant documents in a vector database in order to answer a query.\n",
    "                            I expect a user query as input and will return relevant chunks and a variable containing sources info, relevance scores and chunks.\n",
    "                            \"\"\"\n",
    "        self.memory = []\n",
    "        self.memory_limit = 15\n",
    "        self.sentence_transformer_ef = embedding_functions.SentenceTransformerEmbeddingFunction(model_name=\"all-MiniLM-L6-v2\")\n",
    "        self.collection_name = COLLECTION_NAME\n",
    "\n",
    "    def act(self, query, relevant_info, memory):\n",
    "        if \"RAG initialized\" not in history:\n",
    "            self.collection = self.initialize_db()\n",
    "            self.memory.append(\"RAG initialized\")\n",
    "        self.memory.append(memory)\n",
    "        self.memory = self.memory[-self.memory_limit:]\n",
    "        documents = self.query_db(query)\n",
    "        return documents\n",
    "\n",
    "    def initialize_db(self):\n",
    "        print(\"Initializing RAG system... This may take a minute.\")\n",
    "        self.client = chromadb.Client()\n",
    "\n",
    "        if self.collection_name in [c.name for c in self.client.list_collections()]:\n",
    "            self.client.delete_collection(name = self.collection_name)\n",
    "            #print(f\"Deleted existing collection: {self.collection_name}\"\n",
    "    \n",
    "        collection = self.client.get_or_create_collection(\n",
    "        name = self.collection_name,\n",
    "        embedding_function = self.sentence_transformer_ef\n",
    "        )\n",
    "        self.load_documents(collection, chunking_agent.text_chunks, chunking_agent.metadatas)\n",
    "\n",
    "        return collection\n",
    "\n",
    "    def load_documents(self, collection, document_chunks, metadatas):\n",
    "        collection.add(\n",
    "        ids = [str(uuid.uuid4()) for _ in chunking_agent.text_chunks],\n",
    "        documents = chunking_agent.text_chunks,\n",
    "        metadatas = chunking_agent.metadatas)\n",
    "    \n",
    "    def query_db(self, question):\n",
    "        results = self.collection.query(query_texts=[question], include = [\"documents\", \"metadatas\", \"distances\"], n_results=5)\n",
    "\n",
    "        sources_markdown = \"### Sources Used for Analysis\\n\\n\"\n",
    "        retrieved_documents = results['documents'][0]\n",
    "        retrieved_metadatas = results['metadatas'][0]\n",
    "        retrieved_distances = results['distances'][0]\n",
    "    \n",
    "        for i, (doc, meta, dist) in enumerate(zip(retrieved_documents, retrieved_metadatas, retrieved_distances)):\n",
    "            # Convert distance to a more intuitive similarity score (1 - distance)\n",
    "            relevance_score = 1 - dist\n",
    "            source_info = f\"**Source {i+1}:** {meta.get('source', 'N/A')}, Page {meta.get('page', 'N/A')}\\n\"\n",
    "            relevance_info = f\"**Relevance Score:** {relevance_score:.2f}\\n\\n\"\n",
    "            content_info = f\"```\\n{doc}\\n```\\n\\n---\\n\\n\"\n",
    "            sources_markdown += source_info + relevance_info + content_info\n",
    "        print(f\"Sources, documents and relevance score: {sources_markdown}\")\n",
    "            \n",
    "        return sources_markdown\n",
    "\n",
    "class ResponseAgent:\n",
    "    def __init__(self):\n",
    "        self.name = \"response_agent\"\n",
    "        self.description = \"\"\"I am a response agent that expects as input a user query and relevant documents and info from a RAG search.\n",
    "                            My task is to craft a precise response for the user based on the provided documents. I will return a response text.\n",
    "                            \"\"\"\n",
    "\n",
    "        self.memory = []\n",
    "        self.memory_limit = 15\n",
    "        self.model = genai.GenerativeModel('gemini-1.5-flash')\n",
    "    \n",
    "    def act(self, query, relevant_info, memory):\n",
    "        prompt = self.get_prompt(query, relevant_info, memory)\n",
    "        response = self.model.generate_content(prompt)\n",
    "        print(response.text)\n",
    "        return response.text\n",
    "\n",
    "    def get_prompt(self, query, relevant_info, memory):\n",
    "        prompt = f\"\"\"\n",
    "        Act as a Senior Consultant for medical devices. You receive a query from your client, and answer to it based on the relevant information you receive from the RAG system as document chunks.\n",
    "        Be precise, confident and do not make things up. If the context is not enough to provide a clear answer, state it.\n",
    "        Cite the documents and sources you receive as part of your input and provide strategic recommendation. The structure of your answer will be:\n",
    "        - Salutation\n",
    "        - Precise response to the query based on the documents received from the RAG\n",
    "        - Strategic recommendation to the customer.\n",
    "\n",
    "        As additional resources:\n",
    "        User input: {query}\n",
    "        Relevant documents with sources and relevance scores: {relevant_info}\n",
    "        Memory of previous inputs and info: {memory}\n",
    "        \"\"\"\n",
    "        return prompt"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "id": "1331d425-f4dd-4400-b1e7-d1badb209985",
   "metadata": {},
   "outputs": [],
   "source": [
    "# why not add an agent to do chunking? add pydantic to force the format of the answer\n",
    "# it would make more sense to generalize the response_agent class since it is an llm calling, let's see if we have time\n",
    "\n",
    "class ChunkingAgent():\n",
    "    def __init__(self):\n",
    "        self.name = \"chunking_agent\"\n",
    "        self.description = \"\"\"I am an LLM agent created for semantic chunking. My task is to receive pdf documents and return a list of semantically coherent chunks.\n",
    "                            \"\"\"\n",
    "\n",
    "        self.memory = []\n",
    "        self.memory_limit = 15\n",
    "        self.model = genai.GenerativeModel('gemini-1.5-flash')\n",
    "    \n",
    "    def act(self, query, relevant_info, memory):\n",
    "        fda_design_dict = {'FDA_Design_Control_Guidance.pdf': pymupdf4llm.to_markdown(FILE_PATH_FDA_DESIGN)}\n",
    "        who_dict = {'WHO_Medical_Device_Regulations.pdf': pymupdf4llm.to_markdown(FILE_PATH_WHO)}\n",
    "        fda_policy_dict = {'FDA_Policy_Device_Software_Functions.pdf': pymupdf4llm.to_markdown(FILE_PATH_FDA_POLICY)}\n",
    "        documents = [fda_design_dict, who_dict, fda_policy_dict]\n",
    "        self.text_chunks = []\n",
    "        self.metadatas = []\n",
    "        for document in documents:\n",
    "            source = list(document.keys())[0]\n",
    "            cleaned_chunks = self.chunk_document(list(document.values())[0])\n",
    "            #print(f\"answer from LLM: {chunks.text}\")\n",
    "            #print(f\"chunk list is {cleaned_chunks}\")\n",
    "            self.text_chunks = self.text_chunks.extend(cleaned_chunks)\n",
    "            for i in range(len(cleaned_chunks)):\n",
    "                self.metadatas.append({\"source\": source})\n",
    "        print(f\"metadatas: {self.metadatas}\")\n",
    "        return [self.text_chunks, self.metadatas]\n",
    "\n",
    "    def chunk_document(self, document):\n",
    "        cleaned_chunks = []\n",
    "        max_length = 25000\n",
    "        for i in range(0, len(document), max_length):\n",
    "            text_chunk = document[i : i + max_length]\n",
    "            prompt = self.get_prompt(text_chunk)\n",
    "            chunks = self.model.generate_content(prompt)\n",
    "            cleaned_part = clean_response(chunks)[\"chunks\"]\n",
    "            cleaned_chunks.extend(cleaned_part)\n",
    "        return cleaned_chunks\n",
    "        \n",
    "    def chunk_indexes_documents(self, documents, text_chunk_indexes):\n",
    "        text_chunks = []\n",
    "        for i, document in enumerate(documents):\n",
    "            start = 0\n",
    "            end = 0\n",
    "            for index in text_chunk_indexes[i]:\n",
    "                end = index\n",
    "                text_chunks.append(list(document.values())[0][start:end])\n",
    "                start = end\n",
    "        print(text_chunks[0], text_chunks[5], text_chunks[20])\n",
    "        return text_chunks\n",
    "        \n",
    "    def get_prompt(self, document):\n",
    "        response_format = {\"chunks\": \"\"}\n",
    "        prompt = f\"\"\"\n",
    "        Act as an expert in MedTech regulations. You receive a document about medical device regulations and are expected to divide it into chunks.\n",
    "        Straightforward techniques involve separating paragraph, accounting for end of sentences indicators like '.', '!', '?' and so on.\n",
    "        Make your own techniques using multi-step reasoning (ri-validate your chunks if necessary). Avoid splitting sentences or ideas across different chunks.\n",
    "        Chunks need to be semantically coherent. Each chunk should represent a complete thought, topic, or regulatory requirement.\n",
    "        You MUST return a valid JSON in the form of {response_format}, where in \"chunks\" is a list where each item is a single, coherent, chunk of text from the document. \n",
    "        Make sure to open and close the brackets for the JSON and the list correctly. Make sure to escape possible double quotes in the text.\n",
    "        Document to chunk:\n",
    "        {document}\n",
    "        \"\"\"\n",
    "        return prompt"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "id": "e34d4077-9071-4fb7-b4c6-2d7c39f0bc82",
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Hi! I am your MedTech regulatory companion. How can I help you?\n"
     ]
    },
    {
     "name": "stdin",
     "output_type": "stream",
     "text": [
      "You:  Is our AI-powered MRI analysis tool considered a medical device software?\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Cleaning response ```json\n",
      "{\n",
      "  \"agent_to_call\": \"chunking_agent\",\n",
      "  \"output\": \"Please chunk the following documents into semantically coherent chunks: [List of relevant PDF documents related to the AI-powered MRI analysis tool, its regulatory classification, and relevant MedTech regulations].  Prioritize chunks related to software classification and medical device regulations.\",\n",
      "  \"relevant_info\": \"\"\n",
      "}\n",
      "```\n",
      "\n",
      "rovas\n",
      "Response cleaned is {'agent_to_call': 'chunking_agent', 'output': 'Please chunk the following documents into semantically coherent chunks: [List of relevant PDF documents related to the AI-powered MRI analysis tool, its regulatory classification, and relevant MedTech regulations].  Prioritize chunks related to software classification and medical device regulations.', 'relevant_info': ''}\n",
      "Orch response is {'agent_to_call': 'chunking_agent', 'output': 'Please chunk the following documents into semantically coherent chunks: [List of relevant PDF documents related to the AI-powered MRI analysis tool, its regulatory classification, and relevant MedTech regulations].  Prioritize chunks related to software classification and medical device regulations.', 'relevant_info': ''}\n",
      "Found agent I was looking for: chunking_agent\n",
      "\n",
      "Cleaning response ```json\n",
      "{\n",
      "  \"chunks\": [\n",
      "    \"Center for Devices and Radiological Health\\n\\n## **DESIGN CONTROL GUIDANCE** **FOR** **MEDICAL DEVICE MANUFACTURERS**\\n\\n#### **This Guidance relates to** **FDA 21 CFR 820.30 and Sub-clause 4.4 of ISO 9001** **March 11, 1997**\",\n",
      "    \"#### **FOREWORD**\\n\\nTo ensure that good quality assurance practices are used for the design of medical devices and that they are consistent with quality system requirements worldwide, the Food and Drug Administration revised the Current Good Manufacturing Practice (CGMP) requirements by incorporating them into the Quality System Regulation, 21 CFR Part 820. An important component of the revision is the addition of design controls.\",\n",
      "    \"Because design controls must apply to a wide variety of devices, the regulation does not prescribe the practices that must be used. Instead, it establishes a framework that manufacturers must use when developing and implementing design controls. The framework provides manufacturers with the flexibility needed to develop design controls that both comply with the regulation and are most appropriate for their own design and development processes.\",\n",
      "    \"This guidance is intended to assist manufacturers in understanding the intent of the regulation. Design controls are based upon quality assurance and engineering principles. This guidance complements the regulation by describing its intent from a technical perspective using practical terms and examples.\",\n",
      "    \"Draft guidance was made publicly available in March, 1996. We appreciate the many comments, suggestions for improvement, and encouragement we received from industry, interested parties, and the Global Harmonization Task Force (GHTF) Study Group 3. The comments were systematically reviewed, and revisions made in response to those comments and suggestions are incorporated in this version. As experience is gained with the guidance, FDA will consider the need for additional revisions within the next six to eighteen months.\",\n",
      "    \"The Center publishes the results of its work in scientific journals and in its own technical reports. Through these reports, CDRH also provides assistance to industry and to the medical and healthcare professional communities in complying with the laws and regulations mandated by Congress. These reports are sold by the Government Printing Office (GPO) and by the National Technical Information Service (NTIS). Many reports, including this guidance document, are also available via Internet on the World Wide Web at www.fda.gov.\",\n",
      "    \"We welcome your comments and suggestions for future revisions.\\n\\nD. Bruce Burlington, M.D.\\nDirector\\n\\nCenter for Devices and Radiological Health\",\n",
      "    \"#### **PREFACE**\\n\\nEffective implementation of design controls requires that the regulation and its intent be well understood. The Office of Compliance within CDRH is using several methods to assist manufacturers in developing this understanding. Methods include the use of presentations, teleconferences, practice audits, and written guidance.\",\n",
      "    \"Those persons in medical device companies charged with responsibility for developing, implementing, or applying design controls come from a wide variety of technical and non-technical backgroundsengineering, business administration, life sciences, computer science, and the arts. Therefore, it is important that a tool be provided that conveys the intent of the regulation using practical terminology and examples. That is the purpose of his guidance.\",\n",
      "    \"The response of medical device manufacturers and other interested parties to the March, 1996 draft version of this guidance has significantly influenced this latest version. Most comments centered on the complaint that the guidance was too prescriptive. Therefore, it has been rewritten to be more pragmatic, focusing on principles rather than specific practices.\",\n",
      "    \"It is noteworthy that many comments offered suggestions for improving the guidance, and that the authors of the comments often acknowledged the value of design controls and the potential benefit of good guidance to the medical device industry, the public, and the FDA. Some comments even included examples of past experiences with the implementation of controls.\",\n",
      "    \"Finally, there are several people within CDRH that deserve recognition for their contributions to the development of this guidance. Al Taylor and Bill Midgette of the Office of Science and Technology led the development effort and served as co-chairs of the CDRH Design Control Guidance Team that reviewed the comments received last spring. Team members included Ashley Boulware, Bob Cangelosi, Andrew Lowrey, Deborah Lumbardo, Jack McCracken, Greg O'Connell, and Walter Scott. As the lead person within CDRH with responsibility for implementing the Quality System Regulation, Kim Trautman reviewed the guidance and coordinated its development with the many other concurrent and related activities. Their contributions are gratefully acknowledged.\",\n",
      "    \"FDA would also like to acknowledge the significant contributions made by the Global Harmonization Task Force (GHTF) Study Group 3. The Study Group reviewed and revised this guidance at multiple stages during its development. It is hoped that this cooperative effort will lead to this guidance being accepted as an internationally recognized guidance document through the GHTF later this year.\\n\\nLillian J. Gill\\nDirector\\n\\nOffice of Compliance\",\n",
      "    \"#### **ACKNOWLEDGEMENT**\\n\\nFDA wishes to acknowledge the contributions of the Global Harmonization Task Force (GHTF) Study Group 3 to the development of this guidance. As has been stated in the past, FDA is firmly committed to the international harmonization of standards and regulations governing medical devices. The GHTF was formed in 1992 to further this effort. The GHTF includes representatives of the Canadian Ministry of Health and Welfare; the Japanese Ministry of Health and Welfare; FDA; industry members from the European Union, Australia, Canada, Japan, and the United States; and a few delegates from observing countries.\",\n",
      "    \"Among other efforts, the GHTF Study Group 3 started developing guidance on the application of design controls to medical devices in the spring of 1995. Study Group 3 has recognized FDAs need to publish timely guidance on this topic in conjunction with promulgation of its new Quality System Regulation. The Study Group has therefore devoted considerable time and effort to combine its draft document with the FDA's efforts as well as to review and comment on FDA's subsequent revisions. FDA, for its part, delayed final release of its guidance pending final review by the Study Group. As a result, it is hoped that this document, with some minor editorial revisions to make the guidance global to several regulatory schemes, will be recognized through the GHTF as an international guidance document.\",\n",
      "    \"#### **TABLE OF CONTENTS**\\n\\nFFOREWORD................................................................................................................... i\\n\\nPREFACE...................................................................................................................... iii\\n\\nACKNOWLEDGEMENT.............................................................................................. iv\\n\\nTABLE OF CONTENTS ................................................................................................ v\\n\\nINTRODUCTION .......................................................................................................... 1\\n\\nSECTION A. GENERAL............................................................................................... 7\\n\\nSECTION B. DESIGN AND DEVELOPMENT PLANNING ........................................ 9\\n\\nSECTION C. DESIGN INPUT.................................................................................... 13\\n\\nSECTION D. DESIGN OUTPUT................................................................................ 19\\n\\nSECTION E. DESIGN REVIEW................................................................................. 23\\n\\nSECTION F. DESIGN VERIFICATION..................................................................... 29\\n\\nSECTION G. DESIGN VALIDATION ....................................................................... 33\\n\\nSECTION H. DESIGN TRANSFER............................................................................ 37\\n\\nSECTION I. DESIGN CHANGES............................................................................... 39\\n\\nSECTION J. DESIGN HISTORY FILE (DHF)............................................................ 43\",\n",
      "    \"#### **INTRODUCTION**\\n\\n_I. PURPOSE_\\n\\nThis guidance is intended to assist manufacturers in understanding quality system requirements concerning design controls. Assistance is provided by interpreting the language of the quality systems requirements and explaining the underlying concepts in practical terms.\",\n",
      "    \"Design controls are an interrelated set of practices and procedures that are incorporated into the design and development process, i.e., a system of checks and balances. Design controls make systematic assessment of the design an integral part of development. As a result, deficiencies in design input requirements, and discrepancies between the proposed designs and requirements, are made evident and corrected earlier in the development process. Design controls increase the likelihood that the design transferred to production will translate into a device that is appropriate for its intended use.\",\n",
      "    \"In practice, design controls provide managers and designers with improved visibility of the design process. With improved visibility, managers are empowered to more effectively direct the design processthat is, to recognize problems earlier, make corrections, and adjust resource allocations. Designers benefit both by enhanced understanding of the degree of conformance of a design to user and patient needs, and by improved communications and coordination among all participants in the process.\",\n",
      "    \"The medical device industry encompasses a wide range of technologies and applications, ranging from simple hand tools to complex computer-controlled surgical machines, from implantable screws to artificial organs, from blood-glucose test strips to diagnostic imaging systems and laboratory test equipment. These devices are manufactured by companies varying in size and structure, methods of design and development, and methods of management. These factors significantly influence how design controls are actually applied. Given this diversity, this guidance does not suggest particular methods of implementation, and therefore, must not be used to assess compliance with the quality system requirements. Rather, the intent is to expand upon the distilled language of the quality system requirements with practical explanations and examples of design control principles. Armed with this basic knowledge, manufacturers can and should seek out technology-specific guidance on applying design controls to their particular situation.\",\n",
      "    \"When using this guidance, there could be a tendency to focus only on the time and effort required in developing and incorporating the controls into the design process. However, readers should keep in mind the intrinsic value of design controls as well. It is a well-established fact that the cost to correct design errors is lower when errors are detected early in the design and development process. Large and small companies that have achieved quality systems certification under ISO 9001 cite improvements in productivity, product quality, customer satisfaction, and company competitiveness. Additional benefits are described in comments received from a quality assurance manager of a medical device firm regarding the value of a properly documented design control system:\\n\\n\\\"...there are benefits to an organization and the quality improvement of an organization by having a written design control system. By defining this system on paper, a corporation allows all its employees to understand the requirements, the process, and expectations of design and how the quality of design is assured and perceived by the system. It also provides a baseline to review the system periodically for further improvements based on history, problems, and failures of the system (not the product).\\\"\",\n",
      "    \"_II. SCOPE_\\n\\nThe guidance applies to the design of medical devices as well as the design of the associated manufacturing processes. The guidance is applicable to new designs as well as modifications or improvements to existing device designs. The guidance discusses subjects in the order in which they appear in FDA's Quality System regulation and is cross-referenced to International Organization for Standards (ISO) 9001:1994, _Quality Systems Model for Quality Assurance in Design, Development, Production, Installation, and Servicing_, and the ISO draft international standard ISO/DIS 13485, _Quality Systems  Medical Devices  Particular Requirements for the Application of ISO 9001_, dated April 1996.\",\n",
      "    \"Design controls are a component of a comprehensive quality system that covers the life of a device. The assurance process is a total systems approach that extends from the development of device requirements through design, production, distribution, use, maintenance, and eventually, obsolescence. Design control begins with development and approval of design inputs, and includes the design of a device and the associated manufacturing processes.\",\n",
      "    \"Design control does not end with the transfer of a design to production. Design control applies to all changes to the device or manufacturing process design, including those occurring long after a device has been introduced to the market. This includes evolutionary changes such as performance enhancements as well as revolutionary changes such as corrective actions resulting from the analysis of failed product. The changes are part of a continuous, ongoing effort to design and develop a device that meets the needs of the user and/or patient. Thus, the design control process is revisited many times during the life of a product.\",\n",
      "    \"Some tools and techniques are described in the guidance. Although aspects of their utility are sometimes described, they are included in the guidance for illustrative purposes only. Including them does not mean that they are preferred. There may be alternative ways that are better suited to a particular manufacturer and design activity. The literature contains an abundance of information on tools and techniques. Such topics as project management, design review, process capability, and many others referred to in this guidance are available in textbooks, periodicals, and journals. As a manufacturer applies design controls to a particular task, the appropriate tools and techniques used by competent personnel should be applied to meet the needs of the unique product or process for that manufacturer.\",\n",
      "    \"_III. APPLICATION OF DESIGN CONTROLS_\\n\\nDesign controls may be applied to any product development process. The simple example shown in Figure 1 illustrates the influence of design controls on a design process.\",\n",
      "    \"The development process depicted in the example is a traditional waterfall model. The design proceeds in a logical sequence of phases or stages. Basically, requirements are developed, and a device is designed to meet those requirements. The design is then evaluated, transferred to production, and the device is manufactured. In practice, feedback paths would be required between each phase of the process and previous phases, representing the iterative nature of product development. However, this detail has been omitted from the figure to make the influence of the design controls on the design process more distinct.\",\n",
      "    \"The importance of the design input and verification of design outputs is illustrated by this example. When the design input has been reviewed and the design input requirements are determined to be acceptable, an iterative process of translating those requirements into a device design begins. The first step is conversion of the requirements into system or high-level specifications. Thus, these specifications are a design output. Upon verification that the high-level specifications conform to the design input requirements, they become the design input for the next step in the design process, and so on.\",\n",
      "    \"This basic technique is used repeatedly throughout the design process. Each design input is converted into a new design output; each output is verified as conforming to its input; and it then becomes the design input for another step in the design process. In this manner, the design input requirements are translated into a device design conforming to those requirements.\",\n",
      "    \"The importance of design reviews is also illustrated by the example. The design reviews are conducted at strategic points in the design process. For example, a review is conducted to assure that the design input requirements are adequate before they are converted into the design specifications. Another is used to assure that the device design is adequate before prototypes are produced for simulated use testing and clinical evaluation. Another, a validation review, is conducted prior to transfer of the design to production. Generally, they are used to provide assurance that an activity or phase has been completed in an acceptable manner, and that the next activity or phase can begin.\",\n",
      "    \"As the figure illustrates, design validation encompasses verification and extends the assessment to address whether devices produced in accordance with the design actually satisfy user needs and intended uses.\",\n",
      "    \"An analogy to automobile design and development may help to clarify these concepts. Fuel efficiency is a common design requirement. This requirement might be expressed as the number of miles-per-gallon of a particular grade of gasoline for a specified set of driving conditions. As the design of the car proceeds, the requirements, including the one for fuel efficiency, are converted into the many layers of system and subsystem specifications needed for design. As these various systems and subsystems are designed, design verification methods are used to establish conformance of each design to its own specifications. Because several specifications directly affect fuel efficiency, many of the verification activities help to provide confirmation that the overall design will meet the fuel efficiency requirement. This might include simulated road testing of prototypes or actual road testing. This is establishing by objective evidence that the design output conforms to the fuel efficiency requirement. However, these verification activities alone are not sufficient to validate the design. The design may be validated when a representative sample of users have driven production vehicles under a specified range of driving conditions and judged the fuel efficiency to be adequate. This is providing objective evidence that the particular requirement for a specific intended use can be consistently fulfilled.\",\n",
      "    \"**CONCURRENT ENGINEERING** . Although the waterfall model is a useful tool for introducing design controls, its usefulness in practice is limited. The model does apply to the development of some simpler devices. However, for more complex devices, a concurrent engineering model is more representative of the design processes in use in the industry.\",\n",
      "    \"In a traditional waterfall development scenario, the engineering department completes the product design and formally transfers the design to production. Subsequently, other departments or organizations develop processes to manufacture and service the product. Historically, there has frequently been a divergence between the intent of the designer and the reality of the factory floor, resulting in such undesirable outcomes as low manufacturing yields, rework or redesign of the product, or unexpectedly high cost to service the product.\",\n",
      "    \"One benefit of concurrent engineering is the involvement of production and service personnel throughout the design process, assuring the mutual optimization of the characteristics of a device and its related processes. While the primary motivations of concurrent engineering are shorter development time and reduced production cost, the practical result is often improved product quality.\",\n",
      "    \"Concurrent engineering encompasses a range of practices and techniques. From a design control standpoint, it is sufficient to note that concurrent engineering may blur the line between development and production. On the one hand, the concurrent engineering model properly emphasizes that the development of production processes is a design rather than a manufacturing activity. On the other hand, various components of a design may enter production before the design as a whole has been approved. Thus, concurrent engineering and other more complex models of development usually require a comprehensive matrix of reviews and approvals to ensure that each component and process design is validated prior to entering production, and the product as a whole is validated prior to design release.\",\n",
      "    \"**RISK MANAGEMENT AND DESIGN CONTROLS** . Risk management is the systematic application of management policies, procedures, and practices to the tasks of identifying, analyzing, controlling, and monitoring risk. It is intended to be a framework within which experience, insight, and judgment are applied to successfully manage risk. It is included in this guidance because of its effect on the design process.\",\n",
      "    \"Risk management begins with the development of the design input requirements. As the design evolves, new risks may become evident. To systematically identify and, when necessary, reduce these risks, the risk management process is integrated into the design process. In this way, unacceptable risks can be identified and managed earlier in the design process when changes are easier to make and less costly.\",\n",
      "    \"An example of this is an exposure control system for a general purpose x-ray system. The control function was allocated to software. Late in the development process, risk analysis of the system uncovered several failure modes that could result in overexposure to the patient. Because the problem was not identified until the design was near completion, an expensive, independent, back-up timer had to be added to monitor exposure times.\",\n",
      "    \"**THE QUALITY SYSTEM AND DESIGN CONTROLS** . In addition to procedures and work instructions necessary for the implementation of design controls, policies and procedures may also be needed for other determinants of device quality that should be considered during the design process. The need for policies and procedures for these factors is dependent upon the types of devices manufactured by a company and the risks associated with their use. Management with executive responsibility has the responsibility for determining what is needed.\",\n",
      "    \"Example of topics for which policies and procedures may be appropriate are:\\n\\n  - risk management\\n\\n  - device reliability\\n\\n  - device durability\\n\\n  - device maintainability\\n\\n  - device serviceability\\n\\n  - human factors engineering\\n\\n  - software engineering\\n\\n  - use of standards\\n\\n  - configuration management\\n\\n  - compliance with regulatory requirements\\n\\n  - device evaluation (which may include third party product certification or approval)\\n\\n  - clinical evaluations\\n\\n  - document controls\\n\\n  - use of consultants\\n\\n  - use of subcontractors\\n\\n  - use of company historical data\",\n",
      "    \"#### **SECTION A. GENERAL**\\n\\n_I. REQUIREMENTS_\\n\\n** 820.30(a) General** .\\n\\n(1) Each manufacturer of any class III or class II device, and the class I devices listed in paragraph (a) (2) of this section, shall establish and maintain procedures to control the design of the device in order to ensure that specified design requirements are met.\",\n",
      "    \"(2) The following class I devices are subject to design controls:\\n\\n(i) Devices automated with computer software; and\\n\\n(ii) The devices listed in the chart below.\",\n",
      "    \"|Section|Device|\\n|---|---| \\n|~~868.6810~~<br>878.4460<br>880.6760<br>892.5650<br>892.5740|~~Catheter, Tracheobronchial Suction~~<br>Glove, Surgeons<br>Restraint, Protective<br>System, Applicator, Radionuclide,<br>Manual<br>Source, Radionuclide Teletherapy|\",\n",
      "    \"_II. DEFINITIONS_\\n\\n** 820.3 (n)** _Management with executive responsibility_ means those senior employees of a manufacturer who have the authority to establish or make changes to the manufacturers quality policy and quality system.\",\n",
      "    \"** 820.3 (s)** _Quality_ means the totality of features and characteristics that bear on the ability of a device to sa\"\n",
      "  ]\n",
      "}\n",
      "```\n",
      "\n",
      "rovas\n",
      "Response cleaned is {'chunks': ['Center for Devices and Radiological Health\\n\\n## **DESIGN CONTROL GUIDANCE** **FOR** **MEDICAL DEVICE MANUFACTURERS**\\n\\n#### **This Guidance relates to** **FDA 21 CFR 820.30 and Sub-clause 4.4 of ISO 9001** **March 11, 1997**', '#### **FOREWORD**\\n\\nTo ensure that good quality assurance practices are used for the design of medical devices and that they are consistent with quality system requirements worldwide, the Food and Drug Administration revised the Current Good Manufacturing Practice (CGMP) requirements by incorporating them into the Quality System Regulation, 21 CFR Part 820. An important component of the revision is the addition of design controls.', 'Because design controls must apply to a wide variety of devices, the regulation does not prescribe the practices that must be used. Instead, it establishes a framework that manufacturers must use when developing and implementing design controls. The framework provides manufacturers with the flexibility needed to develop design controls that both comply with the regulation and are most appropriate for their own design and development processes.', 'This guidance is intended to assist manufacturers in understanding the intent of the regulation. Design controls are based upon quality assurance and engineering principles. This guidance complements the regulation by describing its intent from a technical perspective using practical terms and examples.', 'Draft guidance was made publicly available in March, 1996. We appreciate the many comments, suggestions for improvement, and encouragement we received from industry, interested parties, and the Global Harmonization Task Force (GHTF) Study Group 3. The comments were systematically reviewed, and revisions made in response to those comments and suggestions are incorporated in this version. As experience is gained with the guidance, FDA will consider the need for additional revisions within the next six to eighteen months.', 'The Center publishes the results of its work in scientific journals and in its own technical reports. Through these reports, CDRH also provides assistance to industry and to the medical and healthcare professional communities in complying with the laws and regulations mandated by Congress. These reports are sold by the Government Printing Office (GPO) and by the National Technical Information Service (NTIS). Many reports, including this guidance document, are also available via Internet on the World Wide Web at www.fda.gov.', 'We welcome your comments and suggestions for future revisions.\\n\\nD. Bruce Burlington, M.D.\\nDirector\\n\\nCenter for Devices and Radiological Health', '#### **PREFACE**\\n\\nEffective implementation of design controls requires that the regulation and its intent be well understood. The Office of Compliance within CDRH is using several methods to assist manufacturers in developing this understanding. Methods include the use of presentations, teleconferences, practice audits, and written guidance.', 'Those persons in medical device companies charged with responsibility for developing, implementing, or applying design controls come from a wide variety of technical and non-technical backgroundsengineering, business administration, life sciences, computer science, and the arts. Therefore, it is important that a tool be provided that conveys the intent of the regulation using practical terminology and examples. That is the purpose of his guidance.', 'The response of medical device manufacturers and other interested parties to the March, 1996 draft version of this guidance has significantly influenced this latest version. Most comments centered on the complaint that the guidance was too prescriptive. Therefore, it has been rewritten to be more pragmatic, focusing on principles rather than specific practices.', 'It is noteworthy that many comments offered suggestions for improving the guidance, and that the authors of the comments often acknowledged the value of design controls and the potential benefit of good guidance to the medical device industry, the public, and the FDA. Some comments even included examples of past experiences with the implementation of controls.', \"Finally, there are several people within CDRH that deserve recognition for their contributions to the development of this guidance. Al Taylor and Bill Midgette of the Office of Science and Technology led the development effort and served as co-chairs of the CDRH Design Control Guidance Team that reviewed the comments received last spring. Team members included Ashley Boulware, Bob Cangelosi, Andrew Lowrey, Deborah Lumbardo, Jack McCracken, Greg O'Connell, and Walter Scott. As the lead person within CDRH with responsibility for implementing the Quality System Regulation, Kim Trautman reviewed the guidance and coordinated its development with the many other concurrent and related activities. Their contributions are gratefully acknowledged.\", 'FDA would also like to acknowledge the significant contributions made by the Global Harmonization Task Force (GHTF) Study Group 3. The Study Group reviewed and revised this guidance at multiple stages during its development. It is hoped that this cooperative effort will lead to this guidance being accepted as an internationally recognized guidance document through the GHTF later this year.\\n\\nLillian J. Gill\\nDirector\\n\\nOffice of Compliance', '#### **ACKNOWLEDGEMENT**\\n\\nFDA wishes to acknowledge the contributions of the Global Harmonization Task Force (GHTF) Study Group 3 to the development of this guidance. As has been stated in the past, FDA is firmly committed to the international harmonization of standards and regulations governing medical devices. The GHTF was formed in 1992 to further this effort. The GHTF includes representatives of the Canadian Ministry of Health and Welfare; the Japanese Ministry of Health and Welfare; FDA; industry members from the European Union, Australia, Canada, Japan, and the United States; and a few delegates from observing countries.', \"Among other efforts, the GHTF Study Group 3 started developing guidance on the application of design controls to medical devices in the spring of 1995. Study Group 3 has recognized FDAs need to publish timely guidance on this topic in conjunction with promulgation of its new Quality System Regulation. The Study Group has therefore devoted considerable time and effort to combine its draft document with the FDA's efforts as well as to review and comment on FDA's subsequent revisions. FDA, for its part, delayed final release of its guidance pending final review by the Study Group. As a result, it is hoped that this document, with some minor editorial revisions to make the guidance global to several regulatory schemes, will be recognized through the GHTF as an international guidance document.\", '#### **TABLE OF CONTENTS**\\n\\nFFOREWORD................................................................................................................... i\\n\\nPREFACE...................................................................................................................... iii\\n\\nACKNOWLEDGEMENT.............................................................................................. iv\\n\\nTABLE OF CONTENTS ................................................................................................ v\\n\\nINTRODUCTION .......................................................................................................... 1\\n\\nSECTION A. GENERAL............................................................................................... 7\\n\\nSECTION B. DESIGN AND DEVELOPMENT PLANNING ........................................ 9\\n\\nSECTION C. DESIGN INPUT.................................................................................... 13\\n\\nSECTION D. DESIGN OUTPUT................................................................................ 19\\n\\nSECTION E. DESIGN REVIEW................................................................................. 23\\n\\nSECTION F. DESIGN VERIFICATION..................................................................... 29\\n\\nSECTION G. DESIGN VALIDATION ....................................................................... 33\\n\\nSECTION H. DESIGN TRANSFER............................................................................ 37\\n\\nSECTION I. DESIGN CHANGES............................................................................... 39\\n\\nSECTION J. DESIGN HISTORY FILE (DHF)............................................................ 43', '#### **INTRODUCTION**\\n\\n_I. PURPOSE_\\n\\nThis guidance is intended to assist manufacturers in understanding quality system requirements concerning design controls. Assistance is provided by interpreting the language of the quality systems requirements and explaining the underlying concepts in practical terms.', 'Design controls are an interrelated set of practices and procedures that are incorporated into the design and development process, i.e., a system of checks and balances. Design controls make systematic assessment of the design an integral part of development. As a result, deficiencies in design input requirements, and discrepancies between the proposed designs and requirements, are made evident and corrected earlier in the development process. Design controls increase the likelihood that the design transferred to production will translate into a device that is appropriate for its intended use.', 'In practice, design controls provide managers and designers with improved visibility of the design process. With improved visibility, managers are empowered to more effectively direct the design processthat is, to recognize problems earlier, make corrections, and adjust resource allocations. Designers benefit both by enhanced understanding of the degree of conformance of a design to user and patient needs, and by improved communications and coordination among all participants in the process.', 'The medical device industry encompasses a wide range of technologies and applications, ranging from simple hand tools to complex computer-controlled surgical machines, from implantable screws to artificial organs, from blood-glucose test strips to diagnostic imaging systems and laboratory test equipment. These devices are manufactured by companies varying in size and structure, methods of design and development, and methods of management. These factors significantly influence how design controls are actually applied. Given this diversity, this guidance does not suggest particular methods of implementation, and therefore, must not be used to assess compliance with the quality system requirements. Rather, the intent is to expand upon the distilled language of the quality system requirements with practical explanations and examples of design control principles. Armed with this basic knowledge, manufacturers can and should seek out technology-specific guidance on applying design controls to their particular situation.', 'When using this guidance, there could be a tendency to focus only on the time and effort required in developing and incorporating the controls into the design process. However, readers should keep in mind the intrinsic value of design controls as well. It is a well-established fact that the cost to correct design errors is lower when errors are detected early in the design and development process. Large and small companies that have achieved quality systems certification under ISO 9001 cite improvements in productivity, product quality, customer satisfaction, and company competitiveness. Additional benefits are described in comments received from a quality assurance manager of a medical device firm regarding the value of a properly documented design control system:\\n\\n\"...there are benefits to an organization and the quality improvement of an organization by having a written design control system. By defining this system on paper, a corporation allows all its employees to understand the requirements, the process, and expectations of design and how the quality of design is assured and perceived by the system. It also provides a baseline to review the system periodically for further improvements based on history, problems, and failures of the system (not the product).\"', \"_II. SCOPE_\\n\\nThe guidance applies to the design of medical devices as well as the design of the associated manufacturing processes. The guidance is applicable to new designs as well as modifications or improvements to existing device designs. The guidance discusses subjects in the order in which they appear in FDA's Quality System regulation and is cross-referenced to International Organization for Standards (ISO) 9001:1994, _Quality Systems Model for Quality Assurance in Design, Development, Production, Installation, and Servicing_, and the ISO draft international standard ISO/DIS 13485, _Quality Systems \\uf8e7 Medical Devices \\uf8e7 Particular Requirements for the Application of ISO 9001_, dated April 1996.\", 'Design controls are a component of a comprehensive quality system that covers the life of a device. The assurance process is a total systems approach that extends from the development of device requirements through design, production, distribution, use, maintenance, and eventually, obsolescence. Design control begins with development and approval of design inputs, and includes the design of a device and the associated manufacturing processes.', 'Design control does not end with the transfer of a design to production. Design control applies to all changes to the device or manufacturing process design, including those occurring long after a device has been introduced to the market. This includes evolutionary changes such as performance enhancements as well as revolutionary changes such as corrective actions resulting from the analysis of failed product. The changes are part of a continuous, ongoing effort to design and develop a device that meets the needs of the user and/or patient. Thus, the design control process is revisited many times during the life of a product.', 'Some tools and techniques are described in the guidance. Although aspects of their utility are sometimes described, they are included in the guidance for illustrative purposes only. Including them does not mean that they are preferred. There may be alternative ways that are better suited to a particular manufacturer and design activity. The literature contains an abundance of information on tools and techniques. Such topics as project management, design review, process capability, and many others referred to in this guidance are available in textbooks, periodicals, and journals. As a manufacturer applies design controls to a particular task, the appropriate tools and techniques used by competent personnel should be applied to meet the needs of the unique product or process for that manufacturer.', '_III. APPLICATION OF DESIGN CONTROLS_\\n\\nDesign controls may be applied to any product development process. The simple example shown in Figure 1 illustrates the influence of design controls on a design process.', 'The development process depicted in the example is a traditional waterfall model. The design proceeds in a logical sequence of phases or stages. Basically, requirements are developed, and a device is designed to meet those requirements. The design is then evaluated, transferred to production, and the device is manufactured. In practice, feedback paths would be required between each phase of the process and previous phases, representing the iterative nature of product development. However, this detail has been omitted from the figure to make the influence of the design controls on the design process more distinct.', 'The importance of the design input and verification of design outputs is illustrated by this example. When the design input has been reviewed and the design input requirements are determined to be acceptable, an iterative process of translating those requirements into a device design begins. The first step is conversion of the requirements into system or high-level specifications. Thus, these specifications are a design output. Upon verification that the high-level specifications conform to the design input requirements, they become the design input for the next step in the design process, and so on.', 'This basic technique is used repeatedly throughout the design process. Each design input is converted into a new design output; each output is verified as conforming to its input; and it then becomes the design input for another step in the design process. In this manner, the design input requirements are translated into a device design conforming to those requirements.', 'The importance of design reviews is also illustrated by the example. The design reviews are conducted at strategic points in the design process. For example, a review is conducted to assure that the design input requirements are adequate before they are converted into the design specifications. Another is used to assure that the device design is adequate before prototypes are produced for simulated use testing and clinical evaluation. Another, a validation review, is conducted prior to transfer of the design to production. Generally, they are used to provide assurance that an activity or phase has been completed in an acceptable manner, and that the next activity or phase can begin.', 'As the figure illustrates, design validation encompasses verification and extends the assessment to address whether devices produced in accordance with the design actually satisfy user needs and intended uses.', 'An analogy to automobile design and development may help to clarify these concepts. Fuel efficiency is a common design requirement. This requirement might be expressed as the number of miles-per-gallon of a particular grade of gasoline for a specified set of driving conditions. As the design of the car proceeds, the requirements, including the one for fuel efficiency, are converted into the many layers of system and subsystem specifications needed for design. As these various systems and subsystems are designed, design verification methods are used to establish conformance of each design to its own specifications. Because several specifications directly affect fuel efficiency, many of the verification activities help to provide confirmation that the overall design will meet the fuel efficiency requirement. This might include simulated road testing of prototypes or actual road testing. This is establishing by objective evidence that the design output conforms to the fuel efficiency requirement. However, these verification activities alone are not sufficient to validate the design. The design may be validated when a representative sample of users have driven production vehicles under a specified range of driving conditions and judged the fuel efficiency to be adequate. This is providing objective evidence that the particular requirement for a specific intended use can be consistently fulfilled.', '**CONCURRENT ENGINEERING** . Although the waterfall model is a useful tool for introducing design controls, its usefulness in practice is limited. The model does apply to the development of some simpler devices. However, for more complex devices, a concurrent engineering model is more representative of the design processes in use in the industry.', 'In a traditional waterfall development scenario, the engineering department completes the product design and formally transfers the design to production. Subsequently, other departments or organizations develop processes to manufacture and service the product. Historically, there has frequently been a divergence between the intent of the designer and the reality of the factory floor, resulting in such undesirable outcomes as low manufacturing yields, rework or redesign of the product, or unexpectedly high cost to service the product.', 'One benefit of concurrent engineering is the involvement of production and service personnel throughout the design process, assuring the mutual optimization of the characteristics of a device and its related processes. While the primary motivations of concurrent engineering are shorter development time and reduced production cost, the practical result is often improved product quality.', 'Concurrent engineering encompasses a range of practices and techniques. From a design control standpoint, it is sufficient to note that concurrent engineering may blur the line between development and production. On the one hand, the concurrent engineering model properly emphasizes that the development of production processes is a design rather than a manufacturing activity. On the other hand, various components of a design may enter production before the design as a whole has been approved. Thus, concurrent engineering and other more complex models of development usually require a comprehensive matrix of reviews and approvals to ensure that each component and process design is validated prior to entering production, and the product as a whole is validated prior to design release.', '**RISK MANAGEMENT AND DESIGN CONTROLS** . Risk management is the systematic application of management policies, procedures, and practices to the tasks of identifying, analyzing, controlling, and monitoring risk. It is intended to be a framework within which experience, insight, and judgment are applied to successfully manage risk. It is included in this guidance because of its effect on the design process.', 'Risk management begins with the development of the design input requirements. As the design evolves, new risks may become evident. To systematically identify and, when necessary, reduce these risks, the risk management process is integrated into the design process. In this way, unacceptable risks can be identified and managed earlier in the design process when changes are easier to make and less costly.', 'An example of this is an exposure control system for a general purpose x-ray system. The control function was allocated to software. Late in the development process, risk analysis of the system uncovered several failure modes that could result in overexposure to the patient. Because the problem was not identified until the design was near completion, an expensive, independent, back-up timer had to be added to monitor exposure times.', '**THE QUALITY SYSTEM AND DESIGN CONTROLS** . In addition to procedures and work instructions necessary for the implementation of design controls, policies and procedures may also be needed for other determinants of device quality that should be considered during the design process. The need for policies and procedures for these factors is dependent upon the types of devices manufactured by a company and the risks associated with their use. Management with executive responsibility has the responsibility for determining what is needed.', 'Example of topics for which policies and procedures may be appropriate are:\\n\\n  - risk management\\n\\n  - device reliability\\n\\n  - device durability\\n\\n  - device maintainability\\n\\n  - device serviceability\\n\\n  - human factors engineering\\n\\n  - software engineering\\n\\n  - use of standards\\n\\n  - configuration management\\n\\n  - compliance with regulatory requirements\\n\\n  - device evaluation (which may include third party product certification or approval)\\n\\n  - clinical evaluations\\n\\n  - document controls\\n\\n  - use of consultants\\n\\n  - use of subcontractors\\n\\n  - use of company historical data', '#### **SECTION A. GENERAL**\\n\\n_I. REQUIREMENTS_\\n\\n** 820.30(a) General** .\\n\\n(1) Each manufacturer of any class III or class II device, and the class I devices listed in paragraph (a) (2) of this section, shall establish and maintain procedures to control the design of the device in order to ensure that specified design requirements are met.', '(2) The following class I devices are subject to design controls:\\n\\n(i) Devices automated with computer software; and\\n\\n(ii) The devices listed in the chart below.', '|Section|Device|\\n|---|---| \\n|~~868.6810~~<br>878.4460<br>880.6760<br>892.5650<br>892.5740|~~Catheter, Tracheobronchial Suction~~<br>Glove, Surgeons<br>Restraint, Protective<br>System, Applicator, Radionuclide,<br>Manual<br>Source, Radionuclide Teletherapy|', '_II. DEFINITIONS_\\n\\n** 820.3 (n)** _Management with executive responsibility_ means those senior employees of a manufacturer who have the authority to establish or make changes to the manufacturers quality policy and quality system.', '** 820.3 (s)** _Quality_ means the totality of features and characteristics that bear on the ability of a device to sa']}\n",
      "Cleaning response ```json\n",
      "{\n",
      "  \"chunks\": [\n",
      "    \"tisfy fitness-for-use, including safety and performance.\",\n",
      "    \"** 820.3 (v)** _Quality system_ means the organizational structure, responsibilities,\\nprocedures, processes, and resources for implementing quality management.\",\n",
      "    \"**Cross reference to ISO 9001:1994 and ISO/DIS 13485 Section 4.4.1 General.**\",\n",
      "    \"Section A General 3/11/97 Page 7\",\n",
      "    \"_III. DISCUSSION AND POINTS TO CONSIDER_\",\n",
      "    \"The essential quality aspects and the regulatory requirements, such as safety, performance,\\nand dependability of a product (whether hardware, software, services, or processed\\nmaterials) are established during the design and development phase.\",\n",
      "    \"Deficient design can\\nbe a major cause of quality problems.\",\n",
      "    \"The context within which product design is to be carried out should be set by the\\nmanufacturers senior management.\",\n",
      "    \"It is their responsibility to establish a design and\\ndevelopment plan which sets the targets to be met.\",\n",
      "    \"This plan defines the constraints\\nwithin which the design is to be implemented.\",\n",
      "    \"The quality system requirements do not dictate the types of design process that a\\nmanufacturer must use.\",\n",
      "    \"Manufacturers should use processes best suited to their needs.\",\n",
      "    \"However, whatever the processes may be, it is important that the design controls are\\napplied in an appropriate manner.\",\n",
      "    \"This guidance document contains examples of how this might be achieved in a variety of situations.\",\n",
      "    \"It is important to note that the design function may apply to various facets of the operation\\nhaving differing styles and time scales.\",\n",
      "    \"Such facets are related to products, including\\nservices and software, as well as to their manufacturing processes.\",\n",
      "    \"Senior management needs to decide how the design function is to be managed and by\\nwhom.\",\n",
      "    \"Senior management should also ensure that internal policies are established for\\ndesign issues such as:\",\n",
      "    \"- assessing new product ideas\",\n",
      "    \"- training and retraining of design managers and design staff\",\n",
      "    \"- use of consultants\",\n",
      "    \"- evaluation of the design process\",\n",
      "    \"- product evaluation, including third party product certification and approvals\",\n",
      "    \"- patenting or other means of design protection\",\n",
      "    \"It is for senior management to ensure that adequate resources are available to carry out\\nthe design in the required time.\",\n",
      "    \"This may involve reinforcing the skills and equipment\\navailable internally and/or obtaining external resources.\",\n",
      "    \"Section A General 3/11/97 Page 8\",\n",
      "    \"#### **SECTION B. DESIGN AND DEVELOPMENT PLANNING**\",\n",
      "    \"_I. REQUIREMENTS_\",\n",
      "    \"** 820.30(b) Design and development planning.**\",\n",
      "    \"  - Each manufacturer shall establish and maintain plans that describe or reference the\\ndesign and development activities and define responsibility for implementation.\",\n",
      "    \"  - The plans shall identify and describe the interfaces with different groups or\\nactivities that provide, or result in, input to the design and development process.\",\n",
      "    \"  - The plans shall be reviewed, updated, and approved as design and development\\nevolves.\",\n",
      "    \"**Cross-reference to ISO 9001:1994 and ISO/DIS 13485 sections 4.4.2 Design and**\\n**development planning and 4.4.3 Organizational and technical interfaces.**\",\n",
      "    \"_II. DISCUSSION AND POINTS TO CONSIDER_\",\n",
      "    \"Design and development planning is needed to ensure that the design process is\\nappropriately controlled and that device quality objectives are met.\",\n",
      "    \"The plans must be\\nconsistent with the remainder of the design control requirements.\",\n",
      "    \"The following elements\\nwould typically be addressed in the design and development plan or plans:\",\n",
      "    \"  - Description of the goals and objectives of the design and development program; i.e., what is to be developed;\",\n",
      "    \"  - Delineation of organizational responsibilities with respect to assuring quality\\nduring the design and development phase, to include interface with any contractors;\",\n",
      "    \"  - Identification of the major tasks to be undertaken, deliverables for each task, and\\nindividual or organizational responsibilities (staff and resources) for completing\\neach task;\",\n",
      "    \"  - Scheduling of major tasks to meet overall program time constraints;\",\n",
      "    \"  - Identification of major reviews and decision points;\",\n",
      "    \"  - Selection of reviewers, the composition of review teams, and procedures to be\\nfollowed by reviewers;\",\n",
      "    \"  - Controls for design documentation;\",\n",
      "    \"  - Notification activities.\",\n",
      "    \"Planning enables management to exercise greater control over the design and development\\nprocess by clearly communicating policies, procedures, and goals to members of the\",\n",
      "    \"Section B Design and Development Planning               3/11/97 Page 9\",\n",
      "    \"design and development team, and providing a basis for measuring conformance to quality\\nsystem objectives.\",\n",
      "    \"Design activities should be specified at the level of detail necessary for carrying out the\\ndesign process.\",\n",
      "    \"The extent of design and development planning is dependent on the size\\nof the developing organization and the size and complexity of the product to be\\ndeveloped.\",\n",
      "    \"Some manufacturers may have documented policies and procedures which\\napply to all design and development activities.\",\n",
      "    \"For each specific development program, such manufacturers may also prepare a plan which spells out the project-dependent\\nelements in detail, and incorporates the general policies and procedures by reference.\",\n",
      "    \"Other manufacturers may develop a comprehensive design and development plan which is\\nspecifically tailored to each individual project.\",\n",
      "    \"In summary, the form and organization of the planning documents are less important than\\ntheir content.\",\n",
      "    \"The following paragraphs discuss the key elements of design and\\ndevelopment planning.\",\n",
      "    \"**ORGANIZATIONAL RESPONSIBILITIES** . The management responsibility section of\\nthe quality system requirements [1] requires management to establish a quality policy and\\nimplement an organizational structure to ensure quality.\",\n",
      "    \"These are typically documented in\\na quality manual or similarly named document.\",\n",
      "    \"In some cases, however, the design and\\ndevelopment plan, rather than the quality manual, is the best vehicle for describing\\norganizational responsibilities relative to design and development activities.\",\n",
      "    \"The\\nimportance of defining responsibilities with clarity and without ambiguity should be\\nrecognized.\",\n",
      "    \"When input to the design is from a variety of sources, their interrelationships\\nand interfaces (as well as the pertinent responsibilities and authorities) should be defined,\\ndocumented, coordinated, and controlled.\",\n",
      "    \"This might be the case, for example, if a\\nmultidisciplinary product development team is assembled for a specific project, or if the\\nteam includes suppliers, contract manufacturers, users, outside consultants, or independent\\nauditors.\",\n",
      "    \"**TASK BREAKDOWN** . The plan establishes, to the extent possible:\",\n",
      "    \"  - The major tasks required to develop the product\",\n",
      "    \"  - The time involved for each major task\",\n",
      "    \"  - The resources and personnel required\",\n",
      "    \"  - The allocation of responsibilities for completing each major task\",\n",
      "    \"  - The prerequisite information necessary to start each major task and the\\ninterrelationship between tasks\",\n",
      "    \"  - The form of each task output or deliverable\",\n",
      "    \"  - Constraints, such as applicable codes, standards, and regulations\",\n",
      "    \"1  820.20 of the FDA Quality System Regulation; section 4.1 of ISO 9001 and ISO/DIS 13485.\",\n",
      "    \"Section B Design and Development Planning               3/11/97 Page 10\",\n",
      "    \"Tasks for all significant design activities, including verification and validation tasks, should\\nbe included in the design and development plan.\",\n",
      "    \"For example, if clinical trials are\\nanticipated, there may be tasks associated with appropriate regulatory requirements.\",\n",
      "    \"For complex projects, rough estimates may be provided initially, with the details left for\\nthe responsible organizations to develop.\",\n",
      "    \"As development proceeds, the plan should\\nevolve to incorporate more and better information.\",\n",
      "    \"The relationships between tasks should be presented in such a way that they are easily\\nunderstood.\",\n",
      "    \"It should be clear which tasks depend on others, and which tasks need to be\\nperformed concurrently.\",\n",
      "    \"Planning should reflect the degree of perceived development risk; for example, tasks involving new technology or processes should be spelled out in greater\\ndetail, and perhaps be subjected to more reviews and checks, than tasks which are\\nperceived as routine or straightforward.\",\n",
      "    \"The design and development plan may include a schedule showing starting and completion\\ndates for each major task, project milestone, or key decision points.\",\n",
      "    \"The method chosen\\nand the detail will vary depending on the complexity of the project and the level of risk\\nassociated with the device.\",\n",
      "    \"For small projects, the plan may consist of only a simple flow\\ndiagram or computer spreadsheet.\",\n",
      "    \"For larger projects, there are a number of project\\nmanagement tools that are used to develop plans.\",\n",
      "    \"Three of the most commonly used are\\nthe Program Evaluation and Review Technique (PERT), the Critical Path Method (CPM),\\nand the Gantt chart.\",\n",
      "    \"Software is available in many forms for these methods.\",\n",
      "    \"When\\nselecting these tools, be careful to choose one that best fits the needs of the project.\",\n",
      "    \"Some\\nof the software programs are far more complex than may be necessary.\",\n",
      "    \"Unless a manufacturer has experience with the same type of device, the plan will initially\\nbe limited in scope and detail.\",\n",
      "    \"As work proceeds, the plan is refined.\",\n",
      "    \"Lack of experience in\\nplanning often leads to optimistic schedules, but slippage may also occur for reasons\\nbeyond the control of planners, for example, personnel turnover, materiel shortage, or\\nexpected problems with a design element or process.\",\n",
      "    \"Sometimes the schedule can be\\ncompressed by using additional resources, such as diverting staff or equipment from\\nanother project, hiring a contractor, or leasing equipment.\",\n",
      "    \"It is important that the schedule be updated to reflect current knowledge.\",\n",
      "    \"At all times, the\\nplan should be specified at a level of detail enabling management to make informed\\ndecisions, and provide confidence in meeting overall schedule and performance objectives.\",\n",
      "    \"This is important because scheduling pressures have historically been a contributing factor\\nin many design defects which caused injury.\",\n",
      "    \"To the extent that good planning can prevent\\nschedule pressures, the potential for design errors is reduced.\",\n",
      "    \"However, no amount of planning can eliminate all development risk.\",\n",
      "    \"There is inherent\\nconflict between the desire to maximize performance and the need to meet business\\nobjectives, including development deadlines.\",\n",
      "    \"In some corporate cultures, impending\\ndeadlines create enormous pressure to cut corners.\",\n",
      "    \"Planning helps to combat this dilemma by ensuring management awareness of pressure points.\",\n",
      "    \"With awareness, decisions are\",\n",
      "    \"Section B Design and Development Planning               3/11/97 Page 11\",\n",
      "    \"more likely to be made with appropriate oversight and consideration of all relevant factors.\",\n",
      "    \"Thus, when concessions to the clock must be made, they can be justified and supported.\",\n",
      "    \"Section B Design and Development Planning               3/11/97 Page 12\",\n",
      "    \"#### **SECTION C. DESIGN INPUT**\",\n",
      "    \"_I. REQUIREMENTS_\",\n",
      "    \"** 820.30(c) Design input.**\",\n",
      "    \"  - Each manufacturer shall establish and maintain procedures to ensure that the\\ndesign requirements relating to a device are appropriate and address the intended\\nuse of the device, including the needs of the user and patient.\",\n",
      "    \"  - The procedures shall include a mechanism for addressing incomplete, ambiguous,\\nor conflicting requirements.\",\n",
      "    \"  - The design input requirements shall be documented and shall be reviewed and\\napproved by designated individual(s).\",\n",
      "    \"  - The approval, including the date and signature of the individual(s) approving the\\nrequirements, shall be documented.\",\n",
      "    \"**Cross reference to ISO 9001:1994 and ISO/DIS 13485 section 4.4.4 Design input.**\",\n",
      "    \"_II. DEFINITIONS_\",\n",
      "    \"** 820.3(f)** _Design input_ means the physical and performance requirements of a device\\nthat are used as a basis for device design.\",\n",
      "    \"_III. DISCUSSION AND POINTS TO CONSIDER_\",\n",
      "    \"Design input is the starting point for product design.\",\n",
      "    \"The requirements which form the\\ndesign input establish a basis for performing subsequent design tasks and validating the\\ndesign.\",\n",
      "    \"Therefore, development of a solid foundation of requirements is the single most\\nimportant design control activity.\",\n",
      "    \"Many medical device manufacturers have experience with the adverse effects that\\nincomplete requirements can have on the design process.\",\n",
      "    \"A frequent complaint of\\ndevelopers is that theres never time to do it right, but theres always time to do it over.\",\n",
      "    \"If essential requirements are not identified until validation, expensive redesign and rework\\nmay be necessary before a design can be released to production.\",\n",
      "    \"By comparison, the experience of companies that have designed devices using clear-cut,\\ncomprehensive sets of requirements is that rework and redesign are significantly reduced\\nand product quality is improved.\",\n",
      "    \"They know that the development of requirements for a\\nmedical device of even moderate complexity is a formidable, time-consuming task.\",\n",
      "    \"They\\naccept the investment in time and resources required to develop the requirements because\\nthey know the advantages to be gained in the long run.\",\n",
      "    \"Section C. Design Input 3/11/97 Page 13\",\n",
      "    \"Unfortunately, there are a number of common misconceptions regarding the meaning and\\npractical application of the quality system requirements for design input.\",\n",
      "    \"Many seem to\\naris from interpreting the requirements as a literal prescription, rather than a set of\\nprinciples to be followed.\",\n",
      "    \"In this guidance document, the focus is on explaining the\\nprinciples and providing examples of how they may be applied in typical situations.\",\n",
      "    \"**CONCEPT DOCUMENTS VERSUS DESIGN INPUT** In some cases, the marketing\\nstaff, who maintain close contact with customers and users, determine a need for a new\\nproduct, or enhancements to an existing product.\",\n",
      "    \"Alternatively, the idea for a new\\nproduct may evolve out of a research or clinical activity.\",\n",
      "    \"In any case, the result is a\\nconcept document specifying some of the desired characteristics of the new product.\",\n",
      "    \"Some members of the medical device community view these marketing memoranda, or the\\nequivalent, as the design input.\",\n",
      "    \"However, that is not the intent of the quality system\\nrequirements.\",\n",
      "    \"Such concept documents are rarely comprehensive, and should not be\\nexpected to be so.\",\n",
      "    \"Rather, the intent of the quality system requirements is that the product\\nconceptual description be elaborated, expanded, and transformed into a complete set of\\ndesign input requirements which are written to an engineering level of detail.\",\n",
      "    \"This is an important concept.\",\n",
      "    \"The use of qualitative terms in a concept document is both\\nappropriate and practical.\",\n",
      "    \"This is often not the case for a document to be used as a basis\\nfor design.\",\n",
      "    \"Even the simplest of terms can have enormous design implications.\",\n",
      "    \"For\\nexample, the term must be portable in a concept document raises questions in the minds\\nof product developers about issues such as size and weight limitations, resistance to shock\\nand vibration, the need for protection from moisture and corrosion, the capability of\\noperating over a wide temperature range, and many others.\",\n",
      "    \"Thus, a concept document\\nmay be the starting point for development, but it is not the design input requirement.\",\n",
      "    \"This is a key principlethe design input requirements are the result of the first stage of the\\ndesign control process.\",\n",
      "    \"**RESEARCH AND DEVELOPMENT** . Some manufacturers have difficulty in\\ndetermining where research ends and development begins.\",\n",
      "    \"Research activities may be\\nundertaken in an effort to determine new business opportunities or basic characteristics for\\na new product.\",\n",
      "    \"It may be reasonable to develop a rapid prototype to explore the\\nfeasibility of an idea or design approach, for example, prior to developing design input\\nrequirements.\",\n",
      "    \"But manufacturers should avoid falling into the trap of equating the\\nprototype design with a finished product design.\",\n",
      "    \"Prototypes at this stage lack safety\\nfeatures and ancillary functions necessary for a finished product, and are developed under\\nconditions which preclude adequate consideration of product variability due to\\nmanufacturing.\",\n",
      "    \"**RESPONSIBILITY FOR DESIGN INPUT DEVELOPMENT** . Regardless of who\\ndeveloped the initial product concept, product developers play a key role in developing the\\ndesign input requirements.\",\n",
      "    \"When presented with a set of important characteristics, it is the\\nproduct developers who understand the auxiliary issues that must be addressed, as well as\\nthe level of detail necessary to design a product.\",\n",
      "    \"Therefore, a second key principle is that\",\n",
      "    \"Section C. Design Input 3/11/97 Page 14\",\n",
      "    \"the product developer(s) ultimately bear responsibility for translating user and/or patient\\nneeds into a set of requirements which can be validated prior to implementation.\",\n",
      "    \"While\\nthis is primarily an engineering function, the support or full participation of production and\\nservice personnel, key suppliers, etc., may be required to assure that the design input\\nrequirements are complete.\",\n",
      "    \"Care must be exercised in applying this principle.\",\n",
      "    \"Effective development of design input\\nrequirements encompasses input from both the product developer as well as those\\nrepresenting the needs of the user, such as marketing.\",\n",
      "    \"Terminology can be a problem.\",\n",
      "    \"In\\nsome cases, the product conceptual description may be expressed in medical terms.\",\n",
      "    \"Medical terminology is appropriate in requirements when the developers and reviewers are\\nfamil iar with the language, but it is often preferable to translate the concepts into\\nengineering terms at the requirements stage to minimize miscommunication with the\\ndevelopment staff.\",\n",
      "    \"Another problem is incorrect assumptions.\",\n",
      "    \"Product developers make incorrect\\nassumptions about user needs, and marketing personnel make incorrect assumptions about\\nthe needs of the product designers.\",\n",
      "    \"Incorrect assumptions can have serious consequences\\nthat may not be detected until late in the development process.\",\n",
      "    \"Therefore, both product\\ndevelopers and those representing the user must take responsibility for critically examining\\nproposed requirements, exploring stated and implied assumptions, and uncovering\\nproblems.\",\n",
      "    \"Some examples should clarify this point.\",\n",
      "    \"A basic principle is that design input\\nrequirements should specify what the design is intended to do while carefully avoiding\\nspecific design solutions at this stage.\",\n",
      "    \"For example, a concept document might dictate\\nthat the product be housed in a machined aluminum case.\",\n",
      "    \"It would be prudent for product\\ndevelopers to explore why this type of housing was specified.\",\n",
      "    \"Perhaps there is a valid\\nreasonsuperior electrical shielding, mechanical strength, or reduced time to market as\\ncompared to a cast housing.\",\n",
      "    \"Or perhaps machined aluminum was specified because a\\ncompetitors product is made that way, or simply because the user didnt think plastic\\nwould be strong enough.\",\n",
      "    \"Not all incorrect assumptions are made by users.\",\n",
      "    \"Incorrect assumptions made by product\\ndevelopers may be equally damaging.\",\n",
      "    \"Failure to understand the abuse to which a portable\\ninstrument would be subjected might result in the selection of housing materials\\ninadequate for the intended use of the product.\",\n",
      "    \"There are occasions when it may be appropriate to specify part of the design solution in\\nthe design input requirements.\",\n",
      "    \"For example, a manufacturer may want to share\\ncomponents or manufacturing processes across a family of products in order to realize\\neconomies of scale, or simply to help establish a corporate identity.\",\n",
      "    \"In the case of a\\nproduct upgrade, there may be clear consensus regarding the features to be retained.\",\n",
      "    \"However, it is important to realize that every such design constraint reduces\\nimplementation flexibility and should therefore be documented and identified as a possible\\nconflicting requirement for subsequent resolution.\",\n",
      "    \"Section C. Design Input 3/11/97 Page 15\",\n",
      "    \"**SCOPE AND LEVEL OF DETAIL** . Design input requirements must be\\ncomprehensive.\",\n",
      "    \"This may be quite difficult for manufacturers who are implementing a\\nsystem of design controls for the first time.\",\n",
      "    \"Fortunately, the process gets easier with\\npractice.\",\n",
      "    \"It may be helpful to realize that design input requirements fall into three\\ncategories.\",\n",
      "    \"Virtually every product will have requirements of all three types.\",\n",
      "    \"  - Functional requirements specify what the device does, focusing on the operational\\ncapabilities of the device and processing of inputs and the resultant outputs.\",\n",
      "    \"  - Performance requirements specify how much or how well the device must\\nperform, addressing issues such as speed, strength, response times, accuracy, limits\\nof operation, etc.\",\n",
      "    \"This includes a quantitative characterization of the use\\nenvironment, including, for example, temperature, humidity, shock, vibration, and\\nelectromagnetic compatibility.\",\n",
      "    \"Requirements concerning device reliability and\\nsafety also fit into this category.\",\n",
      "    \"  - Interface requirements specify characteristics of the device which are critical to\\ncompatibility with external systems; specifically, those characteristics which are\\nmandated by external systems and outside the control of the developers.\",\n",
      "    \"One\\ninterface which is important in every case is the user and/or patient interface.\",\n",
      "    \"What is the scope of the design input requirements development process and how much detail must be provided?\",\n",
      "    \"The scope is dependent upon the complexity of a device and the\\nrisk associated with its use.\",\n",
      "    \"For most medical devices, numerous requirements\\nencompassing functions, performance, safety, and regulatory concerns are implied by the\\napplication.\",\n",
      "    \"These implied requirements should be explicitly stated, in engineering terms,\\nin the design input requirements.\",\n",
      "    \"Determining the appropriate level of detail requires experience.\",\n",
      "    \"However, some general\\nguideance is possible.\",\n",
      "    \"The marketing literature contains product specifications, but these\\nare superficial.\",\n",
      "    \"The operator and service manuals may contain more detailed\\nspecifications and performance limits, but these also fall short of being comprehensive.\",\n",
      "    \"Some insight as to what is necessary is provided by examining the requirements for a very\\ncommon external interface.\",\n",
      "    \"For the power requirements for AC-powered equipment, it is\\nnot sufficient to simply say that a unit shall be AC-powered.\",\n",
      "    \"It is better to say that the\\nunit shall be operable from AC power in North America, Europe, and Japan, but that is\\nstill insufficient detail to implement or validate the design.\",\n",
      "    \"If one considers the situation\\njust in North America, where the line voltage is typically 120 volts, many systems are\\nspecified to operate over the range of 108 to 132 volts.\",\n",
      "    \"However, to account for the\\npossibility of brownout, critical devices may be specified to operate from 95 to 132 volts\\nor even wider ranges.\",\n",
      "    \"Based on the intended use of the device, the manufacturer must\\nchoose appropriate performance limits.\",\n",
      "    \"There are many cases when it is impractical to establish every functional and performance\\ncharacteristic at the design input stage.\",\n",
      "    \"But in most cases, the form of the requirement can\\nbe determined, and the requirement can be stated with a to-be-determined (TBD)\\nnumerical value or a range of possible values.\",\n",
      "    \"This makes it possible for reviewers to\",\n",
      "    \"Section C. Design Input 3/11/97 Page 16\",\n",
      "    \"assess whether the requirements completely characterize the intended use of the device,\\njudge the impact of omissions, and track incomplete requirements to ensure resolution.\",\n",
      "    \"For complex designs, it is not uncommon for the design input stage to consume as much\\nas thirty percent of the total project time.\",\n",
      "    \"Unfortunately, some managers and developers\\nhave been trained to measure design progress in terms of hardware built, or lines of\\nsoftware code written.\",\n",
      "    \"They fail to realize that building a solid foundation saves time\\nduring the implementation.\",\n",
      "    \"Part of the solution is to structure the requirements\\ndocuments and reviews such that tangible measures of progress are provided.\",\n",
      "    \"At the other extreme, many medical devices have very simple requirements.\",\n",
      "    \"For example,\\nmany new devices are simply replacement parts for a product, or are kits of commodity\\nitems.\",\n",
      "    \"Typically, only the packaging and labeling distinguishes these products from\\nexisting products.\",\n",
      "    \"In such cases, there is no need to recreate the detailed design input\\nrequirements of the item.\",\n",
      "    \"It is acceptable to simply cite the predecessor product\\ndocumentation, add any new product information, and establish the unique packaging and\\nlabeling requirements.\",\n",
      "    \"**ASSESSING DESIGN INPUT REQUIREMENTS FOR ADEQUACY** . Eventually,\\nthe design input must be reviewed for adequacy.\",\n",
      "    \"After review and approval, the design\\ninput becomes a controlled document.\",\n",
      "    \"All future changes will be subject to the change\\ncontrol procedures, as discussed in Section I (Design Changes).\",\n",
      "    \"Any assessment of design input requirements boils down to a matter of judgment.\",\n",
      "    \"As\\ndiscussed in Section E (Design Review), it is important for the review team to be\\nmultidisciplinary and to have the appropriate authority.\",\n",
      "    \"A number of criteria may be\\nemployed by the review team.\"\n",
      "  ]\n",
      "}\n",
      "```\n",
      "\n",
      "rovas\n",
      "Response cleaned is {'chunks': ['tisfy fitness-for-use, including safety and performance.', '** 820.3 (v)** _Quality system_ means the organizational structure, responsibilities,\\nprocedures, processes, and resources for implementing quality management.', '**Cross reference to ISO 9001:1994 and ISO/DIS 13485 Section 4.4.1 General.**', 'Section A General 3/11/97 Page 7', '_III. DISCUSSION AND POINTS TO CONSIDER_', 'The essential quality aspects and the regulatory requirements, such as safety, performance,\\nand dependability of a product (whether hardware, software, services, or processed\\nmaterials) are established during the design and development phase.', 'Deficient design can\\nbe a major cause of quality problems.', 'The context within which product design is to be carried out should be set by the\\nmanufacturers senior management.', 'It is their responsibility to establish a design and\\ndevelopment plan which sets the targets to be met.', 'This plan defines the constraints\\nwithin which the design is to be implemented.', 'The quality system requirements do not dictate the types of design process that a\\nmanufacturer must use.', 'Manufacturers should use processes best suited to their needs.', 'However, whatever the processes may be, it is important that the design controls are\\napplied in an appropriate manner.', 'This guidance document contains examples of how this might be achieved in a variety of situations.', 'It is important to note that the design function may apply to various facets of the operation\\nhaving differing styles and time scales.', 'Such facets are related to products, including\\nservices and software, as well as to their manufacturing processes.', 'Senior management needs to decide how the design function is to be managed and by\\nwhom.', 'Senior management should also ensure that internal policies are established for\\ndesign issues such as:', '- assessing new product ideas', '- training and retraining of design managers and design staff', '- use of consultants', '- evaluation of the design process', '- product evaluation, including third party product certification and approvals', '- patenting or other means of design protection', 'It is for senior management to ensure that adequate resources are available to carry out\\nthe design in the required time.', 'This may involve reinforcing the skills and equipment\\navailable internally and/or obtaining external resources.', 'Section A General 3/11/97 Page 8', '#### **SECTION B. DESIGN AND DEVELOPMENT PLANNING**', '_I. REQUIREMENTS_', '** 820.30(b) Design and development planning.**', '  - Each manufacturer shall establish and maintain plans that describe or reference the\\ndesign and development activities and define responsibility for implementation.', '  - The plans shall identify and describe the interfaces with different groups or\\nactivities that provide, or result in, input to the design and development process.', '  - The plans shall be reviewed, updated, and approved as design and development\\nevolves.', '**Cross-reference to ISO 9001:1994 and ISO/DIS 13485 sections 4.4.2 Design and**\\n**development planning and 4.4.3 Organizational and technical interfaces.**', '_II. DISCUSSION AND POINTS TO CONSIDER_', 'Design and development planning is needed to ensure that the design process is\\nappropriately controlled and that device quality objectives are met.', 'The plans must be\\nconsistent with the remainder of the design control requirements.', 'The following elements\\nwould typically be addressed in the design and development plan or plans:', '  - Description of the goals and objectives of the design and development program; i.e., what is to be developed;', '  - Delineation of organizational responsibilities with respect to assuring quality\\nduring the design and development phase, to include interface with any contractors;', '  - Identification of the major tasks to be undertaken, deliverables for each task, and\\nindividual or organizational responsibilities (staff and resources) for completing\\neach task;', '  - Scheduling of major tasks to meet overall program time constraints;', '  - Identification of major reviews and decision points;', '  - Selection of reviewers, the composition of review teams, and procedures to be\\nfollowed by reviewers;', '  - Controls for design documentation;', '  - Notification activities.', 'Planning enables management to exercise greater control over the design and development\\nprocess by clearly communicating policies, procedures, and goals to members of the', 'Section B Design and Development Planning               3/11/97 Page 9', 'design and development team, and providing a basis for measuring conformance to quality\\nsystem objectives.', 'Design activities should be specified at the level of detail necessary for carrying out the\\ndesign process.', 'The extent of design and development planning is dependent on the size\\nof the developing organization and the size and complexity of the product to be\\ndeveloped.', 'Some manufacturers may have documented policies and procedures which\\napply to all design and development activities.', 'For each specific development program, such manufacturers may also prepare a plan which spells out the project-dependent\\nelements in detail, and incorporates the general policies and procedures by reference.', 'Other manufacturers may develop a comprehensive design and development plan which is\\nspecifically tailored to each individual project.', 'In summary, the form and organization of the planning documents are less important than\\ntheir content.', 'The following paragraphs discuss the key elements of design and\\ndevelopment planning.', '**ORGANIZATIONAL RESPONSIBILITIES** . The management responsibility section of\\nthe quality system requirements [1] requires management to establish a quality policy and\\nimplement an organizational structure to ensure quality.', 'These are typically documented in\\na quality manual or similarly named document.', 'In some cases, however, the design and\\ndevelopment plan, rather than the quality manual, is the best vehicle for describing\\norganizational responsibilities relative to design and development activities.', 'The\\nimportance of defining responsibilities with clarity and without ambiguity should be\\nrecognized.', 'When input to the design is from a variety of sources, their interrelationships\\nand interfaces (as well as the pertinent responsibilities and authorities) should be defined,\\ndocumented, coordinated, and controlled.', 'This might be the case, for example, if a\\nmultidisciplinary product development team is assembled for a specific project, or if the\\nteam includes suppliers, contract manufacturers, users, outside consultants, or independent\\nauditors.', '**TASK BREAKDOWN** . The plan establishes, to the extent possible:', '  - The major tasks required to develop the product', '  - The time involved for each major task', '  - The resources and personnel required', '  - The allocation of responsibilities for completing each major task', '  - The prerequisite information necessary to start each major task and the\\ninterrelationship between tasks', '  - The form of each task output or deliverable', '  - Constraints, such as applicable codes, standards, and regulations', '1  820.20 of the FDA Quality System Regulation; section 4.1 of ISO 9001 and ISO/DIS 13485.', 'Section B Design and Development Planning               3/11/97 Page 10', 'Tasks for all significant design activities, including verification and validation tasks, should\\nbe included in the design and development plan.', 'For example, if clinical trials are\\nanticipated, there may be tasks associated with appropriate regulatory requirements.', 'For complex projects, rough estimates may be provided initially, with the details left for\\nthe responsible organizations to develop.', 'As development proceeds, the plan should\\nevolve to incorporate more and better information.', 'The relationships between tasks should be presented in such a way that they are easily\\nunderstood.', 'It should be clear which tasks depend on others, and which tasks need to be\\nperformed concurrently.', 'Planning should reflect the degree of perceived development risk; for example, tasks involving new technology or processes should be spelled out in greater\\ndetail, and perhaps be subjected to more reviews and checks, than tasks which are\\nperceived as routine or straightforward.', 'The design and development plan may include a schedule showing starting and completion\\ndates for each major task, project milestone, or key decision points.', 'The method chosen\\nand the detail will vary depending on the complexity of the project and the level of risk\\nassociated with the device.', 'For small projects, the plan may consist of only a simple flow\\ndiagram or computer spreadsheet.', 'For larger projects, there are a number of project\\nmanagement tools that are used to develop plans.', 'Three of the most commonly used are\\nthe Program Evaluation and Review Technique (PERT), the Critical Path Method (CPM),\\nand the Gantt chart.', 'Software is available in many forms for these methods.', 'When\\nselecting these tools, be careful to choose one that best fits the needs of the project.', 'Some\\nof the software programs are far more complex than may be necessary.', 'Unless a manufacturer has experience with the same type of device, the plan will initially\\nbe limited in scope and detail.', 'As work proceeds, the plan is refined.', 'Lack of experience in\\nplanning often leads to optimistic schedules, but slippage may also occur for reasons\\nbeyond the control of planners, for example, personnel turnover, materiel shortage, or\\nexpected problems with a design element or process.', 'Sometimes the schedule can be\\ncompressed by using additional resources, such as diverting staff or equipment from\\nanother project, hiring a contractor, or leasing equipment.', 'It is important that the schedule be updated to reflect current knowledge.', 'At all times, the\\nplan should be specified at a level of detail enabling management to make informed\\ndecisions, and provide confidence in meeting overall schedule and performance objectives.', 'This is important because scheduling pressures have historically been a contributing factor\\nin many design defects which caused injury.', 'To the extent that good planning can prevent\\nschedule pressures, the potential for design errors is reduced.', 'However, no amount of planning can eliminate all development risk.', 'There is inherent\\nconflict between the desire to maximize performance and the need to meet business\\nobjectives, including development deadlines.', 'In some corporate cultures, impending\\ndeadlines create enormous pressure to cut corners.', 'Planning helps to combat this dilemma by ensuring management awareness of pressure points.', 'With awareness, decisions are', 'Section B Design and Development Planning               3/11/97 Page 11', 'more likely to be made with appropriate oversight and consideration of all relevant factors.', 'Thus, when concessions to the clock must be made, they can be justified and supported.', 'Section B Design and Development Planning               3/11/97 Page 12', '#### **SECTION C. DESIGN INPUT**', '_I. REQUIREMENTS_', '** 820.30(c) Design input.**', '  - Each manufacturer shall establish and maintain procedures to ensure that the\\ndesign requirements relating to a device are appropriate and address the intended\\nuse of the device, including the needs of the user and patient.', '  - The procedures shall include a mechanism for addressing incomplete, ambiguous,\\nor conflicting requirements.', '  - The design input requirements shall be documented and shall be reviewed and\\napproved by designated individual(s).', '  - The approval, including the date and signature of the individual(s) approving the\\nrequirements, shall be documented.', '**Cross reference to ISO 9001:1994 and ISO/DIS 13485 section 4.4.4 Design input.**', '_II. DEFINITIONS_', '** 820.3(f)** _Design input_ means the physical and performance requirements of a device\\nthat are used as a basis for device design.', '_III. DISCUSSION AND POINTS TO CONSIDER_', 'Design input is the starting point for product design.', 'The requirements which form the\\ndesign input establish a basis for performing subsequent design tasks and validating the\\ndesign.', 'Therefore, development of a solid foundation of requirements is the single most\\nimportant design control activity.', 'Many medical device manufacturers have experience with the adverse effects that\\nincomplete requirements can have on the design process.', 'A frequent complaint of\\ndevelopers is that theres never time to do it right, but theres always time to do it over.', 'If essential requirements are not identified until validation, expensive redesign and rework\\nmay be necessary before a design can be released to production.', 'By comparison, the experience of companies that have designed devices using clear-cut,\\ncomprehensive sets of requirements is that rework and redesign are significantly reduced\\nand product quality is improved.', 'They know that the development of requirements for a\\nmedical device of even moderate complexity is a formidable, time-consuming task.', 'They\\naccept the investment in time and resources required to develop the requirements because\\nthey know the advantages to be gained in the long run.', 'Section C. Design Input 3/11/97 Page 13', 'Unfortunately, there are a number of common misconceptions regarding the meaning and\\npractical application of the quality system requirements for design input.', 'Many seem to\\naris from interpreting the requirements as a literal prescription, rather than a set of\\nprinciples to be followed.', 'In this guidance document, the focus is on explaining the\\nprinciples and providing examples of how they may be applied in typical situations.', '**CONCEPT DOCUMENTS VERSUS DESIGN INPUT** In some cases, the marketing\\nstaff, who maintain close contact with customers and users, determine a need for a new\\nproduct, or enhancements to an existing product.', 'Alternatively, the idea for a new\\nproduct may evolve out of a research or clinical activity.', 'In any case, the result is a\\nconcept document specifying some of the desired characteristics of the new product.', 'Some members of the medical device community view these marketing memoranda, or the\\nequivalent, as the design input.', 'However, that is not the intent of the quality system\\nrequirements.', 'Such concept documents are rarely comprehensive, and should not be\\nexpected to be so.', 'Rather, the intent of the quality system requirements is that the product\\nconceptual description be elaborated, expanded, and transformed into a complete set of\\ndesign input requirements which are written to an engineering level of detail.', 'This is an important concept.', 'The use of qualitative terms in a concept document is both\\nappropriate and practical.', 'This is often not the case for a document to be used as a basis\\nfor design.', 'Even the simplest of terms can have enormous design implications.', 'For\\nexample, the term must be portable in a concept document raises questions in the minds\\nof product developers about issues such as size and weight limitations, resistance to shock\\nand vibration, the need for protection from moisture and corrosion, the capability of\\noperating over a wide temperature range, and many others.', 'Thus, a concept document\\nmay be the starting point for development, but it is not the design input requirement.', 'This is a key principlethe design input requirements are the result of the first stage of the\\ndesign control process.', '**RESEARCH AND DEVELOPMENT** . Some manufacturers have difficulty in\\ndetermining where research ends and development begins.', 'Research activities may be\\nundertaken in an effort to determine new business opportunities or basic characteristics for\\na new product.', 'It may be reasonable to develop a rapid prototype to explore the\\nfeasibility of an idea or design approach, for example, prior to developing design input\\nrequirements.', 'But manufacturers should avoid falling into the trap of equating the\\nprototype design with a finished product design.', 'Prototypes at this stage lack safety\\nfeatures and ancillary functions necessary for a finished product, and are developed under\\nconditions which preclude adequate consideration of product variability due to\\nmanufacturing.', '**RESPONSIBILITY FOR DESIGN INPUT DEVELOPMENT** . Regardless of who\\ndeveloped the initial product concept, product developers play a key role in developing the\\ndesign input requirements.', 'When presented with a set of important characteristics, it is the\\nproduct developers who understand the auxiliary issues that must be addressed, as well as\\nthe level of detail necessary to design a product.', 'Therefore, a second key principle is that', 'Section C. Design Input 3/11/97 Page 14', 'the product developer(s) ultimately bear responsibility for translating user and/or patient\\nneeds into a set of requirements which can be validated prior to implementation.', 'While\\nthis is primarily an engineering function, the support or full participation of production and\\nservice personnel, key suppliers, etc., may be required to assure that the design input\\nrequirements are complete.', 'Care must be exercised in applying this principle.', 'Effective development of design input\\nrequirements encompasses input from both the product developer as well as those\\nrepresenting the needs of the user, such as marketing.', 'Terminology can be a problem.', 'In\\nsome cases, the product conceptual description may be expressed in medical terms.', 'Medical terminology is appropriate in requirements when the developers and reviewers are\\nfamil iar with the language, but it is often preferable to translate the concepts into\\nengineering terms at the requirements stage to minimize miscommunication with the\\ndevelopment staff.', 'Another problem is incorrect assumptions.', 'Product developers make incorrect\\nassumptions about user needs, and marketing personnel make incorrect assumptions about\\nthe needs of the product designers.', 'Incorrect assumptions can have serious consequences\\nthat may not be detected until late in the development process.', 'Therefore, both product\\ndevelopers and those representing the user must take responsibility for critically examining\\nproposed requirements, exploring stated and implied assumptions, and uncovering\\nproblems.', 'Some examples should clarify this point.', 'A basic principle is that design input\\nrequirements should specify what the design is intended to do while carefully avoiding\\nspecific design solutions at this stage.', 'For example, a concept document might dictate\\nthat the product be housed in a machined aluminum case.', 'It would be prudent for product\\ndevelopers to explore why this type of housing was specified.', 'Perhaps there is a valid\\nreasonsuperior electrical shielding, mechanical strength, or reduced time to market as\\ncompared to a cast housing.', 'Or perhaps machined aluminum was specified because a\\ncompetitors product is made that way, or simply because the user didnt think plastic\\nwould be strong enough.', 'Not all incorrect assumptions are made by users.', 'Incorrect assumptions made by product\\ndevelopers may be equally damaging.', 'Failure to understand the abuse to which a portable\\ninstrument would be subjected might result in the selection of housing materials\\ninadequate for the intended use of the product.', 'There are occasions when it may be appropriate to specify part of the design solution in\\nthe design input requirements.', 'For example, a manufacturer may want to share\\ncomponents or manufacturing processes across a family of products in order to realize\\neconomies of scale, or simply to help establish a corporate identity.', 'In the case of a\\nproduct upgrade, there may be clear consensus regarding the features to be retained.', 'However, it is important to realize that every such design constraint reduces\\nimplementation flexibility and should therefore be documented and identified as a possible\\nconflicting requirement for subsequent resolution.', 'Section C. Design Input 3/11/97 Page 15', '**SCOPE AND LEVEL OF DETAIL** . Design input requirements must be\\ncomprehensive.', 'This may be quite difficult for manufacturers who are implementing a\\nsystem of design controls for the first time.', 'Fortunately, the process gets easier with\\npractice.', 'It may be helpful to realize that design input requirements fall into three\\ncategories.', 'Virtually every product will have requirements of all three types.', '  - Functional requirements specify what the device does, focusing on the operational\\ncapabilities of the device and processing of inputs and the resultant outputs.', '  - Performance requirements specify how much or how well the device must\\nperform, addressing issues such as speed, strength, response times, accuracy, limits\\nof operation, etc.', 'This includes a quantitative characterization of the use\\nenvironment, including, for example, temperature, humidity, shock, vibration, and\\nelectromagnetic compatibility.', 'Requirements concerning device reliability and\\nsafety also fit into this category.', '  - Interface requirements specify characteristics of the device which are critical to\\ncompatibility with external systems; specifically, those characteristics which are\\nmandated by external systems and outside the control of the developers.', 'One\\ninterface which is important in every case is the user and/or patient interface.', 'What is the scope of the design input requirements development process and how much detail must be provided?', 'The scope is dependent upon the complexity of a device and the\\nrisk associated with its use.', 'For most medical devices, numerous requirements\\nencompassing functions, performance, safety, and regulatory concerns are implied by the\\napplication.', 'These implied requirements should be explicitly stated, in engineering terms,\\nin the design input requirements.', 'Determining the appropriate level of detail requires experience.', 'However, some general\\nguideance is possible.', 'The marketing literature contains product specifications, but these\\nare superficial.', 'The operator and service manuals may contain more detailed\\nspecifications and performance limits, but these also fall short of being comprehensive.', 'Some insight as to what is necessary is provided by examining the requirements for a very\\ncommon external interface.', 'For the power requirements for AC-powered equipment, it is\\nnot sufficient to simply say that a unit shall be AC-powered.', 'It is better to say that the\\nunit shall be operable from AC power in North America, Europe, and Japan, but that is\\nstill insufficient detail to implement or validate the design.', 'If one considers the situation\\njust in North America, where the line voltage is typically 120 volts, many systems are\\nspecified to operate over the range of 108 to 132 volts.', 'However, to account for the\\npossibility of brownout, critical devices may be specified to operate from 95 to 132 volts\\nor even wider ranges.', 'Based on the intended use of the device, the manufacturer must\\nchoose appropriate performance limits.', 'There are many cases when it is impractical to establish every functional and performance\\ncharacteristic at the design input stage.', 'But in most cases, the form of the requirement can\\nbe determined, and the requirement can be stated with a to-be-determined (TBD)\\nnumerical value or a range of possible values.', 'This makes it possible for reviewers to', 'Section C. Design Input 3/11/97 Page 16', 'assess whether the requirements completely characterize the intended use of the device,\\njudge the impact of omissions, and track incomplete requirements to ensure resolution.', 'For complex designs, it is not uncommon for the design input stage to consume as much\\nas thirty percent of the total project time.', 'Unfortunately, some managers and developers\\nhave been trained to measure design progress in terms of hardware built, or lines of\\nsoftware code written.', 'They fail to realize that building a solid foundation saves time\\nduring the implementation.', 'Part of the solution is to structure the requirements\\ndocuments and reviews such that tangible measures of progress are provided.', 'At the other extreme, many medical devices have very simple requirements.', 'For example,\\nmany new devices are simply replacement parts for a product, or are kits of commodity\\nitems.', 'Typically, only the packaging and labeling distinguishes these products from\\nexisting products.', 'In such cases, there is no need to recreate the detailed design input\\nrequirements of the item.', 'It is acceptable to simply cite the predecessor product\\ndocumentation, add any new product information, and establish the unique packaging and\\nlabeling requirements.', '**ASSESSING DESIGN INPUT REQUIREMENTS FOR ADEQUACY** . Eventually,\\nthe design input must be reviewed for adequacy.', 'After review and approval, the design\\ninput becomes a controlled document.', 'All future changes will be subject to the change\\ncontrol procedures, as discussed in Section I (Design Changes).', 'Any assessment of design input requirements boils down to a matter of judgment.', 'As\\ndiscussed in Section E (Design Review), it is important for the review team to be\\nmultidisciplinary and to have the appropriate authority.', 'A number of criteria may be\\nemployed by the review team.']}\n",
      "Cleaning response ```json\n",
      "{\n",
      "  \"chunks\": [\n",
      "    \"- Design input requirements should be unambiguous. That is, each requirement should be able to be verified by an objective method of analysis, inspection, or testing. For example, it is insufficient to state that a catheter must be able to withstand repeated flexing. A better requirement would state that the catheter should be formed into a 50 mm diameter coil and straightened out for a total of fifty times with no evidence of cracking or deformity. A qualified reviewer could then make a judgment whether this specified test method is representative of the conditions of use.\",\n",
      "    \"- Quantitative limits should be expressed with a measurement tolerance. For example, a diameter of 3.5 mm is an incomplete specification. If the diameter is specified as 3.5000.005 mm, designers have a basis for determining how accurate the manufacturing processes have to be to produce compliant parts, and reviewers have a basis for determining whether the parts will be suitable for the intended use.\",\n",
      "    \"- The set of design input requirements for a product should be self-consistent. It is not unusual for requirements to conflict with one another or with a referenced industry standard due to a simple oversight. Such conflicts should be resolved early in the development process.\",\n",
      "    \"Section C. Design Input 3/11/97 Page 17\",\n",
      "    \"- The environment in which the product is intended to be used should be properly characterized. For example, manufacturers frequently make the mistake of specifying laboratory conditions for devices which are intended for use in the home. Yet, even within a single country, relative humidity in a home may range from 20 percent to 100 percent (condensing) due to climactic and seasonal variations. Household temperatures in many climates routinely exceed 40 C during the hot season. Altitudes may exceed 3,000 m, and the resultant low atmospheric pressure may adversely affect some kinds of medical equipment. If environmental conditions are fully specified, a qualified reviewer can make a determination of whether the specified conditions are representative of the intended use.\",\n",
      "    \"- When industry standards are cited, the citations should be reviewed for completeness and relevance. For example, one medical device manufacturer claimed compliance with an industry standard covering mechanical shock and vibration. However, when the referenced standard was examined by a reviewer, it was found to prescribe only the method of testing, omitting any mention of pass/fail criteria. It was incumbent on the manufacturer in this case to specify appropriate performance limits for the device being tested, as well as the test method.\",\n",
      "    \"**EVOLUTION OF THE DESIGN INPUT REQUIREMENTS** . Large development projects often are implemented in stages. When this occurs, the design input requirements at each stage should be developed and reviewed following the principles set forth in this section. Fortunately, the initial set of requirements, covering the overall product, is by far the most difficult to develop. As the design proceeds, the output from the early stages forms the basis for the subsequent stages, and the information available to designers is inherently more extensive and detailed.\",\n",
      "    \"It is almost inevitable that verification activities will uncover discrepancies which result in changes to the design input requirements. There are two points to be made about this. One is that the change control process for design input requirements must be carefully managed. Often, a design change to correct one problem may create a new problem which must be addressed.  Throughout the development process, it is important that any changes are documented and communicated to developers so that the total impact of the change can be determined. The change control process is crucial to device quality.\",\n",
      "    \"The second point is that extensive rework of the design input requirements suggests that the design input requirements may not be elaborated to a suitable level of detail, or insufficient resources are being devoted to defining and reviewing the requirements. Managers can use this insight to improve the design control process. From a design control perspective, the number of requirements changes made is less important than the thoroughness of the change control process.\",\n",
      "    \"Section C. Design Input 3/11/97 Page 18\",\n",
      "    \"#### **SECTION D. DESIGN OUTPUT**\",\n",
      "    \"_I. REQUIREMENTS_\",\n",
      "    \"** 820.30(d) Design output.**\",\n",
      "    \"- Each manufacturer shall establish and maintain procedures for defining and documenting design output in terms that allow an adequate evaluation of conformance to design input requirements.\",\n",
      "    \"- Design output procedures shall contain or make reference to acceptance criteria and shall ensure that those design outputs that are essential for the proper functioning of the device are identified.\",\n",
      "    \"- Design output shall be documented, reviewed, and approved before release.\",\n",
      "    \"- The approval, including the date and signature of the individual(s) approving the output, shall be documented.\",\n",
      "    \"**Cross-reference to ISO 9001:1994 and ISO/DIS 13485 section 4.4.5 Design output.**\",\n",
      "    \"_II. DEFINITIONS_\",\n",
      "    \"** 820.3(g)** _Design output_ means the results of a design effort at each design phase and at the end of the total design effort. The finished design output is the basis for the device master record. The total finished design output consists of the device, its packaging and labeling, and the device master record.\",\n",
      "    \"** 820.3(y)** _Specification_ means any requirement with which a product, process, service, or other activity must conform.\",\n",
      "    \"_III. DISCUSSION AND POINTS TO CONSIDER_\",\n",
      "    \"The quality system requirements for design output can be separated into two elements: Design output should be expressed in terms that allow adequate assessment of conformance to design input requirements and should identify the characteristics of the design that are crucial to the safety and proper functioning of the device. This raises two fundamental issues for developers:\",\n",
      "    \"- What constitutes design output?\",\n",
      "    \"- Are the form and content of the design output suitable?\",\n",
      "    \"The first issue is important because the typical development project produces voluminous records, some of which may not be categorized as design output. On the other hand, design output must be reasonably comprehensive to be effective. As a general rule, an item is design output if it is a work product, or deliverable item, of a design task listed in\",\n",
      "    \"Section D. Design Output 3/11/97 Page 19\",\n",
      "    \"the design and development plan, and the item defines, describes, or elaborates an element of the design implementation. Examples include block diagrams, flow charts, software high-level code, and system or subsystem design specifications. The design output in one stage is often part of the design input in subsequent stages.\",\n",
      "    \"Design output includes production specifications as well as descriptive materials which define and characterize the design.\",\n",
      "    \"**PRODUCTION SPECIFICATIONS** . Production specifications include drawings and documents used to procure components, fabricate, test, inspect, install, maintain, and service the device, such as the following:\",\n",
      "    \"- assembly drawings\",\n",
      "    \"- component and material specifications\",\n",
      "    \"- production and process specifications\",\n",
      "    \"- software machine code (e.g., diskette or master EPROM)\",\n",
      "    \"- work instructions\",\n",
      "    \"- quality assurance specifications and procedures\",\n",
      "    \"- installation and servicing procedures\",\n",
      "    \"- packaging and labeling specifications, including methods and processes used\",\n",
      "    \"In addition, as discussed in Section H (Design Transfer), production specifications may take on other forms. For example, some manufacturers produce assembly instructions on videotapes rather than written instructions. Similarly, a program diskette, used by a computer-aided milling machine to fabricate a part, would be considered a production specification. The videotape and the software on the program diskette are part of the device master record.\",\n",
      "    \"**OTHER DESCRIPTIVE MATERIALS** . Other design output items might be produced which are necessary to establish conformance to design input requirements, but are not used in its production. For example, for each part which is fabricated by computer-aided machine, there should be an assembly drawing which specifies the dimensions and characteristics of the part. It is a part of the design output because it establishes the basis for the machine tool program used to fabricate the part. Other examples of design output include the following:\",\n",
      "    \"- the results of risk analysis\",\n",
      "    \"- software source code\",\n",
      "    \"- results of verification activities\",\n",
      "    \"- biocompatibility test results\",\n",
      "    \"- bioburden test results\",\n",
      "    \"**FORM AND CONTENT** . Manufacturers must take steps to assure that the design output characterizes all important aspects of the design and is expressed in terms which\",\n",
      "    \"Section D. Design Output 3/11/97 Page 20\",\n",
      "    \"allow adequate verification and validation. Two basic mechanisms are available to manufacturers to accomplish these objectives.\",\n",
      "    \"- First, the manufacturer proactively can specify the form and content of design output at the planning stage. For some types of design output, form and content may be codified in a consensus standard which can be referenced. In other cases, a manufacturer could specify the desired characteristics, or even simply specify that the form and content of an existing document be followed.\",\n",
      "    \"- Second, form and content can be reviewed retroactively as a part of the design verification process. For example, the verification of design output could include assessing whether specified documentation standards have been adhered to.\",\n",
      "    \"As these examples illustrate, conformance with the quality system requirements concerning design output generally requires no extra effort on the part of the manufacturer, but simply the application of some common sense procedures during the planning, execution, and review of design tasks.\",\n",
      "    \"Section D. Design Output 3/11/97 Page 21\",\n",
      "    \"Section D. Design Output 3/11/97 Page 22\",\n",
      "    \"#### **SECTION E. DESIGN REVIEW**\",\n",
      "    \"_I._ _REQUIREMENTS_\",\n",
      "    \"** 820.30(e) Design review.**\",\n",
      "    \"- Each manufacturer shall establish and maintain procedures to ensure that formal documented reviews of the design results are planned and conducted at appropriate stages of the devices design development.\",\n",
      "    \"- The procedures shall ensure that participants at each design review include representatives of all functions concerned with the design stage being reviewed and an individual(s) who does not have direct responsibility for the design stage being reviewed, as well as any specialists needed.\",\n",
      "    \"- The results of a design review, including identification of the design, the date, and the individual(s) performing the review, shall be documented in the design history file (the DHF).\",\n",
      "    \"**Cross-reference to ISO 9001:1994 and ISO/DIS 13485 section 4.4.6 Design review.**\",\n",
      "    \"_II._ _DEFINITIONS_\",\n",
      "    \"** 820.3(h)** _Design review_ means a documented, comprehensive, systematic examination of a design to evaluate the adequacy of the design requirements, to evaluate the capability of the design to meet these requirements, and to identify problems.\",\n",
      "    \"_III. DISCUSSION AND POINTS TO CONSIDER_\",\n",
      "    \"In general, formal design reviews are intended to:\",\n",
      "    \"- provide a systematic assessment of design results, including the device design and the associated designs for production and support processes;\",\n",
      "    \"- provide feedback to designers on existing or emerging problems;\",\n",
      "    \"- assess project progress; and/or\",\n",
      "    \"- provide confirmation that the project is ready to move on to the next stage of development.\",\n",
      "    \"Many types of reviews occur during the course of developing a product. Reviews may have both an internal and external focus. The internal focus is on the feasibility of the design and the produceability of the design with respect to manufacturing and support\",\n",
      "    \"Section E. Design Review 3/11/97 Page 23\",\n",
      "    \"capabilities. The external focus is on the user requirements; that is, the device design is viewed from the perspective of the user.\",\n",
      "    \"The nature of reviews changes as the design progresses. During the initial stages, issues related to design input requirements will predominate. Next, the main function of the reviews may be to evaluate or confirm the choice of solutions being offered by the design team. Then, issues such as the choice of materials and the methods of manufacture become more important. During the final stages, issues related to the verification, validation, and production may predominate.\",\n",
      "    \"The term review is commonly used by manufacturers to describe a variety of design assessment activities. Most, but not all, of these activities meet the definition of formal design reviews. The following exceptions may help to clarify the distinguishing characteristics of design reviews.\",\n",
      "    \"- Each design document which constitutes the formal output, or deliverable, of a design task is normally subject to evaluation activities, sometimes referred to as informal peer review, supervisory review, or technical assessment. These activities, while they may be called reviews, are often better described as verification activities, because they are not intended to be comprehensive, definitive, and multidisciplinary in their scope. Rather, their purpose is to confirm that design output meets design input. Verification activities affect and add to the design output, and are themselves subject to subsequent design review.\",\n",
      "    \"- Developers may conduct routine or ad hoc meetings to discuss an issue, coordinate activities, or assess development progress. Decisions from such meetings may not require formal documentation; however, if a significant issue is resolved, this should be documented. If the outcome results in change to an approved design document, then applicable change control procedures should be followed, as discussed in Section I (Design Changes).\",\n",
      "    \"Control of the design review process is achieved by developing and implementing a formal design review program consistent with quality system requirements. The following issues should be addressed and documented in the design and development plan(s).\",\n",
      "    \"**NUMBER AND TYPE OF REVIEWS** . It is a well-accepted fact that the cost to correct design errors increases as the design nears completion, and the flexibility to implement an optimal solution decreases. When an error is discovered at the end of the development cycle, difficult decisions have to be made regarding an acceptable corrective action. When that corrective action is implemented in haste, the result is often an unintended consequence leading to a new problem. Thus, formal design reviews should be planned to detect problems early. A corollary is that planners should presume that problems will be detected, and allocate a reasonable amount of time to implement corrective actions. Typically, formal reviews are conducted at the end of each phase and at important milestones in the design process.\",\n",
      "    \"As discussed in Section C (Design Input), it is beneficial in almost every case to conduct a formal review of the design input requirements early in the development process. The number of reviews depends upon the complexity of the device.\",\n",
      "    \"- For a simple design, or a minor upgrade to an existing product, it might be appropriate to conduct a single review at the conclusion of the design process.\",\n",
      "    \"- For a product involving multiple subsystems, an early design task is to allocate the design input requirements among the various subsystems. For example, in a microprocessor-based system, designers must decide which functions will be performed by hardware and which by software. In another case, tolerance buildup from several components may combine to create a clearance problem. System designers must establish tolerance specifications for each component to meet the overall dimensional specification. In cases like these, a formal design review is a prudent step to ensure that all such system-level requirements have been allocated satisfactorily prior to engaging in detailed design of each subsystem.\",\n",
      "    \"- For complex systems, additional reviews are often built into the development plan. For example, engineering sketches may be developed for prototyping purposes prior to development of production drawings. Evaluation of the prototype would typically culminate in a formal design review. Similarly, software development commonly includes a high-level design phase, during which requirements are elaborated to a greater level of detail and algorithms are developed to implement key functions. A formal design review would typically be conducted to review this work prior to beginning detailed coding.\",\n",
      "    \"There are a number of approaches to conducting formal design reviews at the end of the design process. In some organizations, engineering essentially completes the design, tests an engineering prototype, and conducts a formal design review prior to turning the design over to manufacturing. In such cases, an additional review will be needed after the design has been validated using production devices.\",\n",
      "    \"In some instances, components having long lead times may enter production prior to completion of the overall device design. The primary motivation for early production is to reduce time to market. The manufacturer runs the business risk that the design review at the end of the design process will uncover a defect that must be corrected in production devices before any devices are distributed.\",\n",
      "    \"All of these approaches to scheduling formal design reviews are valid. What is important is that the manufacturer establish a reasonable rationale for the number and type of reviews, based on sound judgment.\",\n",
      "    \"**SELECTION OF REVIEWERS** . In determining who should participate in a formal design review, planners should consider the qualifications of reviewers, the types of expertise required to make an adequate assessment, and the independence of the reviewers. Each of these concerns is discussed briefly in the following paragraphs.\",\n",
      "    \"**Qualifications** . Formal design reviews should be conducted by person(s) having technical competence and experience at least comparable to the developers. For a small manufacturer, this may require that an outside consultant be retained to participate in the evaluation of the design.\",\n",
      "    \"A manufacturer will often employ one or more specialists to conduct certain types of specialized assessments which are beyond the capabilities of the designers. For example, a mechanical engineer may be retained to perform a structural analysis of a design, and perhaps conduct vibration testing to verify its performance under stress. Such specialists may be assigned to participate in the formal design review. Alternatively, they may be assigned to make an independent assessment and submit observations and recommendations to the reviewers. Either approach is valid.\",\n",
      "    \"**Types of expertise required** . Many medical device designs involve a number of technologies, such as electronics, mechanics, software, materials science, or pneumatics. In addition, a variety of clinical and manufacturing issues may influence the design. Manufacturers should carefully consider which interests should be represented at formal design reviews. Subtle distinctions in reviewer perspective may have dramatic impact on device quality. For example, the marketing department of a small manufacturer shared a new design with several surgeons on their advisory board. The surgeons all thought the design was terrific. Subsequently, the manufacturer invited two experienced operating room nurses to participate in the final design review. During the course of the review, it became apparent that while surgeons may be the customers, nurses are the primary users of the device, and no one up to that point had consulted with any nurses. The nurses at the design review didnt like some of the features of the design. After some further market survey, the manufacturer decided to make changes to the design to accommodate these concerns. It was unfortunate (and expensive) in this case that the user requirements were not considered until late in the development cycle, but the design review was ultimately very successful.\",\n",
      "    \"**Independence** . The formal design review should include at least one individual who does not have direct responsibility for the design stage under review. In a small company, complete independence is very difficult to obtain. Within the context of formal design reviews, the practical solution is simply to ensure a fresh perspective, based on the principle that those who are too close to the design may overlook design errors. Thus, reviewers will often be from the same organization as the developers, but they should not have been significantly involved in the activities under review. As discussed in the following section, the formal design review procedures play a large role in assuring independent and objective reviews.\",\n",
      "    \"**DESIGN REVIEW PROCEDURES** . The manufacturer should have documented formal design review procedures addressing the following:\",\n",
      "    \"- Evaluation of the design (including identification of concerns, i.e., issues and potential problems with the design)\",\n",
      "    \"- Resolution of concerns\",\n",
      "    \"- Implementation of corrective actions\",\n",
      "    \"**Evaluation of the design** . Many formal design reviews take the form of a meeting. At this meeting, the designer(s) may make presentations to explain the design implementation, and persons responsible for verification activities may present their findings to the reviewers. Reviewers may ask for clarification or additional information on any topic, and add their concerns to any raised by the presenters. This portion of the review is focused on finding problems, not resolving them.\",\n",
      "    \"There are many approaches to conducting design review meetings. In simple cases, the technical assessor and reviewer may be the same person, often a project manager or engineering supervisor, and the review meeting is a simple affair in the managers office. For more elaborate reviews, detailed written procedures are desirable to ensure that all pertinent topics are discussed, conclusions accurately recorded, and action items documented and tracked.\",\n",
      "    \"There is a dangerous tendency for design review meetings to become adversarial affairs. The reputation of the designers tends to be linked to the number of discrepancies found, causing the designers to become defensive, while the reviewers score points by finding weaknesses in the design. The resulting contest can be counterproductive. An added complication is the presence of invited guests, often clinicians, who are expected to provide the user perspective. These reviewers are often very reluctant to ask probing questions, especially if they sense that they may become involved in a conflict where all the rules and relationships are not evident.\",\n",
      "    \"These difficulties can be avoided by stating the goals and ground rules for conducting the formal design review clearly at the outset. While the designers are in the best position to explain the best features of the design, they are also most likely to be aware of the designs weaknesses. If the designers and reviewers are encouraged to work together to systematically explore problems and find solutions, the resultant design will be improved and all parties will benefit from the process. Participants must be encouraged to ask questions, avoid making assumptions, and think critically. The focus must be on the design, not the participants.\",\n",
      "    \"Not all formal design reviews involve meetings. For extremely simple designs or design changes, it may be appropriate to specify a procedure in which review materials are distributed or circulated among the reviewers for independent assessment and approval. However, such a procedure negates the benefits of synergy and teamwork, and should be considered only in cases where the design issues are limited in scope and well defined.\",\n",
      "    \"**Resolution of concerns** . The reviewers consider concerns raised during the evaluation portion of the formal design review and decide on an appropriate disposition for each one. There is wide variation in the way companies implement decision-making processes. In some cases, the reviewers play an advisory role to the engineering manager or other company official, who directs the formal design review and ultimately selects a course of\"\n",
      "  ]\n",
      "}\n",
      "```\n",
      "\n",
      "rovas\n",
      "Response cleaned is {'chunks': ['- Design input requirements should be unambiguous. That is, each requirement should be able to be verified by an objective method of analysis, inspection, or testing. For example, it is insufficient to state that a catheter must be able to withstand repeated flexing. A better requirement would state that the catheter should be formed into a 50 mm diameter coil and straightened out for a total of fifty times with no evidence of cracking or deformity. A qualified reviewer could then make a judgment whether this specified test method is representative of the conditions of use.', '- Quantitative limits should be expressed with a measurement tolerance. For example, a diameter of 3.5 mm is an incomplete specification. If the diameter is specified as 3.5000.005 mm, designers have a basis for determining how accurate the manufacturing processes have to be to produce compliant parts, and reviewers have a basis for determining whether the parts will be suitable for the intended use.', '- The set of design input requirements for a product should be self-consistent. It is not unusual for requirements to conflict with one another or with a referenced industry standard due to a simple oversight. Such conflicts should be resolved early in the development process.', 'Section C. Design Input 3/11/97 Page 17', '- The environment in which the product is intended to be used should be properly characterized. For example, manufacturers frequently make the mistake of specifying laboratory conditions for devices which are intended for use in the home. Yet, even within a single country, relative humidity in a home may range from 20 percent to 100 percent (condensing) due to climactic and seasonal variations. Household temperatures in many climates routinely exceed 40 C during the hot season. Altitudes may exceed 3,000 m, and the resultant low atmospheric pressure may adversely affect some kinds of medical equipment. If environmental conditions are fully specified, a qualified reviewer can make a determination of whether the specified conditions are representative of the intended use.', '- When industry standards are cited, the citations should be reviewed for completeness and relevance. For example, one medical device manufacturer claimed compliance with an industry standard covering mechanical shock and vibration. However, when the referenced standard was examined by a reviewer, it was found to prescribe only the method of testing, omitting any mention of pass/fail criteria. It was incumbent on the manufacturer in this case to specify appropriate performance limits for the device being tested, as well as the test method.', '**EVOLUTION OF THE DESIGN INPUT REQUIREMENTS** . Large development projects often are implemented in stages. When this occurs, the design input requirements at each stage should be developed and reviewed following the principles set forth in this section. Fortunately, the initial set of requirements, covering the overall product, is by far the most difficult to develop. As the design proceeds, the output from the early stages forms the basis for the subsequent stages, and the information available to designers is inherently more extensive and detailed.', 'It is almost inevitable that verification activities will uncover discrepancies which result in changes to the design input requirements. There are two points to be made about this. One is that the change control process for design input requirements must be carefully managed. Often, a design change to correct one problem may create a new problem which must be addressed.  Throughout the development process, it is important that any changes are documented and communicated to developers so that the total impact of the change can be determined. The change control process is crucial to device quality.', 'The second point is that extensive rework of the design input requirements suggests that the design input requirements may not be elaborated to a suitable level of detail, or insufficient resources are being devoted to defining and reviewing the requirements. Managers can use this insight to improve the design control process. From a design control perspective, the number of requirements changes made is less important than the thoroughness of the change control process.', 'Section C. Design Input 3/11/97 Page 18', '#### **SECTION D. DESIGN OUTPUT**', '_I. REQUIREMENTS_', '** 820.30(d) Design output.**', '- Each manufacturer shall establish and maintain procedures for defining and documenting design output in terms that allow an adequate evaluation of conformance to design input requirements.', '- Design output procedures shall contain or make reference to acceptance criteria and shall ensure that those design outputs that are essential for the proper functioning of the device are identified.', '- Design output shall be documented, reviewed, and approved before release.', '- The approval, including the date and signature of the individual(s) approving the output, shall be documented.', '**Cross-reference to ISO 9001:1994 and ISO/DIS 13485 section 4.4.5 Design output.**', '_II. DEFINITIONS_', '** 820.3(g)** _Design output_ means the results of a design effort at each design phase and at the end of the total design effort. The finished design output is the basis for the device master record. The total finished design output consists of the device, its packaging and labeling, and the device master record.', '** 820.3(y)** _Specification_ means any requirement with which a product, process, service, or other activity must conform.', '_III. DISCUSSION AND POINTS TO CONSIDER_', 'The quality system requirements for design output can be separated into two elements: Design output should be expressed in terms that allow adequate assessment of conformance to design input requirements and should identify the characteristics of the design that are crucial to the safety and proper functioning of the device. This raises two fundamental issues for developers:', '- What constitutes design output?', '- Are the form and content of the design output suitable?', 'The first issue is important because the typical development project produces voluminous records, some of which may not be categorized as design output. On the other hand, design output must be reasonably comprehensive to be effective. As a general rule, an item is design output if it is a work product, or deliverable item, of a design task listed in', 'Section D. Design Output 3/11/97 Page 19', 'the design and development plan, and the item defines, describes, or elaborates an element of the design implementation. Examples include block diagrams, flow charts, software high-level code, and system or subsystem design specifications. The design output in one stage is often part of the design input in subsequent stages.', 'Design output includes production specifications as well as descriptive materials which define and characterize the design.', '**PRODUCTION SPECIFICATIONS** . Production specifications include drawings and documents used to procure components, fabricate, test, inspect, install, maintain, and service the device, such as the following:', '- assembly drawings', '- component and material specifications', '- production and process specifications', '- software machine code (e.g., diskette or master EPROM)', '- work instructions', '- quality assurance specifications and procedures', '- installation and servicing procedures', '- packaging and labeling specifications, including methods and processes used', 'In addition, as discussed in Section H (Design Transfer), production specifications may take on other forms. For example, some manufacturers produce assembly instructions on videotapes rather than written instructions. Similarly, a program diskette, used by a computer-aided milling machine to fabricate a part, would be considered a production specification. The videotape and the software on the program diskette are part of the device master record.', '**OTHER DESCRIPTIVE MATERIALS** . Other design output items might be produced which are necessary to establish conformance to design input requirements, but are not used in its production. For example, for each part which is fabricated by computer-aided machine, there should be an assembly drawing which specifies the dimensions and characteristics of the part. It is a part of the design output because it establishes the basis for the machine tool program used to fabricate the part. Other examples of design output include the following:', '- the results of risk analysis', '- software source code', '- results of verification activities', '- biocompatibility test results', '- bioburden test results', '**FORM AND CONTENT** . Manufacturers must take steps to assure that the design output characterizes all important aspects of the design and is expressed in terms which', 'Section D. Design Output 3/11/97 Page 20', 'allow adequate verification and validation. Two basic mechanisms are available to manufacturers to accomplish these objectives.', '- First, the manufacturer proactively can specify the form and content of design output at the planning stage. For some types of design output, form and content may be codified in a consensus standard which can be referenced. In other cases, a manufacturer could specify the desired characteristics, or even simply specify that the form and content of an existing document be followed.', '- Second, form and content can be reviewed retroactively as a part of the design verification process. For example, the verification of design output could include assessing whether specified documentation standards have been adhered to.', 'As these examples illustrate, conformance with the quality system requirements concerning design output generally requires no extra effort on the part of the manufacturer, but simply the application of some common sense procedures during the planning, execution, and review of design tasks.', 'Section D. Design Output 3/11/97 Page 21', 'Section D. Design Output 3/11/97 Page 22', '#### **SECTION E. DESIGN REVIEW**', '_I._ _REQUIREMENTS_', '** 820.30(e) Design review.**', '- Each manufacturer shall establish and maintain procedures to ensure that formal documented reviews of the design results are planned and conducted at appropriate stages of the devices design development.', '- The procedures shall ensure that participants at each design review include representatives of all functions concerned with the design stage being reviewed and an individual(s) who does not have direct responsibility for the design stage being reviewed, as well as any specialists needed.', '- The results of a design review, including identification of the design, the date, and the individual(s) performing the review, shall be documented in the design history file (the DHF).', '**Cross-reference to ISO 9001:1994 and ISO/DIS 13485 section 4.4.6 Design review.**', '_II._ _DEFINITIONS_', '** 820.3(h)** _Design review_ means a documented, comprehensive, systematic examination of a design to evaluate the adequacy of the design requirements, to evaluate the capability of the design to meet these requirements, and to identify problems.', '_III. DISCUSSION AND POINTS TO CONSIDER_', 'In general, formal design reviews are intended to:', '- provide a systematic assessment of design results, including the device design and the associated designs for production and support processes;', '- provide feedback to designers on existing or emerging problems;', '- assess project progress; and/or', '- provide confirmation that the project is ready to move on to the next stage of development.', 'Many types of reviews occur during the course of developing a product. Reviews may have both an internal and external focus. The internal focus is on the feasibility of the design and the produceability of the design with respect to manufacturing and support', 'Section E. Design Review 3/11/97 Page 23', 'capabilities. The external focus is on the user requirements; that is, the device design is viewed from the perspective of the user.', 'The nature of reviews changes as the design progresses. During the initial stages, issues related to design input requirements will predominate. Next, the main function of the reviews may be to evaluate or confirm the choice of solutions being offered by the design team. Then, issues such as the choice of materials and the methods of manufacture become more important. During the final stages, issues related to the verification, validation, and production may predominate.', 'The term review is commonly used by manufacturers to describe a variety of design assessment activities. Most, but not all, of these activities meet the definition of formal design reviews. The following exceptions may help to clarify the distinguishing characteristics of design reviews.', '- Each design document which constitutes the formal output, or deliverable, of a design task is normally subject to evaluation activities, sometimes referred to as informal peer review, supervisory review, or technical assessment. These activities, while they may be called reviews, are often better described as verification activities, because they are not intended to be comprehensive, definitive, and multidisciplinary in their scope. Rather, their purpose is to confirm that design output meets design input. Verification activities affect and add to the design output, and are themselves subject to subsequent design review.', '- Developers may conduct routine or ad hoc meetings to discuss an issue, coordinate activities, or assess development progress. Decisions from such meetings may not require formal documentation; however, if a significant issue is resolved, this should be documented. If the outcome results in change to an approved design document, then applicable change control procedures should be followed, as discussed in Section I (Design Changes).', 'Control of the design review process is achieved by developing and implementing a formal design review program consistent with quality system requirements. The following issues should be addressed and documented in the design and development plan(s).', '**NUMBER AND TYPE OF REVIEWS** . It is a well-accepted fact that the cost to correct design errors increases as the design nears completion, and the flexibility to implement an optimal solution decreases. When an error is discovered at the end of the development cycle, difficult decisions have to be made regarding an acceptable corrective action. When that corrective action is implemented in haste, the result is often an unintended consequence leading to a new problem. Thus, formal design reviews should be planned to detect problems early. A corollary is that planners should presume that problems will be detected, and allocate a reasonable amount of time to implement corrective actions. Typically, formal reviews are conducted at the end of each phase and at important milestones in the design process.', 'As discussed in Section C (Design Input), it is beneficial in almost every case to conduct a formal review of the design input requirements early in the development process. The number of reviews depends upon the complexity of the device.', '- For a simple design, or a minor upgrade to an existing product, it might be appropriate to conduct a single review at the conclusion of the design process.', '- For a product involving multiple subsystems, an early design task is to allocate the design input requirements among the various subsystems. For example, in a microprocessor-based system, designers must decide which functions will be performed by hardware and which by software. In another case, tolerance buildup from several components may combine to create a clearance problem. System designers must establish tolerance specifications for each component to meet the overall dimensional specification. In cases like these, a formal design review is a prudent step to ensure that all such system-level requirements have been allocated satisfactorily prior to engaging in detailed design of each subsystem.', '- For complex systems, additional reviews are often built into the development plan. For example, engineering sketches may be developed for prototyping purposes prior to development of production drawings. Evaluation of the prototype would typically culminate in a formal design review. Similarly, software development commonly includes a high-level design phase, during which requirements are elaborated to a greater level of detail and algorithms are developed to implement key functions. A formal design review would typically be conducted to review this work prior to beginning detailed coding.', 'There are a number of approaches to conducting formal design reviews at the end of the design process. In some organizations, engineering essentially completes the design, tests an engineering prototype, and conducts a formal design review prior to turning the design over to manufacturing. In such cases, an additional review will be needed after the design has been validated using production devices.', 'In some instances, components having long lead times may enter production prior to completion of the overall device design. The primary motivation for early production is to reduce time to market. The manufacturer runs the business risk that the design review at the end of the design process will uncover a defect that must be corrected in production devices before any devices are distributed.', 'All of these approaches to scheduling formal design reviews are valid. What is important is that the manufacturer establish a reasonable rationale for the number and type of reviews, based on sound judgment.', '**SELECTION OF REVIEWERS** . In determining who should participate in a formal design review, planners should consider the qualifications of reviewers, the types of expertise required to make an adequate assessment, and the independence of the reviewers. Each of these concerns is discussed briefly in the following paragraphs.', '**Qualifications** . Formal design reviews should be conducted by person(s) having technical competence and experience at least comparable to the developers. For a small manufacturer, this may require that an outside consultant be retained to participate in the evaluation of the design.', 'A manufacturer will often employ one or more specialists to conduct certain types of specialized assessments which are beyond the capabilities of the designers. For example, a mechanical engineer may be retained to perform a structural analysis of a design, and perhaps conduct vibration testing to verify its performance under stress. Such specialists may be assigned to participate in the formal design review. Alternatively, they may be assigned to make an independent assessment and submit observations and recommendations to the reviewers. Either approach is valid.', '**Types of expertise required** . Many medical device designs involve a number of technologies, such as electronics, mechanics, software, materials science, or pneumatics. In addition, a variety of clinical and manufacturing issues may influence the design. Manufacturers should carefully consider which interests should be represented at formal design reviews. Subtle distinctions in reviewer perspective may have dramatic impact on device quality. For example, the marketing department of a small manufacturer shared a new design with several surgeons on their advisory board. The surgeons all thought the design was terrific. Subsequently, the manufacturer invited two experienced operating room nurses to participate in the final design review. During the course of the review, it became apparent that while surgeons may be the customers, nurses are the primary users of the device, and no one up to that point had consulted with any nurses. The nurses at the design review didnt like some of the features of the design. After some further market survey, the manufacturer decided to make changes to the design to accommodate these concerns. It was unfortunate (and expensive) in this case that the user requirements were not considered until late in the development cycle, but the design review was ultimately very successful.', '**Independence** . The formal design review should include at least one individual who does not have direct responsibility for the design stage under review. In a small company, complete independence is very difficult to obtain. Within the context of formal design reviews, the practical solution is simply to ensure a fresh perspective, based on the principle that those who are too close to the design may overlook design errors. Thus, reviewers will often be from the same organization as the developers, but they should not have been significantly involved in the activities under review. As discussed in the following section, the formal design review procedures play a large role in assuring independent and objective reviews.', '**DESIGN REVIEW PROCEDURES** . The manufacturer should have documented formal design review procedures addressing the following:', '- Evaluation of the design (including identification of concerns, i.e., issues and potential problems with the design)', '- Resolution of concerns', '- Implementation of corrective actions', '**Evaluation of the design** . Many formal design reviews take the form of a meeting. At this meeting, the designer(s) may make presentations to explain the design implementation, and persons responsible for verification activities may present their findings to the reviewers. Reviewers may ask for clarification or additional information on any topic, and add their concerns to any raised by the presenters. This portion of the review is focused on finding problems, not resolving them.', 'There are many approaches to conducting design review meetings. In simple cases, the technical assessor and reviewer may be the same person, often a project manager or engineering supervisor, and the review meeting is a simple affair in the managers office. For more elaborate reviews, detailed written procedures are desirable to ensure that all pertinent topics are discussed, conclusions accurately recorded, and action items documented and tracked.', 'There is a dangerous tendency for design review meetings to become adversarial affairs. The reputation of the designers tends to be linked to the number of discrepancies found, causing the designers to become defensive, while the reviewers score points by finding weaknesses in the design. The resulting contest can be counterproductive. An added complication is the presence of invited guests, often clinicians, who are expected to provide the user perspective. These reviewers are often very reluctant to ask probing questions, especially if they sense that they may become involved in a conflict where all the rules and relationships are not evident.', 'These difficulties can be avoided by stating the goals and ground rules for conducting the formal design review clearly at the outset. While the designers are in the best position to explain the best features of the design, they are also most likely to be aware of the designs weaknesses. If the designers and reviewers are encouraged to work together to systematically explore problems and find solutions, the resultant design will be improved and all parties will benefit from the process. Participants must be encouraged to ask questions, avoid making assumptions, and think critically. The focus must be on the design, not the participants.', 'Not all formal design reviews involve meetings. For extremely simple designs or design changes, it may be appropriate to specify a procedure in which review materials are distributed or circulated among the reviewers for independent assessment and approval. However, such a procedure negates the benefits of synergy and teamwork, and should be considered only in cases where the design issues are limited in scope and well defined.', '**Resolution of concerns** . The reviewers consider concerns raised during the evaluation portion of the formal design review and decide on an appropriate disposition for each one. There is wide variation in the way companies implement decision-making processes. In some cases, the reviewers play an advisory role to the engineering manager or other company official, who directs the formal design review and ultimately selects a course of']}\n",
      "Cleaning response ```json\n",
      "{\n",
      "  \"chunks\": [\n",
      "    \"**Implementation of corrective actions** . Not all identified concerns result in corrective actions. The reviewers may decide that the issue is erroneous or immaterial. In most cases, however, resolution involves a design change, a requirements change, or a combination of the two. If the solution is evident, the reviewers may specify the appropriate corrective action; otherwise, an action item will be assigned to study the problem further. In any case, action items and corrective actions are normally tracked under the manufacturers change control procedures.\",\n",
      "    \"**RELATIONSHIP OF DESIGN REVIEW TO VERIFICATION AND VALIDATION** . In practice, design review, verification, and validation overlap one another, and the relationship among them may be confusing. As a general rule, the sequence is: verification, review, validation, review.\",\n",
      "    \"In most cases, verification activities are completed prior to the design review, and the verification results are submitted to the reviewers along with the other design output to be reviewed. Alternatively, some verification activities may be treated as components of the design review, particularly if the verification activity is complex and requires multidisciplinary review.\",\n",
      "    \"Similarly, validation typically involves a variety of activities, including a determination that the appropriate verifications and reviews have been completed. Thus, at the conclusion of the validation effort, a review is usually warranted to assure that the validation is complete and adequate.\",\n",
      "    \"Section E. Design Review 3/11/97 Page 28\",\n",
      "    \"#### **SECTION F. DESIGN VERIFICATION**\",\n",
      "    \"_I. REQUIREMENTS_\",\n",
      "    \"** 820.30(f) Design verification.**  - Each manufacturer shall establish and maintain procedures for verifying the device design. - Design verification shall confirm that the design output meets the design input requirements. - The results of the design verification, including identification of the design, method(s), the date, and the individual(s) performing the verification, shall be documented in the Design History File.\",\n",
      "    \"**Cross-reference to ISO 9001:1994 and ISO/DIS 13485 section 4.4.7 Design verification.**\",\n",
      "    \"_I. DEFINITIONS_\",\n",
      "    \"**820.3(y)** _Specification_ means any requirement with which a product, process, service, or other activity must conform.\",\n",
      "    \"** 820.3(z)** _Validation_ means confirmation by examination and provision of objective evidence that the particular requirements for a specific intended use can be consistently fulfilled.\",\n",
      "    \"**(1)** _Process Validation_ means establishing by objective evidence that a process consistently produces a result or product meeting its predetermined specifications.\",\n",
      "    \"**(2)** _Design Validation_ means establishing by objective evidence that device specifications conform with user needs and intended use(s).\",\n",
      "    \"**820.3(aa)** _Verification_ means confirmation by examination and provision of objective evidence that specified requirements have been fulfilled.\",\n",
      "    \"_III. DISCUSSION AND POINTS TO CONSIDER_\",\n",
      "    \"Verification and validation are associated concepts with very important differences. Various organizations have different definitions for these terms. Medical device manufacturers are encouraged to use the terminology of the quality system requirements in their internal procedures.\",\n",
      "    \"To illustrate the concepts, consider a building design analogy. In a typical scenario, the senior architect establishes the design input requirements and sketches the general appearance and construction of the building, but associates or contractors typically elaborate the details of the various mechanical systems. Verification is the process of checking at each stage whether the output conforms to requirements for that stage. For example: does the air conditioning system deliver the specified cooling capacity to each room? Is the roof rated to withstand so many newtons per square meter of wind loading? Is a fire alarm located within 50 meters of each location in the building?\",\n",
      "    \"At the same time, the architect has to keep in mind the broader question of whether the results are consistent with the ultimate user requirements. Does the air conditioning system keep the occupants comfortable throughout the building? Will the roof withstand weather extremes expected at the building site? Can the fire alarm be heard throughout the building? Those broader concerns are the essence of validation.\",\n",
      "    \"In the initial stages of design, verification is a key quality assurance technique. As the design effort progresses, verification activities become progressively more comprehensive. For example, heat or cooling delivery can be calculated and verified by the air conditioning designer, but the resultant air temperature can only be estimated. Occupant comfort is a function not only of delivered air temperature, but also humidity, heat radiation to or from nearby thermal masses, heat gain or loss through adjacent windows, etc. During the latter design phases, the interaction of these complex factors may be considered during verification of the design.\",\n",
      "    \"Validation follows successful verification, and ensures that each requirement for a particular use is fulfilled. Validation of user needs is possible only after the building is built. The air conditioning and fire alarm performance may be validated by testing and inspection, while the strength of the roof will probably be validated by some sort of analysis linked to building codes which are accepted as meeting the needs of the usersubject to possible confirmation during a subsequent severe storm.\",\n",
      "    \"Validation is the topic of Section G of this guidance document. The remainder of this section focuses on verification principles.\",\n",
      "    \"**TYPES OF VERIFICATION ACTIVITIES** . Verification activities are conducted at all stages and levels of device design. The basis of verification is a three-pronged approach involving tests, inspections, and analyses. Any approach which establishes conformance with a design input requirement is an acceptable means of verifying the design with respect to that requirement. In many cases, a variety of approaches are possible.\",\n",
      "    \"Complex designs require more and different types of verification activities. The nature of verification activities varies according to the type of design output. The intent of this guidance document is not to suggest or recommend verification techniques which should be performed by device manufacturers. Rather, the manufacturer should select and apply appropriate verification techniques based on the generally accepted practices for the technologies employed in their products. Many of these practices are an integral part of the development process, and are routinely performed by developers. The objective of design controls is to ensure adequate oversight by making verification activities explicit and measuring the thoroughness of their execution. Following are a few examples of verification methods and activities.\",\n",
      "    \"- Worst case analysis of an assembly to verify that components are derated properly and not subject to overstress during handling and use.\",\n",
      "    \"- Thermal analysis of an assembly to assure that internal or surface temperatures do not exceed specified limits.\",\n",
      "    \"- Fault tree analysis of a process or design.\",\n",
      "    \"- Failure modes and effects analysis.\",\n",
      "    \"- Package integrity tests.\",\n",
      "    \"- Biocompatibility testing of materials.\",\n",
      "    \"- Bioburden testing of products to be sterilized.\",\n",
      "    \"- Comparison of a design to a previous product having an established history of successful use.\",\n",
      "    \"For some technologies, verification methods may be highly standardized. In other cases, the manufacturer may choose from a variety of applicable methods. In a few cases, the manufacturer must be creative in devising ways to verify a particular aspect of a design.\",\n",
      "    \"Some manufacturers erroneously equate production testing with verification. Whereas verification testing establishes conformance of design output with design input, the aim of production testing is to determine whether the unit under test has been correctly manufactured. In other words, production testing is designed to efficiently screen out manufacturing process errors and perhaps also to detect infant mortality failures. Typically, a small subset of functional and performance tests accomplish this objective with a high degree of accuracy. Therefore, production testing is rarely, if ever, comprehensive enough to verify the design. For example, a leakage test may be used during production to ensure that a hermetically-sealed enclosure was properly assembled. However, the leakage test may not be sensitive enough to detect long-term diffusion of gas through the packaging material.  Permeability of the packaging material is an intrinsic property of the material rather than an assembly issue, and would likely be verified using a more specialized test than is used during production.\",\n",
      "    \"**DOCUMENTATION OF VERIFICATION ACTIVITIES** . Some verification methods result in a document by their nature. For example, a failure modes and effects analysis produces a table listing each system component, its postulated failure modes, and the effect of such failures on system operation.\",\n",
      "    \"Another self-documenting verification method is the traceability matrix. This method is particularly useful when the design input and output are both documents; it also has great utility in software development. In the most common form of the traceability matrix, the input requirements are enumerated in a table, and references are provided to each section in the output documents (or software modules) which address or satisfy each input requirement. The matrix can also be constructed backwards, listing each feature in the design output and tracing which input requirement bears on that feature. This reverse approach is especially useful for detecting hidden assumptions. Hidden assumptions are dangerous because they often lead to overdesign, adding unnecessary cost and complexity to the design. In other cases, hidden assumptions turn out to be undocumented design input requirements which, once exposed, can be properly tracked and verified.\",\n",
      "    \"However, many verification activities are simply some sort of structured assessment of the design output relative to the design input. When this is the case, manufacturers may document completion of verification activities by linking these activities with the signoff procedures for documents. This may be accomplished by establishing a procedure whereby each design output document must be verified and signed by designated persons. The presence of the reviewers signatures on the document signifies that the design output has been verified in accordance with the signoff procedure.\",\n",
      "    \"Section F. Design Verification 3/11/97 Page 30\",\n",
      "    \"Section F. Design Verification 3/11/97 Page 31\",\n",
      "    \"Section F. Design Verification 3/11/97 Page 32\",\n",
      "    \"#### **SECTION G. DESIGN VALIDATION**\",\n",
      "    \"_I. REQUIREMENTS_\",\n",
      "    \"** 820.30(g) Design validation.**  - Each manufacturer shall establish and maintain procedures for validating the device design. - Design validation shall be performed under defined operating conditions on initial production units, lots, or batches, or their equivalents. - Design validation shall ensure that devices conform to defined user needs and intended uses and shall include testing of production units under actual or simulated use conditions. - Design validation shall include software validation and risk analysis, where appropriate. - The results of the design validation, including identification of the design, method(s), the date, and the individual(s) performing the validation, shall be documented in the Design History File.\",\n",
      "    \"**Cross-reference to ISO 9001:1994 and ISO/DIS 13485 section 4.4.8 Design validation.**\",\n",
      "    \"_II. DEFINITIONS_\",\n",
      "    \"**820.3(y)** _Specification_ means any requirement with which a product, process, service, or other activity must conform.\",\n",
      "    \"** 820.3(z)** _Validation_ means confirmation by examination and provision of objective evidence that the particular requirements for a specific intended use can be consistently fulfilled.\",\n",
      "    \"**(1)** _Process Validation_ means establishing by objective evidence that a process consistently produces a result or product meeting its predetermined specifications.\",\n",
      "    \"**(2)** _Design Validation_ means establishing by objective evidence that device specifications conform with user needs and intended use(s).\",\n",
      "    \"**820.3(aa)** _Verification_ means confirmation by examination and provision of objective evidence that specified requirements have been fulfilled.\",\n",
      "    \"_III. DISCUSSION AND POINTS TO CONSIDER_\",\n",
      "    \"Whereas verification is a detailed examination of aspects of a design at various stages in the development, design validation is a cumulative summation of all efforts to assure that the design will conform with user needs and intended use(s), given expected variations in components, materials, manufacturing processes, and the use environment.\",\n",
      "    \"**VALIDATION PLANNING** . Planning for validation should begin early in the design process. The performance characteristics that are to be assessed should be identified, and validation methods and acceptance criteria should be established. For complex designs, a schedule of validation activities and organizational or individual responsibilities will facilitate maintaining control over the process. The validation plan should be reviewed for appropriateness, completeness, and to ensure that user needs and intended uses are addressed.\",\n",
      "    \"**VALIDATION REVIEW** . Validation may expose deficiencies in the original assumptions concerning user needs and intended uses. A formal review process should be used to resolve any such deficiencies. As with verification, the perception of a deficiency might be judged insignificant or erroneous, or a corrective action may be required.\",\n",
      "    \"**VALIDATION METHODS** . Many medical devices do not require clinical trials. However, all devices require clinical evaluation and should be tested in the actual or simulated use environment as a part of validation. This testing should involve devices which are manufactured using the same methods and procedures expected to be used for ongoing production. While testing is always a part of validation, additional validation methods are often used in conjunction with testing, including analysis and inspection methods, compilation of relevant scientific literature, provision of historical evidence that similar designs and/or materials are clinically safe, and full clinical investigations or clinical trials.\",\n",
      "    \"Some manufacturers have historically used their best assembly workers or skilled lab technicians to fabricate test articles, but this practice can obscure problems in the manufacturing process. It may be beneficial to ask the best workers to evaluate and critique the manufacturing process by trying it out, but pilot production should simulate as closely as possible the actual manufacturing conditions.\",\n",
      "    \"Validation should also address product packaging and labeling. These components of the design may have significant human factors implications, and may affect product performance in unexpected ways. For example, packaging materials have been known to cause electrostatic discharge (ESD) failures in electronic devices. If the unit under test is delivered to the test site in the test engineers briefcase, the packaging problem may not become evident until after release to market.\",\n",
      "    \"Validation should include simulation of the expected environmental conditions, such as temperature, humidity, shock and vibration, corrosive atmospheres, etc. For some classes of device, the environmental stresses encountered during shipment and installation far exceed those encountered during actual use, and should be addressed during validation.\",\n",
      "    \"Particular care should be taken to distinguish among customers, users, and patients to ensure that validation addresses the needs of all relevant parties. For a consumer device, the customer, user, and patient may all be the same person. At the other extreme, the person who buys the device may be different from the person who routinely uses it on patients in a clinical setting. Hospital administrators, biomedical engineers, health insurance underwriters, physicians, nurses, medical technicians, and patients have distinct and sometimes competing needs with respect to a device design.\",\n",
      "    \"**VALIDATION DOCUMENTATION** . Validation is a compilation of the results of all validation activities. For a complex design, the detailed results may be contained in a variety of separate documents and summarized in a validation report. Supporting information should be explicitly referenced in the validation report and either included as an appendix or available in the design history file.\",\n",
      "    \"Section G. Design Validation 3/11/97 Page 33\",\n",
      "    \"Section G. Design Validation 3/11/97 Page 34\",\n",
      "    \"Section G. Design Validation 3/11/97 Page 35\",\n",
      "    \"Section G. Design Validation 3/11/97 Page 36\",\n",
      "    \"#### **SECTION H. DESIGN TRANSFER**\",\n",
      "    \"_I. REQUIREMENTS_\",\n",
      "    \"** 820.30(h) Design transfer.**  - Each manufacturer shall establish and maintain procedures to ensure that the device design is correctly translated into production specifications.\",\n",
      "    \"**Cross reference to ISO 9001:1994 and ISO/DIS 13485 section 4.2.3(c) Quality planning.**\",\n",
      "    \"_II. DISCUSSION AND POINTS TO CONSIDER_\",\n",
      "    \"Production specifications must ensure that manufactured devices are repeatedly and reliably produced within product and process capabilities. If a manufactured device deviates outside those capabilities, performance may be compromised. Thus, the process of encapsulating knowledge about the device into production specifications is critical to device quality.\",\n",
      "    \"The level of detail necessary to accomplish this objective varies widely, based on the type of device, the relationship between the design and manufacturing organizations, and the knowledge, experience, and skills of production workers. In some cases, devices are produced by contract manufacturers who have no involvement in the development and little or no contact with the designers. At the other extreme, some devices are handcrafted by skilled artisans with extensive knowledge about the use of the product.\",\n",
      "    \"One normally associates the term production specifications with written documents, such as assembly drawings, component procurement specifications, workmanship standards, manufacturing instructions, and inspection and test specifications. While these types of documents are widely employed in medical device production, other equally acceptable means of conveying design information exist, and manufacturers have the flexibility to employ these alternate means of communication as appropriate. For example, each of the following could constitute production specifications within the meaning of the quality system requirements:\",\n",
      "    \"- documentation (in electronic format as well as paper)\",\n",
      "    \"- training materials, e.g., manufacturing processes, test and inspection methods\",\n",
      "    \"- digital data files, e.g., programmable device files, master EPROM, computer-aided manufacturing (CAM) programming files\",\n",
      "    \"- manufacturing jigs and aids, e.g., molds, sample wiring harness to be duplicated\",\n",
      "    \"Historically, shortcomings in the production specifications tend to be manifested late in the product life cycle. When the design is new, there is often intensive interaction between the design and production teams, providing ample opportunity for undocumented information flow. Later, as production experience is gained, some decoupling often occurs between design and production teams. In addition, key personnel may leave, and their replacements may lack comparable training, experience, or institutional knowledge.\",\n",
      "    \"Particular care should be taken when the product involves new and unproved manufacturing processes, or established processes which are new to the manufacturer. It may not be possible to determine the adequacy of full-scale manufacturing on the basis of successfully building prototypes or models in a laboratory and testing these prototypes or models. The engineering feasibility and production feasibility may be different because the equipment, tools, personnel, operating procedures, supervision and motivation could be different when a manufacturer scales up for routine production.\",\n",
      "    \"No design team can anticipate all factors bearing on the success of the design, but procedures for design transfer should address at least the following basic elements.\",\n",
      "    \"- First, the design and development procedures should include a qualitative assessment of the completeness and adequacy of the production specifications.\",\n",
      "    \"- Second, the procedures should ensure that all documents and articles which constitute the production specifications are reviewed and approved.\",\n",
      "    \"- Third, the procedures should ensure that only approved specifications are used to manufacture production devices.\",\n",
      "    \"The first item in the preceding list may be addressed during design transfer. The second and third elements are among the basic principles of document control and configuration management. As long as the production specifications are traditional paper documents, there is ample information available to guide manufacturers in implementing suitable procedures. When the production specifications include non-traditional means, flexibility and creativity may be needed to achieve comparable rigor.\",\n",
      "    \"Section H. Design Transfer 3/11/97 Page 37\",\n",
      "    \"Section H. Design Transfer 3/11/97 Page 38\",\n",
      "    \"#### **SECTION I. DESIGN CHANGES**\",\n",
      "    \"_I. REQUIREMENTS_\",\n",
      "    \"** 820.30(i) Design changes.**  - Each manufacturer shall establish and maintain procedures for the identification, documentation, validation or where appropriate verification, review, and approval of design changes before their implementation.\",\n",
      "    \"**Cross-reference to ISO 9001:1994 and ISO/DIS 13485 section 4.4.9 Design changes.**\",\n",
      "    \"_II. DISCUSSION AND POINTS TO CONSIDER_\",\n",
      "    \"There are two principal administrative elements involved in controlling design changes:\",\n",
      "    \"- Document controlenumeration of design documents, and tracking their status and revision history. Throughout this section, the term document is used in an inclusive sense to mean all design documents, drawings, and other items of design input or output which characterize the design or some aspect of it.\",\n",
      "    \"- Change controlenumeration of deficiencies and corrective actions arising from verification and review of the design, and tracking their resolution prior to design transfer.\",\n",
      "    \"For a small development project, an adequate process for managing change involves little more than documenting the design change, performing appropriate verification and validation, and keeping records of reviews. The main objectives are ensuring that:\",\n",
      "    \"- corrective actions are tracked to completion;\",\n",
      "    \"- changes are implemented in such a manner that the original problem is resolved and no new problems are created; or if new problems are created, they are also tracked to resolution; and\",\n",
      "    \"- design documentation is updated to accurately reflect the revised design.\",\n",
      "    \"For projects involving more than two persons, coordination and communication of design changes become vitally important. In other words, manufacturers should take steps to avoid the common situation where, for example, Jon and Marie agree to a make a change but neglect to inform Pat of their decision.\",\n",
      "    \"Medical device manufacturers are usually quite comfortable with the processes of document control and change control with respect to managing manufacturing documents. The principles of these processes are reviewed in the following paragraphs. Subsequently, we will explore how these may be applied to design activities.\",\n",
      "    \"**DOCUMENT CONTROL** . The features of a manufacturing document control system typically include the following:\",\n",
      "    \"- Documents should be identified (i.e., named and numbered) in accordance with some logical scheme which links the documents to the product or component they describe or depict and illuminates the drawing hierarchy.\",\n",
      "    \"- A master list or index of documents should be maintained which presents a comprehensive overview of the documentation which collectively defines the product and/or process.\",\n",
      "    \"- Approval procedures should be prescribed which govern entry of documents into the document control system.\",\n",
      "    \"- A history of document revisions should be maintained.\",\n",
      "    \"- Procedures for distributing copies of controlled documents and tracking their location should be prescribed.\",\n",
      "    \"- Files of controlled documents should be periodically inventoried to ensure that the contents are up to date.\",\n",
      "    \"- A person or persons should be assigned specific responsibility to oversee and carry out these procedures. It is desirable that the document cont\"\n",
      "  ]\n",
      "}\n",
      "```\n",
      "\n",
      "rovas\n",
      "Response cleaned is {'chunks': ['**Implementation of corrective actions** . Not all identified concerns result in corrective actions. The reviewers may decide that the issue is erroneous or immaterial. In most cases, however, resolution involves a design change, a requirements change, or a combination of the two. If the solution is evident, the reviewers may specify the appropriate corrective action; otherwise, an action item will be assigned to study the problem further. In any case, action items and corrective actions are normally tracked under the manufacturers change control procedures.', '**RELATIONSHIP OF DESIGN REVIEW TO VERIFICATION AND VALIDATION** . In practice, design review, verification, and validation overlap one another, and the relationship among them may be confusing. As a general rule, the sequence is: verification, review, validation, review.', 'In most cases, verification activities are completed prior to the design review, and the verification results are submitted to the reviewers along with the other design output to be reviewed. Alternatively, some verification activities may be treated as components of the design review, particularly if the verification activity is complex and requires multidisciplinary review.', 'Similarly, validation typically involves a variety of activities, including a determination that the appropriate verifications and reviews have been completed. Thus, at the conclusion of the validation effort, a review is usually warranted to assure that the validation is complete and adequate.', 'Section E. Design Review 3/11/97 Page 28', '#### **SECTION F. DESIGN VERIFICATION**', '_I. REQUIREMENTS_', '** 820.30(f) Design verification.**  - Each manufacturer shall establish and maintain procedures for verifying the device design. - Design verification shall confirm that the design output meets the design input requirements. - The results of the design verification, including identification of the design, method(s), the date, and the individual(s) performing the verification, shall be documented in the Design History File.', '**Cross-reference to ISO 9001:1994 and ISO/DIS 13485 section 4.4.7 Design verification.**', '_I. DEFINITIONS_', '**820.3(y)** _Specification_ means any requirement with which a product, process, service, or other activity must conform.', '** 820.3(z)** _Validation_ means confirmation by examination and provision of objective evidence that the particular requirements for a specific intended use can be consistently fulfilled.', '**(1)** _Process Validation_ means establishing by objective evidence that a process consistently produces a result or product meeting its predetermined specifications.', '**(2)** _Design Validation_ means establishing by objective evidence that device specifications conform with user needs and intended use(s).', '**820.3(aa)** _Verification_ means confirmation by examination and provision of objective evidence that specified requirements have been fulfilled.', '_III. DISCUSSION AND POINTS TO CONSIDER_', 'Verification and validation are associated concepts with very important differences. Various organizations have different definitions for these terms. Medical device manufacturers are encouraged to use the terminology of the quality system requirements in their internal procedures.', 'To illustrate the concepts, consider a building design analogy. In a typical scenario, the senior architect establishes the design input requirements and sketches the general appearance and construction of the building, but associates or contractors typically elaborate the details of the various mechanical systems. Verification is the process of checking at each stage whether the output conforms to requirements for that stage. For example: does the air conditioning system deliver the specified cooling capacity to each room? Is the roof rated to withstand so many newtons per square meter of wind loading? Is a fire alarm located within 50 meters of each location in the building?', 'At the same time, the architect has to keep in mind the broader question of whether the results are consistent with the ultimate user requirements. Does the air conditioning system keep the occupants comfortable throughout the building? Will the roof withstand weather extremes expected at the building site? Can the fire alarm be heard throughout the building? Those broader concerns are the essence of validation.', 'In the initial stages of design, verification is a key quality assurance technique. As the design effort progresses, verification activities become progressively more comprehensive. For example, heat or cooling delivery can be calculated and verified by the air conditioning designer, but the resultant air temperature can only be estimated. Occupant comfort is a function not only of delivered air temperature, but also humidity, heat radiation to or from nearby thermal masses, heat gain or loss through adjacent windows, etc. During the latter design phases, the interaction of these complex factors may be considered during verification of the design.', 'Validation follows successful verification, and ensures that each requirement for a particular use is fulfilled. Validation of user needs is possible only after the building is built. The air conditioning and fire alarm performance may be validated by testing and inspection, while the strength of the roof will probably be validated by some sort of analysis linked to building codes which are accepted as meeting the needs of the usersubject to possible confirmation during a subsequent severe storm.', 'Validation is the topic of Section G of this guidance document. The remainder of this section focuses on verification principles.', '**TYPES OF VERIFICATION ACTIVITIES** . Verification activities are conducted at all stages and levels of device design. The basis of verification is a three-pronged approach involving tests, inspections, and analyses. Any approach which establishes conformance with a design input requirement is an acceptable means of verifying the design with respect to that requirement. In many cases, a variety of approaches are possible.', 'Complex designs require more and different types of verification activities. The nature of verification activities varies according to the type of design output. The intent of this guidance document is not to suggest or recommend verification techniques which should be performed by device manufacturers. Rather, the manufacturer should select and apply appropriate verification techniques based on the generally accepted practices for the technologies employed in their products. Many of these practices are an integral part of the development process, and are routinely performed by developers. The objective of design controls is to ensure adequate oversight by making verification activities explicit and measuring the thoroughness of their execution. Following are a few examples of verification methods and activities.', '- Worst case analysis of an assembly to verify that components are derated properly and not subject to overstress during handling and use.', '- Thermal analysis of an assembly to assure that internal or surface temperatures do not exceed specified limits.', '- Fault tree analysis of a process or design.', '- Failure modes and effects analysis.', '- Package integrity tests.', '- Biocompatibility testing of materials.', '- Bioburden testing of products to be sterilized.', '- Comparison of a design to a previous product having an established history of successful use.', 'For some technologies, verification methods may be highly standardized. In other cases, the manufacturer may choose from a variety of applicable methods. In a few cases, the manufacturer must be creative in devising ways to verify a particular aspect of a design.', 'Some manufacturers erroneously equate production testing with verification. Whereas verification testing establishes conformance of design output with design input, the aim of production testing is to determine whether the unit under test has been correctly manufactured. In other words, production testing is designed to efficiently screen out manufacturing process errors and perhaps also to detect infant mortality failures. Typically, a small subset of functional and performance tests accomplish this objective with a high degree of accuracy. Therefore, production testing is rarely, if ever, comprehensive enough to verify the design. For example, a leakage test may be used during production to ensure that a hermetically-sealed enclosure was properly assembled. However, the leakage test may not be sensitive enough to detect long-term diffusion of gas through the packaging material.  Permeability of the packaging material is an intrinsic property of the material rather than an assembly issue, and would likely be verified using a more specialized test than is used during production.', '**DOCUMENTATION OF VERIFICATION ACTIVITIES** . Some verification methods result in a document by their nature. For example, a failure modes and effects analysis produces a table listing each system component, its postulated failure modes, and the effect of such failures on system operation.', 'Another self-documenting verification method is the traceability matrix. This method is particularly useful when the design input and output are both documents; it also has great utility in software development. In the most common form of the traceability matrix, the input requirements are enumerated in a table, and references are provided to each section in the output documents (or software modules) which address or satisfy each input requirement. The matrix can also be constructed backwards, listing each feature in the design output and tracing which input requirement bears on that feature. This reverse approach is especially useful for detecting hidden assumptions. Hidden assumptions are dangerous because they often lead to overdesign, adding unnecessary cost and complexity to the design. In other cases, hidden assumptions turn out to be undocumented design input requirements which, once exposed, can be properly tracked and verified.', 'However, many verification activities are simply some sort of structured assessment of the design output relative to the design input. When this is the case, manufacturers may document completion of verification activities by linking these activities with the signoff procedures for documents. This may be accomplished by establishing a procedure whereby each design output document must be verified and signed by designated persons. The presence of the reviewers signatures on the document signifies that the design output has been verified in accordance with the signoff procedure.', 'Section F. Design Verification 3/11/97 Page 30', 'Section F. Design Verification 3/11/97 Page 31', 'Section F. Design Verification 3/11/97 Page 32', '#### **SECTION G. DESIGN VALIDATION**', '_I. REQUIREMENTS_', '** 820.30(g) Design validation.**  - Each manufacturer shall establish and maintain procedures for validating the device design. - Design validation shall be performed under defined operating conditions on initial production units, lots, or batches, or their equivalents. - Design validation shall ensure that devices conform to defined user needs and intended uses and shall include testing of production units under actual or simulated use conditions. - Design validation shall include software validation and risk analysis, where appropriate. - The results of the design validation, including identification of the design, method(s), the date, and the individual(s) performing the validation, shall be documented in the Design History File.', '**Cross-reference to ISO 9001:1994 and ISO/DIS 13485 section 4.4.8 Design validation.**', '_II. DEFINITIONS_', '**820.3(y)** _Specification_ means any requirement with which a product, process, service, or other activity must conform.', '** 820.3(z)** _Validation_ means confirmation by examination and provision of objective evidence that the particular requirements for a specific intended use can be consistently fulfilled.', '**(1)** _Process Validation_ means establishing by objective evidence that a process consistently produces a result or product meeting its predetermined specifications.', '**(2)** _Design Validation_ means establishing by objective evidence that device specifications conform with user needs and intended use(s).', '**820.3(aa)** _Verification_ means confirmation by examination and provision of objective evidence that specified requirements have been fulfilled.', '_III. DISCUSSION AND POINTS TO CONSIDER_', 'Whereas verification is a detailed examination of aspects of a design at various stages in the development, design validation is a cumulative summation of all efforts to assure that the design will conform with user needs and intended use(s), given expected variations in components, materials, manufacturing processes, and the use environment.', '**VALIDATION PLANNING** . Planning for validation should begin early in the design process. The performance characteristics that are to be assessed should be identified, and validation methods and acceptance criteria should be established. For complex designs, a schedule of validation activities and organizational or individual responsibilities will facilitate maintaining control over the process. The validation plan should be reviewed for appropriateness, completeness, and to ensure that user needs and intended uses are addressed.', '**VALIDATION REVIEW** . Validation may expose deficiencies in the original assumptions concerning user needs and intended uses. A formal review process should be used to resolve any such deficiencies. As with verification, the perception of a deficiency might be judged insignificant or erroneous, or a corrective action may be required.', '**VALIDATION METHODS** . Many medical devices do not require clinical trials. However, all devices require clinical evaluation and should be tested in the actual or simulated use environment as a part of validation. This testing should involve devices which are manufactured using the same methods and procedures expected to be used for ongoing production. While testing is always a part of validation, additional validation methods are often used in conjunction with testing, including analysis and inspection methods, compilation of relevant scientific literature, provision of historical evidence that similar designs and/or materials are clinically safe, and full clinical investigations or clinical trials.', 'Some manufacturers have historically used their best assembly workers or skilled lab technicians to fabricate test articles, but this practice can obscure problems in the manufacturing process. It may be beneficial to ask the best workers to evaluate and critique the manufacturing process by trying it out, but pilot production should simulate as closely as possible the actual manufacturing conditions.', 'Validation should also address product packaging and labeling. These components of the design may have significant human factors implications, and may affect product performance in unexpected ways. For example, packaging materials have been known to cause electrostatic discharge (ESD) failures in electronic devices. If the unit under test is delivered to the test site in the test engineers briefcase, the packaging problem may not become evident until after release to market.', 'Validation should include simulation of the expected environmental conditions, such as temperature, humidity, shock and vibration, corrosive atmospheres, etc. For some classes of device, the environmental stresses encountered during shipment and installation far exceed those encountered during actual use, and should be addressed during validation.', 'Particular care should be taken to distinguish among customers, users, and patients to ensure that validation addresses the needs of all relevant parties. For a consumer device, the customer, user, and patient may all be the same person. At the other extreme, the person who buys the device may be different from the person who routinely uses it on patients in a clinical setting. Hospital administrators, biomedical engineers, health insurance underwriters, physicians, nurses, medical technicians, and patients have distinct and sometimes competing needs with respect to a device design.', '**VALIDATION DOCUMENTATION** . Validation is a compilation of the results of all validation activities. For a complex design, the detailed results may be contained in a variety of separate documents and summarized in a validation report. Supporting information should be explicitly referenced in the validation report and either included as an appendix or available in the design history file.', 'Section G. Design Validation 3/11/97 Page 33', 'Section G. Design Validation 3/11/97 Page 34', 'Section G. Design Validation 3/11/97 Page 35', 'Section G. Design Validation 3/11/97 Page 36', '#### **SECTION H. DESIGN TRANSFER**', '_I. REQUIREMENTS_', '** 820.30(h) Design transfer.**  - Each manufacturer shall establish and maintain procedures to ensure that the device design is correctly translated into production specifications.', '**Cross reference to ISO 9001:1994 and ISO/DIS 13485 section 4.2.3(c) Quality planning.**', '_II. DISCUSSION AND POINTS TO CONSIDER_', 'Production specifications must ensure that manufactured devices are repeatedly and reliably produced within product and process capabilities. If a manufactured device deviates outside those capabilities, performance may be compromised. Thus, the process of encapsulating knowledge about the device into production specifications is critical to device quality.', 'The level of detail necessary to accomplish this objective varies widely, based on the type of device, the relationship between the design and manufacturing organizations, and the knowledge, experience, and skills of production workers. In some cases, devices are produced by contract manufacturers who have no involvement in the development and little or no contact with the designers. At the other extreme, some devices are handcrafted by skilled artisans with extensive knowledge about the use of the product.', 'One normally associates the term production specifications with written documents, such as assembly drawings, component procurement specifications, workmanship standards, manufacturing instructions, and inspection and test specifications. While these types of documents are widely employed in medical device production, other equally acceptable means of conveying design information exist, and manufacturers have the flexibility to employ these alternate means of communication as appropriate. For example, each of the following could constitute production specifications within the meaning of the quality system requirements:', '- documentation (in electronic format as well as paper)', '- training materials, e.g., manufacturing processes, test and inspection methods', '- digital data files, e.g., programmable device files, master EPROM, computer-aided manufacturing (CAM) programming files', '- manufacturing jigs and aids, e.g., molds, sample wiring harness to be duplicated', 'Historically, shortcomings in the production specifications tend to be manifested late in the product life cycle. When the design is new, there is often intensive interaction between the design and production teams, providing ample opportunity for undocumented information flow. Later, as production experience is gained, some decoupling often occurs between design and production teams. In addition, key personnel may leave, and their replacements may lack comparable training, experience, or institutional knowledge.', 'Particular care should be taken when the product involves new and unproved manufacturing processes, or established processes which are new to the manufacturer. It may not be possible to determine the adequacy of full-scale manufacturing on the basis of successfully building prototypes or models in a laboratory and testing these prototypes or models. The engineering feasibility and production feasibility may be different because the equipment, tools, personnel, operating procedures, supervision and motivation could be different when a manufacturer scales up for routine production.', 'No design team can anticipate all factors bearing on the success of the design, but procedures for design transfer should address at least the following basic elements.', '- First, the design and development procedures should include a qualitative assessment of the completeness and adequacy of the production specifications.', '- Second, the procedures should ensure that all documents and articles which constitute the production specifications are reviewed and approved.', '- Third, the procedures should ensure that only approved specifications are used to manufacture production devices.', 'The first item in the preceding list may be addressed during design transfer. The second and third elements are among the basic principles of document control and configuration management. As long as the production specifications are traditional paper documents, there is ample information available to guide manufacturers in implementing suitable procedures. When the production specifications include non-traditional means, flexibility and creativity may be needed to achieve comparable rigor.', 'Section H. Design Transfer 3/11/97 Page 37', 'Section H. Design Transfer 3/11/97 Page 38', '#### **SECTION I. DESIGN CHANGES**', '_I. REQUIREMENTS_', '** 820.30(i) Design changes.**  - Each manufacturer shall establish and maintain procedures for the identification, documentation, validation or where appropriate verification, review, and approval of design changes before their implementation.', '**Cross-reference to ISO 9001:1994 and ISO/DIS 13485 section 4.4.9 Design changes.**', '_II. DISCUSSION AND POINTS TO CONSIDER_', 'There are two principal administrative elements involved in controlling design changes:', '- Document controlenumeration of design documents, and tracking their status and revision history. Throughout this section, the term document is used in an inclusive sense to mean all design documents, drawings, and other items of design input or output which characterize the design or some aspect of it.', '- Change controlenumeration of deficiencies and corrective actions arising from verification and review of the design, and tracking their resolution prior to design transfer.', 'For a small development project, an adequate process for managing change involves little more than documenting the design change, performing appropriate verification and validation, and keeping records of reviews. The main objectives are ensuring that:', '- corrective actions are tracked to completion;', '- changes are implemented in such a manner that the original problem is resolved and no new problems are created; or if new problems are created, they are also tracked to resolution; and', '- design documentation is updated to accurately reflect the revised design.', 'For projects involving more than two persons, coordination and communication of design changes become vitally important. In other words, manufacturers should take steps to avoid the common situation where, for example, Jon and Marie agree to a make a change but neglect to inform Pat of their decision.', 'Medical device manufacturers are usually quite comfortable with the processes of document control and change control with respect to managing manufacturing documents. The principles of these processes are reviewed in the following paragraphs. Subsequently, we will explore how these may be applied to design activities.', '**DOCUMENT CONTROL** . The features of a manufacturing document control system typically include the following:', '- Documents should be identified (i.e., named and numbered) in accordance with some logical scheme which links the documents to the product or component they describe or depict and illuminates the drawing hierarchy.', '- A master list or index of documents should be maintained which presents a comprehensive overview of the documentation which collectively defines the product and/or process.', '- Approval procedures should be prescribed which govern entry of documents into the document control system.', '- A history of document revisions should be maintained.', '- Procedures for distributing copies of controlled documents and tracking their location should be prescribed.', '- Files of controlled documents should be periodically inventoried to ensure that the contents are up to date.', '- A person or persons should be assigned specific responsibility to oversee and carry out these procedures. It is desirable that the document cont']}\n",
      "Cleaning response ```json\n",
      "{\n",
      "  \"chunks\": [\n",
      "    \"rol system be administered by a person who is not directly involved with developing or using the documents. For a small manufacturer, document control might be a part-time job for a technician or clerical staff person. More typically, one or more librarians or full-time clerical or paraprofessional employees are required to administer the system.\",\n",
      "    \"- There should be a procedure for removal and deletion of obsolete documents.\",\n",
      "    \"**CHANGE CONTROL** . Manufacturing change control is usually implemented using a set of standardized procedures similar to the following:\",\n",
      "    \"- A change request might be originated by a developer, manager, reviewer, marketing representative, user, customer, quality assurance representative, or production personnel, and identifies a design problem which the requester believes should be corrected. Change requests are typically reviewed following the manufacturers prescribed review process, and the request might be rejected, deferred, or accepted.\",\n",
      "    \"- If a change request is accepted and corrective action is straightforward, a change order might be issued on the spot to implement the change. The change order pertains to an explicitly identified document or group of documents, and specifies the detailed revision of the document content which will fix the identified problem.\",\n",
      "    \"- Often, the change request results in an assignment to developers to further study the problem and develop a suitable corrective action. If the change is extensive, wholesale revision of affected documents may be warranted in lieu of issuing change orders.\",\n",
      "    \"- Change requests and change orders should be communicated to all persons whose work might be impacted by the change.\",\n",
      "    \"Section I. Design Changes 3/11/97 Page 40\",\n",
      "    \"- It may not be practical to immediately revise documents affected by a change order. Instead, the common practice is to distribute and attach a copy of the change order to each controlled copy of the original document.\",\n",
      "    \"- Change control procedures should incorporate review and assessment of the impact of the design change on the design input requirements and intended uses.\",\n",
      "    \"- A mechanism should be established to track all change requests and change orders to ensure proper disposition.\",\n",
      "    \"- Change control procedures are usually administered by the document control staff.\",\n",
      "    \"**APPLICATION OF DOCUMENT AND CHANGE CONTROLS TO DESIGN** . The design control system has to be concerned with the creation and revision of documents, as well as the management of finished documents. Additional mechanisms are required to provide needed flexibility while preserving the integrity of design documentation. These additional mechanisms are embodied in the procedures for review and approval of various documents.\",\n",
      "    \"It is important that the design change procedures always include re-verifying and re-validating the design. Fortunately, most design changes occur early in the design process, prior to extensive design validation. Thus, for most design changes, a simple inspection is all that is required. The later in the development cycle that the change occurs, the more important the validation review becomes. There are numerous cases when seemingly innocuous design changes made late in the design phase or following release of the design to market have had disastrous consequences.\",\n",
      "    \"For example, a manufacturer encountered problems in the field with a valve sticking in a ventilator due to moisture in the breathing circuit. The problem was resolved by slightly increasing the weight of the disc.  Since the change was minor, minimal testing was performed to verify the change. Subsequently, when the revised valves entered production, significant numbers of valves began failing. Investigation revealed that the heavier disc was causing the valve cage to separate due to higher inertia. This failure mode was more serious than the original sticking problem, and resulted in a safety recall.\",\n",
      "    \"Section I. Design Changes 3/11/97 Page 41\",\n",
      "    \"Section I. Design Changes 3/11/97 Page 42\",\n",
      "    \"#### **SECTION J. DESIGN HISTORY FILE (DHF)**\",\n",
      "    \"_I. REQUIREMENTS_\",\n",
      "    \"** 820.30(j) Design history file.**\",\n",
      "    \"- Each manufacturer shall establish and maintain a DHF for each type of device.\",\n",
      "    \"- The DHF shall contain or reference the records necessary to demonstrate that the design was developed in accordance with the approved design plan and the requirements of this part.\",\n",
      "    \"**Cross-reference to ISO 9001:1994 and ISO/DIS 13485 section 4.16 Control of quality records.**\",\n",
      "    \"_II. DEFINITIONS_\",\n",
      "    \"** 820.3(e)** _Design history file_ (DHF) means a compilation of records which describes the design history of a finished device.\",\n",
      "    \"_III. DISCUSSION AND POINTS TO CONSIDER_\",\n",
      "    \"There is no specific requirement in ISO 9001 or ISO 13485 for a design history file. However, in order to market a medical device in the United States, a manufacturer must comply with the U. S. Food and Drug Administration (FDA) quality system regulation, which requires a design history file. For this reason, some guidance is provided on the U. S. FDA design history file.\",\n",
      "    \"Other national regulations require some form of documentation and records. Product documentation required by Canada, Europe, and Japan contain certain elements of the U. S. FDA design history file requirements without requiring all the elements to be compiled in a file.\",\n",
      "    \"Virtually every section of the design control requirements specifies information which should be recorded. The compilation of these records is sometimes referred to as the design history file. Throughout this guidance document, suggestions are made when warranted as to the form and content of documents contained in the design history file.\",\n",
      "    \"The primary beneficiary of the device history file is the device manufacturer. For example, in one case, a microprocessor-controlled enteral feeding pump was reported to be behaving erratically in the field. Some of the symptoms pointed to software problems. But the manufacturer admitted that they did not possess a copy of the software source code for the product. The software had been developed by a contractor who had delivered only a master EPROM (memory chip) which was duplicated by the manufacturer to install the\",\n",
      "    \"Section J. Design History File 3/11/97 Page 43\",\n",
      "    \"software in each machine. The contractor had subsequently withdrawn following a contractual dispute, leaving the manufacturer with no rights to the source code developed by the contractor, and no practical way to maintain the software. For this and other reasons, the product was the subject of a mandatory recall and all known units were collected and destroyed.\",\n",
      "    \"This is admittedly an extreme case, but many similar cases have been documented in which the manufacturer lacked design information necessary to validate a design and maintain it throughout the product life cycle. This occurs for the most innocent of reasons contracts expire, companies reorganize, employees move on to new projects or new jobs. Even when the designer is available, he or she may forget why a particular decision was made years, months, or even weeks before. Since design decisions often directly affect the well-being of device users and patients, it is to the manufacturers benefit to maintain the knowledge base which forms a basis for the product design.\",\n",
      "    \"Except for small projects, it is unusual for all design history documents to be filed in a single location. For example, many design engineers maintain laboratory notebooks which are typically retained in the engineers personal files. In addition, the design history may include memoranda and electronic mail correspondence which are stored at various physical locations. Quality system plans applicable to a development project may reside in the quality assurance department, while the chief engineer may be responsible for maintaining design and development plans. These diverse records need not be consolidated at a single location.  The intent is simply that manufacturers have access to the information when it is needed. If a manufacturer has established procedures for multiple filing systems which together satisfy that intent, there is no need to create additional procedures or records.\",\n",
      "    \"As an example of the level of detail which may be entailed, some manufacturers have policies covering laboratory notebooks. Manufacturers typically find that without such written procedures, a breakdown in communications eventually occurs, resulting in a loss of control. These procedures might address the following points:\",\n",
      "    \"- Laboratory notebooks are the property of the manufacturer, not the individual.\",\n",
      "    \"- A separate notebook is to be maintained for each project, and surrendered to the engineering librarian at the conclusion of the engineers active participation in the project.\",\n",
      "    \"- Laboratory notebooks are to be surrendered if the employee leaves the company.\",\n",
      "    \"- Product development supervisors shall review employees laboratory notebooks at specified intervals to ensure that records are complete, accurate, and legible.\",\n",
      "    \"There are no requirements on the location or organization of the design history file. In some cases, especially for simple designs, the designer will assemble and maintain the entire design history file. For larger projects, a document control system will likely be established for design documents, and these files will likely be maintained in some central location, usually within the product development department.\",\n",
      "    \"Section J. Design History File 3/11/97 Page 44\",\n",
      "    \"Based on the structure (or lack thereof) of the product development organization, more or less extensive controls will be required. For example, company policy should state unequivocally that all design history documentation is the property of the manufacturer, not the employee or contractor. Design and development contracts should explicitly specify the manufacturers right to design information and establish standards for the form and content of design documentation. Finally, certain basic design information may be maintained in a single project file in a specified location. This may include the following:\",\n",
      "    \"- Detailed design and development plan specifying design tasks and deliverables.\",\n",
      "    \"- Copies of approved design input documents and design output documents.\",\n",
      "    \"- Documentation of design reviews.\",\n",
      "    \"- Validation documentation.\",\n",
      "    \"- When applicable, copies of controlled design documents and change control records.\",\n",
      "    \"END OF DOCUMENT: DCGD.DOC (Microsoft Word 7.0) or DCGD.PDF (Adobe Acrobat format)\",\n",
      "    \"Section J. Design History File 3/11/97 Page 45\"\n",
      "  ]\n",
      "}\n",
      "```\n",
      "\n",
      "rovas\n",
      "Response cleaned is {'chunks': ['rol system be administered by a person who is not directly involved with developing or using the documents. For a small manufacturer, document control might be a part-time job for a technician or clerical staff person. More typically, one or more librarians or full-time clerical or paraprofessional employees are required to administer the system.', '- There should be a procedure for removal and deletion of obsolete documents.', '**CHANGE CONTROL** . Manufacturing change control is usually implemented using a set of standardized procedures similar to the following:', '- A change request might be originated by a developer, manager, reviewer, marketing representative, user, customer, quality assurance representative, or production personnel, and identifies a design problem which the requester believes should be corrected. Change requests are typically reviewed following the manufacturers prescribed review process, and the request might be rejected, deferred, or accepted.', '- If a change request is accepted and corrective action is straightforward, a change order might be issued on the spot to implement the change. The change order pertains to an explicitly identified document or group of documents, and specifies the detailed revision of the document content which will fix the identified problem.', '- Often, the change request results in an assignment to developers to further study the problem and develop a suitable corrective action. If the change is extensive, wholesale revision of affected documents may be warranted in lieu of issuing change orders.', '- Change requests and change orders should be communicated to all persons whose work might be impacted by the change.', 'Section I. Design Changes 3/11/97 Page 40', '- It may not be practical to immediately revise documents affected by a change order. Instead, the common practice is to distribute and attach a copy of the change order to each controlled copy of the original document.', '- Change control procedures should incorporate review and assessment of the impact of the design change on the design input requirements and intended uses.', '- A mechanism should be established to track all change requests and change orders to ensure proper disposition.', '- Change control procedures are usually administered by the document control staff.', '**APPLICATION OF DOCUMENT AND CHANGE CONTROLS TO DESIGN** . The design control system has to be concerned with the creation and revision of documents, as well as the management of finished documents. Additional mechanisms are required to provide needed flexibility while preserving the integrity of design documentation. These additional mechanisms are embodied in the procedures for review and approval of various documents.', 'It is important that the design change procedures always include re-verifying and re-validating the design. Fortunately, most design changes occur early in the design process, prior to extensive design validation. Thus, for most design changes, a simple inspection is all that is required. The later in the development cycle that the change occurs, the more important the validation review becomes. There are numerous cases when seemingly innocuous design changes made late in the design phase or following release of the design to market have had disastrous consequences.', 'For example, a manufacturer encountered problems in the field with a valve sticking in a ventilator due to moisture in the breathing circuit. The problem was resolved by slightly increasing the weight of the disc.  Since the change was minor, minimal testing was performed to verify the change. Subsequently, when the revised valves entered production, significant numbers of valves began failing. Investigation revealed that the heavier disc was causing the valve cage to separate due to higher inertia. This failure mode was more serious than the original sticking problem, and resulted in a safety recall.', 'Section I. Design Changes 3/11/97 Page 41', 'Section I. Design Changes 3/11/97 Page 42', '#### **SECTION J. DESIGN HISTORY FILE (DHF)**', '_I. REQUIREMENTS_', '** 820.30(j) Design history file.**', '- Each manufacturer shall establish and maintain a DHF for each type of device.', '- The DHF shall contain or reference the records necessary to demonstrate that the design was developed in accordance with the approved design plan and the requirements of this part.', '**Cross-reference to ISO 9001:1994 and ISO/DIS 13485 section 4.16 Control of quality records.**', '_II. DEFINITIONS_', '** 820.3(e)** _Design history file_ (DHF) means a compilation of records which describes the design history of a finished device.', '_III. DISCUSSION AND POINTS TO CONSIDER_', 'There is no specific requirement in ISO 9001 or ISO 13485 for a design history file. However, in order to market a medical device in the United States, a manufacturer must comply with the U. S. Food and Drug Administration (FDA) quality system regulation, which requires a design history file. For this reason, some guidance is provided on the U. S. FDA design history file.', 'Other national regulations require some form of documentation and records. Product documentation required by Canada, Europe, and Japan contain certain elements of the U. S. FDA design history file requirements without requiring all the elements to be compiled in a file.', 'Virtually every section of the design control requirements specifies information which should be recorded. The compilation of these records is sometimes referred to as the design history file. Throughout this guidance document, suggestions are made when warranted as to the form and content of documents contained in the design history file.', 'The primary beneficiary of the device history file is the device manufacturer. For example, in one case, a microprocessor-controlled enteral feeding pump was reported to be behaving erratically in the field. Some of the symptoms pointed to software problems. But the manufacturer admitted that they did not possess a copy of the software source code for the product. The software had been developed by a contractor who had delivered only a master EPROM (memory chip) which was duplicated by the manufacturer to install the', 'Section J. Design History File 3/11/97 Page 43', 'software in each machine. The contractor had subsequently withdrawn following a contractual dispute, leaving the manufacturer with no rights to the source code developed by the contractor, and no practical way to maintain the software. For this and other reasons, the product was the subject of a mandatory recall and all known units were collected and destroyed.', 'This is admittedly an extreme case, but many similar cases have been documented in which the manufacturer lacked design information necessary to validate a design and maintain it throughout the product life cycle. This occurs for the most innocent of reasons contracts expire, companies reorganize, employees move on to new projects or new jobs. Even when the designer is available, he or she may forget why a particular decision was made years, months, or even weeks before. Since design decisions often directly affect the well-being of device users and patients, it is to the manufacturers benefit to maintain the knowledge base which forms a basis for the product design.', 'Except for small projects, it is unusual for all design history documents to be filed in a single location. For example, many design engineers maintain laboratory notebooks which are typically retained in the engineers personal files. In addition, the design history may include memoranda and electronic mail correspondence which are stored at various physical locations. Quality system plans applicable to a development project may reside in the quality assurance department, while the chief engineer may be responsible for maintaining design and development plans. These diverse records need not be consolidated at a single location.  The intent is simply that manufacturers have access to the information when it is needed. If a manufacturer has established procedures for multiple filing systems which together satisfy that intent, there is no need to create additional procedures or records.', 'As an example of the level of detail which may be entailed, some manufacturers have policies covering laboratory notebooks. Manufacturers typically find that without such written procedures, a breakdown in communications eventually occurs, resulting in a loss of control. These procedures might address the following points:', '- Laboratory notebooks are the property of the manufacturer, not the individual.', '- A separate notebook is to be maintained for each project, and surrendered to the engineering librarian at the conclusion of the engineers active participation in the project.', '- Laboratory notebooks are to be surrendered if the employee leaves the company.', '- Product development supervisors shall review employees laboratory notebooks at specified intervals to ensure that records are complete, accurate, and legible.', 'There are no requirements on the location or organization of the design history file. In some cases, especially for simple designs, the designer will assemble and maintain the entire design history file. For larger projects, a document control system will likely be established for design documents, and these files will likely be maintained in some central location, usually within the product development department.', 'Section J. Design History File 3/11/97 Page 44', 'Based on the structure (or lack thereof) of the product development organization, more or less extensive controls will be required. For example, company policy should state unequivocally that all design history documentation is the property of the manufacturer, not the employee or contractor. Design and development contracts should explicitly specify the manufacturers right to design information and establish standards for the form and content of design documentation. Finally, certain basic design information may be maintained in a single project file in a specified location. This may include the following:', '- Detailed design and development plan specifying design tasks and deliverables.', '- Copies of approved design input documents and design output documents.', '- Documentation of design reviews.', '- Validation documentation.', '- When applicable, copies of controlled design documents and change control records.', 'END OF DOCUMENT: DCGD.DOC (Microsoft Word 7.0) or DCGD.PDF (Adobe Acrobat format)', 'Section J. Design History File 3/11/97 Page 45']}\n",
      "Cleaning response ```json\n",
      "{\n",
      "  \"chunks\": [\n",
      "    \"# MEDICAL DEVICE REGULATIONS\\n\\n## _Global overview and_ _guiding principles_\\n\\n**WORLD HEALTH ORGANIZATION**\\n\\n**GENEVA**\\n\\n\\n### MEDICAL DEVICE REGULATIONS\\n\\n##### _Global overview and_ _guiding principles_\",\n",
      "    \"WORLD HEALTH ORGANIZATION\\n\\nGENEVA\\n\\n\\nWHO Library Cataloguing-in-Publication Data\\n\\n\\nWorld Health Organization.\\n\\n\\nMedical device regulations : global overview and guiding principles.\\n\\n\\n1.Equipment and supplies  legislation 2.Equipment and supplies \\nstandards 3.Policy making 4.Risk management 5.Quality control I.Title.\\n\\n\\nISBN 92 4 154618 2 (NLM Classification: WA 26)\",\n",
      "    \"**Acknowledgements**\\nThis guide was prepared under the principal authorship of Dr Michael Cheng. It is based\\non a similar publication issued by the Pan American Health Organization (PAHO) in\\n1999 that reviewed the Canadian Medical Devices Regulatory System.\\nThe comments and suggestions made by members of the Global Harmonization Task\\nForce and those of many other reviewers are gratefully acknowledged.\\nThe Department of Blood Safety and Clinical Technology thanks the Governments of\\nItaly and Luxembourg for their continued support to its work on medical devices.\",\n",
      "    \"** World Health Organization 2003**\\n**All rights reserved.**\\n\\nThe designations employed and the presentation of the material in this publication do not imply the expression\\nof any opinion whatsoever on the part of the World Health Organization concerning the legal status of any\\ncountry, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries.\",\n",
      "    \"The mention of specific organizations, companies or products does not imply that they are endorsed or\\nrecommended by the World Health Organization in preference to others of a similar nature that are not\\nmentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial\\ncapital letters.\",\n",
      "    \"Neither the World Health Organization nor the principal author warrant that the information contained in\\nthis publication is complete and correct and shall not be liable for any damages incurred as a result of its use.\",\n",
      "    \"Publications of the World Health Organization can be obtained from Marketing and Dissemination, World\\nHealth Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (Fax: +41 22 791 4857; email:\\nbookorders@who.int). Requests for permission to reproduce or translate WHO publications  whether for\\nsale or for noncommercial distribution  should be addressed to Publications, at the above address (fax: +41\\n22 791 4806; email: permissions@who.int).\",\n",
      "    \"Designed by minimum graphics\\nPrinted in France\\n\\n##### **Contents**\\n\\nForeword v\\n\\nGlossary vii\\n\\nNote on the definition of medical devices vii\\n\\n**Chapter 1. Introduction** **1**\\n\\n**Chapter 2. Medical device safety** **3**\\n2.1 Medical device safety and risk management 3\\n2.2 Effectiveness/performance of medical devices 4\\n2.3 Phases in the life span of a medical device 5\\n2.4 Participants in ensuring the safety of medical devices 6\\n2.5 The role of each participant/stakeholder 7\\n2.6 Shared responsibility for medical device safety and performance 8\\n\\n**Chapter 3. Governmental regulation of medical devices** **9**\\n3.1 Critical elements for regulatory attention 9\\n3.2 Stages of regulatory control 10\\n3.3 A common framework for medical device regulations 10\\n3.4 Regulatory tools and general requirements 11\\n\\n3.4.1 Product control 11\\n\\n3.4.2 Vendor establishment control 12\\n\\n3.4.3 Post-market surveillance/vigilance 12\\n3.4.4 Quality system requirements 13\\n\\n**Chapter 4. Global Harmonization Task Force (GHTF)** **15**\\n4.1 Objectives 15\\n4.2 Scope of the four GHTF study groups 15\\n\\n4.3 Benefits of the GHTF 16\\n\\n4.4 Final documents from the GHTF 17\\n\\n4.5 Global Medical Device Nomenclature (GMDN) 17\\n\\n**Chapter 5. Standards** **18**\\n\\n5.1 What are standards? 18\\n\\n5.2 Why do we need standards? 19\\n5.3 Voluntary and mandatory standards 19\\n5.4 Standards development process 20\\n5.5 Conformity assessment with standards 20\\n5.6 National and international standards systems 21\\n\\n5.7 Identification of standards 21\\n\\n5.8 Current trends in the use of standards in medical device regulations 22\\n\\n**Chapter 6. Optimizing the use of regulatory resources** **24**\\n6.1 Increasing knowledge of the medical device sector 24\\n\\n6.2 Establishing basic regulatory programmes 25\\n6.2.1 Basic legislation 25\\n6.2.2 Sharing problem reports 25\\n6.3 Drafting a comprehensive policy or guideline on medical device\\n\\nmanagement 26\\n6.3.1 Advantages of a national policy 26\\n\\n6.3.2 Classification of medical devices 26\\n\\n6.3.3 Medical device product control 27\\n6.3.4 Product representation control 27\\n\\n6.3.5 Vendor establishment control 28\\n\\n6.3.6 The control of home-use, refurbished, and donated devices 28\\n6.3.7 The re-use of medical devices that are labelled for single use 29\\n\\n6.3.8 Post-market surveillance 30\\n\\n6.3.9 Recognition and use of established national or\\n\\ninternational standards 31\\n\\n6.4 Promoting compliance and cooperation 31\\n6.5 Setting priorities for regulatory programme development 32\\n6.6 Cautions in interpreting medical device export certificates 34\\n\\n**Chapter 7. Priorities on the international agenda** **36**\\n\\nAnnex 1. Resources for medical device information 37\\n\\nAnnex 2. Final documents of the GHTF as they relate to the Common\\nRegulatory Framework 40\\nAnnex 3. Relationship between ISO9001:1994 and ISO13485:1996 41\\n\\nAnnex 4. Aide-mmoire for National Medical Device Administrations 42\",\n",
      "    \"**iii**\\n\\nMEDICAL DEVICE REGULATIONS\\n\\n##### **Foreword**\\n\\nThe term _medical devices_ covers a vast range of equipment, from simple tongue depressors\\nto haemodialysis machines. Like medicines and other health technologies, they are essential\\nfor patient care  at the bedside, at the rural health clinic or at the large, specialized\\nhospital.\",\n",
      "    \"Medical devices also cost governments a substantial amount of money. In 2000, the\\nestimated one and a half million different medical devices available on the market\\nrepresented over US$145 billion. With innovation and the rapid advancement of\\ntechnologies, medical devices are currently one of the fastest growing industries, and the\\nglobal market figure for 2006 is expected to exceed US$260 billion.\",\n",
      "    \"Yet many countries lack access to high-quality devices and equipment that are\\nappropriate for their specific epidemiological needs. This is particularly true in developing\\ncountries, where health technology assessments are rare and where little regulatory controls\\nexist to prevent the importation or use of substandard devices. With the vast majority of\\ndevices in developing countries being imported, this leaves them prey to unscrupulous\\nmarket influences and puts patients lives at risk.\",\n",
      "    \"Governments need to put in place policies that will address all elements related to\\nmedical devices, ranging from access to high quality, affordable products, through to\\ntheir safe and appropriate use and disposal. The health technology life cycle diagram\\n(back cover) illustrates the policy process that needs to be in place. However, policies will\\nbe unsuccessful unless they are translated into national regulations that are enforced by\\nlegislation and correlating sanctions, and that form an integral part of the overall national\\nhealth system.\",\n",
      "    \"Surprisingly, regulatory controls for medical devices are scarce in the developing world,\\neven though implementation of national medical device regulations will often address the\\nvery issues raised in countries as major concerns for patient safety. Examples of these\\nissues include the illegal re-processing and re-packaging of used syringes for re-sale; the\\navailability on the market of equipment that fails minimum quality and safety standards;\\nor simply no trace of what devices are being sold in the country, nor by whom. Such a\\nlisting is essential to enable governments to issue alerts or recalls for unsafe or ineffective\\nitems.\",\n",
      "    \"The purpose of this publication is to provide guidance to Member States wishing to\\ncreate or modify their own regulatory systems for medical devices. It is recognized that\\nthere is no single template that will respond to the needs of every country. Some countries\\nmay have production facilities that will require good manufacturing practice and complex\\nquality controls; others may depend principally on the donation of equipment from external\\nsources and need different policies to protect their population against unsafe and\\ninappropriate technology. Resources, both human and financial, remain a significant factor\\nin the progressive development of national regulatory authorities. Nevertheless, there are\\nmany ways that governments can benefit from the wealth of experience of others, and\",\n",
      "    \"start to build efficient medical device regulatory systems. This publication highlights the\\nmost important of these.\\nIn essence, governments are encouraged to follow the growing movement towards\\nharmonized regulatory systems because a proliferation of different national regulations\\nincreases costs, hinders access to health care technologies, and can even unwittingly\\njeopardize the safety of the patient.\",\n",
      "    \"Secondly, Member States can adopt where appropriate the device approvals of the\\nadvanced regulatory systems, since this process represents a vast, and often unnecessary\\ndrain on scarce resources.\",\n",
      "    \"This will allow countries with weak regulatory systems to place emphasis and initial\\nresources on areas such as vendor and device registration, training, and surveillance and\\ninformation exchange systems on the assessment of medical devices in use.\\nWHO is reinforcing its role in providing technical support to Member States who wish\\nto implement improved medical device regulatory systems. We hope that this guide provides\\na useful framework within which countries can assess and address their needs to protect\\ntheir populations from the risks of unsafe technology.\",\n",
      "    \"_Dr Vladimir K. Lepakhin_\\n\\nAssistant Director-General\\n\\nHealth Technology and Pharmaceuticals\\n\\n**vi**\\n\\nMEDICAL DEVICE REGULATIONS\\n\\n##### **Glossary**\\n\\n**Note on the definition of medical devices**\\n\\nThe term medical devices includes everything from highly sophisticated computerized\\nmedical equipment down to simple wooden tongue depressors. The intended primary\\nmode of action of a medical device on the human body, in contrast with that of medicinal\\nproducts, is not metabolic, immunological, or pharmacological.\",\n",
      "    \"Several different international classification systems for medical devices are still in use\\nin the world today. The World Health Organization, with its partners, is working towards\\nachieving harmonization in medical device nomenclature, which will have a significant\\nimpact on patient safety (see section 4.5). This is particularly important to be able to\\nidentify adverse incident reports and recalls.\",\n",
      "    \"The Global Harmonization Task Force has proposed the following harmonized definition\\nfor medical devices (see GHTF document SG1/N029R11).\\n\\nMedical device means any instrument, apparatus, implement, machine, appliance,\\nimplant, _in vitro_ reagent or calibrator, software, material or other similar or related\\narticle, intended by the manufacturer to be used, alone or in combination, for human\\nbeings for one or more of the specific purposes of:\\n\\n   - diagnosis, prevention, monitoring, treatment or alleviation of disease\\n\\n   - diagnosis, monitoring, treatment, alleviation of or compensation for an injury\\n\\n   - investigation, replacement, modification, or support of the anatomy or of a\\nphysiological process\\n\\n   - supporting or sustaining life\\n\\n   - control of conception\\n\\n   - disinfection of medical devices\\n\\n   - providing information for medical purposes by means of _in vitro_ examination of\\nspecimens derived from the human body and which does not achieve its primary\\nintended action in or on the human body by pharmacological, immunological or\\nmetabolic means, but which may be assisted in its function by such means.\",\n",
      "    \"_Note:_ An accessory is not considered to be a medical device. However, where an\\naccessory is intended specifically by its manufacturer to be used together with the\\nparent medical device to enable the medical device to achieve its intended purpose,\\nit should be subject to the same procedures and GHTF guidance documents as apply\\nto the medical device itself.\",\n",
      "    \"_Note:_ The definition of a device for _in vitro_ examination includes, for example,\\nreagents, calibrators, sample collection devices, control materials, and related\\ninstruments or apparatus. The information provided by such an _in vitro_ diagnostic\\ndevice may be for diagnostic, monitoring or compatibility purposes. In some\\njurisdictions, reagents and the like may be covered by separate regulations.\",\n",
      "    \"_Note:_ Products, which are considered to be medical devices in some jurisdictions\\nbut for which there is not yet a harmonized approach, are:\\n\\n           - aids for disabled/handicapped people\\n\\n           - devices for the treatment/diagnosis of diseases and injuries in animals\\n\\n           - spare parts for medical devices\\n\\n           - devices incorporating animal and human tissues which may meet the requirements\\nof the above definition but be subject to different controls.\",\n",
      "    \"A country may develop its own guidance document for any detailed descriptions they\\nmay require.\\n***\\n\\nTerms in regulations are legally binding and therefore have restricted meanings. For\\nexample, manufacturer, distributor, vendors, retailers all have precise definitions in\\nregulations, and their definitions vary in the regulations of different countries. A regulation\\nnormally has an accompanying list of definitions of terms used. A harmonized definition\\nof many important terms such as performance, effectiveness, vigilance and incidents, are\\nstill under development.\",\n",
      "    \"This guideline, however, is written to promote a general understanding of medical\\ndevice issues and their regulations. Therefore, the words used here are non-binding but\\ncarry general meanings.\",\n",
      "    \"**Adverse Event** a problem that can or does result in permanent impairment, injury or\\ndeath to the patient or the user.\",\n",
      "    \"**Effectiveness** a device is clinically effective when it produces the effect intended by the\\nmanufacturer relative to the medical conditions. For example, if a device is intended\\nfor pain relief, one expects the device to actually relieve pain and would also expect\\nthe manufacturer to possess objective evidence, such as clinical test results, that the\\ndevice does in fact relieve pain. Effectiveness can be thought of as efficacy in the real\\nworld clinical environment.\",\n",
      "    \"**Efficacy** not used in this guideline, generally means effectiveness under an ideal controlled\\nsetting.\",\n",
      "    \"**Incident** an unusual (unexpected) event associated with the use of a medical device.\\nMay or may not lead to problems. All incidents should be investigated for potential\\nproblems (see section 6.3.8).\",\n",
      "    \"**Manufacturer** any person who produces medical devices.\",\n",
      "    \"**Performance** means technical performance plus effectiveness (see section 2.2).\",\n",
      "    \"**Person** includes an establishment (in that case, person-in-charge or person responsible).\",\n",
      "    \"**Placing on-market** Pre-market and post-market are established regulatory terms.\\nPost-market really refers to when the products are on the market. Placing onmarket aims to distinguish the regulations governing the commercial aspects\",\n",
      "    \"commensurate with the life span diagram (a memory anchor used in this publication).\\nPlacing on-market also provides a convenient reference for countries that wish to\\nestablish regulatory programmes.\",\n",
      "    \"**Post-market surveillance and vigilance** The different terms in post-market surveillance\\nare currently used by different countries with varying meanings. The Global\\nHarmonization Task Force is in the process of defining the different terms. This\\nGuide uses the US FDA terms which are well described on the internet (www.fda.gov/\\ncdrh/postsurv/).\",\n",
      "    \"In this Guide post-market surveillance is a broad term that covers any and all\\nmonitoring activities including the vigilance system for medical devices in use.\",\n",
      "    \"In Europe, vigilance concerns the responsability of the manufacturer to inform the\\ncompetent authority of incidents, according to national/European legislation.\",\n",
      "    \"**Problem** a broad term that covers possible faults of the device, difficulties in using the\\ndevice or an undesirable outcome associated with the use of the device. A problem\\nmay not lead to an adverse event but corrective or preventive actions are required.\",\n",
      "    \"**Vendor** any person who sells medical devices. This person could be a manufacturer, an\\nimporter, a distributor, a wholesaler, or a retailer.\\n\\n\\n**ix**\\n\\nGLOSSARY\\n\\nCHAPTER 1\\n\\n##### **Introduction**\\n\\nThe regulation of medical devices is a vast and rapidly evolving field that is often\\ncomplicated by legal technicalities. For example, legal terms and their meanings are\\nsometimes non-uniform even within one regulatory system. In an attempt to make this\\ncomplex subject easier to grasp, this Guide presents a common framework that integrates\\nthe regulatory systems of the five countries or regions with the most advanced medical\\ndevice regulations. Non-technical language, graphics, tables and memory anchors are\\nused to present an overview of medical device safety issues and regulatory philosophy.\",\n",
      "    \"The Guide begins by explaining how safety is a risk management issue, and how\\noptimum safety and performance require cooperation among all who are involved in the\\nlife span of a medical device. The critical elements of medical device regulations are\\nillustrated using a common framework for regulatory development; as well as the current\\nregulatory tools of the Global Harmonization Task Force (GHTF) and all the key\\ndocuments it has issued in the past three years.\",\n",
      "    \"Understanding the different phases in the life span of a medical device and the common\\nframework are first steps to successful harmonization and simplification worldwide.\",\n",
      "    \"**Summary of contents**\\n**Chapter 2** describes the nature of medical device safety as a risk management process that\\nmust encompass the life span of medical devices from their conception to disposal. A Life\\nSpan Diagram facilitates understanding and serves as a memory anchor. Optimum safety\\nand performance require cooperation among all those involved in the life span of a medical\\ndevice: the manufacturer, importer/vendor, government, user and public  each has a\\nspecific role to play in risk management.\",\n",
      "    \"**Chapter 3** considers the role of the government. The critical elements of the life span of\\nmedical devices that require regulatory attention are highlighted. A common regulatory\\nframework is proposed integrating the five regulatory systems with the most advanced\\nmedical device regulations, along with the applicable regulatory tools.\",\n",
      "    \"**Chapter 4** introduces the work of the Global Harmonization Task Force (GHTF), whose\\nmission is to harmonize the implementation of medical device regulations across the globe.\\nThe objectives of its four Study Groups as they relate to the Medical Device Life Span\\nDiagram are described. In order to facilitate ease of reference for countries wishing to\\nadopt them, Annex 2 provides a summary of all final GHTF documents as they relate to\\nthe common regulatory framework.\",\n",
      "    \"**Chapter 5** provides an introduction to standards. It describes the use of voluntary standards\\nand their increasing prominence in medical device regulation. Countries are urged to\\nestablish national standards management systems and, where possible, to adopt\\ninternational standards and to participate in their development and amendment.\",\n",
      "    \"**Chapter 6** suggests various steps for governments seeking to establish an affordable\\nregulatory programme from the ground up for ensuring the safety and performance of\\nmedical devices. The need for knowledge, policies, legislation and enforcement of medical\\ndevice safety is discussed. Governments are encouraged to avoid setting up resource\\ndemanding pre-market regulations, but rather to take advantage of existing approval\\nsystems and international standards. An explanation of the meaning of different medical\\ndevice export certificates is offered. Cooperation from all stakeholders is encouraged\\nto increase programme effectiveness while reducing regulatory costs.\",\n",
      "    \"**Chapter 7** proposes two actions that could be undertaken at the international level to\\naddress priority needs for product control and their safe and effective use:\\n\\ni) The establishment of a uniform certification format that will be used globally so that\\ndifferent countries can certify that medical devices being exported comply with their\\ndomestic regulatory requirements. This certification will help the importing countries\\nto regulate medical devices.\",\n",
      "    \"ii) Support for a centre to coordinate and relay medical device problems, recalls, and\\nalerts to the global community. This will enhance the safety and performance of medical\\ndevices in use around the world.\",\n",
      "    \"**Annexes 14** also provide a selection of further reading and information on the issues\\nraised in this publication.\",\n",
      "    \"**2**\\n\\nMEDICAL DEVICE REGULATIONS\\n\\nCHAPTER 2\\n##### **Medical device safety**\\n\\nThe optimum assurance of medical device safety has several essential elements:\\n\\n - Absolute safety cannot be guaranteed\\n\\n  - It is a risk management issue\\n\\n  - It is closely aligned with device effectiveness/performance\\n\\n  - It must be considered throughout the life span of the device\\n\\n  - It requires shared responsibility among the stakeholders\\n\\nEach of these features is discussed below.\",\n",
      "    \"**2.1 Medical device safety and risk management**\\nSafety can only be considered in relative terms. All devices carry a certain degree of risk\\nand could cause problems in specific circumstances. Many medical device problems cannot\\nbe detected until extensive market experience is gained. For example, an implantable\\ndevice may fail in a manner that was not predictable at the time of implantation; the\\nfailure may reflect conditions unique to certain patients. For other devices, component\\nfailure can also be unpredictable or random. The current approach to device safety is to\\nestimate the potential of a device becoming a hazard that could result in safety problems\\nand harm. This estimate is often referred to as the _**risk assessment**_ .\",\n",
      "    \"Hazard is a potential for an adverse event, a source of danger. Risk is a measure of the\\ncombination of (1) the hazard; (2) the likelihood of occurrence of the adverse event; (3)\\nthe severity or overall impact. Risk assessment begins with _**risk analysis**_ to identify all\\npossible hazards, followed by _**risk evaluation**_ to estimate the risk of each hazard. In\\ngeneral, risk assessment is based on experience, evidence, computation, or even guesswork.\\nRisk assessment is complex, as it can be influenced by personal perception and other\\nfactors such as cultural background, economic conditions, and political climates.\",\n",
      "    \"In practice, risk assessment of medical devices is based on the experience of health care\\nprofessionals and on safety design engineering. In the United States, governmental risk\\nassessment of medical devices is based mainly on recommendations from members of 16\\nmedical specialty panels, and devices are categorized into three classes. In the European\\nUnion and Canada, the classification schemes for medical devices are predominantly rulebased. These rules categorize medical devices according to their perceived potential hazards.\",\n",
      "    \"Canada assigns four classes of devices. The European Union assigns three classes with\\nclass II being sub-divided into IIa and IIb (effectively, also four classes). The Global\\nHarmonization Task Force (GHTF) is proposing a harmonized scheme for medical device\\nclassification (see www.GHTF.org document SG1/N015R18).\",\n",
      "    \"In classifying devices, potential areas of hazard that warrant consideration include the\\ndegree of invasiveness, duration of contact, the body system affected, and local versus\\nsystemic effects. An invasive device is usually considered to have higher potential hazard\\nthan an equivalent non-invasive device (e.g. there are invasive and non-invasive blood\\npressure monitors). Similarly, devices that have a long duration of contact, that affect\\nvital organs such the heart or the great arteries, or that have systemic effects are assigned\\nhigher classes of potential hazard or risk. The degree of regulation imposed on any device\\nis proportional to its potential hazard. This approach is known as _**risk management**_ .\",\n",
      "    \"The first requirement of the Essential principles of safety and performance of medical\\ndevices recommended by the GHTF (SG1-N020R5) illustrates such an approach. It states\\nthat:\\n\\nMedical devices should be designed and manufactured in such a way that, when\\nused under the conditions and for the purposes intended and, where applicable, by\\nvirtue of the technical knowledge, experience, education or training of intended\\nusers, they will not compromise the clinica\"\n",
      "  ]\n",
      "}\n",
      "```\n",
      "\n",
      "rovas\n",
      "Response cleaned is {'chunks': ['# MEDICAL DEVICE REGULATIONS\\n\\n## _Global overview and_ _guiding principles_\\n\\n**WORLD HEALTH ORGANIZATION**\\n\\n**GENEVA**\\n\\n\\n### MEDICAL DEVICE REGULATIONS\\n\\n##### _Global overview and_ _guiding principles_', 'WORLD HEALTH ORGANIZATION\\n\\nGENEVA\\n\\n\\nWHO Library Cataloguing-in-Publication Data\\n\\n\\nWorld Health Organization.\\n\\n\\nMedical device regulations : global overview and guiding principles.\\n\\n\\n1.Equipment and supplies  legislation 2.Equipment and supplies \\nstandards 3.Policy making 4.Risk management 5.Quality control I.Title.\\n\\n\\nISBN 92 4 154618 2 (NLM Classification: WA 26)', '**Acknowledgements**\\nThis guide was prepared under the principal authorship of Dr Michael Cheng. It is based\\non a similar publication issued by the Pan American Health Organization (PAHO) in\\n1999 that reviewed the Canadian Medical Devices Regulatory System.\\nThe comments and suggestions made by members of the Global Harmonization Task\\nForce and those of many other reviewers are gratefully acknowledged.\\nThe Department of Blood Safety and Clinical Technology thanks the Governments of\\nItaly and Luxembourg for their continued support to its work on medical devices.', '** World Health Organization 2003**\\n**All rights reserved.**\\n\\nThe designations employed and the presentation of the material in this publication do not imply the expression\\nof any opinion whatsoever on the part of the World Health Organization concerning the legal status of any\\ncountry, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries.', 'The mention of specific organizations, companies or products does not imply that they are endorsed or\\nrecommended by the World Health Organization in preference to others of a similar nature that are not\\nmentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial\\ncapital letters.', 'Neither the World Health Organization nor the principal author warrant that the information contained in\\nthis publication is complete and correct and shall not be liable for any damages incurred as a result of its use.', 'Publications of the World Health Organization can be obtained from Marketing and Dissemination, World\\nHealth Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (Fax: +41 22 791 4857; email:\\nbookorders@who.int). Requests for permission to reproduce or translate WHO publications  whether for\\nsale or for noncommercial distribution  should be addressed to Publications, at the above address (fax: +41\\n22 791 4806; email: permissions@who.int).', 'Designed by minimum graphics\\nPrinted in France\\n\\n##### **Contents**\\n\\nForeword v\\n\\nGlossary vii\\n\\nNote on the definition of medical devices vii\\n\\n**Chapter 1. Introduction** **1**\\n\\n**Chapter 2. Medical device safety** **3**\\n2.1 Medical device safety and risk management 3\\n2.2 Effectiveness/performance of medical devices 4\\n2.3 Phases in the life span of a medical device 5\\n2.4 Participants in ensuring the safety of medical devices 6\\n2.5 The role of each participant/stakeholder 7\\n2.6 Shared responsibility for medical device safety and performance 8\\n\\n**Chapter 3. Governmental regulation of medical devices** **9**\\n3.1 Critical elements for regulatory attention 9\\n3.2 Stages of regulatory control 10\\n3.3 A common framework for medical device regulations 10\\n3.4 Regulatory tools and general requirements 11\\n\\n3.4.1 Product control 11\\n\\n3.4.2 Vendor establishment control 12\\n\\n3.4.3 Post-market surveillance/vigilance 12\\n3.4.4 Quality system requirements 13\\n\\n**Chapter 4. Global Harmonization Task Force (GHTF)** **15**\\n4.1 Objectives 15\\n4.2 Scope of the four GHTF study groups 15\\n\\n4.3 Benefits of the GHTF 16\\n\\n4.4 Final documents from the GHTF 17\\n\\n4.5 Global Medical Device Nomenclature (GMDN) 17\\n\\n**Chapter 5. Standards** **18**\\n\\n5.1 What are standards? 18\\n\\n5.2 Why do we need standards? 19\\n5.3 Voluntary and mandatory standards 19\\n5.4 Standards development process 20\\n5.5 Conformity assessment with standards 20\\n5.6 National and international standards systems 21\\n\\n5.7 Identification of standards 21\\n\\n5.8 Current trends in the use of standards in medical device regulations 22\\n\\n**Chapter 6. Optimizing the use of regulatory resources** **24**\\n6.1 Increasing knowledge of the medical device sector 24\\n\\n6.2 Establishing basic regulatory programmes 25\\n6.2.1 Basic legislation 25\\n6.2.2 Sharing problem reports 25\\n6.3 Drafting a comprehensive policy or guideline on medical device\\n\\nmanagement 26\\n6.3.1 Advantages of a national policy 26\\n\\n6.3.2 Classification of medical devices 26\\n\\n6.3.3 Medical device product control 27\\n6.3.4 Product representation control 27\\n\\n6.3.5 Vendor establishment control 28\\n\\n6.3.6 The control of home-use, refurbished, and donated devices 28\\n6.3.7 The re-use of medical devices that are labelled for single use 29\\n\\n6.3.8 Post-market surveillance 30\\n\\n6.3.9 Recognition and use of established national or\\n\\ninternational standards 31\\n\\n6.4 Promoting compliance and cooperation 31\\n6.5 Setting priorities for regulatory programme development 32\\n6.6 Cautions in interpreting medical device export certificates 34\\n\\n**Chapter 7. Priorities on the international agenda** **36**\\n\\nAnnex 1. Resources for medical device information 37\\n\\nAnnex 2. Final documents of the GHTF as they relate to the Common\\nRegulatory Framework 40\\nAnnex 3. Relationship between ISO9001:1994 and ISO13485:1996 41\\n\\nAnnex 4. Aide-mmoire for National Medical Device Administrations 42', '**iii**\\n\\nMEDICAL DEVICE REGULATIONS\\n\\n##### **Foreword**\\n\\nThe term _medical devices_ covers a vast range of equipment, from simple tongue depressors\\nto haemodialysis machines. Like medicines and other health technologies, they are essential\\nfor patient care  at the bedside, at the rural health clinic or at the large, specialized\\nhospital.', 'Medical devices also cost governments a substantial amount of money. In 2000, the\\nestimated one and a half million different medical devices available on the market\\nrepresented over US$145 billion. With innovation and the rapid advancement of\\ntechnologies, medical devices are currently one of the fastest growing industries, and the\\nglobal market figure for 2006 is expected to exceed US$260 billion.', 'Yet many countries lack access to high-quality devices and equipment that are\\nappropriate for their specific epidemiological needs. This is particularly true in developing\\ncountries, where health technology assessments are rare and where little regulatory controls\\nexist to prevent the importation or use of substandard devices. With the vast majority of\\ndevices in developing countries being imported, this leaves them prey to unscrupulous\\nmarket influences and puts patients lives at risk.', 'Governments need to put in place policies that will address all elements related to\\nmedical devices, ranging from access to high quality, affordable products, through to\\ntheir safe and appropriate use and disposal. The health technology life cycle diagram\\n(back cover) illustrates the policy process that needs to be in place. However, policies will\\nbe unsuccessful unless they are translated into national regulations that are enforced by\\nlegislation and correlating sanctions, and that form an integral part of the overall national\\nhealth system.', 'Surprisingly, regulatory controls for medical devices are scarce in the developing world,\\neven though implementation of national medical device regulations will often address the\\nvery issues raised in countries as major concerns for patient safety. Examples of these\\nissues include the illegal re-processing and re-packaging of used syringes for re-sale; the\\navailability on the market of equipment that fails minimum quality and safety standards;\\nor simply no trace of what devices are being sold in the country, nor by whom. Such a\\nlisting is essential to enable governments to issue alerts or recalls for unsafe or ineffective\\nitems.', 'The purpose of this publication is to provide guidance to Member States wishing to\\ncreate or modify their own regulatory systems for medical devices. It is recognized that\\nthere is no single template that will respond to the needs of every country. Some countries\\nmay have production facilities that will require good manufacturing practice and complex\\nquality controls; others may depend principally on the donation of equipment from external\\nsources and need different policies to protect their population against unsafe and\\ninappropriate technology. Resources, both human and financial, remain a significant factor\\nin the progressive development of national regulatory authorities. Nevertheless, there are\\nmany ways that governments can benefit from the wealth of experience of others, and', 'start to build efficient medical device regulatory systems. This publication highlights the\\nmost important of these.\\nIn essence, governments are encouraged to follow the growing movement towards\\nharmonized regulatory systems because a proliferation of different national regulations\\nincreases costs, hinders access to health care technologies, and can even unwittingly\\njeopardize the safety of the patient.', 'Secondly, Member States can adopt where appropriate the device approvals of the\\nadvanced regulatory systems, since this process represents a vast, and often unnecessary\\ndrain on scarce resources.', 'This will allow countries with weak regulatory systems to place emphasis and initial\\nresources on areas such as vendor and device registration, training, and surveillance and\\ninformation exchange systems on the assessment of medical devices in use.\\nWHO is reinforcing its role in providing technical support to Member States who wish\\nto implement improved medical device regulatory systems. We hope that this guide provides\\na useful framework within which countries can assess and address their needs to protect\\ntheir populations from the risks of unsafe technology.', '_Dr Vladimir K. Lepakhin_\\n\\nAssistant Director-General\\n\\nHealth Technology and Pharmaceuticals\\n\\n**vi**\\n\\nMEDICAL DEVICE REGULATIONS\\n\\n##### **Glossary**\\n\\n**Note on the definition of medical devices**\\n\\nThe term medical devices includes everything from highly sophisticated computerized\\nmedical equipment down to simple wooden tongue depressors. The intended primary\\nmode of action of a medical device on the human body, in contrast with that of medicinal\\nproducts, is not metabolic, immunological, or pharmacological.', 'Several different international classification systems for medical devices are still in use\\nin the world today. The World Health Organization, with its partners, is working towards\\nachieving harmonization in medical device nomenclature, which will have a significant\\nimpact on patient safety (see section 4.5). This is particularly important to be able to\\nidentify adverse incident reports and recalls.', 'The Global Harmonization Task Force has proposed the following harmonized definition\\nfor medical devices (see GHTF document SG1/N029R11).\\n\\nMedical device means any instrument, apparatus, implement, machine, appliance,\\nimplant, _in vitro_ reagent or calibrator, software, material or other similar or related\\narticle, intended by the manufacturer to be used, alone or in combination, for human\\nbeings for one or more of the specific purposes of:\\n\\n   - diagnosis, prevention, monitoring, treatment or alleviation of disease\\n\\n   - diagnosis, monitoring, treatment, alleviation of or compensation for an injury\\n\\n   - investigation, replacement, modification, or support of the anatomy or of a\\nphysiological process\\n\\n   - supporting or sustaining life\\n\\n   - control of conception\\n\\n   - disinfection of medical devices\\n\\n   - providing information for medical purposes by means of _in vitro_ examination of\\nspecimens derived from the human body and which does not achieve its primary\\nintended action in or on the human body by pharmacological, immunological or\\nmetabolic means, but which may be assisted in its function by such means.', '_Note:_ An accessory is not considered to be a medical device. However, where an\\naccessory is intended specifically by its manufacturer to be used together with the\\nparent medical device to enable the medical device to achieve its intended purpose,\\nit should be subject to the same procedures and GHTF guidance documents as apply\\nto the medical device itself.', '_Note:_ The definition of a device for _in vitro_ examination includes, for example,\\nreagents, calibrators, sample collection devices, control materials, and related\\ninstruments or apparatus. The information provided by such an _in vitro_ diagnostic\\ndevice may be for diagnostic, monitoring or compatibility purposes. In some\\njurisdictions, reagents and the like may be covered by separate regulations.', '_Note:_ Products, which are considered to be medical devices in some jurisdictions\\nbut for which there is not yet a harmonized approach, are:\\n\\n           - aids for disabled/handicapped people\\n\\n           - devices for the treatment/diagnosis of diseases and injuries in animals\\n\\n           - spare parts for medical devices\\n\\n           - devices incorporating animal and human tissues which may meet the requirements\\nof the above definition but be subject to different controls.', 'A country may develop its own guidance document for any detailed descriptions they\\nmay require.\\n***\\n\\nTerms in regulations are legally binding and therefore have restricted meanings. For\\nexample, manufacturer, distributor, vendors, retailers all have precise definitions in\\nregulations, and their definitions vary in the regulations of different countries. A regulation\\nnormally has an accompanying list of definitions of terms used. A harmonized definition\\nof many important terms such as performance, effectiveness, vigilance and incidents, are\\nstill under development.', 'This guideline, however, is written to promote a general understanding of medical\\ndevice issues and their regulations. Therefore, the words used here are non-binding but\\ncarry general meanings.', '**Adverse Event** a problem that can or does result in permanent impairment, injury or\\ndeath to the patient or the user.', '**Effectiveness** a device is clinically effective when it produces the effect intended by the\\nmanufacturer relative to the medical conditions. For example, if a device is intended\\nfor pain relief, one expects the device to actually relieve pain and would also expect\\nthe manufacturer to possess objective evidence, such as clinical test results, that the\\ndevice does in fact relieve pain. Effectiveness can be thought of as efficacy in the real\\nworld clinical environment.', '**Efficacy** not used in this guideline, generally means effectiveness under an ideal controlled\\nsetting.', '**Incident** an unusual (unexpected) event associated with the use of a medical device.\\nMay or may not lead to problems. All incidents should be investigated for potential\\nproblems (see section 6.3.8).', '**Manufacturer** any person who produces medical devices.', '**Performance** means technical performance plus effectiveness (see section 2.2).', '**Person** includes an establishment (in that case, person-in-charge or person responsible).', '**Placing on-market** Pre-market and post-market are established regulatory terms.\\nPost-market really refers to when the products are on the market. Placing onmarket aims to distinguish the regulations governing the commercial aspects', 'commensurate with the life span diagram (a memory anchor used in this publication).\\nPlacing on-market also provides a convenient reference for countries that wish to\\nestablish regulatory programmes.', '**Post-market surveillance and vigilance** The different terms in post-market surveillance\\nare currently used by different countries with varying meanings. The Global\\nHarmonization Task Force is in the process of defining the different terms. This\\nGuide uses the US FDA terms which are well described on the internet (www.fda.gov/\\ncdrh/postsurv/).', 'In this Guide post-market surveillance is a broad term that covers any and all\\nmonitoring activities including the vigilance system for medical devices in use.', 'In Europe, vigilance concerns the responsability of the manufacturer to inform the\\ncompetent authority of incidents, according to national/European legislation.', '**Problem** a broad term that covers possible faults of the device, difficulties in using the\\ndevice or an undesirable outcome associated with the use of the device. A problem\\nmay not lead to an adverse event but corrective or preventive actions are required.', '**Vendor** any person who sells medical devices. This person could be a manufacturer, an\\nimporter, a distributor, a wholesaler, or a retailer.\\n\\n\\n**ix**\\n\\nGLOSSARY\\n\\nCHAPTER 1\\n\\n##### **Introduction**\\n\\nThe regulation of medical devices is a vast and rapidly evolving field that is often\\ncomplicated by legal technicalities. For example, legal terms and their meanings are\\nsometimes non-uniform even within one regulatory system. In an attempt to make this\\ncomplex subject easier to grasp, this Guide presents a common framework that integrates\\nthe regulatory systems of the five countries or regions with the most advanced medical\\ndevice regulations. Non-technical language, graphics, tables and memory anchors are\\nused to present an overview of medical device safety issues and regulatory philosophy.', 'The Guide begins by explaining how safety is a risk management issue, and how\\noptimum safety and performance require cooperation among all who are involved in the\\nlife span of a medical device. The critical elements of medical device regulations are\\nillustrated using a common framework for regulatory development; as well as the current\\nregulatory tools of the Global Harmonization Task Force (GHTF) and all the key\\ndocuments it has issued in the past three years.', 'Understanding the different phases in the life span of a medical device and the common\\nframework are first steps to successful harmonization and simplification worldwide.', '**Summary of contents**\\n**Chapter 2** describes the nature of medical device safety as a risk management process that\\nmust encompass the life span of medical devices from their conception to disposal. A Life\\nSpan Diagram facilitates understanding and serves as a memory anchor. Optimum safety\\nand performance require cooperation among all those involved in the life span of a medical\\ndevice: the manufacturer, importer/vendor, government, user and public  each has a\\nspecific role to play in risk management.', '**Chapter 3** considers the role of the government. The critical elements of the life span of\\nmedical devices that require regulatory attention are highlighted. A common regulatory\\nframework is proposed integrating the five regulatory systems with the most advanced\\nmedical device regulations, along with the applicable regulatory tools.', '**Chapter 4** introduces the work of the Global Harmonization Task Force (GHTF), whose\\nmission is to harmonize the implementation of medical device regulations across the globe.\\nThe objectives of its four Study Groups as they relate to the Medical Device Life Span\\nDiagram are described. In order to facilitate ease of reference for countries wishing to\\nadopt them, Annex 2 provides a summary of all final GHTF documents as they relate to\\nthe common regulatory framework.', '**Chapter 5** provides an introduction to standards. It describes the use of voluntary standards\\nand their increasing prominence in medical device regulation. Countries are urged to\\nestablish national standards management systems and, where possible, to adopt\\ninternational standards and to participate in their development and amendment.', '**Chapter 6** suggests various steps for governments seeking to establish an affordable\\nregulatory programme from the ground up for ensuring the safety and performance of\\nmedical devices. The need for knowledge, policies, legislation and enforcement of medical\\ndevice safety is discussed. Governments are encouraged to avoid setting up resource\\ndemanding pre-market regulations, but rather to take advantage of existing approval\\nsystems and international standards. An explanation of the meaning of different medical\\ndevice export certificates is offered. Cooperation from all stakeholders is encouraged\\nto increase programme effectiveness while reducing regulatory costs.', '**Chapter 7** proposes two actions that could be undertaken at the international level to\\naddress priority needs for product control and their safe and effective use:\\n\\ni) The establishment of a uniform certification format that will be used globally so that\\ndifferent countries can certify that medical devices being exported comply with their\\ndomestic regulatory requirements. This certification will help the importing countries\\nto regulate medical devices.', 'ii) Support for a centre to coordinate and relay medical device problems, recalls, and\\nalerts to the global community. This will enhance the safety and performance of medical\\ndevices in use around the world.', '**Annexes 14** also provide a selection of further reading and information on the issues\\nraised in this publication.', '**2**\\n\\nMEDICAL DEVICE REGULATIONS\\n\\nCHAPTER 2\\n##### **Medical device safety**\\n\\nThe optimum assurance of medical device safety has several essential elements:\\n\\n - Absolute safety cannot be guaranteed\\n\\n  - It is a risk management issue\\n\\n  - It is closely aligned with device effectiveness/performance\\n\\n  - It must be considered throughout the life span of the device\\n\\n  - It requires shared responsibility among the stakeholders\\n\\nEach of these features is discussed below.', '**2.1 Medical device safety and risk management**\\nSafety can only be considered in relative terms. All devices carry a certain degree of risk\\nand could cause problems in specific circumstances. Many medical device problems cannot\\nbe detected until extensive market experience is gained. For example, an implantable\\ndevice may fail in a manner that was not predictable at the time of implantation; the\\nfailure may reflect conditions unique to certain patients. For other devices, component\\nfailure can also be unpredictable or random. The current approach to device safety is to\\nestimate the potential of a device becoming a hazard that could result in safety problems\\nand harm. This estimate is often referred to as the _**risk assessment**_ .', 'Hazard is a potential for an adverse event, a source of danger. Risk is a measure of the\\ncombination of (1) the hazard; (2) the likelihood of occurrence of the adverse event; (3)\\nthe severity or overall impact. Risk assessment begins with _**risk analysis**_ to identify all\\npossible hazards, followed by _**risk evaluation**_ to estimate the risk of each hazard. In\\ngeneral, risk assessment is based on experience, evidence, computation, or even guesswork.\\nRisk assessment is complex, as it can be influenced by personal perception and other\\nfactors such as cultural background, economic conditions, and political climates.', 'In practice, risk assessment of medical devices is based on the experience of health care\\nprofessionals and on safety design engineering. In the United States, governmental risk\\nassessment of medical devices is based mainly on recommendations from members of 16\\nmedical specialty panels, and devices are categorized into three classes. In the European\\nUnion and Canada, the classification schemes for medical devices are predominantly rulebased. These rules categorize medical devices according to their perceived potential hazards.', 'Canada assigns four classes of devices. The European Union assigns three classes with\\nclass II being sub-divided into IIa and IIb (effectively, also four classes). The Global\\nHarmonization Task Force (GHTF) is proposing a harmonized scheme for medical device\\nclassification (see www.GHTF.org document SG1/N015R18).', 'In classifying devices, potential areas of hazard that warrant consideration include the\\ndegree of invasiveness, duration of contact, the body system affected, and local versus\\nsystemic effects. An invasive device is usually considered to have higher potential hazard\\nthan an equivalent non-invasive device (e.g. there are invasive and non-invasive blood\\npressure monitors). Similarly, devices that have a long duration of contact, that affect\\nvital organs such the heart or the great arteries, or that have systemic effects are assigned\\nhigher classes of potential hazard or risk. The degree of regulation imposed on any device\\nis proportional to its potential hazard. This approach is known as _**risk management**_ .', 'The first requirement of the Essential principles of safety and performance of medical\\ndevices recommended by the GHTF (SG1-N020R5) illustrates such an approach. It states\\nthat:\\n\\nMedical devices should be designed and manufactured in such a way that, when\\nused under the conditions and for the purposes intended and, where applicable, by\\nvirtue of the technical knowledge, experience, education or training of intended\\nusers, they will not compromise the clinica']}\n",
      "Cleaning response ```json\n",
      "{\n",
      "  \"chunks\": [\n",
      "    \"l condition or the safety of patients, or the safety and health of users or, where applicable, other persons, provided that any risks which may be associated with their use constitute acceptable risks when weighed against the benefits to the patient and are compatible with a high level of protection of health and safety.\",\n",
      "    \"This statement highlights the risk/benefit nature of medical devices.\",\n",
      "    \"The goal, therefore, is to maximize benefit and minimize risk.\",\n",
      "    \"Manufacturers of medical devices also use the risk management approach.\",\n",
      "    \"The International Organization for Standardization (ISO) has produced a document (ISO 14971:2000) providing manufacturers with a framework including risk analysis, risk evaluation and risk control for risk management in medical device design, development, manufacturing as well as for monitoring the safety and performance of the device after sale.\",\n",
      "    \"**2.2 Effectiveness/performance** [1] **of medical devices** Every device has a designed purpose.\",\n",
      "    \"A device is _**clinically effective**_ when it produces the effect intended by the manufacturer relative to the medical condition.\",\n",
      "    \"For example, if a device is intended for pain relief, one expects the device to actually relieve pain and would also expect the manufacturer to possess objective, scientific evidence, such as clinical test results, that the device does in fact relieve pain.\",\n",
      "    \"Clinical effectiveness is a good indicator of device performance.\",\n",
      "    \"_**Performance**_, however, may include technical functions in addition to clinical effectiveness.\",\n",
      "    \"For example, an alarm feature may not directly contribute to clinical effectiveness but would serve other useful purposes.\",\n",
      "    \"Furthermore, it is easier to measure objectively and quantify performance than clinical effectiveness.\",\n",
      "    \"Performance is closely linked to safety.\",\n",
      "    \"For example, a blood collection syringe with a blunt needle would perform badly for collecting blood and could inflict injury.\",\n",
      "    \"A patient monitor that does not perform well could pose serious clinical safety problems to the patient.\",\n",
      "    \"Thus, the safety and performance of medical devices are normally considered together.\",\n",
      "    \"The above discussion highlights the inherent risk of a medical device.\",\n",
      "    \"It is incumbent on the medical device manufacturer to demonstrate that all possible risks associated with the device are identified and adequately addressed.\",\n",
      "    \"The role of the regulatory authority is to ensure that the manufacturer has effectively implemented the risk management process and fulfilled other regulatory requirements.\",\n",
      "    \"The following section expands this issue and illustrates how other aspects in the life span of medical devices can affect their safety and performance.\",\n",
      "    \"**2.3 Phases in the life span of a medical device** Figure 1 illustrates the major phases in the life span of a medical device from conception and development to disposal.\",\n",
      "    \"The activity phases are simplified to make it easier to understand the regulatory system.\",\n",
      "    \"For example, the development phase includes development planning, design verification\\/validation, prototype testing and clinical trials.\",\n",
      "    \"In practice, the phases outlined below may overlap and interact.\",\n",
      "    \"_**Figure 1. Major phases in the life span of a medical device**_\",\n",
      "    \"It is important to recognize that any of these phases can affect the safety and performance of a medical device.\",\n",
      "    \"Examples of how each phase can create health hazards are described below:\",\n",
      "    \"1. Conception and development The scientific principles upon which a device is based are fundamental to its safety and performance.\",\n",
      "    \"For example, a cardiac pacemaker should deliver a minute electrical impulse of a certain size and shape that simulates the natural functioning of the heart.\",\n",
      "    \"Significant deviation from this may compromise safety and performance.\",\n",
      "    \"The more complex the device, the higher the risk of user error.\",\n",
      "    \"Soundness of concept and adequacy of design, construction, and testing (including verification, validation and clinical trials) require the scrutiny of scientific experts to ensure that design parameters and performance characteristics do not impose unwarranted risks.\",\n",
      "    \"2. Manufacture Good, functional medical devices are produced when the manufacturing process is adequately managed.\",\n",
      "    \"However, poor manufacturing management can produce inconsistency in the quality of products, such that non-conforming devices can filter through the production line to the market, even when the original prototype has been well-designed.\",\n",
      "    \"This consideration has led to the development of good manufacturing practice (GMP) for drugs, biological products and medical devices.\",\n",
      "    \"Now, GMP is more commonly referred to as quality systems in manufacturing, and these are addressed later in this guide.\",\n",
      "    \"3. Packaging and labelling Properly packaged medical devices pose little risk to individuals handling them, even if the medical device is biohazardous.\",\n",
      "    \"This highlights the importance of well-designed packaging systems in delivering clean, sterile and protected medical devices to the point of use.\",\n",
      "    \"Shipping is one of the hazards a medical device and its packaging must survive.\",\n",
      "    \"Subtle damage can result during transportation and handling unless the total packaging system is designed robustly and can withstand various stresses.\",\n",
      "    \"Well-sealed packaging is essential for those medical devices that must be maintained sterile.\",\n",
      "    \"Labelling is crucial in identifying the medical device and specifying instructions for its proper use.\",\n",
      "    \"As for drugs, mislabelling of medical devices can result in serious consequences for the user.\",\n",
      "    \"Hazard warnings or cautions and clear instructions for use are very important.\",\n",
      "    \"4. Advertising Advertisement has the potential to create expectations and powerfully influence the belief in a medical devices capabilities.\",\n",
      "    \"It is important, therefore, that medical device marketing and advertising are regulated to prevent misrepresentation of a medical device and its performance.\",\n",
      "    \"Misleading or fraudulent advertising of medical devices may increase sales.\",\n",
      "    \"However, from the buyers perspective, the purchase of an inappropriate medical device is a waste of money that may deprive the patient of more appropriate treatment and could lead to patient or user injury.\",\n",
      "    \"5. Sale The sale of medical devices by the vendor is a critical stage that leads to the device being put into actual use.\",\n",
      "    \"If the vendor is not subject to regulation, then there is higher risk of exposing the public to low quality or ineffective devices.\",\n",
      "    \"6. Use Users of medical devices can have a profound effect on their safety and effective performance.\",\n",
      "    \"Unfamiliarity with a certain technology or operating procedure, and the use of products for clinical indications outside the scope of those specified in the labelling, can cause device failure even in the absence of any inherent design or manufacturing defects.\",\n",
      "    \"Within the clinical engineering community it is widely believed that user error underlies at least half of all medical device-related injuries and deaths.\",\n",
      "    \"The re-use of disposable devices contrary to the manufacturers instructions, and without proper control or precautions for minimizing associated risks, can be dangerous (see 6.3.7).\",\n",
      "    \"The lack of, or inappropriate, calibration and maintenance of medical devices can seriously jeopardize their safety and performance.\",\n",
      "    \"These issues are often overlooked or underestimated.\",\n",
      "    \"7. Disposal Disposal of certain types of devices should follow specific and stringent safety rules.\",\n",
      "    \"For example, devices that are contaminated after use (e.g. syringes) or devices that contain toxic chemicals, can present hazards to people or the environment and must be disposed of properly.\",\n",
      "    \"It is people who manage each phase in the life span of a medical device, and these people should be identified and called on to participate in ensuring medical device safety.\",\n",
      "    \"**2.4 Participants in ensuring the safety of medical devices** As shown in Figure 2, the manufacturer usually manages the first three phases of the medical devices life span.\",\n",
      "    \"The term Vendor includes importers, distributors, retailers and manufacturers who sell medical equipment.\",\n",
      "    \"The User is usually a professional in a health care facility, but may also be the patients.\",\n",
      "    \"In addition to these three categories of person who are directly involved with the different phases of medical devices, the Public\\/Patient and the Government are also key interested parties.\",\n",
      "    \"The public are the ultimate beneficiary of medical devices, and in the case of over-the-counter (home-use) devices, they are the user as well.\",\n",
      "    \"The government has the responsibility of overseeing that medical devices sold in the country are safe and effective.\",\n",
      "    \"_**Figure 2. Persons who directly manage the different phases of medical devices**_\",\n",
      "    \"Together, the Manufacturer, Vendor, User, Public and Government are the stakeholders.\",\n",
      "    \"All five play critical roles in ensuring the safety of medical devices.\",\n",
      "    \"The most important factor that ensures the cooperation of all these stakeholders is an informed and common understanding of the issues.\",\n",
      "    \"Shared understanding and responsibility are achieved through communication and mutual education, which can be effectively achieved by having all stakeholders participate in establishing the process that ensures safety and performance of medical devices.\",\n",
      "    \"**2.5 The role of each participant\\/stakeholder** _**The manufacturer**_, as the creator of the device, must ensure that it is manufactured to meet or exceed the required standards of safety and performance.\",\n",
      "    \"This includes the three phases (design\\/development\\/testing, manufacturing, packaging and labelling) that lead to a product being ready for the market.\",\n",
      "    \"The term user error is defined as an act that has a different result than that intended by the manufacturer or expected by the operator.\",\n",
      "    \"User error may result from a mismatch between variables, for example the operator, device, task, or environment.\",\n",
      "    \"By incorporating human factor engineering principles in design, and appropriate training for users, the risk of user errors can be minimized.\",\n",
      "    \"_**The vendor**_ provides the interface between the product and the user.\",\n",
      "    \"He\\/she should ensure that the products sold comply with regulatory requirements.\",\n",
      "    \"With increasing public interest in health and a competitive marketplace, vendors should be careful to avoid making misleading or fraudulent claims about their products or issuing false compliance certificates.\",\n",
      "    \"In addition, used or refurbished devices should be clearly labelled as such.\",\n",
      "    \"Vendors should provide after-sale service.\",\n",
      "    \"Medical devices often require specialized training from the manufacturer for proper use and service; therefore, the vendor should make training a condition to the manufacturer or importer in accepting to sell the device.\",\n",
      "    \"In turn, vendors should take responsibility in supporting or training their customers.\",\n",
      "    \"Participating in post-market surveillance (receiving and reporting customer complaints\\/incidents) is critical for ensuring medical device safety and performance.\",\n",
      "    \"The vendor must fulfil these obligations specified by the regulatory authority.\",\n",
      "    \"For example, the vendor must make arrangements for processing complaint\\/incident reports relating to medical device safety and performance.\",\n",
      "    \"In the case of home-use medical devices, the vendor should recognize that the device being sold might end up in the hands of a layperson who may need special instructions for the proper use and maintenance of the device.\",\n",
      "    \"In this situation, efforts must be made to provide non-technical instructions and to educate and help the customer.\",\n",
      "    \"_**The user**_ should make sure that he\\/she has qualifications and training in the proper use of the device, and is familiar with the indications, contra-indications and operating procedures recommended by the manufacturer.\",\n",
      "    \"It is crucial that experience gained with medical devices be shared with other users, the vendor and manufacturer to prevent future problems.\",\n",
      "    \"This can be done by reporting any incidents to a coordinating centre from which warnings can be issued.\",\n",
      "    \"When using medical devices, users should always bear in mind that the safety and health of the patients are in their hands.\",\n",
      "    \"The user has the responsibility to employ the medical device only for the intended indications (or to assure that any non-indicated use of the medical device does not compromise the safety of the patient and other users).\",\n",
      "    \"The user also has the responsibility to ensure proper maintenance of medical devices during active use and safe disposal of obsolete medical devices.\",\n",
      "    \"_**The public**_ are the ultimate beneficiary of medical devices.\",\n",
      "    \"They should be fully aware that all devices carry a certain risk and that they can help to promote safety and performance through self education and by putting customer pressure (see section 6.4) on manufacturers to comply with standards.\",\n",
      "    \"Medical devices are increasingly available for home use, making the Public the direct user.\",\n",
      "    \"Purchasers of home-use medical devices should be aware of associated risks and take the responsibility to become educated in the functions and correct operating procedures for those devices.\",\n",
      "    \"_**The government**_ has the responsibility to oversee the efforts of manufacturers and vendors and ensure that medical devices sold or made available in the country are safe and effective.\",\n",
      "    \"It should provide leadership in creating healthy cooperation among stakeholders in establishing policies and regulations that are fair and clear to all.\",\n",
      "    \"Policies and regulations should be reviewed periodically to respond to changes in technologies by incorporating appropriate amendments.\",\n",
      "    \"**2.6 Shared responsibility for medical device safety and performance** In conclusion, the ideal conditions that will ensure the safety and performance of medical devices require shared responsibility by all stakeholders.\",\n",
      "    \"This need for cooperation is illustrated below.\",\n",
      "    \"The circle formed by the stakeholders illustrates the shared responsibility.\",\n",
      "    \"The diamond handshake symbolizes cooperation and two-way communication (2-way arrow), and the star highlights how the fundamental elements for cooperation function best when all stakeholders communicate with each other.\",\n",
      "    \"_**Figure 3. Ideal conditions for ensuring the safety and performance of medical devices**_\",\n",
      "    \"CHAPTER 3 Governmental regulation of medical devices\",\n",
      "    \"The previous section has demonstrated that medical device safety requires that all stakeholders co-operate and share responsibilities.\",\n",
      "    \"The roles of each party have been described.\",\n",
      "    \"This section will concentrate on how governments can fulfil part of their duties through the implementation of regulations.\",\n",
      "    \"The common regulatory terms pre-market and post-market are introduced and illustrated with the device life span diagram.\",\n",
      "    \"The term placing on-market, although not an official regulatory term, is introduced here to provide a logical understanding of an important stage in the regulatory mechanism.\",\n",
      "    \"**3.1 Critical elements for regulatory attention** The safety and performance of medical devices depend on two critical elements:\",\n",
      "    \"_**Figure 4. Product and use : two critical elements**_\",\n",
      "    \"_**Pre-market review**_ contributes to product control, and _**post-market surveillance**_ ensures that medical devices in use continue to be safe and effective.\",\n",
      "    \"There is an important third element, which is the representation of the product to the user.\",\n",
      "    \"This is controlled through labelling (during the pre-market stage) and advertising of the product (see section 6.3.4).\",\n",
      "    \"Another aspect of product representation, however, is verbal presentation by the vendor.\",\n",
      "    \"User\\/public education is key in guarding against misrepresentation.\",\n",
      "    \"_**Figure 5. Product representation: the third critical element**_\",\n",
      "    \"**3.2 Stages of regulatory control** We can identify the control of these three critical elements by relating them to the now familiar Life Span diagram shown below.\",\n",
      "    \"_**Figure 6. Common stages of government regulations**_\",\n",
      "    \"Pre-market control is performed on the device to ensure that the _**product**_ to be placed on-market complies with regulatory requirements.\",\n",
      "    \"Labelling and advertising control is maintained for correct _**product representation**_.\",\n",
      "    \"Placing-on-market control ensures establishment registration, device listing and after-sale obligations.\",\n",
      "    \"Post-market surveillance\\/vigilance ensures the continued safety and performance of devices in _**use**_.\",\n",
      "    \"**3.3 A common framework for medical device regulations** The items or activities that are most commonly subjected to regulation are show in Table 1.\",\n",
      "    \"_**Table 1. A common framework for medical device regulations**_\",\n",
      "    \"**3.4 Regulatory tools and general requirements** The requirements for the three stages of regulatory control of the five founding members of the GHTF are summarized below.\",\n",
      "    \"Note that although the different governing bodies use different terms, their functions are actually quite similar.\",\n",
      "    \"_**Table 2. Tools and general requirements of the five members of the GHTF**_\",\n",
      "    \"3.4.1 Product control Although different authorities have different systems of pre-market review, they all apply the risk management philosophy.\",\n",
      "    \"All medical devices must satisfy safety and performance, quality system (some low-risk devices may be exempt) and labelling requirements.\",\n",
      "    \"However, the degree of regulatory scrutiny increases with the potential risks of the medical device, as evidenced by the risk-based device classification system (SG1-N015R14) proposed by the GHTF.\",\n",
      "    \"Authorities acknowledge product clearance for the market in various ways.\",\n",
      "    \"In Australia, the Therapeutic Goods Administration issues an ARTG (Australian Register of Therapeutic Goods) number to devices cleared for the market.\",\n",
      "    \"In Canada, a Device Licence is awarded by the Therapeutic Products Directorate.\",\n",
      "    \"In the European Union, after receiving the EC certificate from a notified body, the manufacturer places the CE mark on or with the device.\",\n",
      "    \"In Japan, a Shounin is issued by the Pharmaceutical and Medical Safety Bureau of the Ministry of Health, Labor and Welfare.\",\n",
      "    \"In the United States, the manufacturer of the device receives a Marketing Clearance (510K) or an Approval Letter (PMA) from the FDA.\",\n",
      "    \"In Canada, devices of classes III and IV are subject to in-depth regulatory scrutiny, while class II devices require only the manufacturers declaration of device safety and effectiveness before sale.\",\n",
      "    \"Class I devices are exempted from pre-market submission, but they must still satisfy the safety, effectiveness and labelling requirements.\",\n",
      "    \"In the European system, manufacturers of devices of classes II and III, as well as devices of class I with either measuring function or sterility requirements, must submit to the regulator (competent authority): (1) a Declaration of Conformity to the appropriate EC Directives, and (2) details of the conformity assessment procedure followed.\",\n",
      "    \"In addition, for higher risk class devices that require design examination or type examination, the corresponding EC-Certificates issued by a notified body must also be submitted to the competent authority.\",\n",
      "    \"Other medical devices of class I are exempt from pre-market submissions, although they must follow the essential principles of safety and performance in their design, construction and labelling requirements.\",\n",
      "    \"In Australia, all registrable devices must undergo rigorous pre-market evaluation before market entry.\",\n",
      "    \"Listable devices are less rigorously regulated, but may be evaluated for safety (not efficacy) if there are regulatory concerns about the risk profile of the product.\",\n",
      "    \"Devices manufactured for a particular person, or those built within a health facility and not commercially supplied, are exempt from the requirement to be registered or listed.\",\n",
      "    \"Under some circumstances, the manufacturing facilities may need to be licensed.\",\n",
      "    \"In Japan, class I devices are granted Todokede by the regional authorities.\",\n",
      "    \"Some class II low-risk devices are granted Todokede if their safety and effectiveness have been established previously.\",\n",
      "    \"All devices above class II must obtain a central government licence for market entry.\",\n",
      "    \"The Ministry of Health, Labor and Welfare is working on the Pharmaceutical Administration Law (PAL) revision towards risk-based medical device regulation, in line with the GHTF principles.\",\n",
      "    \"The new PAL revision should become effective in 2005.\",\n",
      "    \"In the United States, most Class III and new devices that are not substantially equivalent to a legally marketed product that does not require a Pre-Market Approval application, require clearance through the PMA or Product Development Protocol processes.\",\n",
      "    \"Most class II and some class I devices require pre-market entry notification (termed 510k, an information package for the FDA, which is subject to less stringent review than the PMA process.\",\n",
      "    \"The 510k submission must demonstrate how the proposed medical device is substantially equivalent to a medical device that is already on the US market.\",\n",
      "    \"Most class I and some class II (low-risk) devices are exempt from 510k submission before sale, but are still subject to general control requirements.\",\n",
      "    \"3.4.2 Vendor establishment control Vendor information facilitates governments in tracking medical device vendors.\",\n",
      "    \"In Australia, the sponsor must hold an Enterprise Identification Number before being permitted to apply to register or list products.\",\n",
      "    \"Similarly, in Canada, any individual or company wishing to sell medical devices must apply for permission to obtain an establishment licence.\"\n",
      "  ]\n",
      "}\n",
      "```\n",
      "\n",
      "rovas\n",
      "Response cleaned is {'chunks': ['l condition or the safety of patients, or the safety and health of users or, where applicable, other persons, provided that any risks which may be associated with their use constitute acceptable risks when weighed against the benefits to the patient and are compatible with a high level of protection of health and safety.', 'This statement highlights the risk/benefit nature of medical devices.', 'The goal, therefore, is to maximize benefit and minimize risk.', 'Manufacturers of medical devices also use the risk management approach.', 'The International Organization for Standardization (ISO) has produced a document (ISO 14971:2000) providing manufacturers with a framework including risk analysis, risk evaluation and risk control for risk management in medical device design, development, manufacturing as well as for monitoring the safety and performance of the device after sale.', '**2.2 Effectiveness/performance** [1] **of medical devices** Every device has a designed purpose.', 'A device is _**clinically effective**_ when it produces the effect intended by the manufacturer relative to the medical condition.', 'For example, if a device is intended for pain relief, one expects the device to actually relieve pain and would also expect the manufacturer to possess objective, scientific evidence, such as clinical test results, that the device does in fact relieve pain.', 'Clinical effectiveness is a good indicator of device performance.', '_**Performance**_, however, may include technical functions in addition to clinical effectiveness.', 'For example, an alarm feature may not directly contribute to clinical effectiveness but would serve other useful purposes.', 'Furthermore, it is easier to measure objectively and quantify performance than clinical effectiveness.', 'Performance is closely linked to safety.', 'For example, a blood collection syringe with a blunt needle would perform badly for collecting blood and could inflict injury.', 'A patient monitor that does not perform well could pose serious clinical safety problems to the patient.', 'Thus, the safety and performance of medical devices are normally considered together.', 'The above discussion highlights the inherent risk of a medical device.', 'It is incumbent on the medical device manufacturer to demonstrate that all possible risks associated with the device are identified and adequately addressed.', 'The role of the regulatory authority is to ensure that the manufacturer has effectively implemented the risk management process and fulfilled other regulatory requirements.', 'The following section expands this issue and illustrates how other aspects in the life span of medical devices can affect their safety and performance.', '**2.3 Phases in the life span of a medical device** Figure 1 illustrates the major phases in the life span of a medical device from conception and development to disposal.', 'The activity phases are simplified to make it easier to understand the regulatory system.', 'For example, the development phase includes development planning, design verification/validation, prototype testing and clinical trials.', 'In practice, the phases outlined below may overlap and interact.', '_**Figure 1. Major phases in the life span of a medical device**_', 'It is important to recognize that any of these phases can affect the safety and performance of a medical device.', 'Examples of how each phase can create health hazards are described below:', '1. Conception and development The scientific principles upon which a device is based are fundamental to its safety and performance.', 'For example, a cardiac pacemaker should deliver a minute electrical impulse of a certain size and shape that simulates the natural functioning of the heart.', 'Significant deviation from this may compromise safety and performance.', 'The more complex the device, the higher the risk of user error.', 'Soundness of concept and adequacy of design, construction, and testing (including verification, validation and clinical trials) require the scrutiny of scientific experts to ensure that design parameters and performance characteristics do not impose unwarranted risks.', '2. Manufacture Good, functional medical devices are produced when the manufacturing process is adequately managed.', 'However, poor manufacturing management can produce inconsistency in the quality of products, such that non-conforming devices can filter through the production line to the market, even when the original prototype has been well-designed.', 'This consideration has led to the development of good manufacturing practice (GMP) for drugs, biological products and medical devices.', 'Now, GMP is more commonly referred to as quality systems in manufacturing, and these are addressed later in this guide.', '3. Packaging and labelling Properly packaged medical devices pose little risk to individuals handling them, even if the medical device is biohazardous.', 'This highlights the importance of well-designed packaging systems in delivering clean, sterile and protected medical devices to the point of use.', 'Shipping is one of the hazards a medical device and its packaging must survive.', 'Subtle damage can result during transportation and handling unless the total packaging system is designed robustly and can withstand various stresses.', 'Well-sealed packaging is essential for those medical devices that must be maintained sterile.', 'Labelling is crucial in identifying the medical device and specifying instructions for its proper use.', 'As for drugs, mislabelling of medical devices can result in serious consequences for the user.', 'Hazard warnings or cautions and clear instructions for use are very important.', '4. Advertising Advertisement has the potential to create expectations and powerfully influence the belief in a medical devices capabilities.', 'It is important, therefore, that medical device marketing and advertising are regulated to prevent misrepresentation of a medical device and its performance.', 'Misleading or fraudulent advertising of medical devices may increase sales.', 'However, from the buyers perspective, the purchase of an inappropriate medical device is a waste of money that may deprive the patient of more appropriate treatment and could lead to patient or user injury.', '5. Sale The sale of medical devices by the vendor is a critical stage that leads to the device being put into actual use.', 'If the vendor is not subject to regulation, then there is higher risk of exposing the public to low quality or ineffective devices.', '6. Use Users of medical devices can have a profound effect on their safety and effective performance.', 'Unfamiliarity with a certain technology or operating procedure, and the use of products for clinical indications outside the scope of those specified in the labelling, can cause device failure even in the absence of any inherent design or manufacturing defects.', 'Within the clinical engineering community it is widely believed that user error underlies at least half of all medical device-related injuries and deaths.', 'The re-use of disposable devices contrary to the manufacturers instructions, and without proper control or precautions for minimizing associated risks, can be dangerous (see 6.3.7).', 'The lack of, or inappropriate, calibration and maintenance of medical devices can seriously jeopardize their safety and performance.', 'These issues are often overlooked or underestimated.', '7. Disposal Disposal of certain types of devices should follow specific and stringent safety rules.', 'For example, devices that are contaminated after use (e.g. syringes) or devices that contain toxic chemicals, can present hazards to people or the environment and must be disposed of properly.', 'It is people who manage each phase in the life span of a medical device, and these people should be identified and called on to participate in ensuring medical device safety.', '**2.4 Participants in ensuring the safety of medical devices** As shown in Figure 2, the manufacturer usually manages the first three phases of the medical devices life span.', 'The term Vendor includes importers, distributors, retailers and manufacturers who sell medical equipment.', 'The User is usually a professional in a health care facility, but may also be the patients.', 'In addition to these three categories of person who are directly involved with the different phases of medical devices, the Public/Patient and the Government are also key interested parties.', 'The public are the ultimate beneficiary of medical devices, and in the case of over-the-counter (home-use) devices, they are the user as well.', 'The government has the responsibility of overseeing that medical devices sold in the country are safe and effective.', '_**Figure 2. Persons who directly manage the different phases of medical devices**_', 'Together, the Manufacturer, Vendor, User, Public and Government are the stakeholders.', 'All five play critical roles in ensuring the safety of medical devices.', 'The most important factor that ensures the cooperation of all these stakeholders is an informed and common understanding of the issues.', 'Shared understanding and responsibility are achieved through communication and mutual education, which can be effectively achieved by having all stakeholders participate in establishing the process that ensures safety and performance of medical devices.', '**2.5 The role of each participant/stakeholder** _**The manufacturer**_, as the creator of the device, must ensure that it is manufactured to meet or exceed the required standards of safety and performance.', 'This includes the three phases (design/development/testing, manufacturing, packaging and labelling) that lead to a product being ready for the market.', 'The term user error is defined as an act that has a different result than that intended by the manufacturer or expected by the operator.', 'User error may result from a mismatch between variables, for example the operator, device, task, or environment.', 'By incorporating human factor engineering principles in design, and appropriate training for users, the risk of user errors can be minimized.', '_**The vendor**_ provides the interface between the product and the user.', 'He/she should ensure that the products sold comply with regulatory requirements.', 'With increasing public interest in health and a competitive marketplace, vendors should be careful to avoid making misleading or fraudulent claims about their products or issuing false compliance certificates.', 'In addition, used or refurbished devices should be clearly labelled as such.', 'Vendors should provide after-sale service.', 'Medical devices often require specialized training from the manufacturer for proper use and service; therefore, the vendor should make training a condition to the manufacturer or importer in accepting to sell the device.', 'In turn, vendors should take responsibility in supporting or training their customers.', 'Participating in post-market surveillance (receiving and reporting customer complaints/incidents) is critical for ensuring medical device safety and performance.', 'The vendor must fulfil these obligations specified by the regulatory authority.', 'For example, the vendor must make arrangements for processing complaint/incident reports relating to medical device safety and performance.', 'In the case of home-use medical devices, the vendor should recognize that the device being sold might end up in the hands of a layperson who may need special instructions for the proper use and maintenance of the device.', 'In this situation, efforts must be made to provide non-technical instructions and to educate and help the customer.', '_**The user**_ should make sure that he/she has qualifications and training in the proper use of the device, and is familiar with the indications, contra-indications and operating procedures recommended by the manufacturer.', 'It is crucial that experience gained with medical devices be shared with other users, the vendor and manufacturer to prevent future problems.', 'This can be done by reporting any incidents to a coordinating centre from which warnings can be issued.', 'When using medical devices, users should always bear in mind that the safety and health of the patients are in their hands.', 'The user has the responsibility to employ the medical device only for the intended indications (or to assure that any non-indicated use of the medical device does not compromise the safety of the patient and other users).', 'The user also has the responsibility to ensure proper maintenance of medical devices during active use and safe disposal of obsolete medical devices.', '_**The public**_ are the ultimate beneficiary of medical devices.', 'They should be fully aware that all devices carry a certain risk and that they can help to promote safety and performance through self education and by putting customer pressure (see section 6.4) on manufacturers to comply with standards.', 'Medical devices are increasingly available for home use, making the Public the direct user.', 'Purchasers of home-use medical devices should be aware of associated risks and take the responsibility to become educated in the functions and correct operating procedures for those devices.', '_**The government**_ has the responsibility to oversee the efforts of manufacturers and vendors and ensure that medical devices sold or made available in the country are safe and effective.', 'It should provide leadership in creating healthy cooperation among stakeholders in establishing policies and regulations that are fair and clear to all.', 'Policies and regulations should be reviewed periodically to respond to changes in technologies by incorporating appropriate amendments.', '**2.6 Shared responsibility for medical device safety and performance** In conclusion, the ideal conditions that will ensure the safety and performance of medical devices require shared responsibility by all stakeholders.', 'This need for cooperation is illustrated below.', 'The circle formed by the stakeholders illustrates the shared responsibility.', 'The diamond handshake symbolizes cooperation and two-way communication (2-way arrow), and the star highlights how the fundamental elements for cooperation function best when all stakeholders communicate with each other.', '_**Figure 3. Ideal conditions for ensuring the safety and performance of medical devices**_', 'CHAPTER 3 Governmental regulation of medical devices', 'The previous section has demonstrated that medical device safety requires that all stakeholders co-operate and share responsibilities.', 'The roles of each party have been described.', 'This section will concentrate on how governments can fulfil part of their duties through the implementation of regulations.', 'The common regulatory terms pre-market and post-market are introduced and illustrated with the device life span diagram.', 'The term placing on-market, although not an official regulatory term, is introduced here to provide a logical understanding of an important stage in the regulatory mechanism.', '**3.1 Critical elements for regulatory attention** The safety and performance of medical devices depend on two critical elements:', '_**Figure 4. Product and use : two critical elements**_', '_**Pre-market review**_ contributes to product control, and _**post-market surveillance**_ ensures that medical devices in use continue to be safe and effective.', 'There is an important third element, which is the representation of the product to the user.', 'This is controlled through labelling (during the pre-market stage) and advertising of the product (see section 6.3.4).', 'Another aspect of product representation, however, is verbal presentation by the vendor.', 'User/public education is key in guarding against misrepresentation.', '_**Figure 5. Product representation: the third critical element**_', '**3.2 Stages of regulatory control** We can identify the control of these three critical elements by relating them to the now familiar Life Span diagram shown below.', '_**Figure 6. Common stages of government regulations**_', 'Pre-market control is performed on the device to ensure that the _**product**_ to be placed on-market complies with regulatory requirements.', 'Labelling and advertising control is maintained for correct _**product representation**_.', 'Placing-on-market control ensures establishment registration, device listing and after-sale obligations.', 'Post-market surveillance/vigilance ensures the continued safety and performance of devices in _**use**_.', '**3.3 A common framework for medical device regulations** The items or activities that are most commonly subjected to regulation are show in Table 1.', '_**Table 1. A common framework for medical device regulations**_', '**3.4 Regulatory tools and general requirements** The requirements for the three stages of regulatory control of the five founding members of the GHTF are summarized below.', 'Note that although the different governing bodies use different terms, their functions are actually quite similar.', '_**Table 2. Tools and general requirements of the five members of the GHTF**_', '3.4.1 Product control Although different authorities have different systems of pre-market review, they all apply the risk management philosophy.', 'All medical devices must satisfy safety and performance, quality system (some low-risk devices may be exempt) and labelling requirements.', 'However, the degree of regulatory scrutiny increases with the potential risks of the medical device, as evidenced by the risk-based device classification system (SG1-N015R14) proposed by the GHTF.', 'Authorities acknowledge product clearance for the market in various ways.', 'In Australia, the Therapeutic Goods Administration issues an ARTG (Australian Register of Therapeutic Goods) number to devices cleared for the market.', 'In Canada, a Device Licence is awarded by the Therapeutic Products Directorate.', 'In the European Union, after receiving the EC certificate from a notified body, the manufacturer places the CE mark on or with the device.', 'In Japan, a Shounin is issued by the Pharmaceutical and Medical Safety Bureau of the Ministry of Health, Labor and Welfare.', 'In the United States, the manufacturer of the device receives a Marketing Clearance (510K) or an Approval Letter (PMA) from the FDA.', 'In Canada, devices of classes III and IV are subject to in-depth regulatory scrutiny, while class II devices require only the manufacturers declaration of device safety and effectiveness before sale.', 'Class I devices are exempted from pre-market submission, but they must still satisfy the safety, effectiveness and labelling requirements.', 'In the European system, manufacturers of devices of classes II and III, as well as devices of class I with either measuring function or sterility requirements, must submit to the regulator (competent authority): (1) a Declaration of Conformity to the appropriate EC Directives, and (2) details of the conformity assessment procedure followed.', 'In addition, for higher risk class devices that require design examination or type examination, the corresponding EC-Certificates issued by a notified body must also be submitted to the competent authority.', 'Other medical devices of class I are exempt from pre-market submissions, although they must follow the essential principles of safety and performance in their design, construction and labelling requirements.', 'In Australia, all registrable devices must undergo rigorous pre-market evaluation before market entry.', 'Listable devices are less rigorously regulated, but may be evaluated for safety (not efficacy) if there are regulatory concerns about the risk profile of the product.', 'Devices manufactured for a particular person, or those built within a health facility and not commercially supplied, are exempt from the requirement to be registered or listed.', 'Under some circumstances, the manufacturing facilities may need to be licensed.', 'In Japan, class I devices are granted Todokede by the regional authorities.', 'Some class II low-risk devices are granted Todokede if their safety and effectiveness have been established previously.', 'All devices above class II must obtain a central government licence for market entry.', 'The Ministry of Health, Labor and Welfare is working on the Pharmaceutical Administration Law (PAL) revision towards risk-based medical device regulation, in line with the GHTF principles.', 'The new PAL revision should become effective in 2005.', 'In the United States, most Class III and new devices that are not substantially equivalent to a legally marketed product that does not require a Pre-Market Approval application, require clearance through the PMA or Product Development Protocol processes.', 'Most class II and some class I devices require pre-market entry notification (termed 510k, an information package for the FDA, which is subject to less stringent review than the PMA process.', 'The 510k submission must demonstrate how the proposed medical device is substantially equivalent to a medical device that is already on the US market.', 'Most class I and some class II (low-risk) devices are exempt from 510k submission before sale, but are still subject to general control requirements.', '3.4.2 Vendor establishment control Vendor information facilitates governments in tracking medical device vendors.', 'In Australia, the sponsor must hold an Enterprise Identification Number before being permitted to apply to register or list products.', 'Similarly, in Canada, any individual or company wishing to sell medical devices must apply for permission to obtain an establishment licence.']}\n",
      "Cleaning response ```json\n",
      "{\n",
      "  \"chunks\": [\n",
      "    \"In the United States, the establishment (manufacturers, initial importer, specifications developer, contract sterilizer, re-packager and/or re-labeller) must be registered with the FDA.\",\n",
      "    \"With all five authorities, the licensing or registration process also imposes obligations on the vendor for post-market surveillance and/or duties.\",\n",
      "    \"It is critically important that the safety and performance of medical devices are continually assessed when they are in use, as these characteristics can only be proven if one measures how a device stands up in these conditions.\",\n",
      "    \"No amount of rigour in the pre-marketing review process can predict all possible device failures or incidents arising from device misuse.\",\n",
      "    \"It is through actual use that unforeseen problems related to safety and performance can occur.\",\n",
      "    \"Different terms in medical device vigilance and post-market surveillance have varying meanings in different countries.\",\n",
      "    \"Whilst the GHTF is defining these terms, this document will use the definitions of the US FDA (see www.fda.gov/cdrh/postsurv/).\",\n",
      "    \"Post-market surveillance is a broad term that covers all monitoring activities of medical devices in use.\",\n",
      "    \"The two principal activities within surveillance are post-market surveillance studies and adverse event reporting.\",\n",
      "    \"In post-market surveillance studies, specific and structured data collections are required of the manufacturer in one of two situations: (1) as a condition of product approval, or (2) to re-affirm product safety when post-market adverse event reports suggest that pre-market safety claims are inconsistent with actual use and result in unacceptable risk.\",\n",
      "    \"Japanese authorities and the FDA actively make use of surveillance data collection to augment the findings of pre-market trials.\",\n",
      "    \"Adverse event reporting requires the registration and investigation of adverse events relating to the use of a device, and the authority necessary to oblige the manufacturer to recall or modify a defective device.\",\n",
      "    \"All founding members of the GHTF have mandatory requirements for vendors or manufacturers to report all device-related events that have resulted, or could result, in serious injury or death.\",\n",
      "    \"In some countries, mandatory adverse event reporting is also extended to users.\",\n",
      "    \"Post-market surveillance is interrelated to the quality system requirements described in the following section.\",\n",
      "    \"A Quality System is defined as the organizational structure, responsibilities, procedures, processes and resources needed to implement quality management.\",\n",
      "    \"Quality system standards are generic management standards and are described in section 5.1.\",\n",
      "    \"The international quality system standards for medical devices are issued by the International Organization for Standardization (ISO) (ISO13485:1996 and ISO13488: 1996).\",\n",
      "    \"ISO13485:1996 includes all the elements of ISO9001:1994 plus a set of minimum supplementary requirements for medical devices.\",\n",
      "    \"The relationship between ISO9001:1994 and ISO13485:1996 is described in Annex 3.\",\n",
      "    \"ISO13488:1996 is the same as ISO13485: 1994, but without the design control requirements.\",\n",
      "    \"A new standard, ISO13485:200?, is currently being developed and will become the international reference standard for medical devices.\",\n",
      "    \"Regulations for quality systems may cover the methods, facilities and controls used by the manufacturer in the design, manufacture, packaging, labelling, storage, installation, servicing and post-market handling of medical devices.\",\n",
      "    \"Therefore, quality system requirements can influence all phases in the medical device life span.\",\n",
      "    \"Applicable requirements depend upon the risk class of the device and on the regulatory system of the country.\",\n",
      "    \"Design control is normally not required for regulatory scrutiny in medium- to low-risk devices.\",\n",
      "    \"When applied to the manufacturing process, quality system requirements impose strict quality assurance on every aspect of production.\",\n",
      "    \"The result is a tightly controlled manufacturing system, commonly known as Good Manufacturing Practice (GMP), which reduces the likelihood of non-conforming products.\",\n",
      "    \"This practice ensures consistency in the quality and provides the basis for greater reliability in device safety and performance.\",\n",
      "    \"Elements of the quality system are periodically subject to audits, management review, and corrective or preventive actions that will maintain product quality.\",\n",
      "    \"Continuous monitoring and corrective action requirements are interrelated to post-market surveillance previously described.\",\n",
      "    \"The key advantage regarding quality systems is that they represent a preventive approach to assuring medical device quality versus the previous reactive approach by inspection and rejection at the end of the manufacturing line.\",\n",
      "    \"Prevention has been proven to be more efficient and cost effective in controlling manufacturing processes and maintaining medical device quality.\",\n",
      "    \"It is important to note that since the majority of medical devices are in the medium- to low-risk classes, their compliance with regulations often depends upon the declarations of manufacturers, thus the question of quality assurance naturally arises.\",\n",
      "    \"This is why it is critical for manufacturers to conform with quality system standards and for this conformity to be subject to periodic audit by governmental or third party agencies.\",\n",
      "    \"All founding members of the GHTF have quality system requirements for their manufacturers, who are subject to periodic inspection by the government and/or accredited third party agencies.\",\n",
      "    \"The applicable standard is determined by the risk class of the device and depends upon the regulatory system of the country or region.\",\n",
      "    \"With the rapid growth in the global market for medical devices, there is a need to harmonize national standards in order to minimize regulatory barriers and to facilitate trade.\",\n",
      "    \"Harmonization also reduces the cost of local industry and government regulations.\",\n",
      "    \"The next chapter summarizes the work of the Global Harmonization Task Force to find common elements and ways to unify the different national standards and regulatory practices.\",\n",
      "    \"Medical devices, like drugs, are used worldwide.\",\n",
      "    \"With the rapid growth in the global market for medical devices, there is a need to harmonize national standards in order to minimize regulatory barriers, facilitate trade and improve access to new technologies.\",\n",
      "    \"Harmonization also reduces the cost of implementing regulations for governments and local industry.\",\n",
      "    \"The Global Harmonization Task Force (GHTF) was founded in 1993 by the governments and industry representatives of Australia, Canada, Japan, the European Union, and the United States of America to address these issues.\",\n",
      "    \"The purpose of the GHTF is to encourage a convergence in standards and regulatory practices related to the safety, performance and quality of medical devices.\",\n",
      "    \"The GHTF also promotes technological innovation and facilitates international trade.\",\n",
      "    \"The primary means by which its goals are accomplished is via the publication and dissemination of harmonized guidance documents for basic regulatory practices.\",\n",
      "    \"These documents, which are developed by four different GHTF Study Groups, can then be adopted/implemented by member national regulatory authorities or others.\",\n",
      "    \"Technical committee members include representatives from national medical device regulatory authorities and the regulated industry.\",\n",
      "    \"Study Group 1: is charged with comparing operational medical device regulatory systems around the world and from that comparison, isolating the elements/principles that are suitable for harmonization and those that may present obstacles to uniform regulations.\",\n",
      "    \"In addition, the group is also responsible for developing a standardized format for pre-market submissions and harmonized product labelling requirements.\",\n",
      "    \"Study Group 2: examines the requirements for: 1. the reporting of adverse events involving medical devices, 2. post-market surveillance and other forms of vigilance.\",\n",
      "    \"In addition, it is responsible for recommending ways of harmonizing the requirements, and for providing a discussion forum for harmonization initiatives.\",\n",
      "    \"Study Group 3: is responsible for examining existing quality system requirements in countries that already have well-developed device regulatory systems and identifying areas suitable for harmonization.\",\n",
      "    \"Study Group 4: is charged with the task of examining quality system auditing practices (initially among the founding members of the GHTF) and developing guidance documents that lay out harmonized principles for medical device auditing.\",\n",
      "    \"It may be helpful to relate the roles of these four groups to the medical device life span.\",\n",
      "    \"With the exception of commercial activities including advertising and sales, which give freedom to local variations, the GHTF Study Groups are involved in all aspects that have direct impact on the safety and performance of medical devices.\",\n",
      "    \"Therefore, recommendations from the GHTF Task Forces can provide excellent reference or guidance for countries that are establishing medical devices regulation programmes.\",\n",
      "    \"By following recommendations from the GHTF, countries can ensure that their regulatory controls are not in significant conflict with global harmonization recommendations.\",\n",
      "    \"The GHTF is directing and converging the harmonized guidance documents.\",\n",
      "    \"Critical issues such as safety and performance requirements, quality systems, standards and procedures of post-market surveillance are studied in-depth by experts from different countries to reach consensual recommendations and these are incorporated into the GHTF final guidance documents.\",\n",
      "    \"Global harmonization and cooperation in post-market surveillance will facilitate an international devices data bank that allows rapid, global access to device information, alerts or recalls.\",\n",
      "    \"This will promote the safety and effectiveness of medical devices.\",\n",
      "    \"Where a countrys programme is harmonized with the programmes of other countries, regulatory burdens and costs for local government and industry will be significantly reduced, while regulatory cooperation, commerce and international trade will be enhanced.\",\n",
      "    \"Other emerging issues of international significance can be put to the GHTF for a common solution.\",\n",
      "    \"GHTF provides an opportunity for countries to participate and observe regulatory developments that they could adopt.\",\n",
      "    \"The current trend towards a regional harmonization will be useful for countries and can be supported by WHOs parallel regional structure.\",\n",
      "    \"For example, at the 1998 GHTF Meeting in Australia, the Asian Harmonisation Working Party (AHWP) held its first formal meeting and at the 1999 GHTF meeting in the United States, medical device regulators of the Americas launched a regional GHTF group.\",\n",
      "    \"As at June 2003, 19 final guidance documents supported by consensus of the regulators and industry representatives of the GHTF founding members have been published.\",\n",
      "    \"These are listed in Annex 2 with an indication of how they relate to the common framework developed in this Guide.\",\n",
      "    \"Each document is identified by study group (SG) and document numbers.\",\n",
      "    \"Details of other recommendations under development by GHTF Study Groups may also be found at www.ghtf.org.\",\n",
      "    \"Achieving consistency in nomenclature is fundamental to the overall goal of international harmonization, particularly for the identification of devices involved in adverse incident reports.\",\n",
      "    \"In 1993, the European Commission mandated the Comit Europen de Normalisation (CEN) to produce a standard indicating the structure of a nomenclature system that could meet the needs of the global market.\",\n",
      "    \"The International Standards Organization was invited to participate to ensure that international considerations were addressed.\",\n",
      "    \"The resulting standard was adopted as EN/ISO 15225 Nomenclature  Specification for a nomenclature system for medical devices for the purposes of regulatory data exchange.\",\n",
      "    \"Before the creation of the Global Medical Device Nomenclature (GMDN) in 1997, a multitude of nomenclatures were being used, including the Universal Medical Device Nomenclature System.\",\n",
      "    \"With the introduction of the European Directives for medical device regulations, the need for a standardized international nomenclature became clear.\",\n",
      "    \"WHO supports wide consultation to adopt a single, harmonized option.\",\n",
      "    \"The GMDN, endorsed by the GHTF as the global nomenclature to be used by regulators for the classification and registration of medical devices, is intended: 1. to give a common generic description for every general term that describes characteristics of a medical device.\",\n",
      "    \"This is to be used for identifying similar devices to those involved in an adverse incident report; 2. to identify a device, using the generic term, for having been awarded a specific design or other certificate; 3. to serve as a basis for E-commerce  to provide a generic basis for purchasing individual types of manufactured devices, by establishing a heading for comparison of products from different manufacturers.\",\n",
      "    \"Further information on the GMDN can be found at http://www.gmdn.info/\",\n",
      "    \"The understanding of standards systems, the standards development process and their use in conformity assessment has become essential in establishing medical device regulations.\",\n",
      "    \"In this chapter, a general introduction to standards will be provided.\",\n",
      "    \"This is followed by a description of current trends in the use of voluntary standards in medical device regulations and related recommendations of the GHTF.\",\n",
      "    \"The formal definition of a standard that should be adopted in the medical device domain is given by the ISO:\",\n",
      "    \"Standards are documented agreements containing technical specifications or other precise criteria to be used consistently as rules, guidelines or definitions of characteristics, to ensure that materials, products, process and services are fit for their purpose.\",\n",
      "    \"Standards can establish a wide range of specifications for products, processes and services (see www.iso.org for definitions).\",\n",
      "    \"1. Prescriptive specifications obligate product characteristics, e.g. device dimensions, biomaterials, test or calibration procedures, as well as definitions of terms and terminologies.\",\n",
      "    \"2. Design specifications set out the specific design or technical characteristics of a product, e.g. operating room facilities or medical gas systems.\",\n",
      "    \"3. Performance specifications ensure that a product meets a prescribed test, e.g. strength requirements, measurement accuracy, battery capacity, or maximum defibrillator energy.\",\n",
      "    \"4. Management specifications set out requirements for the processes and procedures companies put in place, e.g. quality systems for manufacturing or environmental management systems.\",\n",
      "    \"A standard may contain a combination of specifications.\",\n",
      "    \"Prescriptive, design and performance specifications have been commonplace in standards.\",\n",
      "    \"Management specifications are also rapidly gaining prominence.\",\n",
      "    \"Recent years have seen the development and application of what are known as generic management system standards, where generic means that the standards requirements can be applied to any organization, regardless of the product it makes or the service it delivers, and management system refers to what the organization does to manage its processes.\",\n",
      "    \"Two of the most widely known series of generic management system standards are the ISO 9000 series for managing quality systems, and the ISO 14000 series for environmental management systems.\",\n",
      "    \"Wide ranging information and assistance related to these standards and their application is available at www.iso.org.\",\n",
      "    \"ISO13485 and ISO13488 are specific ISO quality systems standards for medical device manufacturing.\",\n",
      "    \"Terms such as outcome-oriented standards, objectives standards, function-focused standards and result-oriented standards are also employed.\",\n",
      "    \"Essentially, these terms indicate that the standards specify the objectives (ends) to be achieved while leaving the methods (means) to the implementers.\",\n",
      "    \"This can minimize possible constrictive effects of standards.\",\n",
      "    \"Standards can serve different purposes.\",\n",
      "    \"They can: 1. Provide reference criteria that a product, process or service must meet.\",\n",
      "    \"2. Provide information that enhances safety, reliability and performance of products, processes and services.\",\n",
      "    \"3. Assure consumers about reliability or other characteristics of goods or services provided in the marketplace.\",\n",
      "    \"4. Give consumers more choice by allowing one firms products to be substituted for, or combined with, those of another.\",\n",
      "    \"Although we take for granted the advantage of being able to order shoes or clothes simply by referring to a size, this is only possible because manufacturers follow some industrial standards in making shoes and clothes.\",\n",
      "    \"In contrast, incompatibility between electrical plugs and receptacles is a prime example of different countries failing to follow the same standards.\",\n",
      "    \"When North Americans want to use a portable computer or other electrical appliance in Europe or Asia, they can be frustrated to find that the plug and voltage are not compatible.\",\n",
      "    \"With the world becoming a global village, the need and benefits of standardization are becoming more and more important internationally for manufacturing, trade and communications.\",\n",
      "    \"Quality systems and other management standards can provide common references to the kind of process, service or management practice expected.\",\n",
      "    \"The Internet functions effectively because globally agreed-upon interconnection protocols exist.\",\n",
      "    \"Global communication would be very difficult without international standardization.\",\n",
      "    \"Health care workers are well aware of incompatible consumables or replacement parts in medical devices of similar function that are made by different manufacturers (e.g. IV set, X-ray cassettes).\",\n",
      "    \"The lack of available consumables and repair parts is an important cause of medical equipment problems that are constantly encountered in developing countries.\",\n",
      "    \"Most medical devices are used globally.\",\n",
      "    \"The safety, performance and consistent quality of medical devices is, therefore, an international public health interest.\",\n",
      "    \"Thus, global harmonization of medical device standards and regulations is critical.\",\n",
      "    \"In section 5.8, we shall further describe the need to use voluntary standards to provide detailed information in meeting regulatory requirements.\",\n",
      "    \"Most standards are voluntary.\",\n",
      "    \"However, a standard may be mandated by a company, professional society, industry, government or trade agreement.\",\n",
      "    \"A standard may be called a regulation when it becomes mandatory.\",\n",
      "    \"This mandate may, or may not, have a legal basis.\",\n",
      "    \"When a standard is mandated by a government or an international trade agreement, it normally becomes legally obligatory based on regulations or a law established by the government or the contracts between international bodies.\",\n",
      "    \"Countries that are considering making standards mandatory should take into account the potential consequences under international agreements on technical barriers to trade.\",\n",
      "    \"Figure 8 provides an example of the many steps used by standards development organizations (see www.iso.org for ISOs six-step process in the development of international standards).\",\n",
      "    \"In general, good standards have the following attributes:\",\n",
      "    \"1. Their development has been overseen by a recognized body, thus ensuring that the process is transparent and not dominated by vested interests.\",\n",
      "    \"2. The development process has been open to input from all interested parties and the resulting document based on consensus.\",\n",
      "    \"Consensus, in a practical sense, means that significant agreement among the stakeholders is reached in the preparation of the standard, including steps taken to resolve all objections.\",\n",
      "    \"This process implies more than the votes of a majority, but not necessarily unanimity.\",\n",
      "    \"3. Good technical standards are based on consolidated results of science, technology and experience, and are aimed at the promotion of optimum community benefits.\",\n",
      "    \"4. Standards do not hinder innovations and must be periodically reviewed to remain in tune with technological advances.\",\n",
      "    \"There are four common industrial methods for assessing conformity to a standard.\",\n",
      "    \"1. A products conformity to standards is commonly assessed by direct testing.\",\n",
      "    \"2. A process can be assessed by audit.\",\n",
      "    \"Certification organizations or regulatory authorities attest that products or processes conform to a standard by authorizing the display of their certification mark.\",\n",
      "    \"3. The conformity to management standard by an organization is known as management systems registration, a relatively new term used primarily in North America.\",\n",
      "    \"Formally established audit procedures are followed by certified auditors who are supported by technical experts of the domain under audit.\",\n",
      "    \"Management System Registration bodies (Registrars) issue registration certificates to companies that meet a management standard such as ISO9000, or to medical device manufacturers that meet the ISO13485/ISO9001 standards.\",\n",
      "    \"Note that in North America, the term registration is used for an organization while certification is reserved for products.\",\n",
      "    \"Many other countries use certification for both a product and an organization.\",\n",
      "    \"4. Accreditation is used by an authoritative body to give formal recognition that an organization or a person is competent to carry out a specific task.\",\n",
      "    \"For example, in Europe, Notified Bodies are notified or accredited by the relevant State Competent Authority to carry out conformity assessment of medical devices.\",\n",
      "    \"In Canada, a Quality System Registrar needs an accreditation from Health Canada before that Registrar begins assessing medical device manufacturers for conformity with quality system standards.\",\n",
      "    \"The International Laboratory Accreditation Cooperation (ILAC) uses accreditation to provide formal recognition to competent laboratories around the world.\",\n",
      "    \"A country may have many voluntary standards bodies.\",\n",
      "    \"However, normally there is one official national organization that coordinates and accredits the standards development bodies in the country.\",\n",
      "    \"This official national organization would have the authority to endorse a document as a national standard in accordance with official criteria, and it also represents the country in the various international standards organizations.\",\n",
      "    \"In the United States, the American National Standards Institute (ANSI), a private, non-profit organization, is an official national\"\n",
      "  ]\n",
      "}\n",
      "```\n",
      "\n",
      "rovas\n",
      "Response cleaned is {'chunks': ['In the United States, the establishment (manufacturers, initial importer, specifications developer, contract sterilizer, re-packager and/or re-labeller) must be registered with the FDA.', 'With all five authorities, the licensing or registration process also imposes obligations on the vendor for post-market surveillance and/or duties.', 'It is critically important that the safety and performance of medical devices are continually assessed when they are in use, as these characteristics can only be proven if one measures how a device stands up in these conditions.', 'No amount of rigour in the pre-marketing review process can predict all possible device failures or incidents arising from device misuse.', 'It is through actual use that unforeseen problems related to safety and performance can occur.', 'Different terms in medical device vigilance and post-market surveillance have varying meanings in different countries.', 'Whilst the GHTF is defining these terms, this document will use the definitions of the US FDA (see www.fda.gov/cdrh/postsurv/).', 'Post-market surveillance is a broad term that covers all monitoring activities of medical devices in use.', 'The two principal activities within surveillance are post-market surveillance studies and adverse event reporting.', 'In post-market surveillance studies, specific and structured data collections are required of the manufacturer in one of two situations: (1) as a condition of product approval, or (2) to re-affirm product safety when post-market adverse event reports suggest that pre-market safety claims are inconsistent with actual use and result in unacceptable risk.', 'Japanese authorities and the FDA actively make use of surveillance data collection to augment the findings of pre-market trials.', 'Adverse event reporting requires the registration and investigation of adverse events relating to the use of a device, and the authority necessary to oblige the manufacturer to recall or modify a defective device.', 'All founding members of the GHTF have mandatory requirements for vendors or manufacturers to report all device-related events that have resulted, or could result, in serious injury or death.', 'In some countries, mandatory adverse event reporting is also extended to users.', 'Post-market surveillance is interrelated to the quality system requirements described in the following section.', 'A Quality System is defined as the organizational structure, responsibilities, procedures, processes and resources needed to implement quality management.', 'Quality system standards are generic management standards and are described in section 5.1.', 'The international quality system standards for medical devices are issued by the International Organization for Standardization (ISO) (ISO13485:1996 and ISO13488: 1996).', 'ISO13485:1996 includes all the elements of ISO9001:1994 plus a set of minimum supplementary requirements for medical devices.', 'The relationship between ISO9001:1994 and ISO13485:1996 is described in Annex 3.', 'ISO13488:1996 is the same as ISO13485: 1994, but without the design control requirements.', 'A new standard, ISO13485:200?, is currently being developed and will become the international reference standard for medical devices.', 'Regulations for quality systems may cover the methods, facilities and controls used by the manufacturer in the design, manufacture, packaging, labelling, storage, installation, servicing and post-market handling of medical devices.', 'Therefore, quality system requirements can influence all phases in the medical device life span.', 'Applicable requirements depend upon the risk class of the device and on the regulatory system of the country.', 'Design control is normally not required for regulatory scrutiny in medium- to low-risk devices.', 'When applied to the manufacturing process, quality system requirements impose strict quality assurance on every aspect of production.', 'The result is a tightly controlled manufacturing system, commonly known as Good Manufacturing Practice (GMP), which reduces the likelihood of non-conforming products.', 'This practice ensures consistency in the quality and provides the basis for greater reliability in device safety and performance.', 'Elements of the quality system are periodically subject to audits, management review, and corrective or preventive actions that will maintain product quality.', 'Continuous monitoring and corrective action requirements are interrelated to post-market surveillance previously described.', 'The key advantage regarding quality systems is that they represent a preventive approach to assuring medical device quality versus the previous reactive approach by inspection and rejection at the end of the manufacturing line.', 'Prevention has been proven to be more efficient and cost effective in controlling manufacturing processes and maintaining medical device quality.', 'It is important to note that since the majority of medical devices are in the medium- to low-risk classes, their compliance with regulations often depends upon the declarations of manufacturers, thus the question of quality assurance naturally arises.', 'This is why it is critical for manufacturers to conform with quality system standards and for this conformity to be subject to periodic audit by governmental or third party agencies.', 'All founding members of the GHTF have quality system requirements for their manufacturers, who are subject to periodic inspection by the government and/or accredited third party agencies.', 'The applicable standard is determined by the risk class of the device and depends upon the regulatory system of the country or region.', 'With the rapid growth in the global market for medical devices, there is a need to harmonize national standards in order to minimize regulatory barriers and to facilitate trade.', 'Harmonization also reduces the cost of local industry and government regulations.', 'The next chapter summarizes the work of the Global Harmonization Task Force to find common elements and ways to unify the different national standards and regulatory practices.', 'Medical devices, like drugs, are used worldwide.', 'With the rapid growth in the global market for medical devices, there is a need to harmonize national standards in order to minimize regulatory barriers, facilitate trade and improve access to new technologies.', 'Harmonization also reduces the cost of implementing regulations for governments and local industry.', 'The Global Harmonization Task Force (GHTF) was founded in 1993 by the governments and industry representatives of Australia, Canada, Japan, the European Union, and the United States of America to address these issues.', 'The purpose of the GHTF is to encourage a convergence in standards and regulatory practices related to the safety, performance and quality of medical devices.', 'The GHTF also promotes technological innovation and facilitates international trade.', 'The primary means by which its goals are accomplished is via the publication and dissemination of harmonized guidance documents for basic regulatory practices.', 'These documents, which are developed by four different GHTF Study Groups, can then be adopted/implemented by member national regulatory authorities or others.', 'Technical committee members include representatives from national medical device regulatory authorities and the regulated industry.', 'Study Group 1: is charged with comparing operational medical device regulatory systems around the world and from that comparison, isolating the elements/principles that are suitable for harmonization and those that may present obstacles to uniform regulations.', 'In addition, the group is also responsible for developing a standardized format for pre-market submissions and harmonized product labelling requirements.', 'Study Group 2: examines the requirements for: 1. the reporting of adverse events involving medical devices, 2. post-market surveillance and other forms of vigilance.', 'In addition, it is responsible for recommending ways of harmonizing the requirements, and for providing a discussion forum for harmonization initiatives.', 'Study Group 3: is responsible for examining existing quality system requirements in countries that already have well-developed device regulatory systems and identifying areas suitable for harmonization.', 'Study Group 4: is charged with the task of examining quality system auditing practices (initially among the founding members of the GHTF) and developing guidance documents that lay out harmonized principles for medical device auditing.', 'It may be helpful to relate the roles of these four groups to the medical device life span.', 'With the exception of commercial activities including advertising and sales, which give freedom to local variations, the GHTF Study Groups are involved in all aspects that have direct impact on the safety and performance of medical devices.', 'Therefore, recommendations from the GHTF Task Forces can provide excellent reference or guidance for countries that are establishing medical devices regulation programmes.', 'By following recommendations from the GHTF, countries can ensure that their regulatory controls are not in significant conflict with global harmonization recommendations.', 'The GHTF is directing and converging the harmonized guidance documents.', 'Critical issues such as safety and performance requirements, quality systems, standards and procedures of post-market surveillance are studied in-depth by experts from different countries to reach consensual recommendations and these are incorporated into the GHTF final guidance documents.', 'Global harmonization and cooperation in post-market surveillance will facilitate an international devices data bank that allows rapid, global access to device information, alerts or recalls.', 'This will promote the safety and effectiveness of medical devices.', 'Where a countrys programme is harmonized with the programmes of other countries, regulatory burdens and costs for local government and industry will be significantly reduced, while regulatory cooperation, commerce and international trade will be enhanced.', 'Other emerging issues of international significance can be put to the GHTF for a common solution.', 'GHTF provides an opportunity for countries to participate and observe regulatory developments that they could adopt.', 'The current trend towards a regional harmonization will be useful for countries and can be supported by WHOs parallel regional structure.', 'For example, at the 1998 GHTF Meeting in Australia, the Asian Harmonisation Working Party (AHWP) held its first formal meeting and at the 1999 GHTF meeting in the United States, medical device regulators of the Americas launched a regional GHTF group.', 'As at June 2003, 19 final guidance documents supported by consensus of the regulators and industry representatives of the GHTF founding members have been published.', 'These are listed in Annex 2 with an indication of how they relate to the common framework developed in this Guide.', 'Each document is identified by study group (SG) and document numbers.', 'Details of other recommendations under development by GHTF Study Groups may also be found at www.ghtf.org.', 'Achieving consistency in nomenclature is fundamental to the overall goal of international harmonization, particularly for the identification of devices involved in adverse incident reports.', 'In 1993, the European Commission mandated the Comit Europen de Normalisation (CEN) to produce a standard indicating the structure of a nomenclature system that could meet the needs of the global market.', 'The International Standards Organization was invited to participate to ensure that international considerations were addressed.', 'The resulting standard was adopted as EN/ISO 15225 Nomenclature  Specification for a nomenclature system for medical devices for the purposes of regulatory data exchange.', 'Before the creation of the Global Medical Device Nomenclature (GMDN) in 1997, a multitude of nomenclatures were being used, including the Universal Medical Device Nomenclature System.', 'With the introduction of the European Directives for medical device regulations, the need for a standardized international nomenclature became clear.', 'WHO supports wide consultation to adopt a single, harmonized option.', 'The GMDN, endorsed by the GHTF as the global nomenclature to be used by regulators for the classification and registration of medical devices, is intended: 1. to give a common generic description for every general term that describes characteristics of a medical device.', 'This is to be used for identifying similar devices to those involved in an adverse incident report; 2. to identify a device, using the generic term, for having been awarded a specific design or other certificate; 3. to serve as a basis for E-commerce  to provide a generic basis for purchasing individual types of manufactured devices, by establishing a heading for comparison of products from different manufacturers.', 'Further information on the GMDN can be found at http://www.gmdn.info/', 'The understanding of standards systems, the standards development process and their use in conformity assessment has become essential in establishing medical device regulations.', 'In this chapter, a general introduction to standards will be provided.', 'This is followed by a description of current trends in the use of voluntary standards in medical device regulations and related recommendations of the GHTF.', 'The formal definition of a standard that should be adopted in the medical device domain is given by the ISO:', 'Standards are documented agreements containing technical specifications or other precise criteria to be used consistently as rules, guidelines or definitions of characteristics, to ensure that materials, products, process and services are fit for their purpose.', 'Standards can establish a wide range of specifications for products, processes and services (see www.iso.org for definitions).', '1. Prescriptive specifications obligate product characteristics, e.g. device dimensions, biomaterials, test or calibration procedures, as well as definitions of terms and terminologies.', '2. Design specifications set out the specific design or technical characteristics of a product, e.g. operating room facilities or medical gas systems.', '3. Performance specifications ensure that a product meets a prescribed test, e.g. strength requirements, measurement accuracy, battery capacity, or maximum defibrillator energy.', '4. Management specifications set out requirements for the processes and procedures companies put in place, e.g. quality systems for manufacturing or environmental management systems.', 'A standard may contain a combination of specifications.', 'Prescriptive, design and performance specifications have been commonplace in standards.', 'Management specifications are also rapidly gaining prominence.', 'Recent years have seen the development and application of what are known as generic management system standards, where generic means that the standards requirements can be applied to any organization, regardless of the product it makes or the service it delivers, and management system refers to what the organization does to manage its processes.', 'Two of the most widely known series of generic management system standards are the ISO 9000 series for managing quality systems, and the ISO 14000 series for environmental management systems.', 'Wide ranging information and assistance related to these standards and their application is available at www.iso.org.', 'ISO13485 and ISO13488 are specific ISO quality systems standards for medical device manufacturing.', 'Terms such as outcome-oriented standards, objectives standards, function-focused standards and result-oriented standards are also employed.', 'Essentially, these terms indicate that the standards specify the objectives (ends) to be achieved while leaving the methods (means) to the implementers.', 'This can minimize possible constrictive effects of standards.', 'Standards can serve different purposes.', 'They can: 1. Provide reference criteria that a product, process or service must meet.', '2. Provide information that enhances safety, reliability and performance of products, processes and services.', '3. Assure consumers about reliability or other characteristics of goods or services provided in the marketplace.', '4. Give consumers more choice by allowing one firms products to be substituted for, or combined with, those of another.', 'Although we take for granted the advantage of being able to order shoes or clothes simply by referring to a size, this is only possible because manufacturers follow some industrial standards in making shoes and clothes.', 'In contrast, incompatibility between electrical plugs and receptacles is a prime example of different countries failing to follow the same standards.', 'When North Americans want to use a portable computer or other electrical appliance in Europe or Asia, they can be frustrated to find that the plug and voltage are not compatible.', 'With the world becoming a global village, the need and benefits of standardization are becoming more and more important internationally for manufacturing, trade and communications.', 'Quality systems and other management standards can provide common references to the kind of process, service or management practice expected.', 'The Internet functions effectively because globally agreed-upon interconnection protocols exist.', 'Global communication would be very difficult without international standardization.', 'Health care workers are well aware of incompatible consumables or replacement parts in medical devices of similar function that are made by different manufacturers (e.g. IV set, X-ray cassettes).', 'The lack of available consumables and repair parts is an important cause of medical equipment problems that are constantly encountered in developing countries.', 'Most medical devices are used globally.', 'The safety, performance and consistent quality of medical devices is, therefore, an international public health interest.', 'Thus, global harmonization of medical device standards and regulations is critical.', 'In section 5.8, we shall further describe the need to use voluntary standards to provide detailed information in meeting regulatory requirements.', 'Most standards are voluntary.', 'However, a standard may be mandated by a company, professional society, industry, government or trade agreement.', 'A standard may be called a regulation when it becomes mandatory.', 'This mandate may, or may not, have a legal basis.', 'When a standard is mandated by a government or an international trade agreement, it normally becomes legally obligatory based on regulations or a law established by the government or the contracts between international bodies.', 'Countries that are considering making standards mandatory should take into account the potential consequences under international agreements on technical barriers to trade.', 'Figure 8 provides an example of the many steps used by standards development organizations (see www.iso.org for ISOs six-step process in the development of international standards).', 'In general, good standards have the following attributes:', '1. Their development has been overseen by a recognized body, thus ensuring that the process is transparent and not dominated by vested interests.', '2. The development process has been open to input from all interested parties and the resulting document based on consensus.', 'Consensus, in a practical sense, means that significant agreement among the stakeholders is reached in the preparation of the standard, including steps taken to resolve all objections.', 'This process implies more than the votes of a majority, but not necessarily unanimity.', '3. Good technical standards are based on consolidated results of science, technology and experience, and are aimed at the promotion of optimum community benefits.', '4. Standards do not hinder innovations and must be periodically reviewed to remain in tune with technological advances.', 'There are four common industrial methods for assessing conformity to a standard.', '1. A products conformity to standards is commonly assessed by direct testing.', '2. A process can be assessed by audit.', 'Certification organizations or regulatory authorities attest that products or processes conform to a standard by authorizing the display of their certification mark.', '3. The conformity to management standard by an organization is known as management systems registration, a relatively new term used primarily in North America.', 'Formally established audit procedures are followed by certified auditors who are supported by technical experts of the domain under audit.', 'Management System Registration bodies (Registrars) issue registration certificates to companies that meet a management standard such as ISO9000, or to medical device manufacturers that meet the ISO13485/ISO9001 standards.', 'Note that in North America, the term registration is used for an organization while certification is reserved for products.', 'Many other countries use certification for both a product and an organization.', '4. Accreditation is used by an authoritative body to give formal recognition that an organization or a person is competent to carry out a specific task.', 'For example, in Europe, Notified Bodies are notified or accredited by the relevant State Competent Authority to carry out conformity assessment of medical devices.', 'In Canada, a Quality System Registrar needs an accreditation from Health Canada before that Registrar begins assessing medical device manufacturers for conformity with quality system standards.', 'The International Laboratory Accreditation Cooperation (ILAC) uses accreditation to provide formal recognition to competent laboratories around the world.', 'A country may have many voluntary standards bodies.', 'However, normally there is one official national organization that coordinates and accredits the standards development bodies in the country.', 'This official national organization would have the authority to endorse a document as a national standard in accordance with official criteria, and it also represents the country in the various international standards organizations.', 'In the United States, the American National Standards Institute (ANSI), a private, non-profit organization, is an official national']}\n",
      "Cleaning response ```json\n",
      "{\n",
      "  \"chunks\": [\n",
      "    \"In Canada, it is the Standards Council of Canada (SCC), a crown (government) corporation.\",\n",
      "    \"In Europe there is a committee composed of CEN (Comit Europen de Normalisation), CENELEC (the European Committee for Electrotechnical Standardization) and ETSI (the European Telecommunication Standards Institute) that supercedes the various European national standards bodies that were in place previously.\",\n",
      "    \"For developing countries, reference to a standards system not only helps medical device administration, it is also important for other industrial and economic developments.\",\n",
      "    \"International development agencies increasingly realize that a standardized infrastructure is a basic requirement for the success of economic policies that will improve productivity, market competitiveness and export capability.\",\n",
      "    \"The three major international standardization organizations are the International Organization for Standardization (ISO), the International Electrotechnical Commission (IEC), and the International Telecommunication Union (ITU).\",\n",
      "    \"Generally, ITU covers telecommunications, IEC covers electrical and electronic engineering, and ISO covers the remainder.\",\n",
      "    \"For information technology, risk management, quality systems and many other areas, joint ISO/IEC technical committees manage standardization.\",\n",
      "    \"Other organizations also produce documents on international standardization.\",\n",
      "    \"Their documents are usually adopted by ISO/IEC/ITU as international standards if they have been developed in accordance with international consensus criteria.\",\n",
      "    \"Any grouping of five member countries can also propose a standard to be considered by ISO for adoption as an international standard.\",\n",
      "    \"Useful web sites include: www.iso.ch, www.IEC.ch, and www.itu.int/ for the ISO, IEC and ITU respectively.\",\n",
      "    \"From here, links to national or regional standard organizations are indicated.\",\n",
      "    \"Standards are generally designated by an alphabetical prefix and a number.\",\n",
      "    \"The letters (e.g. ISO, IEC, ANSI, CAN, EN, DIN) indicate the body that has approved them, while the numbers identify the specific standard and the year in which it was finalized.\",\n",
      "    \"The standard reference code often gives an indication of adoption where standards are equivalent.\",\n",
      "    \"For example: CAN/CSA-Z386-94 means a standard developed in 1994 by the Canadian Standards Association (CSA, one of four accredited Canadian standards development organizations) and designated by the Standards Council of Canada (SCC) as a Canadian national standard.\",\n",
      "    \"ANSI/AAMI/ISO 15223:2000 means the international standard ISO 15223 (established in 2000) adopted by the Association for the Advancement of Medical Instrumentations in the United States, which in turn is designated by the American National Standards Institute (ANSI) as an American national standard.\",\n",
      "    \"UNI EN ISO 9001 indicates an Italian national standard (UNI) which is an adoption of a European standard (EN), which is itself an adoption of the International Standard ISO9001.\",\n",
      "    \"Although a standard can be set and mandated by an authority, the current trend is for the adoption of voluntary standards established by consensus from all interested parties (the stakeholders).\",\n",
      "    \"The use of voluntary standards originated from the realization that while regulations generally address the essential safety and performance principles, manufacturers and users still need to know detailed specifications pertaining to specific products.\",\n",
      "    \"The provision of such specifications and detailed requirements for the multitude of devices presents an enormous task for regulatory authorities.\",\n",
      "    \"Fortunately, the wealth of voluntary standards already existing or being developed provide such precise specifications.\",\n",
      "    \"The use of voluntary/consensus standards has many advantages including the following: They are normally developed by experts with access to the vast resources available in the professional and industrial communities.\",\n",
      "    \"By taking advantage of such existing resources, the government can overcome its own limited resources for providing product specific technical requirements and characteristics.\",\n",
      "    \"Conformity to standards can also be assessed by an accredited third party (such as a notified body in Europe), which is a well-established industrial practice around the world.\",\n",
      "    \"The use of international standards facilitates harmonized regulatory processes and world trade, and thus improves global access to new technology.\",\n",
      "    \"As technology advances, it is much easier to update standards than to change regulations.\",\n",
      "    \"Timely development and periodic revision by expert groups make medical device standards effective and efficient tools for supporting health care.\",\n",
      "    \"Manufacturers have the flexibility to choose appropriate standards or other means to demonstrate compliance with regulatory requirements.\",\n",
      "    \"Regulatory authorities can recognize a standard, fully or partially, provided they clearly specify and publicize their intent.\",\n",
      "    \"Several standards can also be recognized as a group to satisfy the requirements for a particular device.\",\n",
      "    \"In some countries, the publication of government-recognized standards mandates product compliance.\",\n",
      "    \"Medical devices intended for global use should follow international standards.\",\n",
      "    \"For example, the ISO Technical Report (ISO 16142:2000) lists a number of significant international standards that may be suitable for demonstrating compliance with certain features of the essential principles of safety and performance of medical devices.\",\n",
      "    \"The GHTF has issued the following recommendations regarding the recognition and use of standards: International standards are a building block for harmonized regulatory processes to assure the safety, quality and performance of medical devices.\",\n",
      "    \"To achieve this purpose, the following principles are recommended: Regulatory Authorities and industry should encourage and support the development of international standards for medical devices to demonstrate compliance with the Essential Principles of Safety and Performance of Medical Devices (GHTF document SG1 NO20R5 referred to hereafter as the Essential Principles).\",\n",
      "    \"Regulatory Authorities developing new medical device regulations should encourage the use of international standards.\",\n",
      "    \"Regulatory Authorities should provide a mechanism for recognizing international standards to provide manufacturers with a method of demonstrating compliance with the Essential Principles.\",\n",
      "    \"When an international standard is not applied or not applied in full, this is acceptable if an appropriate level of compliance with the Essential Principles can be demonstrated.\",\n",
      "    \"While it may be preferable for harmonization purposes to use international standards, it may be appropriate for Regulatory Authorities to accept the use of national/regional standards or industry standards as a means of demonstrating compliance.\",\n",
      "    \"Standards Bodies developing or revising standards for use with medical devices should consider the suitability of such standards for demonstrating compliance with the Essential Principles and to identify which of the Essential Principles they satisfy.\",\n",
      "    \"The use of standards should preferably reflect current, broadly applicable technology while not discouraging the use of new technologies.\",\n",
      "    \"Standards may represent the current state of the art in a technological field.\",\n",
      "    \"However, not all devices, or elements of device safety and/or performance may be addressed by recognized standards, especially for new types of devices and emerging technologies.\",\n",
      "    \"Implementing a full regulatory programme can be very expensive and demanding on resources.\",\n",
      "    \"The work of the GHTF and the trend to use international standards are, in effect, tackling this problem by steering manufacturers more and more toward producing medical devices with uniform standards.\",\n",
      "    \"The methods and procedures relating to governmental regulations are also converging.\",\n",
      "    \"These developments create opportunities for countries to establish low-cost programmes that promote the safety and performance of medical devices by taking full advantage of what others have already done in this field.\",\n",
      "    \"Local adoption of harmonized recommendations will facilitate international exports of medical devices manufactured locally.\",\n",
      "    \"A good approach to setting a clear direction for all stakeholders is to establish a comprehensive national policy or guideline on medical device management.\",\n",
      "    \"The government can subsequently bring in legislation and enforcement to suit the countrys conditions and needs.\",\n",
      "    \"Five principal activities are identified: Increasing the knowledge of the medical device sector; Establishing basic regulatory programmes; Drafting a comprehensive policy/guideline including the recognition and use of standards; Promoting compliance and cooperation; Setting priorities for regulatory programme development.\",\n",
      "    \"Several key activities are suggested: Access the Internet for a great deal of freely available, relevant information.\",\n",
      "    \"A list of web site addresses is provided in Annex 1.\",\n",
      "    \"Participate actively in the projects of the GHTF Task Forces in order to benefit from the experience of experts from other countries.\",\n",
      "    \"Form a partnership with a country that is a member of the GHTF and has a functioning regulatory programme on medical devices.\",\n",
      "    \"Make connections with national and international medical device problem coordinating centres.\",\n",
      "    \"Become an active member of a regional harmonization organization (e.g. Asian Harmonization Working Party (AHWP); the Latin American and Caribbean regional group (contact the GHTF for information on regional groups).\",\n",
      "    \"As discussed previously, medical device safety and performance is multi-phased and requires cooperation among all stakeholders.\",\n",
      "    \"It is essential to identify the stakeholders in each country by maintaining a list of manufacturers, importers, distributors, retailers, institutional users (both public and private health care facilities), lay users (estimated from the number of home-use medical device vendors), and concerned citizens groups.\",\n",
      "    \"A basic regulatory programme should also include other important activities: holding education/consultation sessions with the stakeholders to discuss the issues; creating an atmosphere conducive to mutual trust and open discussions; and, inviting input from the stakeholders.\",\n",
      "    \"The government should not overlook the willingness of stakeholders to help suggest solutions for issues that affect them.\",\n",
      "    \"Such sessions will help to share understanding of issues affecting the safety and performance of medical devices, and should lead to the development of a policy/guideline that sets a direction for everyone (see Section 6.3).\",\n",
      "    \"Apart from the rich source of practical suggestions that stakeholders can offer, they are more likely to comply with any requirements that they have participated in devising.\",\n",
      "    \"If there are significant numbers of medical devices being sold or used in the country, then two basic programmes should be set up as soon as is possible: (1) Basic legislation; (2) Problem sharing.\",\n",
      "    \"If the government has not already passed legislation, this should be done: To prohibit misleading or fraudulent advertising of medical devices.\",\n",
      "    \"_**Advertising**_ has a powerful influence on people.\",\n",
      "    \"A prohibition on the misleading or fraudulent advertisement of health devices should be an essential legislation.\",\n",
      "    \"This is particularly important since, as people are becoming more health conscious, the development of home-use medical devices is rapidly expanding.\",\n",
      "    \"Advertising control does not have to place demands on resources.\",\n",
      "    \"For example, in Canada, even though the prohibition of misleading or fraudulent advertising is legislated, the Government does not routinely screen device advertising.\",\n",
      "    \"The Government, however, will respond to inquiries or complaints made by the public or health care professionals.\",\n",
      "    \"If the advertiser cannot convincingly prove their claims, the government can take action to prohibit the advertisement.\",\n",
      "    \"To empower the government to stop the sale of a device and issue alerts to the public under urgent hazardous conditions.\",\n",
      "    \"Again, this is essential legislation in case the manufacturer or the vendor has not taken adequate action to ensure the safety of their product.\",\n",
      "    \"The government should establish a national coordinating agency to receive and manage problem reports from all sources.\",\n",
      "    \"This information can then be shared with other users in the country and in other countries as well.\",\n",
      "    \"The objective is to improve the protection of the health and safety of patients, users and others by disseminating information, which can prevent repetition of adverse events.\",\n",
      "    \"If the government has no funding to set up such an agency, it should encourage the users, hospital technicians, clinical engineers and vendors to form a network.\",\n",
      "    \"There is a high possibility that they will support such a programme, since it is in their own self-interest.\",\n",
      "    \"Hospitals and universities are likely to have the resources and willingness to coordinate such activities.\",\n",
      "    \"An advisory panel of experts and/or scientific testing laboratories in these institutions would be very useful for investigating problems.\",\n",
      "    \"For example, they could confirm bacterial contamination, or investigate possible electrical hazards.\",\n",
      "    \"Going through the exercise of drafting a policy or guideline will clarify, for both the government and the other stakeholders, what the issues are and how to address them.\",\n",
      "    \"The resulting policy/guideline will also set a direction for how to manage potential problems.\",\n",
      "    \"Moreover, it will provide a foundation for shared understanding and shared responsibility of all the concerned parties (see section 2.6).\",\n",
      "    \"After a policy or guideline on medical device management is established, its implementation and integration into national legislation will depend on national context and resources available.\",\n",
      "    \"Effective national policies have a legislative base.\",\n",
      "    \"Although this is regrettably not always the case, they still serve as a framework of rules for decision-making and guidance.\",\n",
      "    \"In some countries, a national policy may automatically have legal recognition.\",\n",
      "    \"Some of the advantages of a national policy are as follows: it obligates an examination of the country-wide conditions for holistic planning; it is written in non-legal terms, hence is easier for lay people to understand; it can provide more explanatory information than a regulatory document; a guideline can be written as a policy supplement to include more detailed information on means and procedures to achieve policy objectives; policies and guidelines do not require a legal and lengthy process to modify them.\",\n",
      "    \"The policy on medical device management can also include instructions for the role of each stakeholder (see section 2.5).\",\n",
      "    \"For example, the role of the user can be expanded to include issues such as the care and maintenance of devices, introducing an integrated approach to medical device management.\",\n",
      "    \"Depending on the culture and legal system, a country may find it more effective to legislate all key requirements of the policy.\",\n",
      "    \"Some countries may prefer to legislate the items gradually as the need is demonstrated and as resources for monitoring and enforcement become available (see section 6.5).\",\n",
      "    \"Countries that have decided to accept devices that are approved by other countries can simplify the pre-market control regulations (section 6.3.3) by including this in their legislation.\",\n",
      "    \"The GHTF document SG1 N015R18 has been drafted to provide a rule-based system in classifying medical devices (see section 3.4.1).\",\n",
      "    \"It contains 16 rules and decision trees to demonstrate how these rules should be used to classify specific devices.\",\n",
      "    \"The document will be of value to countries developing or amending regulations.\",\n",
      "    \"Regulatory authorities that are developing new classification schemes or amending existing ones are encouraged to consider the adoption of this system, as this will help to reduce the diversity of systems worldwide and facilitate the process of harmonization.\",\n",
      "    \"Pre-market approval is one of the most important aspects of any comprehensive policy.\",\n",
      "    \"The difficulty of establishing a local pre-market review team is not just financial but also depends on whether specialized scientific and clinical expertise is available in the country.\",\n",
      "    \"However, with the work of the GHTF and the ability to look at approval decisions in other countries, it is now feasible for many countries to avoid the expense of a local pre market review team.\",\n",
      "    \"Global statistics on medical device manufacturers reveal that the US, Japan and EU countries manufacture approximately 85% of the medical devices in the world (see Figure 9 below).\",\n",
      "    \"They already have comprehensive regulatory systems in place that follow the Essential Principles of Safety and Performance of Medical Devices recommended by the GHTF.\",\n",
      "    \"This is a positive development for the other countries of the world that import most of their medical devices.\",\n",
      "    \"As an alternative to a local pre-market review team, a government can adopt a policy of accepting devices that are manufactured in compliance with the regulations of another country.\",\n",
      "    \"The choices include, for example, devices with an Australian, Canadian or Japanese License, devices with a European CE mark, or devices that have been granted marketing clearance by the US-FDA.\",\n",
      "    \"In this way the citizens of the importing country will be assured of the same risk exposure as the citizens of the exporting countries.\",\n",
      "    \"Whether to grant local marketing rights to that device remains a local government decision, which may rest on local socioeconomic considerations and technology assessment information.\",\n",
      "    \"Since it may be necessary to verify the authenticity of EU regulatory compliance, device suppliers can be asked to obtain an export certificate, the nominal cost of which may be passed on to the importer.\",\n",
      "    \"However, since export certificates can differ in purpose and format, it is important to be cautious when relying on them (section 6.6 discusses this issue).\",\n",
      "    \"A similar approach can be used for local medical device manufacturers.\",\n",
      "    \"The government can require that local manufacturers make submissions for compliance acceptance to a country that has an accepted pre-market review team.\",\n",
      "    \"In fact, this is what the manufacturers have to do anyway if they want to sell internationally.\",\n",
      "    \"If a country has competent private organizations, the government has the option to authorize such organizations to perform the pre-market assessment, as is now carried out by the European Union.\",\n",
      "    \"The Quality System certification of local manufacturing facilities is usually delegated to authorized third party agents (such as the notified bodies in the EU, or Quality Systems Registrars in Australia and Canada).\",\n",
      "    \"In the case of the United States, the FDA, following the completion of an inspection, can issue a letter to the firm denoting their compliance status.\",\n",
      "    \"Currently the cost of inspection is borne by the FDA, and is performed, almost without exception, by FDA employees.\",\n",
      "    \"In avoiding the expense and effort of a pre-market review team, a government can concentrate on implementing vendor and device registration and surveillance programmes for devices in use.\",\n",
      "    \"Product representation is controlled through labelling during the pre-market stage and advertising of the product during the on-market stage.\",\n",
      "    \"Labelling requirements include identification of the device, instructions for use, as well as safety- and performance-related information.\",\n",
      "    \"A harmonized format for labelling is recommended by the GHTF (SG1 N009R6).\",\n",
      "    \"Advertising control is an important tool for ensuring that the public is protected from misleading and fraudulent claims as described in section 6.2.1.\",\n",
      "    \"Vendor establishment control allows the government to be informed of which establishments are selling what devices.\",\n",
      "    \"Its main purpose is to establish contact with vendors in case of adverse events and also to inform the local vendors of their responsibility for after-sale obligations.\",\n",
      "    \"In most countries, only one level of in-country vendor is required to be registered for control.\",\n",
      "    \"For example, if the importer or the distributor were already registered, then it would not be necessary to register the retailers of the same device.\",\n",
      "    \"There are two general ways to accomplish vendor establishment control: (1) Sales notification, and (2) establishment license or registration.\",\n",
      "    \"_**Sales notification**_ is generally a less effective method.\",\n",
      "    \"Vendors are automatically permitted to sell medical devices provided that they notify the regulatory authority, either before or after the sale, as required by the authority.\",\n",
      "    \"_**Establishment License or Registration**_, on the other hand, requires that the vendor either obtains a license or is registered before they are allowed to sell medical devices.\",\n",
      "    \"This method has several advantages: It ensures that the government has a record of the vendor; It enables the government to place emphasis on after-sale obligations; It provides a means for the government to enforce requirements; for example, it will be able to suspend a license if the vendor does not fulfil after-sale responsibilities; It allows the government to require an annual renewal of the license or registration in order to maintain updated information on the vendors.\",\n",
      "    \"Since the latter method places considerable demand on the government, the government can impose a fee on the licensing or registration process.\",\n",
      "    \"This fee will help defray the cost of administration.\",\n",
      "    \"The fee may also help to strengthen the vendors efforts to fulfil their obligations so that they avoid losing the license that they have paid for.\",\n",
      "    \"Experience from Canada reveals that an establishment licence is a more effective means than sales notification for keeping records of the vendors (see www.hc-sc.gc.ca/hpfb-dgpsa/tpd-dpt/ for Canadian guidance documents on establishment licensing).\",\n",
      "    \"A recent development in the medical device market is the rapid increase in the number and variety of home-use medical devices.\",\n",
      "    \"This results in a shift from institution-based professional users of medical devices to their employment by lay users.\",\n",
      "    \"Here, education of the consumer is key to safety and performance.\",\n",
      "    \"Formerly, used or refurbished medical devices were traded to developing countries, mainly by third parties, and the vendors were often opportunistic merchants with no technical expertise.\",\n",
      "    \"Many recipient countries had very bad experiences with used equipment because there were no after-sale technical support or spare parts.\",\n",
      "    \"By 2002, at least five countries had imposed a total ban on the import of used equipment and 17 others have partial bans depending on the type of equipment.\",\n",
      "    \"The situation has changed rapidly over the past 10 years due to shrinking health care budgets and rapid technological innovations.\",\n",
      "    \"Refurbished medical equipment is increasingly being used within the United States and other industrialized countries.\",\n",
      "    \"As larger hospitals purchase the latest models, they trade in their superseded equipment which is often still in good condition.\",\n",
      "    \"This equipment can remain suitable for a wide range of applications, both for city and rural hospitals, and large global medical device manufacturers are now participating in the business of refurbishment.\",\n",
      "    \"As a result of the increasing use of refurbished equipment in industrialized countries, the question of regulations is raised.\",\n",
      "    \"Work is under way to define the scope of refurbished equipment and the different requirements for their regulation.\"\n",
      "  ]\n",
      "}\n",
      "```\n",
      "\n",
      "rovas\n",
      "Response cleaned is {'chunks': ['In Canada, it is the Standards Council of Canada (SCC), a crown (government) corporation.', 'In Europe there is a committee composed of CEN (Comit Europen de Normalisation), CENELEC (the European Committee for Electrotechnical Standardization) and ETSI (the European Telecommunication Standards Institute) that supercedes the various European national standards bodies that were in place previously.', 'For developing countries, reference to a standards system not only helps medical device administration, it is also important for other industrial and economic developments.', 'International development agencies increasingly realize that a standardized infrastructure is a basic requirement for the success of economic policies that will improve productivity, market competitiveness and export capability.', 'The three major international standardization organizations are the International Organization for Standardization (ISO), the International Electrotechnical Commission (IEC), and the International Telecommunication Union (ITU).', 'Generally, ITU covers telecommunications, IEC covers electrical and electronic engineering, and ISO covers the remainder.', 'For information technology, risk management, quality systems and many other areas, joint ISO/IEC technical committees manage standardization.', 'Other organizations also produce documents on international standardization.', 'Their documents are usually adopted by ISO/IEC/ITU as international standards if they have been developed in accordance with international consensus criteria.', 'Any grouping of five member countries can also propose a standard to be considered by ISO for adoption as an international standard.', 'Useful web sites include: www.iso.ch, www.IEC.ch, and www.itu.int/ for the ISO, IEC and ITU respectively.', 'From here, links to national or regional standard organizations are indicated.', 'Standards are generally designated by an alphabetical prefix and a number.', 'The letters (e.g. ISO, IEC, ANSI, CAN, EN, DIN) indicate the body that has approved them, while the numbers identify the specific standard and the year in which it was finalized.', 'The standard reference code often gives an indication of adoption where standards are equivalent.', 'For example: CAN/CSA-Z386-94 means a standard developed in 1994 by the Canadian Standards Association (CSA, one of four accredited Canadian standards development organizations) and designated by the Standards Council of Canada (SCC) as a Canadian national standard.', 'ANSI/AAMI/ISO 15223:2000 means the international standard ISO 15223 (established in 2000) adopted by the Association for the Advancement of Medical Instrumentations in the United States, which in turn is designated by the American National Standards Institute (ANSI) as an American national standard.', 'UNI EN ISO 9001 indicates an Italian national standard (UNI) which is an adoption of a European standard (EN), which is itself an adoption of the International Standard ISO9001.', 'Although a standard can be set and mandated by an authority, the current trend is for the adoption of voluntary standards established by consensus from all interested parties (the stakeholders).', 'The use of voluntary standards originated from the realization that while regulations generally address the essential safety and performance principles, manufacturers and users still need to know detailed specifications pertaining to specific products.', 'The provision of such specifications and detailed requirements for the multitude of devices presents an enormous task for regulatory authorities.', 'Fortunately, the wealth of voluntary standards already existing or being developed provide such precise specifications.', 'The use of voluntary/consensus standards has many advantages including the following: They are normally developed by experts with access to the vast resources available in the professional and industrial communities.', 'By taking advantage of such existing resources, the government can overcome its own limited resources for providing product specific technical requirements and characteristics.', 'Conformity to standards can also be assessed by an accredited third party (such as a notified body in Europe), which is a well-established industrial practice around the world.', 'The use of international standards facilitates harmonized regulatory processes and world trade, and thus improves global access to new technology.', 'As technology advances, it is much easier to update standards than to change regulations.', 'Timely development and periodic revision by expert groups make medical device standards effective and efficient tools for supporting health care.', 'Manufacturers have the flexibility to choose appropriate standards or other means to demonstrate compliance with regulatory requirements.', 'Regulatory authorities can recognize a standard, fully or partially, provided they clearly specify and publicize their intent.', 'Several standards can also be recognized as a group to satisfy the requirements for a particular device.', 'In some countries, the publication of government-recognized standards mandates product compliance.', 'Medical devices intended for global use should follow international standards.', 'For example, the ISO Technical Report (ISO 16142:2000) lists a number of significant international standards that may be suitable for demonstrating compliance with certain features of the essential principles of safety and performance of medical devices.', 'The GHTF has issued the following recommendations regarding the recognition and use of standards: International standards are a building block for harmonized regulatory processes to assure the safety, quality and performance of medical devices.', 'To achieve this purpose, the following principles are recommended: Regulatory Authorities and industry should encourage and support the development of international standards for medical devices to demonstrate compliance with the Essential Principles of Safety and Performance of Medical Devices (GHTF document SG1 NO20R5 referred to hereafter as the Essential Principles).', 'Regulatory Authorities developing new medical device regulations should encourage the use of international standards.', 'Regulatory Authorities should provide a mechanism for recognizing international standards to provide manufacturers with a method of demonstrating compliance with the Essential Principles.', 'When an international standard is not applied or not applied in full, this is acceptable if an appropriate level of compliance with the Essential Principles can be demonstrated.', 'While it may be preferable for harmonization purposes to use international standards, it may be appropriate for Regulatory Authorities to accept the use of national/regional standards or industry standards as a means of demonstrating compliance.', 'Standards Bodies developing or revising standards for use with medical devices should consider the suitability of such standards for demonstrating compliance with the Essential Principles and to identify which of the Essential Principles they satisfy.', 'The use of standards should preferably reflect current, broadly applicable technology while not discouraging the use of new technologies.', 'Standards may represent the current state of the art in a technological field.', 'However, not all devices, or elements of device safety and/or performance may be addressed by recognized standards, especially for new types of devices and emerging technologies.', 'Implementing a full regulatory programme can be very expensive and demanding on resources.', 'The work of the GHTF and the trend to use international standards are, in effect, tackling this problem by steering manufacturers more and more toward producing medical devices with uniform standards.', 'The methods and procedures relating to governmental regulations are also converging.', 'These developments create opportunities for countries to establish low-cost programmes that promote the safety and performance of medical devices by taking full advantage of what others have already done in this field.', 'Local adoption of harmonized recommendations will facilitate international exports of medical devices manufactured locally.', 'A good approach to setting a clear direction for all stakeholders is to establish a comprehensive national policy or guideline on medical device management.', 'The government can subsequently bring in legislation and enforcement to suit the countrys conditions and needs.', 'Five principal activities are identified: Increasing the knowledge of the medical device sector; Establishing basic regulatory programmes; Drafting a comprehensive policy/guideline including the recognition and use of standards; Promoting compliance and cooperation; Setting priorities for regulatory programme development.', 'Several key activities are suggested: Access the Internet for a great deal of freely available, relevant information.', 'A list of web site addresses is provided in Annex 1.', 'Participate actively in the projects of the GHTF Task Forces in order to benefit from the experience of experts from other countries.', 'Form a partnership with a country that is a member of the GHTF and has a functioning regulatory programme on medical devices.', 'Make connections with national and international medical device problem coordinating centres.', 'Become an active member of a regional harmonization organization (e.g. Asian Harmonization Working Party (AHWP); the Latin American and Caribbean regional group (contact the GHTF for information on regional groups).', 'As discussed previously, medical device safety and performance is multi-phased and requires cooperation among all stakeholders.', 'It is essential to identify the stakeholders in each country by maintaining a list of manufacturers, importers, distributors, retailers, institutional users (both public and private health care facilities), lay users (estimated from the number of home-use medical device vendors), and concerned citizens groups.', 'A basic regulatory programme should also include other important activities: holding education/consultation sessions with the stakeholders to discuss the issues; creating an atmosphere conducive to mutual trust and open discussions; and, inviting input from the stakeholders.', 'The government should not overlook the willingness of stakeholders to help suggest solutions for issues that affect them.', 'Such sessions will help to share understanding of issues affecting the safety and performance of medical devices, and should lead to the development of a policy/guideline that sets a direction for everyone (see Section 6.3).', 'Apart from the rich source of practical suggestions that stakeholders can offer, they are more likely to comply with any requirements that they have participated in devising.', 'If there are significant numbers of medical devices being sold or used in the country, then two basic programmes should be set up as soon as is possible: (1) Basic legislation; (2) Problem sharing.', 'If the government has not already passed legislation, this should be done: To prohibit misleading or fraudulent advertising of medical devices.', '_**Advertising**_ has a powerful influence on people.', 'A prohibition on the misleading or fraudulent advertisement of health devices should be an essential legislation.', 'This is particularly important since, as people are becoming more health conscious, the development of home-use medical devices is rapidly expanding.', 'Advertising control does not have to place demands on resources.', 'For example, in Canada, even though the prohibition of misleading or fraudulent advertising is legislated, the Government does not routinely screen device advertising.', 'The Government, however, will respond to inquiries or complaints made by the public or health care professionals.', 'If the advertiser cannot convincingly prove their claims, the government can take action to prohibit the advertisement.', 'To empower the government to stop the sale of a device and issue alerts to the public under urgent hazardous conditions.', 'Again, this is essential legislation in case the manufacturer or the vendor has not taken adequate action to ensure the safety of their product.', 'The government should establish a national coordinating agency to receive and manage problem reports from all sources.', 'This information can then be shared with other users in the country and in other countries as well.', 'The objective is to improve the protection of the health and safety of patients, users and others by disseminating information, which can prevent repetition of adverse events.', 'If the government has no funding to set up such an agency, it should encourage the users, hospital technicians, clinical engineers and vendors to form a network.', 'There is a high possibility that they will support such a programme, since it is in their own self-interest.', 'Hospitals and universities are likely to have the resources and willingness to coordinate such activities.', 'An advisory panel of experts and/or scientific testing laboratories in these institutions would be very useful for investigating problems.', 'For example, they could confirm bacterial contamination, or investigate possible electrical hazards.', 'Going through the exercise of drafting a policy or guideline will clarify, for both the government and the other stakeholders, what the issues are and how to address them.', 'The resulting policy/guideline will also set a direction for how to manage potential problems.', 'Moreover, it will provide a foundation for shared understanding and shared responsibility of all the concerned parties (see section 2.6).', 'After a policy or guideline on medical device management is established, its implementation and integration into national legislation will depend on national context and resources available.', 'Effective national policies have a legislative base.', 'Although this is regrettably not always the case, they still serve as a framework of rules for decision-making and guidance.', 'In some countries, a national policy may automatically have legal recognition.', 'Some of the advantages of a national policy are as follows: it obligates an examination of the country-wide conditions for holistic planning; it is written in non-legal terms, hence is easier for lay people to understand; it can provide more explanatory information than a regulatory document; a guideline can be written as a policy supplement to include more detailed information on means and procedures to achieve policy objectives; policies and guidelines do not require a legal and lengthy process to modify them.', 'The policy on medical device management can also include instructions for the role of each stakeholder (see section 2.5).', 'For example, the role of the user can be expanded to include issues such as the care and maintenance of devices, introducing an integrated approach to medical device management.', 'Depending on the culture and legal system, a country may find it more effective to legislate all key requirements of the policy.', 'Some countries may prefer to legislate the items gradually as the need is demonstrated and as resources for monitoring and enforcement become available (see section 6.5).', 'Countries that have decided to accept devices that are approved by other countries can simplify the pre-market control regulations (section 6.3.3) by including this in their legislation.', 'The GHTF document SG1 N015R18 has been drafted to provide a rule-based system in classifying medical devices (see section 3.4.1).', 'It contains 16 rules and decision trees to demonstrate how these rules should be used to classify specific devices.', 'The document will be of value to countries developing or amending regulations.', 'Regulatory authorities that are developing new classification schemes or amending existing ones are encouraged to consider the adoption of this system, as this will help to reduce the diversity of systems worldwide and facilitate the process of harmonization.', 'Pre-market approval is one of the most important aspects of any comprehensive policy.', 'The difficulty of establishing a local pre-market review team is not just financial but also depends on whether specialized scientific and clinical expertise is available in the country.', 'However, with the work of the GHTF and the ability to look at approval decisions in other countries, it is now feasible for many countries to avoid the expense of a local pre market review team.', 'Global statistics on medical device manufacturers reveal that the US, Japan and EU countries manufacture approximately 85% of the medical devices in the world (see Figure 9 below).', 'They already have comprehensive regulatory systems in place that follow the Essential Principles of Safety and Performance of Medical Devices recommended by the GHTF.', 'This is a positive development for the other countries of the world that import most of their medical devices.', 'As an alternative to a local pre-market review team, a government can adopt a policy of accepting devices that are manufactured in compliance with the regulations of another country.', 'The choices include, for example, devices with an Australian, Canadian or Japanese License, devices with a European CE mark, or devices that have been granted marketing clearance by the US-FDA.', 'In this way the citizens of the importing country will be assured of the same risk exposure as the citizens of the exporting countries.', 'Whether to grant local marketing rights to that device remains a local government decision, which may rest on local socioeconomic considerations and technology assessment information.', 'Since it may be necessary to verify the authenticity of EU regulatory compliance, device suppliers can be asked to obtain an export certificate, the nominal cost of which may be passed on to the importer.', 'However, since export certificates can differ in purpose and format, it is important to be cautious when relying on them (section 6.6 discusses this issue).', 'A similar approach can be used for local medical device manufacturers.', 'The government can require that local manufacturers make submissions for compliance acceptance to a country that has an accepted pre-market review team.', 'In fact, this is what the manufacturers have to do anyway if they want to sell internationally.', 'If a country has competent private organizations, the government has the option to authorize such organizations to perform the pre-market assessment, as is now carried out by the European Union.', 'The Quality System certification of local manufacturing facilities is usually delegated to authorized third party agents (such as the notified bodies in the EU, or Quality Systems Registrars in Australia and Canada).', 'In the case of the United States, the FDA, following the completion of an inspection, can issue a letter to the firm denoting their compliance status.', 'Currently the cost of inspection is borne by the FDA, and is performed, almost without exception, by FDA employees.', 'In avoiding the expense and effort of a pre-market review team, a government can concentrate on implementing vendor and device registration and surveillance programmes for devices in use.', 'Product representation is controlled through labelling during the pre-market stage and advertising of the product during the on-market stage.', 'Labelling requirements include identification of the device, instructions for use, as well as safety- and performance-related information.', 'A harmonized format for labelling is recommended by the GHTF (SG1 N009R6).', 'Advertising control is an important tool for ensuring that the public is protected from misleading and fraudulent claims as described in section 6.2.1.', 'Vendor establishment control allows the government to be informed of which establishments are selling what devices.', 'Its main purpose is to establish contact with vendors in case of adverse events and also to inform the local vendors of their responsibility for after-sale obligations.', 'In most countries, only one level of in-country vendor is required to be registered for control.', 'For example, if the importer or the distributor were already registered, then it would not be necessary to register the retailers of the same device.', 'There are two general ways to accomplish vendor establishment control: (1) Sales notification, and (2) establishment license or registration.', '_**Sales notification**_ is generally a less effective method.', 'Vendors are automatically permitted to sell medical devices provided that they notify the regulatory authority, either before or after the sale, as required by the authority.', '_**Establishment License or Registration**_, on the other hand, requires that the vendor either obtains a license or is registered before they are allowed to sell medical devices.', 'This method has several advantages: It ensures that the government has a record of the vendor; It enables the government to place emphasis on after-sale obligations; It provides a means for the government to enforce requirements; for example, it will be able to suspend a license if the vendor does not fulfil after-sale responsibilities; It allows the government to require an annual renewal of the license or registration in order to maintain updated information on the vendors.', 'Since the latter method places considerable demand on the government, the government can impose a fee on the licensing or registration process.', 'This fee will help defray the cost of administration.', 'The fee may also help to strengthen the vendors efforts to fulfil their obligations so that they avoid losing the license that they have paid for.', 'Experience from Canada reveals that an establishment licence is a more effective means than sales notification for keeping records of the vendors (see www.hc-sc.gc.ca/hpfb-dgpsa/tpd-dpt/ for Canadian guidance documents on establishment licensing).', 'A recent development in the medical device market is the rapid increase in the number and variety of home-use medical devices.', 'This results in a shift from institution-based professional users of medical devices to their employment by lay users.', 'Here, education of the consumer is key to safety and performance.', 'Formerly, used or refurbished medical devices were traded to developing countries, mainly by third parties, and the vendors were often opportunistic merchants with no technical expertise.', 'Many recipient countries had very bad experiences with used equipment because there were no after-sale technical support or spare parts.', 'By 2002, at least five countries had imposed a total ban on the import of used equipment and 17 others have partial bans depending on the type of equipment.', 'The situation has changed rapidly over the past 10 years due to shrinking health care budgets and rapid technological innovations.', 'Refurbished medical equipment is increasingly being used within the United States and other industrialized countries.', 'As larger hospitals purchase the latest models, they trade in their superseded equipment which is often still in good condition.', 'This equipment can remain suitable for a wide range of applications, both for city and rural hospitals, and large global medical device manufacturers are now participating in the business of refurbishment.', 'As a result of the increasing use of refurbished equipment in industrialized countries, the question of regulations is raised.', 'Work is under way to define the scope of refurbished equipment and the different requirements for their regulation.']}\n",
      "Cleaning response ```json\n",
      "{\n",
      "  \"chunks\": [\n",
      "    \"of refurbished equipment,\\nit is important for developing countries to ensure that companies supplying refurbished\\nequipment will fulfil after-sale obligations including the continued availability of technical\\nsupport and maintenance services.\",\n",
      "    \"_Donated devices_\",\n",
      "    \"Donated equipment can be of great value to health facilities with limited resources, but\\ndonations are not always useful, nor totally free.\",\n",
      "    \"At the same time, many developing\\ncountries are increasingly dependent on donor assistance to meet their equipment needs.\",\n",
      "    \"Failing international regulations, WHO has produced a set of guidelines to assist\\ngovernments and organizations dealing with equipment donation.\",\n",
      "    \"The four underlying\\nprinciples of good donation practice can be summarized as follows:\",\n",
      "    \"i) health care equipment donations should benefit the recipient, and should be based on a\\nneeds assessment and analysis of the environment in which the donations will be placed\",\n",
      "    \"ii) donations should be given with due respect for the wishes and authority of the recipient\\nand according to a pre-agreed plan\",\n",
      "    \"iii) there should be no double standard in quality: if an item is unacceptable in the donor\\ncountry, it is also unacceptable as a donation\",\n",
      "    \"iv) there should be effective communication between the donor and the recipient: all\\ndonations should respond to an expressed need by the recipient and should never\\narrive unannounced.\",\n",
      "    \"6.3.7 The re-use of medical devices that are labelled for single use\",\n",
      "    \"Special attention must be exercised in any attempt to re-use devices that are labelled for\\nsingle use.\",\n",
      "    \"The following points provide a glimpse of this complex issue.\",\n",
      "    \"1. Devices labelled for single use are designed with the intention by manufacturers that\\nthey will not be re-used. Therefore:\",\n",
      "    \"a. Some devices may not be truly taken apart for proper cleaning.\",\n",
      "    \"b. Single use devices may not be re-sterilized properly.\",\n",
      "    \"c. The mechanical integrity and/or functionality of some single use devices may not\\nstand up to rigorous reprocessing.\",\n",
      "    \"d. It may never have been determined how cleaning chemicals or sterilizing agents\\naffect the re-processed devices or the patient.\",\n",
      "    \"2. Because of materials used or the design of the device, some models within a particular\\ntype of device may be suitable for safe reprocessing while others may not.\",\n",
      "    \"There may\\nnot be evidence of how many times a device may be safely reprocessed.\",\n",
      "    \"3. Some devices should never be re-used.\",\n",
      "    \"For example, single use injection syringes because\\nthe risk of infection is very high.\",\n",
      "    \"Field data from developing countries revealed that the\\nre-use of injection syringes/needles is a major source of HIV and hepatitis infections.\",\n",
      "    \"In considering the reprocessing and the re-use of a device labelled for single use, one\\nshould first obtain thorough knowledge of possible hazards and assess the impact on\\npatients against the potential cost savings.\",\n",
      "    \"Are there adequate facilities and trained persons\\nto do the reprocessing?\",\n",
      "    \"Some possible hazards may not even be foreseen.\",\n",
      "    \"The ethical\\nquestions and the potential consequences of patient infection must be considered, along\\nwith the question of legal responsibility for reprocessing and re-use of single use devices.\",\n",
      "    \"In the United States, FDA subjects the reprocessor of a single use device to the same\\nregulatory requirements as those for the original manufacturer of the device.\",\n",
      "    \"The resources in Annex 1 provide a list of references on home-use, refurbished and\\ndonated devices.\",\n",
      "    \"6.3.8 Post-market surveillance\",\n",
      "    \"In addition to the basic problem-sharing centre described in section 6.2.2, a complete\\nprogramme of post-market surveillance should be described in the policy/guideline.\",\n",
      "    \"This\\nprogramme should include the major components of after-sale obligations for the vendor, including:\",\n",
      "    \"- implant registration: facilitates notifying the patient of pertinent post-implant\\ninformation\",\n",
      "    \"- distribution record: for complete and rapid removal of devices in case of problems\",\n",
      "    \"- recall procedures: in case of device recall, the procedures are in place and can be\\nimplemented\",\n",
      "    \"- mandatory reporting: reporting of any adverse events of devices in use\",\n",
      "    \"- complaint handling: procedures and records of reported problems relating to safety or\\nperformance\",\n",
      "    \"It is important to note the following points:\",\n",
      "    \"1. An incident with a medical device is an unusual (or unexpected) event associated with\\nits use.\",\n",
      "    \"Not all incidents lead to adverse events, but all incidents should be investigated\\nto identify product or use problems that can or do result in permanent impairment or\\ninjury to the patient or user.\",\n",
      "    \"The problems should then be addressed so they will not\\nrecur.\",\n",
      "    \"Products can contribute to adverse outcomes by their complex nature or labelling, unique features and functions, or failure to meet manufacturing specifications.\",\n",
      "    \"Users\\ncan contribute to adverse outcomes by failure to follow labelled instructions or\\ninstructions for use, lack of training, misapplication of the product, and failure to provide\\nroutine maintenance on the product.\",\n",
      "    \"Patients can contribute to adverse outcomes by\\nnot following health care guidelines appropriate to the product, failure to get regular\\nmedical and surgical monitoring and assessments, and failure to report product\\nproblems.\",\n",
      "    \"Even the environment can contribute to adverse outcomes: low lighting at night, fewer\\nhealth care workers available after regular working hours, no after-hours vendor support\\nto resolve product questions, etc.\",\n",
      "    \"All of these factors are important to consider in\\ndetermining why an adverse event occurs and how it might be prevented in the future.\",\n",
      "    \"Care should be taken not to discourage reporting by assigning culpability.\",\n",
      "    \"Problem\\nresolution and prevention remain the ultimate goals and are fundamental in assuring\\nsafety for all.\",\n",
      "    \"WHO is committed to patient safety, which is an Organization-wide\\ninitiative supported by World Health Assembly Resolution WHA 55.18.\",\n",
      "    \"2. Most of the obligatory surveillance activities rest with the vendor, but the user is the\\nultimate monitor of device performance and reporter of problems encountered.\",\n",
      "    \"The\\nsurveillance programme should be promoted and developed to encourage cooperation\\namong all stakeholders.\",\n",
      "    \"Section 6.4 suggests how this can be accomplished.\",\n",
      "    \"3. The quality of problem reports improves when users possess some technical knowledge\\nof the devices.\",\n",
      "    \"Both clinical engineers and biomedical equipment technicians in health\\ncare facilities can be very helpful in this task.\",\n",
      "    \"If the problem report is to be added to the\\nproblem databank for trend and other statistical analyses, the report must follow certain\\nstandards for it to be useful.\",\n",
      "    \"Governments should adopt recommended formats and\\nprocedures (see documents of the GHTF Study Group 2).\",\n",
      "    \"4. The chance of discovering device problems increases with the number of devices in use.\",\n",
      "    \"Therefore, it is useful to be connected to an international database, which will maximize\\nthe effectiveness of post-market surveillance.\",\n",
      "    \"5. Finally, if user errors are frequent, then a user qualification programme that is controlled\\nthrough a professional association can be a useful tool that will not make undue demands\\non government resources.\",\n",
      "    \"Similarly, as a proactive measure, this tool can be implemented\\nfor devices of high-risk classes.\",\n",
      "    \"6.3.9 Recognition and use of established national or international standards\",\n",
      "    \"The use of voluntary standards has been described in the preceding section.\",\n",
      "    \"This practice\\ncan reduce cost, simplify the regulatory process and promote international harmonization.\",\n",
      "    \"A national regulatory agency will need to establish a procedure for official recognition\\nof voluntary standards.\",\n",
      "    \"This process of recognition may vary from country to country.\",\n",
      "    \"If\\nthere is no existing national standards body, an organization may be created/designated\\nby the competent authority to research and recommend official recognition of standards.\",\n",
      "    \"If there is already a national standards body, they can collaborate with the medical device\\nregulatory authority to agree upon and adopt standards for recognition.\",\n",
      "    \"In general,\\nappropriate international standards should receive priority for recognition.\",\n",
      "    \"The policy of\\nrecognition and the standards that are recognized should be made clear to all stakeholders.\",\n",
      "    \"Examples of such policies and lists of recognized standards can be obtained from the\\nfollowing web-sites:\",\n",
      "    \"European Union: www.newapproach.org\",\n",
      "    \"United States: www.fda.gov/cdrh/modact/fr0225ap.pdf\",\n",
      "    \"Canada: www.hc-sc.gc.ca/hpfb-dgpsa/tpd-dpt\",\n",
      "    \"**6.4 Promoting compliance and cooperation**\",\n",
      "    \"Promotional activity is a powerful tool that encourages compliance and reduces the burden\\nof enforcement.\",\n",
      "    \"Often, bad practices are the results of not knowing better alternatives.\",\n",
      "    \"If\\nthe regulatory authority properly disseminates the policy to the stakeholders and it is\\nunderstood, it has already made the most important step towards the harmonized\\ncompliance of all the parties concerned.\",\n",
      "    \"User/public education is crucial for guarding\\nagainst misuse and misrepresentation of medical devices.\",\n",
      "    \"We should remember that medical device users, the patients and the public, are people\\nfor whom medical devices are designed (the customers).\",\n",
      "    \"Since they are the people upon\\nwhich device safety and performance will directly impact, they can readily become great\\nallies to the government in applying customer pressure for compliance.\",\n",
      "    \"Governments\\nshould appeal to the customers own self-interests to participate in the system.\",\n",
      "    \"Manufacturers and vendors, for their part, are currently embarking on customer-focused\\nmissions: they want to provide quality products and quality services to their customers.\",\n",
      "    \"This is positive.\",\n",
      "    \"Governments can capitalize on such developments by encouraging\\nvoluntary cooperation.\",\n",
      "    \"This will result in a low-cost programme that ensures the safety\\nand performance of medical devices.\",\n",
      "    \"Participation in regional cooperation is recommended as a means for regulator-to-\\nregulator interaction facilitating increased learning and sharing of ideas to develop\\nregulations with the minimum cost and maximized benefit.\",\n",
      "    \"WHOs regional and country\\ninfrastructure puts it in a good position to support such exchanges.\",\n",
      "    \"**6.5 Setting priorities for regulatory programme development**\",\n",
      "    \"Regulatory programmes for medical devices can be developed in stages according to a\\ncountrys needs as they are stated in the national policy and identified in consultation\\nwith all stakeholders.\",\n",
      "    \"In countries where resources are limited, this guide recommends\\nthe initial implementation of the basic programmes that are described in section 6.2.\",\n",
      "    \"As\\nmore resources become available, programme expansion can follow the ladder suggested\\nin Figure 10.\",\n",
      "    \"In follow-up to this Global Overview of Medical Device Regulations, there\\nis a need to provide countries with a model programme on which they can establish their\\nown, appropriate regulatory system, based on international experience.\",\n",
      "    \"_**Figure 10. Suggested priorities for regulatory programme development**_\",\n",
      "    \"**CLEAR POLICY GUIDELINES**\",\n",
      "    \"The means to determine device acceptance criteria are described in section 6.3.3.\",\n",
      "    \"Preventing sub-standard devices from appearing in the market place should be the first\\npriority for every government.\",\n",
      "    \"For most countries, this will mean an effective _**import**_\\n_**control**_ that will ensure that the acceptance criteria specified in the policy are strictly\\nenforced.\",\n",
      "    \"It is critical that medical device regulatory authorities cooperate closely with\\nthe customs department so that the customs process is efficient enough to prevent\\nunnecessary holding of acceptable goods needed for health care.\",\n",
      "    \"Here, customs enforcement\\nofficers need a clear policy, and sufficient education and training.\",\n",
      "    \"They should be well\\ninformed of the medical device acceptance criteria.\",\n",
      "    \"High priority should be given to establishment registration, device listing and the\\nadoption of a medical device nomenclature system.\",\n",
      "    \"This will enable the government to\\nmonitor the kind of devices that are used or that are available on the local market.\",\n",
      "    \"In case\\nof a medical device alert or recall, it is essential to know where all similar devices are in\\nuse.\",\n",
      "    \"The distribution records are the key to this identification.\",\n",
      "    \"It is the vendors responsibility\\nto keep distribution records, and it should be a government priority to register the vendor\\nestablishments and the medical devices they sell.\",\n",
      "    \"The government can also make use of\\nthe advantages described in section 6.3.5 to make this programme self-financing.\",\n",
      "    \"The recall of a device frequently indicates a high potential for serious problems.\",\n",
      "    \"Random\\ninspection during actual recall incidents would verify the true efficiency and effectiveness\\nof the procedures and ensure that vendors fulfil their responsibilities.\",\n",
      "    \"Mandatory problem reporting requires that serious problems are reported and relayed\\nto other users for preventive purposes.\",\n",
      "    \"However, there seems to be a concern among users\\nthat the information given in medical device problem reporting can become a personal\\nlegal liability if it turns out the problem was actually caused by the incorrect use of the\\ndevice.\",\n",
      "    \"This means there is a general reluctance to report problems associated with the\\nuse of medical devices even where such reporting is mandatory by law, e.g. in the United\\nStates and some countries in Europe.\",\n",
      "    \"Regulatory authorities both in Europe and North America are experiencing a lack of cooperation from device users.\",\n",
      "    \"Therefore, the\\ngovernment should address this issue with a problem solving rather than finger pointing\\napproach.\",\n",
      "    \"Above all, it is critical that the dissemination of information to the public must\\nbe handled with great discretion so that it does not unduly damage the reputation of a\\nhealth care professional, the health care institution or the company/manufacturer.\",\n",
      "    \"The\\nGHTF has a guidance document (SG2 N8R4) that provides advice in such delicate cases.\",\n",
      "    \"The following quotations from this document lists the concerns that should be considered\\nbefore releasing information nationally:\",\n",
      "    \"1. is the information collected, or received, of _relevance nationally_ ?\",\n",
      "    \"2. if yes, _for whom_ ?  other authorities/manufacturer/distributor/user/hospitals/patients/\\nacademics/the public?\",\n",
      "    \"3. can the persons, natural or legal, who should have the information be _traced and located_\\nand given information directly?\",\n",
      "    \"4. will information have to be _released to the public_ in order to reach the persons who\\nneed it, but whom cannot be reached directly?\",\n",
      "    \"5. does the public _need_ this information?\",\n",
      "    \"6. is the information of _use, or of benefit_, to the public at large?\",\n",
      "    \"It is important for regulatory authorities to communicate with other countries to keep\\nthemselves informed about incidents that have not occurred locally.\",\n",
      "    \"WHO follows Standard\\nOperating Procedures for the issuing of alerts among Member States, and may also work\\nwith the GHTF to assist in the appropriate dissemination of information to countries.\",\n",
      "    \"Risk management becomes more effective with a larger population database.\",\n",
      "    \"There will\\nbe a need to exchange information with other regulatory authorities, and this should be\\ndone in a meaningful and systematic manner.\",\n",
      "    \"The GHTF guidance document SG2 N20R10\\nprovides advice on how to determine if and when a regulatory authority should consider\\nsharing information globally.\",\n",
      "    \"Complaints are an early indication of potential problems, and they should not be ignored.\",\n",
      "    \"Proper investigation may lead to the discovery of more serious problems.\",\n",
      "    \"However,\\ninterpreting the degree of urgency of a complaint may demand considerable technical\\nknowledge and experience.\",\n",
      "    \"It is essential to involve the manufacturer/vendor and the user\\nin the investigation.\",\n",
      "    \"User errors can be minimized through design incorporating human\\nfactor principles and user experience can help manufacturers to improve product safety.\",\n",
      "    \"For local production, a government can take advantage of the quality system approach\\n(see sections 3.4.4 and 6.3.3).\",\n",
      "    \"The key is to ensure that the quality system registrars or\\nnotified bodies are accredited by national competent authorities (see section 5.5) and that\\napplicable quality standards are used for the classified medical devices.\",\n",
      "    \"**6.6 Cautions in interpreting medical device export certificates**\",\n",
      "    \"Importers should be well aware of the fact that there are different kinds of certificates\\nthat testify the characteristics of medical devices being exported.\",\n",
      "    \"For example, Canada\\ncurrently has two kinds of certificates applicable to medical devices; Japan has three, and\\nthe United States has four.\",\n",
      "    \"These are briefly described below:\",\n",
      "    \"Canada\",\n",
      "    \"1. The **Canadian Export Certificate for Medical Devices** .\",\n",
      "    \"This certificate allows vendors to\\nexport medical devices that are not manufactured for sale or consumption in Canada.\",\n",
      "    \"This certificate has legal status (Section 37 of the Food and Drug Act and Section 89 of\\nthe Medical Devices Regulations).\",\n",
      "    \"(The United States issues analogous certificates under\\nSections 801 and 802 of the Federal Food, Drug and Cosmetic Act, see below)\",\n",
      "    \"2. The **Canadian Manufacturers Certificate for Medical Devices** .\",\n",
      "    \"This certificate requires\\nthe manufacturers to make the following declaration before a commissioner or a notary:\",\n",
      "    \"a. Each device is manufactured, produced and sold in Canada in accordance with the\\nrequirements of Canadas Food and Drug Act and Regulations thereunder; and\",\n",
      "    \"b. tests have been conducted in respect of each device and that the tests indicate that\\nthe nature of the benefits claimed to be obtainable through the use of each device\\nand the performance characteristics of each device are justified.\",\n",
      "    \"This declaration is submitted to Health Canada for verification and counter-signature\\nfor compliance.\",\n",
      "    \"Japan\",\n",
      "    \"1. The Evaluation and Licensing Division (MHLW) can issue Export Certificate (FSC)\\nfor a medical device that has been approved by the MHLW.\",\n",
      "    \"This is the certificate to\\nconfirm that the product was manufactured under the PAL requirement (GMP) and\\nhas the approval to be sold in Japan.\",\n",
      "    \"(Yakuhatsu #418/422)\",\n",
      "    \"2. There are two other certificates: one is to certify Approved Manufacturer by the\\nMHLW; the other is to certify that the product was manufactured under the PAL\\nrequirement (GMP) in Japan.\",\n",
      "    \"These certificates can be requested by the importing country.\",\n",
      "    \"The United States of America\",\n",
      "    \"1. The **United States Export Certificate Section 801(e)(2)** grants permission for the export\\nof unapproved medical devices which are not equivalent to devices cleared for marketing\\nin the USA, after the firm has submitted to the FDA proof of safety of the device and\\nobtained a letter from the foreign government granting permission to import the device.\",\n",
      "    \"2. The **United States Certificate of Exportability Section 801(e)(1)** certifies the export of\\ndevices that are not approved for use within the USA, distribution of which would be\\nconsidered adulterated or misbranded under U.S. law because they lack marketing\\npermission, U.S. labelling, and/or are not being manufactured under QS Regulation.\",\n",
      "    \"These devices must be equivalent in design and intended use to class I and II medical\\ndevices already granted marketing permission by FDA, labelled for export, and must\\nbe in compliance with the specification of the purchaser and the laws of the foreign\\ncountry.\",\n",
      "    \"3. The **United States Certificate of Exportability Section 802** certifies the export of\\nunapproved devices which are manufactured in compliance with the requirements of\\nthe QS Regulation or equivalent FDA recognized international standard and which are\\nauthorized for marketing in a tier one country.\",\n",
      "    \"Tier one countries included those in\\nthe European Union, the European Economic Area, Australia, Canada, Israel, Japan,\\nNew Zealand and South Africa.\",\n",
      "    \"4. The **United States Certificate to Foreign Government** is issued for devices that are legally\\nmarketed in the U.S. and in compliance with the Food, Drug & Cosmetic Act.\",\n",
      "    \"The World Health Organization\",\n",
      "    \"The widely used **WHO Export Certificate** at present applies only to pharmaceutical products.\",\n",
      "    \"Comments\",\n",
      "    \"The Canadian Export Certificate and the United States certificates all impose the condition\\nthat the exported device does not contravene any known requirement of the laws of the\\nimporting country.\",\n",
      "    \"However, this does not provide protections for countries that do not\\nhave regulations or a national policy on medical device acceptance.\",\n",
      "    \"Countries are therefore\\n urged to use these guidelines to develop or reinforce their national medical device regulatory\\nauthority so that their populations are protected against unsafe products.\",\n",
      "    \"**35**\",\n",
      "    \"CHAPTER 7\",\n",
      "    \"##### **Priorities on the international agenda**\",\n",
      "    \"In order to minimize substandard medical devices in global trade, there is a need to establish\\na uniform format for different countries to certify that the medical device being exported\\ncomplies with their domestic regulatory requirements.\",\n",
      "    \"This certification process will greatly help importing countries to control medical devices.\",\n",
      "    \"One option for generating this certificate could be to follow the same process as that used\\nto develop the WHO Export Certificate for Pharmaceutical Products, with detailed item\\ndescriptions tailored to medical devices.\",\n",
      "    \"Post-market surveillance/vigilance is essential to ensure that medical devices in use\\ncontinue to be safe and effective.\",\n",
      "    \"Because of the worldwide increase in the use of medical\\ndevices, the ability to access coordinated and analysed global post-market surveillance/\\nvigilance data would greatly enhance medical device safety.\",\n",
      "    \"Participation and reporting\\ncriteria may be based on the recommendations of the GHTF Study Group 2 (see Annex 2).\",\n",
      "    \"International agencies, and the governments and industries of major medical device\\nproducing countries could consider supporting the establishment of this global shared\\ndatabase, under the leadership of an international body.\",\n",
      "    \"**36**\",\n",
      "    \"ANNEX 1\",\n",
      "    \"##### **Resources for medical device** **information**\",\n",
      "    \"**The Global Harmonization Task Force: www.ghtf.org**\",\n",
      "    \"It provides general information and reports from the four study groups.\",\n",
      "    \"It also offers\\nan extensive list of web sites of countries around the world.\",\n",
      "    \"**Australia** : Therapeutic Goods Administration: www.health.gov.au/tga\",\n",
      "    \"**Canada** : Health Canada site: www.hc-sc.gc.ca\",\n",
      "    \"All medical devices guidance documents and medical device related information can be\\nobtained from www.hc-sc.gc.ca/hpfb-dgpsa/tpd-dpt/\",\n",
      "    \"**European Union** : http://europa.eu.int/comm/enterprise/medical_devices/index.htm\",\n",
      "    \"EU Member States with a different linguistic regime:\",\n",
      "    \"France: www.afssaps.sante.fr/\",\n",
      "    \"Germany: www.bfarm.de/de/index.php\",\n",
      "    \"Spain: www.msc.es/farmacia/home.htm\",\n",
      "    \"**Japan** : Ministry of Health, Labor and Welfare: www.mhlw.go.jp/english/index.html\",\n",
      "    \"For publications: www.mac.doc.gov/japan/source/menu/medpharm/medpub.html\",\n",
      "    \"**United Kingdom** : www.Medical-devices.gov.uk\",\n",
      "    \"**United States of America** : Food and Drug Administration: www.fda.gov/default.htm\",\n",
      "    \"Corresponding medical device-related information site: www.fda.gov/cdrh/index.html.\",\n",
      "    \"(this site also offers Device Advice  www.fda.gov/cdrh/devadvice/  a self-service\\nsite for medical device and radiation product information)\",\n",
      "    \"The FDA enforcement report site: www.fda.gov/opacom/Enforce.html also offers useful\\ninformation for import control.\",\n",
      "    \"**Some addresses to obtain Medical Device Incident Reporting Forms**\",\n",
      "    \"International\",\n",
      "    \"Adverse event and Product Defect Reporting Systems\",\n",
      "    \"ECRI (formerly the Emergency Care Research Institute)\",\n",
      "    \"WHO Collaborating Centre\",\n",
      "    \"www.ecri.org\",\n",
      "    \"E-mail: accidents@ecri.org\",\n",
      "    \"Tel: +1 610 825 6000, ext 5223\",\n",
      "    \"United Kingdom\",\n",
      "    \"Adverse Incident Centre\",\n",
      "    \"Medicines & Healthcare Products Regulatory Agency\",\n",
      "    \"Hannibal House, Elephant & Castle\",\n",
      "    \"London SE1 6TQ\",\n",
      "    \"Tel hotline: +44 20 7972 8080\",\n",
      "    \"Fax: +44 20 7972 8109\",\n",
      "    \"E-mail: aic@mhra.gsi. gov.uk\",\n",
      "    \"Australia\",\n",
      "    \"Medical Device Problems and Adverse Events\",\n",
      "    \"Therapeutic Goods Administration\",\n",
      "    \"PO Box 100\",\n",
      "    \"Woden ACT 2606\",\n",
      "    \"Tel: +61 (02) 6232 8713\",\n",
      "    \"Fax: +61 (02) 6232 8555\",\n",
      "    \"E-mail: iris@health.gov.au\",\n",
      "    \"www.health.gov.au/tga/docs/html/therprob.htm\",\n",
      "    \"**Reuse, refurbished, home-use, donated, and maintenance of medical devices**\",\n",
      "    \"Reuse of medical devices that are labelled single-use\",\n",
      "    \"Enforcement Priorities for Single-Use Devices Reprocessed by Third Parties and Hospitals\",\n",
      "    \"August 14, 2000 www.fda.gov/cdrh/reuse/1168.html\",\n",
      "    \"Frequently-Asked-Questions about the Reprocessing and Reuse of Single-Use Devices by\\nThird Party and Hospital Reprocessors: Food and Drug Administration (USA)\",\n",
      "    \"www.fda.gov/cdrh/reuse/reuse-faq.html\",\n",
      "    \"Special Report: Reuse of Single-U\"\n",
      "  ]\n",
      "}\n",
      "```\n",
      "\n",
      "rovas\n",
      "Response cleaned is {'chunks': ['of refurbished equipment,\\nit is important for developing countries to ensure that companies supplying refurbished\\nequipment will fulfil after-sale obligations including the continued availability of technical\\nsupport and maintenance services.', '_Donated devices_', 'Donated equipment can be of great value to health facilities with limited resources, but\\ndonations are not always useful, nor totally free.', 'At the same time, many developing\\ncountries are increasingly dependent on donor assistance to meet their equipment needs.', 'Failing international regulations, WHO has produced a set of guidelines to assist\\ngovernments and organizations dealing with equipment donation.', 'The four underlying\\nprinciples of good donation practice can be summarized as follows:', 'i) health care equipment donations should benefit the recipient, and should be based on a\\nneeds assessment and analysis of the environment in which the donations will be placed', 'ii) donations should be given with due respect for the wishes and authority of the recipient\\nand according to a pre-agreed plan', 'iii) there should be no double standard in quality: if an item is unacceptable in the donor\\ncountry, it is also unacceptable as a donation', 'iv) there should be effective communication between the donor and the recipient: all\\ndonations should respond to an expressed need by the recipient and should never\\narrive unannounced.', '6.3.7 The re-use of medical devices that are labelled for single use', 'Special attention must be exercised in any attempt to re-use devices that are labelled for\\nsingle use.', 'The following points provide a glimpse of this complex issue.', '1. Devices labelled for single use are designed with the intention by manufacturers that\\nthey will not be re-used. Therefore:', 'a. Some devices may not be truly taken apart for proper cleaning.', 'b. Single use devices may not be re-sterilized properly.', 'c. The mechanical integrity and/or functionality of some single use devices may not\\nstand up to rigorous reprocessing.', 'd. It may never have been determined how cleaning chemicals or sterilizing agents\\naffect the re-processed devices or the patient.', '2. Because of materials used or the design of the device, some models within a particular\\ntype of device may be suitable for safe reprocessing while others may not.', 'There may\\nnot be evidence of how many times a device may be safely reprocessed.', '3. Some devices should never be re-used.', 'For example, single use injection syringes because\\nthe risk of infection is very high.', 'Field data from developing countries revealed that the\\nre-use of injection syringes/needles is a major source of HIV and hepatitis infections.', 'In considering the reprocessing and the re-use of a device labelled for single use, one\\nshould first obtain thorough knowledge of possible hazards and assess the impact on\\npatients against the potential cost savings.', 'Are there adequate facilities and trained persons\\nto do the reprocessing?', 'Some possible hazards may not even be foreseen.', 'The ethical\\nquestions and the potential consequences of patient infection must be considered, along\\nwith the question of legal responsibility for reprocessing and re-use of single use devices.', 'In the United States, FDA subjects the reprocessor of a single use device to the same\\nregulatory requirements as those for the original manufacturer of the device.', 'The resources in Annex 1 provide a list of references on home-use, refurbished and\\ndonated devices.', '6.3.8 Post-market surveillance', 'In addition to the basic problem-sharing centre described in section 6.2.2, a complete\\nprogramme of post-market surveillance should be described in the policy/guideline.', 'This\\nprogramme should include the major components of after-sale obligations for the vendor, including:', '- implant registration: facilitates notifying the patient of pertinent post-implant\\ninformation', '- distribution record: for complete and rapid removal of devices in case of problems', '- recall procedures: in case of device recall, the procedures are in place and can be\\nimplemented', '- mandatory reporting: reporting of any adverse events of devices in use', '- complaint handling: procedures and records of reported problems relating to safety or\\nperformance', 'It is important to note the following points:', '1. An incident with a medical device is an unusual (or unexpected) event associated with\\nits use.', 'Not all incidents lead to adverse events, but all incidents should be investigated\\nto identify product or use problems that can or do result in permanent impairment or\\ninjury to the patient or user.', 'The problems should then be addressed so they will not\\nrecur.', 'Products can contribute to adverse outcomes by their complex nature or labelling, unique features and functions, or failure to meet manufacturing specifications.', 'Users\\ncan contribute to adverse outcomes by failure to follow labelled instructions or\\ninstructions for use, lack of training, misapplication of the product, and failure to provide\\nroutine maintenance on the product.', 'Patients can contribute to adverse outcomes by\\nnot following health care guidelines appropriate to the product, failure to get regular\\nmedical and surgical monitoring and assessments, and failure to report product\\nproblems.', 'Even the environment can contribute to adverse outcomes: low lighting at night, fewer\\nhealth care workers available after regular working hours, no after-hours vendor support\\nto resolve product questions, etc.', 'All of these factors are important to consider in\\ndetermining why an adverse event occurs and how it might be prevented in the future.', 'Care should be taken not to discourage reporting by assigning culpability.', 'Problem\\nresolution and prevention remain the ultimate goals and are fundamental in assuring\\nsafety for all.', 'WHO is committed to patient safety, which is an Organization-wide\\ninitiative supported by World Health Assembly Resolution WHA 55.18.', '2. Most of the obligatory surveillance activities rest with the vendor, but the user is the\\nultimate monitor of device performance and reporter of problems encountered.', 'The\\nsurveillance programme should be promoted and developed to encourage cooperation\\namong all stakeholders.', 'Section 6.4 suggests how this can be accomplished.', '3. The quality of problem reports improves when users possess some technical knowledge\\nof the devices.', 'Both clinical engineers and biomedical equipment technicians in health\\ncare facilities can be very helpful in this task.', 'If the problem report is to be added to the\\nproblem databank for trend and other statistical analyses, the report must follow certain\\nstandards for it to be useful.', 'Governments should adopt recommended formats and\\nprocedures (see documents of the GHTF Study Group 2).', '4. The chance of discovering device problems increases with the number of devices in use.', 'Therefore, it is useful to be connected to an international database, which will maximize\\nthe effectiveness of post-market surveillance.', '5. Finally, if user errors are frequent, then a user qualification programme that is controlled\\nthrough a professional association can be a useful tool that will not make undue demands\\non government resources.', 'Similarly, as a proactive measure, this tool can be implemented\\nfor devices of high-risk classes.', '6.3.9 Recognition and use of established national or international standards', 'The use of voluntary standards has been described in the preceding section.', 'This practice\\ncan reduce cost, simplify the regulatory process and promote international harmonization.', 'A national regulatory agency will need to establish a procedure for official recognition\\nof voluntary standards.', 'This process of recognition may vary from country to country.', 'If\\nthere is no existing national standards body, an organization may be created/designated\\nby the competent authority to research and recommend official recognition of standards.', 'If there is already a national standards body, they can collaborate with the medical device\\nregulatory authority to agree upon and adopt standards for recognition.', 'In general,\\nappropriate international standards should receive priority for recognition.', 'The policy of\\nrecognition and the standards that are recognized should be made clear to all stakeholders.', 'Examples of such policies and lists of recognized standards can be obtained from the\\nfollowing web-sites:', 'European Union: www.newapproach.org', 'United States: www.fda.gov/cdrh/modact/fr0225ap.pdf', 'Canada: www.hc-sc.gc.ca/hpfb-dgpsa/tpd-dpt', '**6.4 Promoting compliance and cooperation**', 'Promotional activity is a powerful tool that encourages compliance and reduces the burden\\nof enforcement.', 'Often, bad practices are the results of not knowing better alternatives.', 'If\\nthe regulatory authority properly disseminates the policy to the stakeholders and it is\\nunderstood, it has already made the most important step towards the harmonized\\ncompliance of all the parties concerned.', 'User/public education is crucial for guarding\\nagainst misuse and misrepresentation of medical devices.', 'We should remember that medical device users, the patients and the public, are people\\nfor whom medical devices are designed (the customers).', 'Since they are the people upon\\nwhich device safety and performance will directly impact, they can readily become great\\nallies to the government in applying customer pressure for compliance.', 'Governments\\nshould appeal to the customers own self-interests to participate in the system.', 'Manufacturers and vendors, for their part, are currently embarking on customer-focused\\nmissions: they want to provide quality products and quality services to their customers.', 'This is positive.', 'Governments can capitalize on such developments by encouraging\\nvoluntary cooperation.', 'This will result in a low-cost programme that ensures the safety\\nand performance of medical devices.', 'Participation in regional cooperation is recommended as a means for regulator-to-\\nregulator interaction facilitating increased learning and sharing of ideas to develop\\nregulations with the minimum cost and maximized benefit.', 'WHOs regional and country\\ninfrastructure puts it in a good position to support such exchanges.', '**6.5 Setting priorities for regulatory programme development**', 'Regulatory programmes for medical devices can be developed in stages according to a\\ncountrys needs as they are stated in the national policy and identified in consultation\\nwith all stakeholders.', 'In countries where resources are limited, this guide recommends\\nthe initial implementation of the basic programmes that are described in section 6.2.', 'As\\nmore resources become available, programme expansion can follow the ladder suggested\\nin Figure 10.', 'In follow-up to this Global Overview of Medical Device Regulations, there\\nis a need to provide countries with a model programme on which they can establish their\\nown, appropriate regulatory system, based on international experience.', '_**Figure 10. Suggested priorities for regulatory programme development**_', '**CLEAR POLICY GUIDELINES**', 'The means to determine device acceptance criteria are described in section 6.3.3.', 'Preventing sub-standard devices from appearing in the market place should be the first\\npriority for every government.', 'For most countries, this will mean an effective _**import**_\\n_**control**_ that will ensure that the acceptance criteria specified in the policy are strictly\\nenforced.', 'It is critical that medical device regulatory authorities cooperate closely with\\nthe customs department so that the customs process is efficient enough to prevent\\nunnecessary holding of acceptable goods needed for health care.', 'Here, customs enforcement\\nofficers need a clear policy, and sufficient education and training.', 'They should be well\\ninformed of the medical device acceptance criteria.', 'High priority should be given to establishment registration, device listing and the\\nadoption of a medical device nomenclature system.', 'This will enable the government to\\nmonitor the kind of devices that are used or that are available on the local market.', 'In case\\nof a medical device alert or recall, it is essential to know where all similar devices are in\\nuse.', 'The distribution records are the key to this identification.', 'It is the vendors responsibility\\nto keep distribution records, and it should be a government priority to register the vendor\\nestablishments and the medical devices they sell.', 'The government can also make use of\\nthe advantages described in section 6.3.5 to make this programme self-financing.', 'The recall of a device frequently indicates a high potential for serious problems.', 'Random\\ninspection during actual recall incidents would verify the true efficiency and effectiveness\\nof the procedures and ensure that vendors fulfil their responsibilities.', 'Mandatory problem reporting requires that serious problems are reported and relayed\\nto other users for preventive purposes.', 'However, there seems to be a concern among users\\nthat the information given in medical device problem reporting can become a personal\\nlegal liability if it turns out the problem was actually caused by the incorrect use of the\\ndevice.', 'This means there is a general reluctance to report problems associated with the\\nuse of medical devices even where such reporting is mandatory by law, e.g. in the United\\nStates and some countries in Europe.', 'Regulatory authorities both in Europe and North America are experiencing a lack of cooperation from device users.', 'Therefore, the\\ngovernment should address this issue with a problem solving rather than finger pointing\\napproach.', 'Above all, it is critical that the dissemination of information to the public must\\nbe handled with great discretion so that it does not unduly damage the reputation of a\\nhealth care professional, the health care institution or the company/manufacturer.', 'The\\nGHTF has a guidance document (SG2 N8R4) that provides advice in such delicate cases.', 'The following quotations from this document lists the concerns that should be considered\\nbefore releasing information nationally:', '1. is the information collected, or received, of _relevance nationally_ ?', '2. if yes, _for whom_ ?  other authorities/manufacturer/distributor/user/hospitals/patients/\\nacademics/the public?', '3. can the persons, natural or legal, who should have the information be _traced and located_\\nand given information directly?', '4. will information have to be _released to the public_ in order to reach the persons who\\nneed it, but whom cannot be reached directly?', '5. does the public _need_ this information?', '6. is the information of _use, or of benefit_, to the public at large?', 'It is important for regulatory authorities to communicate with other countries to keep\\nthemselves informed about incidents that have not occurred locally.', 'WHO follows Standard\\nOperating Procedures for the issuing of alerts among Member States, and may also work\\nwith the GHTF to assist in the appropriate dissemination of information to countries.', 'Risk management becomes more effective with a larger population database.', 'There will\\nbe a need to exchange information with other regulatory authorities, and this should be\\ndone in a meaningful and systematic manner.', 'The GHTF guidance document SG2 N20R10\\nprovides advice on how to determine if and when a regulatory authority should consider\\nsharing information globally.', 'Complaints are an early indication of potential problems, and they should not be ignored.', 'Proper investigation may lead to the discovery of more serious problems.', 'However,\\ninterpreting the degree of urgency of a complaint may demand considerable technical\\nknowledge and experience.', 'It is essential to involve the manufacturer/vendor and the user\\nin the investigation.', 'User errors can be minimized through design incorporating human\\nfactor principles and user experience can help manufacturers to improve product safety.', 'For local production, a government can take advantage of the quality system approach\\n(see sections 3.4.4 and 6.3.3).', 'The key is to ensure that the quality system registrars or\\nnotified bodies are accredited by national competent authorities (see section 5.5) and that\\napplicable quality standards are used for the classified medical devices.', '**6.6 Cautions in interpreting medical device export certificates**', 'Importers should be well aware of the fact that there are different kinds of certificates\\nthat testify the characteristics of medical devices being exported.', 'For example, Canada\\ncurrently has two kinds of certificates applicable to medical devices; Japan has three, and\\nthe United States has four.', 'These are briefly described below:', 'Canada', '1. The **Canadian Export Certificate for Medical Devices** .', 'This certificate allows vendors to\\nexport medical devices that are not manufactured for sale or consumption in Canada.', 'This certificate has legal status (Section 37 of the Food and Drug Act and Section 89 of\\nthe Medical Devices Regulations).', '(The United States issues analogous certificates under\\nSections 801 and 802 of the Federal Food, Drug and Cosmetic Act, see below)', '2. The **Canadian Manufacturers Certificate for Medical Devices** .', 'This certificate requires\\nthe manufacturers to make the following declaration before a commissioner or a notary:', 'a. Each device is manufactured, produced and sold in Canada in accordance with the\\nrequirements of Canadas Food and Drug Act and Regulations thereunder; and', 'b. tests have been conducted in respect of each device and that the tests indicate that\\nthe nature of the benefits claimed to be obtainable through the use of each device\\nand the performance characteristics of each device are justified.', 'This declaration is submitted to Health Canada for verification and counter-signature\\nfor compliance.', 'Japan', '1. The Evaluation and Licensing Division (MHLW) can issue Export Certificate (FSC)\\nfor a medical device that has been approved by the MHLW.', 'This is the certificate to\\nconfirm that the product was manufactured under the PAL requirement (GMP) and\\nhas the approval to be sold in Japan.', '(Yakuhatsu #418/422)', '2. There are two other certificates: one is to certify Approved Manufacturer by the\\nMHLW; the other is to certify that the product was manufactured under the PAL\\nrequirement (GMP) in Japan.', 'These certificates can be requested by the importing country.', 'The United States of America', '1. The **United States Export Certificate Section 801(e)(2)** grants permission for the export\\nof unapproved medical devices which are not equivalent to devices cleared for marketing\\nin the USA, after the firm has submitted to the FDA proof of safety of the device and\\nobtained a letter from the foreign government granting permission to import the device.', '2. The **United States Certificate of Exportability Section 801(e)(1)** certifies the export of\\ndevices that are not approved for use within the USA, distribution of which would be\\nconsidered adulterated or misbranded under U.S. law because they lack marketing\\npermission, U.S. labelling, and/or are not being manufactured under QS Regulation.', 'These devices must be equivalent in design and intended use to class I and II medical\\ndevices already granted marketing permission by FDA, labelled for export, and must\\nbe in compliance with the specification of the purchaser and the laws of the foreign\\ncountry.', '3. The **United States Certificate of Exportability Section 802** certifies the export of\\nunapproved devices which are manufactured in compliance with the requirements of\\nthe QS Regulation or equivalent FDA recognized international standard and which are\\nauthorized for marketing in a tier one country.', 'Tier one countries included those in\\nthe European Union, the European Economic Area, Australia, Canada, Israel, Japan,\\nNew Zealand and South Africa.', '4. The **United States Certificate to Foreign Government** is issued for devices that are legally\\nmarketed in the U.S. and in compliance with the Food, Drug & Cosmetic Act.', 'The World Health Organization', 'The widely used **WHO Export Certificate** at present applies only to pharmaceutical products.', 'Comments', 'The Canadian Export Certificate and the United States certificates all impose the condition\\nthat the exported device does not contravene any known requirement of the laws of the\\nimporting country.', 'However, this does not provide protections for countries that do not\\nhave regulations or a national policy on medical device acceptance.', 'Countries are therefore\\n urged to use these guidelines to develop or reinforce their national medical device regulatory\\nauthority so that their populations are protected against unsafe products.', '**35**', 'CHAPTER 7', '##### **Priorities on the international agenda**', 'In order to minimize substandard medical devices in global trade, there is a need to establish\\na uniform format for different countries to certify that the medical device being exported\\ncomplies with their domestic regulatory requirements.', 'This certification process will greatly help importing countries to control medical devices.', 'One option for generating this certificate could be to follow the same process as that used\\nto develop the WHO Export Certificate for Pharmaceutical Products, with detailed item\\ndescriptions tailored to medical devices.', 'Post-market surveillance/vigilance is essential to ensure that medical devices in use\\ncontinue to be safe and effective.', 'Because of the worldwide increase in the use of medical\\ndevices, the ability to access coordinated and analysed global post-market surveillance/\\nvigilance data would greatly enhance medical device safety.', 'Participation and reporting\\ncriteria may be based on the recommendations of the GHTF Study Group 2 (see Annex 2).', 'International agencies, and the governments and industries of major medical device\\nproducing countries could consider supporting the establishment of this global shared\\ndatabase, under the leadership of an international body.', '**36**', 'ANNEX 1', '##### **Resources for medical device** **information**', '**The Global Harmonization Task Force: www.ghtf.org**', 'It provides general information and reports from the four study groups.', 'It also offers\\nan extensive list of web sites of countries around the world.', '**Australia** : Therapeutic Goods Administration: www.health.gov.au/tga', '**Canada** : Health Canada site: www.hc-sc.gc.ca', 'All medical devices guidance documents and medical device related information can be\\nobtained from www.hc-sc.gc.ca/hpfb-dgpsa/tpd-dpt/', '**European Union** : http://europa.eu.int/comm/enterprise/medical_devices/index.htm', 'EU Member States with a different linguistic regime:', 'France: www.afssaps.sante.fr/', 'Germany: www.bfarm.de/de/index.php', 'Spain: www.msc.es/farmacia/home.htm', '**Japan** : Ministry of Health, Labor and Welfare: www.mhlw.go.jp/english/index.html', 'For publications: www.mac.doc.gov/japan/source/menu/medpharm/medpub.html', '**United Kingdom** : www.Medical-devices.gov.uk', '**United States of America** : Food and Drug Administration: www.fda.gov/default.htm', 'Corresponding medical device-related information site: www.fda.gov/cdrh/index.html.', '(this site also offers Device Advice  www.fda.gov/cdrh/devadvice/  a self-service\\nsite for medical device and radiation product information)', 'The FDA enforcement report site: www.fda.gov/opacom/Enforce.html also offers useful\\ninformation for import control.', '**Some addresses to obtain Medical Device Incident Reporting Forms**', 'International', 'Adverse event and Product Defect Reporting Systems', 'ECRI (formerly the Emergency Care Research Institute)', 'WHO Collaborating Centre', 'www.ecri.org', 'E-mail: accidents@ecri.org', 'Tel: +1 610 825 6000, ext 5223', 'United Kingdom', 'Adverse Incident Centre', 'Medicines & Healthcare Products Regulatory Agency', 'Hannibal House, Elephant & Castle', 'London SE1 6TQ', 'Tel hotline: +44 20 7972 8080', 'Fax: +44 20 7972 8109', 'E-mail: aic@mhra.gsi. gov.uk', 'Australia', 'Medical Device Problems and Adverse Events', 'Therapeutic Goods Administration', 'PO Box 100', 'Woden ACT 2606', 'Tel: +61 (02) 6232 8713', 'Fax: +61 (02) 6232 8555', 'E-mail: iris@health.gov.au', 'www.health.gov.au/tga/docs/html/therprob.htm', '**Reuse, refurbished, home-use, donated, and maintenance of medical devices**', 'Reuse of medical devices that are labelled single-use', 'Enforcement Priorities for Single-Use Devices Reprocessed by Third Parties and Hospitals', 'August 14, 2000 www.fda.gov/cdrh/reuse/1168.html', 'Frequently-Asked-Questions about the Reprocessing and Reuse of Single-Use Devices by\\nThird Party and Hospital Reprocessors: Food and Drug Administration (USA)', 'www.fda.gov/cdrh/reuse/reuse-faq.html', 'Special Report: Reuse of Single-U']}\n",
      "Cleaning response ```json\n",
      "{\n",
      "  \"chunks\": [\n",
      "    \"se Medical Devices: Making Informed Decisions: ECRI (USA), info@ecri.org\",\n",
      "    \"Reuse of Single-Use Medical Devices in Canadian Acute-Care HealthCare Facilities: Canadian Healthcare Association, http://www.hc-sc.gc.ca/\",\n",
      "    \"Single-use Medical Devices: Implications and Consequences of Reuse: Medicines and Healthcare Products Regulatory Agency (UK) www.medical-devices.gov.uk/\",\n",
      "    \"Patients in Danger: The Reuse of Single-Use Medical Devices in Europe: European Confederation of Medical Devices Associations, Belgium: www.eucomed.be/\",\n",
      "    \"Reuse of Single Use Devices, 1999 Conference Proceedings and Tapes: Association for the Advancement of Medical Instrumentation (USA) www.aami.org/resources/reuse/index.html\",\n",
      "    \"Refurbished medical devices US Department of Commerce: www.ita.doc.gov/td/mdequip/regulations.html#used\",\n",
      "    \"International Association of Medical Equipment Remarketers and Servicers www.iamers.org/index.html\",\n",
      "    \"Home-use medical devices Home-use Medical Devices: a need for consumer education; Leadership in Health Services, vol. 4, no. 1, Jan/Feb. 1995, Canadian Healthcare Association\",\n",
      "    \"Donated medical devices/equipment Guidelines for Health Care Equipment Donation, World Health Organization, WHO/ARA/97.3\",\n",
      "    \"Guidelines for Medical Equipment Donation: American College of Clinical Engineering, 1995\",\n",
      "    \"Maintenance of medical devices/equipment Chapter on Management of Medical Equipment, District Health Facilities: guidelines for operation and development, World Health Organization, Western Pacific Series No.22\",\n",
      "    \"El mantenimiento del material medico esencial: una prioridad insoslayable, Foro Mundial de la Salud, volumen 15, 1994\",\n",
      "    \"ANNEX 1. RESOURCES FOR MEDICAL DEVICE INFORMATION\",\n",
      "    \"ANNEX 2. Final documents of the GHTF as they relate to the Common Regulatory Framework (Table depicting regulatory stages, control/monitor, person, and items or activities regulated for pre-market, placing on-market, and post-market phases of medical devices).\",\n",
      "    \"ANNEX 3. Relationship between ISO9001:1994 and ISO13485:1996 (Table comparing requirements specified in ISO 9001:1994 and additional requirements for medical devices in ISO 13485:1996)\",\n",
      "    \"ANNEX 4. Aide-mmoire for National Medical Device Administrations. A medical device can range from a simple wooden tongue depressor or stethoscope to the most sophisticated implants or medical imaging devices. In general, a medical device is an instrument, apparatus, or machine used to prevent, diagnose or treat disease. It also serves to detect, measure, restore or modify the structure or function of the body for a given health purpose. Typically a medical device achieves its purpose without entering metabolic pathways.\",\n",
      "    \"Optimum safety and performance require cooperation among all involved in the life span of a medical device: the government, the manufacturer, the importer/vendor, the user and the public \\u2013 each has a specific role to play in this risk management.\",\n",
      "    \"Many countries procure medical devices that may be sub-standard. Some manufacturers of medical devices may also be unaware of minimum standards. Governments that are unable to carry out pre-market review, either for imported devices or those manufactured locally, could assure regulatory compliance by taking advantage of the work of major device manufacturing countries. A priority in local regulatory development should be the establishment of vendor and product registrations.\",\n",
      "    \"Education and training of users, and the continued assessment of medical devices in use is as important as product control. It is critical to have access to a system for informing and collaborating with the manufacturer, vendor, all users, the public and relevant international organizations of hazards/issues related to medical devices.\",\n",
      "    \"WORDS OF ADVICE: Collaborate with all stakeholders to establish a clear and comprehensive national policy on medical devices; Adopt recommendations on global harmonization for regulatory requirements and procedures; Ensure that classified medical devices are manufactured in conformity with applicable quality system standards; Link to networks that monitor medical devices and participate in post-market surveillance and medical device alert issues.\",\n",
      "    \"Checklist: outlines responsibilities for Government, Manufacturers, Importer/vendor, User, and Public regarding medical devices.\",\n",
      "    \"National medical device regulatory or monitoring programme: diagram showing phases in the life span of a medical device (Development, Conception & Manufacture, Packaging & Labelling, Advertising, Sale, Use, Disposal), highlighting the roles of Manufacturer, Vendor, and User. Priority should be given to vendor and product registrations, user training and post-market surveillance of devices.\",\n",
      "    \"Pre-market control: Close cooperation is needed with the manufacturer/importer of the product. Important activities include: Collaboration on acceptance criteria; Collaboration on international quality systems and product-specific standards; Agreement on systems for conformity assessments; Clinical trials/testing; Appropriate and effective customs control system on imported medical devices.\",\n",
      "    \"Sales monitoring: A national database on vendors and products is essential for effective control of medical devices. Important activities include: Vendor registration; Product registration; Prohibition of fraudulent/misleading advertising; After sales obligations, including distribution records, complaint handling, problem reporting, recall procedures.\",\n",
      "    \"Post-market surveillance: Correct use is the ultimate determinant of safety and effectiveness. Important activities include: Training of user before use; Regular maintenance of devices in accordance with operation and service manuals; User networks and medical device vigilance systems to facilitate alert notification; Adequate management and disposal of discarded devices.\",\n",
      "    \"RECOGNITION AND USE OF NATIONAL AND INTERNATIONAL STANDARDS: Regulations address essential safety and performance principles (see Global Harmonization Task Force web site, Doc SG1-N020R5). Detailed technical requirements and characteristics are provided by voluntary product standards developed by national and international expert groups (see ISO TR 16142:1999). The international quality systems standard for medical device manufacturing is ISO 13485. Governments should have a procedure to recognize and publicize standards as a guide for all stakeholders.\",\n",
      "    \"Attributes of good technical standards: their development has been overseen by a recognized body ensuring that the process is transparent and not dominated by untoward interests; the development process has been open to input from all interested parties and the resulting document based on consensus; good technical standards are based on consolidated results in science, technology and experience, and aimed at the promotion of optimum community benefits; standards do not hinder innovation and must be periodically reviewed to remain in tune with technological advances.\",\n",
      "    \"Devices intended for global use should follow international standards (ISO, IEC). A standard can be recognized fully or partially, provided this is clearly specified. Several standards can also be recognized to satisfy the requirements of a particular device. Conformity of a device can be assessed by accredited third party agencies, such as a notified body. In some countries, the publication of government recognized standards mandates product compliance.\",\n",
      "    \"ANNEX 4. AIDE-MMOIRE FOR NATIONAL MEDICAL DEVICE ADMINISTRATIONS\",\n",
      "    \"DEPARTMENT OF BLOOD SAFETY AND CLINICAL TECHNOLOGY WORLD HEALTH ORGANIZATION 1211\\u2013GENEVA\\u201327 92 4 154618 2 SWITZERLAND Fax 41 22 791 4836 E-mail bct@who.int www.who.int/bct\"\n",
      "  ]\n",
      "}\n",
      "```\n",
      "\n",
      "rovas\n",
      "Response cleaned is {'chunks': ['se Medical Devices: Making Informed Decisions: ECRI (USA), info@ecri.org', 'Reuse of Single-Use Medical Devices in Canadian Acute-Care HealthCare Facilities: Canadian Healthcare Association, http://www.hc-sc.gc.ca/', 'Single-use Medical Devices: Implications and Consequences of Reuse: Medicines and Healthcare Products Regulatory Agency (UK) www.medical-devices.gov.uk/', 'Patients in Danger: The Reuse of Single-Use Medical Devices in Europe: European Confederation of Medical Devices Associations, Belgium: www.eucomed.be/', 'Reuse of Single Use Devices, 1999 Conference Proceedings and Tapes: Association for the Advancement of Medical Instrumentation (USA) www.aami.org/resources/reuse/index.html', 'Refurbished medical devices US Department of Commerce: www.ita.doc.gov/td/mdequip/regulations.html#used', 'International Association of Medical Equipment Remarketers and Servicers www.iamers.org/index.html', 'Home-use medical devices Home-use Medical Devices: a need for consumer education; Leadership in Health Services, vol. 4, no. 1, Jan/Feb. 1995, Canadian Healthcare Association', 'Donated medical devices/equipment Guidelines for Health Care Equipment Donation, World Health Organization, WHO/ARA/97.3', 'Guidelines for Medical Equipment Donation: American College of Clinical Engineering, 1995', 'Maintenance of medical devices/equipment Chapter on Management of Medical Equipment, District Health Facilities: guidelines for operation and development, World Health Organization, Western Pacific Series No.22', 'El mantenimiento del material medico esencial: una prioridad insoslayable, Foro Mundial de la Salud, volumen 15, 1994', 'ANNEX 1. RESOURCES FOR MEDICAL DEVICE INFORMATION', 'ANNEX 2. Final documents of the GHTF as they relate to the Common Regulatory Framework (Table depicting regulatory stages, control/monitor, person, and items or activities regulated for pre-market, placing on-market, and post-market phases of medical devices).', 'ANNEX 3. Relationship between ISO9001:1994 and ISO13485:1996 (Table comparing requirements specified in ISO 9001:1994 and additional requirements for medical devices in ISO 13485:1996)', 'ANNEX 4. Aide-mmoire for National Medical Device Administrations. A medical device can range from a simple wooden tongue depressor or stethoscope to the most sophisticated implants or medical imaging devices. In general, a medical device is an instrument, apparatus, or machine used to prevent, diagnose or treat disease. It also serves to detect, measure, restore or modify the structure or function of the body for a given health purpose. Typically a medical device achieves its purpose without entering metabolic pathways.', 'Optimum safety and performance require cooperation among all involved in the life span of a medical device: the government, the manufacturer, the importer/vendor, the user and the public  each has a specific role to play in this risk management.', 'Many countries procure medical devices that may be sub-standard. Some manufacturers of medical devices may also be unaware of minimum standards. Governments that are unable to carry out pre-market review, either for imported devices or those manufactured locally, could assure regulatory compliance by taking advantage of the work of major device manufacturing countries. A priority in local regulatory development should be the establishment of vendor and product registrations.', 'Education and training of users, and the continued assessment of medical devices in use is as important as product control. It is critical to have access to a system for informing and collaborating with the manufacturer, vendor, all users, the public and relevant international organizations of hazards/issues related to medical devices.', 'WORDS OF ADVICE: Collaborate with all stakeholders to establish a clear and comprehensive national policy on medical devices; Adopt recommendations on global harmonization for regulatory requirements and procedures; Ensure that classified medical devices are manufactured in conformity with applicable quality system standards; Link to networks that monitor medical devices and participate in post-market surveillance and medical device alert issues.', 'Checklist: outlines responsibilities for Government, Manufacturers, Importer/vendor, User, and Public regarding medical devices.', 'National medical device regulatory or monitoring programme: diagram showing phases in the life span of a medical device (Development, Conception & Manufacture, Packaging & Labelling, Advertising, Sale, Use, Disposal), highlighting the roles of Manufacturer, Vendor, and User. Priority should be given to vendor and product registrations, user training and post-market surveillance of devices.', 'Pre-market control: Close cooperation is needed with the manufacturer/importer of the product. Important activities include: Collaboration on acceptance criteria; Collaboration on international quality systems and product-specific standards; Agreement on systems for conformity assessments; Clinical trials/testing; Appropriate and effective customs control system on imported medical devices.', 'Sales monitoring: A national database on vendors and products is essential for effective control of medical devices. Important activities include: Vendor registration; Product registration; Prohibition of fraudulent/misleading advertising; After sales obligations, including distribution records, complaint handling, problem reporting, recall procedures.', 'Post-market surveillance: Correct use is the ultimate determinant of safety and effectiveness. Important activities include: Training of user before use; Regular maintenance of devices in accordance with operation and service manuals; User networks and medical device vigilance systems to facilitate alert notification; Adequate management and disposal of discarded devices.', 'RECOGNITION AND USE OF NATIONAL AND INTERNATIONAL STANDARDS: Regulations address essential safety and performance principles (see Global Harmonization Task Force web site, Doc SG1-N020R5). Detailed technical requirements and characteristics are provided by voluntary product standards developed by national and international expert groups (see ISO TR 16142:1999). The international quality systems standard for medical device manufacturing is ISO 13485. Governments should have a procedure to recognize and publicize standards as a guide for all stakeholders.', 'Attributes of good technical standards: their development has been overseen by a recognized body ensuring that the process is transparent and not dominated by untoward interests; the development process has been open to input from all interested parties and the resulting document based on consensus; good technical standards are based on consolidated results in science, technology and experience, and aimed at the promotion of optimum community benefits; standards do not hinder innovation and must be periodically reviewed to remain in tune with technological advances.', 'Devices intended for global use should follow international standards (ISO, IEC). A standard can be recognized fully or partially, provided this is clearly specified. Several standards can also be recognized to satisfy the requirements of a particular device. Conformity of a device can be assessed by accredited third party agencies, such as a notified body. In some countries, the publication of government recognized standards mandates product compliance.', 'ANNEX 4. AIDE-MMOIRE FOR NATIONAL MEDICAL DEVICE ADMINISTRATIONS', 'DEPARTMENT OF BLOOD SAFETY AND CLINICAL TECHNOLOGY WORLD HEALTH ORGANIZATION 1211GENEVA27 92 4 154618 2 SWITZERLAND Fax 41 22 791 4836 E-mail bct@who.int www.who.int/bct']}\n"
     ]
    },
    {
     "ename": "AttributeError",
     "evalue": "'NoneType' object has no attribute 'extend'",
     "output_type": "error",
     "traceback": [
      "\u001b[1;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[1;31mAttributeError\u001b[0m                            Traceback (most recent call last)",
      "Cell \u001b[1;32mIn[7], line 30\u001b[0m\n\u001b[0;32m     27\u001b[0m count_rag \u001b[38;5;241m=\u001b[39m \u001b[38;5;241m0\u001b[39m\n\u001b[0;32m     28\u001b[0m count_final \u001b[38;5;241m=\u001b[39m \u001b[38;5;241m0\u001b[39m\n\u001b[1;32m---> 30\u001b[0m \u001b[43morchestrator\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mrun\u001b[49m\u001b[43m(\u001b[49m\u001b[43m)\u001b[49m\n",
      "Cell \u001b[1;32mIn[1], line 30\u001b[0m, in \u001b[0;36mOrchestratorAgent.run\u001b[1;34m(self)\u001b[0m\n\u001b[0;32m     28\u001b[0m \u001b[38;5;28;01mif\u001b[39;00m agent\u001b[38;5;241m.\u001b[39mname \u001b[38;5;241m==\u001b[39m orch_response[\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124magent_to_call\u001b[39m\u001b[38;5;124m\"\u001b[39m]:\n\u001b[0;32m     29\u001b[0m     \u001b[38;5;28mprint\u001b[39m(\u001b[38;5;124mf\u001b[39m\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mFound agent I was looking for: \u001b[39m\u001b[38;5;132;01m{\u001b[39;00magent\u001b[38;5;241m.\u001b[39mname\u001b[38;5;132;01m}\u001b[39;00m\u001b[38;5;130;01m\\n\u001b[39;00m\u001b[38;5;124m\"\u001b[39m)\n\u001b[1;32m---> 30\u001b[0m     response \u001b[38;5;241m=\u001b[39m \u001b[43magent\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mact\u001b[49m\u001b[43m(\u001b[49m\u001b[43morch_response\u001b[49m\u001b[43m[\u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43moutput\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m]\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43morch_response\u001b[49m\u001b[43m[\u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mrelevant_info\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m]\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;28;43mself\u001b[39;49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mmemory\u001b[49m\u001b[43m)\u001b[49m\n\u001b[0;32m     31\u001b[0m     \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39mmemory\u001b[38;5;241m.\u001b[39mappend(\u001b[38;5;124mf\u001b[39m\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mAgent \u001b[39m\u001b[38;5;132;01m{\u001b[39;00magent\u001b[38;5;241m.\u001b[39mname\u001b[38;5;132;01m}\u001b[39;00m\u001b[38;5;124m responded \u001b[39m\u001b[38;5;132;01m{\u001b[39;00mresponse\u001b[38;5;132;01m}\u001b[39;00m\u001b[38;5;124m\"\u001b[39m)\n\u001b[0;32m     32\u001b[0m     \u001b[38;5;66;03m#controllo da togliere\u001b[39;00m\n",
      "Cell \u001b[1;32mIn[6], line 26\u001b[0m, in \u001b[0;36mChunkingAgent.act\u001b[1;34m(self, query, relevant_info, memory)\u001b[0m\n\u001b[0;32m     23\u001b[0m cleaned_chunks \u001b[38;5;241m=\u001b[39m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39mchunk_document(\u001b[38;5;28mlist\u001b[39m(document\u001b[38;5;241m.\u001b[39mvalues())[\u001b[38;5;241m0\u001b[39m])\n\u001b[0;32m     24\u001b[0m \u001b[38;5;66;03m#print(f\"answer from LLM: {chunks.text}\")\u001b[39;00m\n\u001b[0;32m     25\u001b[0m \u001b[38;5;66;03m#print(f\"chunk list is {cleaned_chunks}\")\u001b[39;00m\n\u001b[1;32m---> 26\u001b[0m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39mtext_chunks \u001b[38;5;241m=\u001b[39m \u001b[38;5;28;43mself\u001b[39;49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mtext_chunks\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mextend\u001b[49m(cleaned_chunks)\n\u001b[0;32m     27\u001b[0m \u001b[38;5;28;01mfor\u001b[39;00m i \u001b[38;5;129;01min\u001b[39;00m \u001b[38;5;28mrange\u001b[39m(\u001b[38;5;28mlen\u001b[39m(cleaned_chunks)):\n\u001b[0;32m     28\u001b[0m     \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39mmetadatas\u001b[38;5;241m.\u001b[39mappend({\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124msource\u001b[39m\u001b[38;5;124m\"\u001b[39m: source})\n",
      "\u001b[1;31mAttributeError\u001b[0m: 'NoneType' object has no attribute 'extend'"
     ]
    }
   ],
   "source": [
    "# Instantiate agent objects\n",
    "\n",
    "def clean_response(response):\n",
    "    response_text = response.text\n",
    "    print(f\"Cleaning response {response.text}\")\n",
    "    start_index = response_text.find(\"{\")\n",
    "    end_index = response_text.rfind(\"}\")\n",
    "    print(\"rovas\")\n",
    "    if start_index != -1 and end_index != -1:\n",
    "        response_cleaned = json.loads(response_text[start_index : end_index + 1])\n",
    "        print(f\"Response cleaned is {response_cleaned}\")\n",
    "        return response_cleaned\n",
    "    else:\n",
    "        return response_text\n",
    "\n",
    "chunking_agent = ChunkingAgent()\n",
    "ragagent = RAGAgent()\n",
    "response_agent = ResponseAgent()\n",
    "orchestrator = OrchestratorAgent([chunking_agent, ragagent, response_agent])\n",
    "\n",
    "final_answer = None\n",
    "history = []\n",
    "query1 = \"Is our AI-powered MRI analysis tool considered a medical device software?\"\n",
    "query2 = \"What are the design control requirements for verification and validation?\"\n",
    "query3 = \"Compare FDA and WHO approaches to risk management for medical devices\"\n",
    "query4 = \"What documentation is needed for a mobile app that monitors heart rate?\"\n",
    "count_rag = 0\n",
    "count_final = 0\n",
    "\n",
    "orchestrator.run()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "fde820ce-0e23-4632-bba8-aa08b63e92bf",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "d263bcd6-d7e8-4566-9b6a-578686f4df6b",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "f89678ba-472f-4dea-92b8-f0378fcf9f93",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "987ea1f8-4a2b-4255-bcac-e5b23e55bc24",
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3 (ipykernel)",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.9.23"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
